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ABSTRACT 
Annual Ryegrass Toxicity is a severe and constant threat to the Australian agricultural 
industry, particularly the international export market worth in excess of $AU27.6 
billion, due to real or perceived safety issues.  ARGT primarily manifests as severe 
neurological dysfunction, predominantly affecting sheep and cattle, caused by 
ingestion of a glycolipids tunicaminyl-uracil toxin, corynetoxins (CTs) produced by 
the bacterium Rathayibacter toxicus (R. toxicus) (Masters et al.,  2006) that uses a 
nematode vector to attach to and infect the seedheads of annual ryegrass (L. rigidum).  
Currently, there is little known of the factors that trigger and control toxin production.  
Several studies have speculated that a bacteriophage specific to R. toxicus may be 
implicated. 
Current diagnostic and detection strategies to predict and effectively monitor ARGT 
both in the field and within livestock are severely limited, especially for pre-clinical 
exposure which is completely undetectable using current conventional strategies.  The 
investigation presented in this thesis has utilised genomic-based technologies to 
develop improved strategies for detection of molecular indicators of toxicity in (1) the 
field and (2) within livestock to facilitate pre-clinical detection of ARGT.  The first 
strategy involved development of a rapid and comprehensive Polymerase Chain 
Reaction (PCR)-based assay to detect known, or in the case of the phage, suspected, 
factors contributing to ARGT in the field.  Results support the application of the PCR-
based assays in providing a useful, complimentary tool in the assessment of the 
likelihood of pasture and feed to cause ARGT and to better enable a better 
understanding of the complex aetiology of ARGT.  In addition, sequencing of 
bacteriophage isolate NCPPB 3778 was also undertaken in an attempt to identify 
associated “signature genes” to further elucidate its potential role in toxin production.  
  v 
The partial sequence analysis determined for NCPPB 3778 however, revealed an 
absence of obvious virulence determinants or clear homologies for virulence or toxin 
related genes. 
The second strategy involved using an in vitro toxicogenomic strategy for detection of 
genomic biomarkers of pre-clinical exposure to ARGT in livestock.  Firstly, 
bioequivalence of corynetoxins and the commercially available tunicamycins were 
evaluated.  Comparative toxicogenomic analysis revealed that exposure to certain 
doses of tunicamycins and corynetoxins produced specific alterations in gene 
expression that were non-equivalent.  Therefore, based on the non-equivalence 
observed, the long-standing use of tunicamycins as a substitute to experimentally 
model ARGT at the genomic level may be in question.  As such, only corynetoxins 
were analysed to identify candidate in vitro genomic biomarkers as early predictors of 
pre-clinical.  Five candidate genomic markers were identified as consistently highly 
differentially regulated in both the low and high dose treatments using the in vitro 
toxicogenomic approach.  These candidate biomarkers included:  Cytochrome c 
oxidase (mt_Co1), Fibronectin (FN), MAPK10 N-terminal kinase gene (JNK3), 
Glutathione transferase α (GSTα) and GADD45a (GA45).  Several of these biomarker 
candidates have been demonstrated in previous studies as differentially regulated in 
response to other toxins and have been reported as useful biomarkers of exposure.  
Ultimately, these preliminary candidates may offer the opportunity for the 
development of future diagnostic or prognostic tools in early prediction tests for 
ARGT. 
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CHAPTER 1 
Introduction 
1.1 Prelude: Agriculture in Australia: Disease and Diagnostics 
Agriculture is essential to the Australian economy, representing the largest renewable 
resource sector and responsible for injecting billions of dollars into the economy 
annually.  The preliminary estimate of the gross Value of Agricultural Commodities 
Produced (VACP) for Australia in 2005-06 was $37.3 billion, with the value of 
agricultural exports representing approximately $27.6 billion [Australian Bureau of 
Statistics “Value of Principal Agricultural Commodities Produced,” Australia, 
Preliminary Publication, 2005-06].  Australia has the enviable position of having one 
of the world's most pest and disease-free agricultural production environments 
(Agriculture Protection Board of Australia, 2004).  This ‘clean and green’ status has 
provided access to extensive overseas markets and international trade, which has 
facilitated thriving export opportunities for Australian commodities.  Despite 
Australia being relatively free from many of the world’s agricultural diseases, the 
agricultural sector is still vulnerable to many endemic pathogenic organisms and 
toxins capable of causing devastating losses with potentially severe and 
unprecedented economic repercussions. 
Poisoning by low molecular weight natural toxicants causes considerable economic 
loss in livestock production worldwide (Nielsen, 1988).  Increasing attention is also 
being paid to human health risks posed by the possible transfer of natural toxicants 
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into animal products consumed by humans (Hall and Beasley, 1990; Colegate et al.,  
1998).  Many plants, bacteria or fungi associated with plants produce chemicals that 
are toxic to animals and humans.  Animals are exposed to these plant-associated 
toxins (PATs) through grazing or via contaminated feed, while humans can ingest 
foods such as grains contaminated with these toxins, or contaminant residues in 
animal-derived food such as meat and dairy products.  Examples of plant, fungal or 
bacterial toxins include aflatoxin (Hudler, 1998), ochratoxin (Al-Anati and Petzinger, 
2006), trichothecene toxins (Eppley and Bailey, 1973), zearalenone (Kuiper-
Goodman et al.,  1987; Tanaka et al.,  1988), fumonisin (Gelderblom et al.,  1988), 
cyclopiazonic acid (Seidler et al.,  1989), corynetoxins (Vogel et al.,  1981), 
pyrrolizidine alkaloids (Stegelmeier et al.,  1999); Huxtable, R. J., 1989), lupin 
alkaloids (Leonard, 1953) and 1960; Bohlmann and Schumann, 1967), phomopsins 
(Marasas, 1974; Culvenor et al.,  1977; Lacey et al.,  1987) and ergot alkaloids (van 
Dongen and de Groot, 1995).  Each year, outbreaks of PATs-related disease are 
recorded causing high mortality and morbidity, with devastating losses to Australia’s 
valuable agricultural sector. 
Annual Ryegrass Toxicity (ARGT) is a plant associated toxin-related disease caused 
by livestock ingesting annual ryegrass contaminated with corynetoxins, produced by 
the soil-borne bacterium Rathayibacter toxicus (R. toxicus).  ARGT has a tremendous 
impact on livestock within Australia in terms of animal health, welfare and 
productivity, which is exacerbated by the lack of effective diagnostics and treatment 
for the disease (Stynes and Wise, 1980).  In Australia, more than 100,000 sheep and 
thousands of cattle die from ARGT in some years with up to a 90% mortality rate 
(Edgar, 2004).  The financial impact upon individual farmers, the livestock industry 
and agricultural sector is significant.  Recent estimates have placed the costs 
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associated with ARGT in Western Australia alone in excess of $35 million annually 
(J. Allen, Department of Agriculture Western Australia, personal communication).  
The Department of Agriculture stopped collecting outbreak information in 1994.  
Therefore, more recent published data of ARGT-related stock losses are not available. 
As not all cases are reported, it is likely that stock mortalities are actually much 
higher. 
Corynetoxins are one of the most significant plant-associated toxins in Australia, with 
respect to extreme toxicity, cumulative nature and threat to the agricultural sector and 
affect trade, due to real or perceived food safety issues.  Food safety is an important 
factor influencing international trade (Edgar, 2004).  Corynetoxins have been 
highlighted as a potential food safety threat to Australia (Edgar, 1997).  In 1996, 
fodder contaminated with corynetoxins was exported to Japan causing several 
incidents of ARGT poisoning in Japanese beef and dairy cattle.  Australian authorities 
have since been warned that any further incident of corynetoxin poisoning overseas, 
caused by exported Australian fodder, will result in long-term market losses and 
potentially compromise international trade of commodities (Than et al.,  2002).  In 
addition to this threat to animal health and international trade, there is also an 
unquantified potential of contamination of the human food supply directly (grain 
products) or indirectly (food products from animals exposed) with corynetoxins.  The 
risks associated with the transfer of corynetoxins into animal products such as meat 
and milk are largely unquantified.  A limited number of studies investigating the 
potential for residual toxicity in meat (Bourke and Carrigan, 1993) and milk (Stewart 
et al.,  2004) have indicated that the risks are low.  However, valid concerns regarding 
food safety for long-lived species such as humans, where more subtle health issues are 
of importance, remain to be investigated (JA Edgar, CSIRO Livestock Industries, 
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personal communication].  Whilst there have been no cases of human disease 
attributed to corynetoxin poisoning, their acute toxicity, mechanism of action and 
cumulative nature highlights the requirement for further research to demonstrate that 
biologically active corynetoxin residues are not present in the meat/milk of animals 
grazing ARGT affected pastures (Colegate et al.,  1998). 
Diagnostic and detection strategies are imperative for protection of Australia’s 
valuable agricultural sector by limiting the impact of a potential outbreak and/or 
export of contaminated goods.  Retrospective analysis of the 1996 incident has 
indicated that early identification of corynetoxin by assay may have prevented this 
incident.  As a result, accurate determination of corynetoxin effect levels in fodder for 
export was recognized as a priority by the respective government authorities and 
quality assurance programs to prevent the release of contaminated fodder onto 
domestic and international stockfeed markets (Masters et al.,  2006).   
While any of the current methods for detection of corynetoxins, in combination with 
clinical signs in livestock, can be used to confirm a diagnosis of ARGT, the predictive 
application relating bacterial presence to toxicity is problematic i.e. bacterial presence 
not necessarily being indicative of toxin production (Roberts and Bucat, 1992).  The 
cautious approach to predictive capability was highlighted by several presenters at an 
ARGT workshop (El Cabello Blanco, Western Australia, November 2002) and was 
related to paddock sampling issues and the highly complex ecosystem that contributes 
to ARGT.  Furthermore, the application of current diagnostic and detection 
approaches to predict and monitor ARGT potential both in the field and within 
livestock are limited due to the cumulative effect of the toxin sub clinically and the 
molecular triggers for toxin production remaining largely undefined. 
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 Development of improved diagnostic and detection strategies for prediction of ARGT 
is critical for all reasons previously outlined and forms the basis of this thesis. 
1.2 Annual Ryegrass Toxicity (ARGT) 
1.2.1 Discovery of the disease and its biotic associations 
Annual Ryegrass Toxicity (ARGT) was first described in mid-north South Australia 
approximately 50 years ago with infection of ARGT spreading slowly at first, then 
more rapidly, later appearing in the south-west of Western Australia (Berry and Wise, 
1975); (Roberts and Bucat, 1992).  The condition was originally termed ‘annual 
ryegrass toxicity’ as a result of the causative nematode-bacterium complex 
parasitizing annual ryegrass (Lolium rigidum) grazed by sheep, cattle and 
occasionally horses.  The disease was first reported in the 1960s by (McIntosh et al.,  
1967) who described a disease in sheep and cattle grazing annual ryegrass that was 
characterized by incoordination, convulsions and death.  This same group also 
demonstrated that the disease could be experimentally reproduced in guinea pigs 
when fed annual ryegrass, but only if the seeds were parasitized by an Anguina 
species nematode gall.  Based on these observations, they concluded that “a powerful 
toxin was present and was a hazard” (McIntosh et al.,  1967).  Price (1973) identified 
that a nematode (Anguina funesta) acted as a ‘mechanical vector’ for a 
corynebacterium species (Rathayibacter toxicus), and that the natural bacterial 
infection of ryegrass did not occur in the nematodes absence.  Further, Lanigan found 
that presence of the nematode was not an indicator of toxicity (Lanigan et al.,  1976).   
The origin of the toxin was initially unclear and eagerly contested in the literature. 
Stynes et al., (1979) hypothesized that corynetoxins were produced by the plant in 
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response to bacterial galls.  This was based on observations that the plant rather than 
the bacterial component of the seed gall was found to be more toxic.  It was not until 
1983 however, that R. toxicus was shown to be the source of the toxins which were 
later termed ‘corynetoxins’ (Payne et al.,  1983).   
The presence of ultramicroscopic “virus-like” particles associated with R. toxicus 
were reported for the first time by Bird et al., (1980).  Riley and Gooden (1991) later 
identified these particles as bacteriophage specific to R. toxicus, consequently 
classifying the bacteriophage NCPPB 3778.  Two years later, Ophel et al., (1993) 
identified a positive correlation between bacteriophage presence and toxin production 
in culture.  Based on this study, toxin production is considered to be regulated by a 
bacteriophage NCPPB 3778 (Riley and Gooden 1991; Ophel et al.,  1993).   
Australia is the only country in which significant livestock losses result from ARGT.  
Most outbreaks occur during summer grazing in the wheat-sheep zones of South and 
Western Australia, where annual ryegrass is a major component of improved pastures 
(Culvenor and Jago, 1985).  However, sporadic reports of ARGT have been 
documented in South Africa, with the grass infection possibly introduced from 
Australia in contaminated ryegrass seed (Schneider, 1981).  More recently in 
Australia, R. toxicus has been identified as the causative agent for other severe 
neurological disorders causing high mortality and morbidity in livestock grazing 
annual beard grass (Polypogon monseliensis) in flood-prone areas of south-east South 
Australia (McKay et al., 1993) and blown grass (Agrostis avenacea) on the Darling 
River floodplains of northern New South Wales (Stuart et al.,  1994; Bourke et al.,  
1992; Schena et al.,  1995).  Annual ryegrass (L. rigidum) is not a prominent pasture 
species in either of these regions.   
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The occurrence of ARGT in Australia appears to be largely determined by the 
geographic distribution of the three organisms: R. toxicus, A. funesta and L. rigidum.  
R. toxicus is widely distributed in Australia and is apparently non-host and vector 
specific as discussed above and later in Sect: 1.2.3 (Riley et al.,  2003).  The potential 
for spread of ARGT is therefore considerable.  The status of R. toxicus in Victoria 
remains unclear; however there have been no reports of an ARGT-like disorder.  
Although, there have been no stock deaths attributed to ARGT in Victoria, the 
presence of the nematode vector was first recorded in 1985 in a number of localities 
and R. toxicus in one (Jago and Culvenor, 1987).   
1.2.2 Lifecycle: nematode, bacterium and ryegrass interaction 
The bacterium (R. toxicus) is soil-borne, but gains access to annual ryegrass (L. 
rigidum) in winter by adhering to the surface of the parasitic, seed-gall nematode (A. 
funesta).  The Anguina sp nematode is an essential vector for R. toxicus, which cannot 
penetrate developing ryegrass unaided.  The nematode initiates seed galls, and in 
some galls the bacterium predominates multiplying rapidly, producing a yellow slime, 
which spills out over the seed head, leaving a gall containing virtually only bacterial 
cells (Stynes et al.,  1979).  By the time the seed heads begin to emerge these galls are 
full of bacteria.  It is at this stage, seed-set, that trace amounts of toxins are detected 
with the amount increasing as the plant undergoes senescence (Stynes and Bird, 
1980).  As the pasture matures, bacterial slime dries to an orange appearance, and 
toxin levels reach a maximum.  Only bacterial galls are toxic, with the concentration 
of corynetoxin present in the wall of the bacterial gall rather than in the bacterial 
component (Lanigan et al.,  1976; Stynes et al.,  1979).  As depicted in Figure 1.1 
galls colonized by bacteria are typically bright yellow and galls containing nematodes 
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are dark brown and approximately twice as thick as those colonized by bacteria (Bird 
et al.,  1980). 
Seasonal patterns are observed each year in field outbreaks of ARGT.  Most cases of 
poisoning in grazing livestock occur between mid October and December (late spring 
to early summer), after the seed heads have developed maximum toxicity and while 
the pastures are undergoing senescence.  These observations suggest a close 
relationship between the physiological maturation of the plant and accumulation of 
the toxin (Stynes and Bird, 1983).  Furthermore, infected ryegrass in the field can 
remain toxic until replaced by new growth the next season.  Moreover, poisonous 
harvested seed containing bacterial galls if kept dry and protected from the weather 
can remain toxic for years.  As a result, outbreaks of ARGT can occur at any time of 
year in livestock through ingestion of toxic hay or, to a more limited extent grain 
(Nogawa et al.,  1997).   
1.2.3 Bacterium  
The causative bacterium ‘Rathayibacter toxicus’ (R. toxicus) was first isolated by 
Kerr in 1968 (Fisher, 1978).  As mentioned above, R. toxicus is a bacterium 
responsible for production of the highly potent animal and human toxin ‘corynetoxin’ 
responsible for various grass toxicities, most notably ARGT.   
The bacterium was initially reported by Bird and Stynes (Bird and Stynes, 1977) as 
indistinguishable from Corynebacterium rathayi (C. rathayi) based on its appearance 
as a yellow slime covering the inflorescences of the host, presence of the capsule, its 
vectoral relationship with an Anguina nematode species and its occurrence in grasses.  
Riley and coworkers used serology (Riley, 1987), allozyme electrophoresis (Riley et 
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al.,  1991), adhesion to nematodes (Riley et al.,  1991) and bacteriophage specificity 
(Riley IT, 1991) to demonstrate that the bacterium associated with L. rigidum was not 
C. rathayi, instead describing it as a new species Clavibacter toxicus (Riley and 
Ophel, 1992a).  More recently however, the bacterium was reclassified as 
Rathayibacter toxicus (R. toxicus) based on the composition of its peptidoglycan and 
16S rRNA gene sequence (Lee et al.,  1997; Sasaki et al.,  1998).  In particular, the 
genus Rathayibacter is characterized by possessing a B2γ type cell wall 
peptidoglycan (Schleifer and Kandler, 1972), with 2, 4- diaminobutyric acid, 
predominant manaquinones of the MK-10 type, phosphatidylgylycerol and 
diphosphatidylglycerol as basic polar lipids (Collins and Bradbury, 1984), (Suzuki et 
al.,  1996); (Zgurskaya et al.,  1992) and a high G+C content of 67 mol% G + C 
(Riley and Ophel, 1992a; Sasaki et al.,  1998).  Figure 1.2 depicts a phylogenetic tree 
derived from the 16S rDNA sequences of actinomycetes containing DAB in their cell 
wall (Sasaki et al.,  1998). 
It has been reported that R. toxicus is not vector specific to a particular species of 
Anguina (Riley and McKay, 1990) and host specific either with infection of grass 
determined largely by the specificity of the nematode vector (Agarkova et al.,  2006).  
R. toxicus has been demonstrated to colonise and produce toxin in a wide range of 
cereal and fodder grasses, including species consumed by humans (Chatel et al.,  
1979).  This makes R. toxicus a high-threat risk foreign pathogen (Edgar, 2004). 
R. toxicus is gram positive, coryneform, soil borne bacteria which is obligatory 
aerobic and produces non-spore forming rods (generally 0.6-0.75x1.5 μm).  R. toxicus 
has an external coating or “capsule” (0.2 μm thick) which has specific adhesive 
properties enabling the bacterium to stick to the cuticle of the nematode vector (Bird 
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and Stynes, 1977).  The capsule is one of the most definitive characteristics of the 
corynebacterium allowing it to adhere to the cuticle surface of particular Anguina sp 
and offering associated protective properties (Bird and Stynes, 1977).   
R. toxicus is difficult to isolate from plant material (McIntosh et al.,  1967).  R. 
toxicus grows slowly on artificial media and is often overgrown by saprophytic 
bacteria.  The bacterium catabolises a limited range of sugars and requires growth 
factors (Riley and Ophel, 1992a).  Figure 1.3 depicts the characteristic flat, smooth, 
pale yellow colonies of R. toxicus grown in vitro on 523M agar after 5d culture at  
30 ْC (Riley and Ophel, 1992b).   
Little is known about the genetic diversity of R. toxicus.  The genome of R. toxicus 
appears highly conserved with allozyme electrophoresis producing incomplete data 
(Johnston et al., 1996; Riley 1987; Riley and Gooden 1991).  A recent study 
(Agarkova et al.,  2006) revealed little variation among strains when typing R. toxicus 
using serology and bacteriophage sensitivity.  This study characterised 22 strains of R. 
toxicus using two DNA based methods, amplified fragment length polymorphism 
(AFLP) and pulsed-field gel electrophoresis (PFGE).  Based on the AFLP and PFGE 
data, the population of R. toxicus appeared very stable indicating that the population 
has not undergone changes for many years.  Further, this study reported that the R. 
toxicus genome is represented by a single linear chromosome, estimated to be 2.35-
Mb replicon.  No plasmids were detected.  The description of a linear chromosome for 
R. toxicus is unusual but not unique for a bacterial genome.  Interestingly, the R. 
toxicus genome is a similar size and linear form to the related gram-positive plant 
pathogenic Clavibacter. michiganensis subsp. sepedonicus (Brown et al.,  2002). 
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Currently, very little is known of the factors or mechanisms controlling corynetoxin 
production within R. toxicus.  It has been well documented that a number of 
microorganisms produce similar toxins to give themselves a selective ecological 
advantage against other organisms in their environment (Mitchell, 1991), whether this 
is also true for R. toxicus remains unclear. 
1.2.4 T oxin production and role of Bacteriophage NCPPB 3778 
Bird et al., (1980) were the first to identify the presence of ultramicroscopic “virus-
like” particles associated with R. toxicus and suggested that these particles may be 
“corynephages”.  However, there was insufficient evidence available at that time to 
establish phage properties for these particles.  Stynes and Bird (1983) went onto 
investigate a possible relationship between toxicity and the presence of these “virus-
like” particles.  They observed that the particles were located in and around the 
bacteria and particularly in the gall wall, a site which is known to contain the greatest 
amount of toxin.  Furthermore, particles were found present in galls only after 
anthesis.  The presence of particles in some galls but not others they believed was 
significant and that differences observed in toxicity may be reflective of the relative 
proportion of galls which contained these particles.  The synchronous accumulation of 
particles with the production of toxin raised speculation as to the origin of the toxin. 
Eleven years later, Riley and Gooden (1991) described the isolation of a 
bacteriophage specific to R. toxicus.  Figure 1.4 depicts the published electron 
micrograph of the bacteriophage isolated from R. toxicus associated with ARGT. 
Riley and Gooden (1991) suggested that this bacteriophage could serve as a tool for 
rapid identification of bacterial strains suspected of being toxigenic as traditional tests 
had not proven definitive (Price et al.,  1979a); J. Lloyd’s communication with Bird & 
Chapter 1 
  12 
Stynes, 1977) and that the bacteriophage may also play a significant role in its 
biology. 
In 1993, Ophel et al. for the first time observed that R. toxicus produces toxin in vitro 
when infected by the lytic bacteriophage NCPPB 3778.  Ophel also examined intact 
phage NCPPB 3778 using TEM and reported that phage particles were approximately 
35-40 nm in diameter with flexible tails 100- to 130-nm long.  The ratio of tail-length 
to head-length was 2.4 to 2.78, and tail-length to head-width was 2.2 to 2.9.  Phage 
NCPPB 3778 was also demonstrated as having nucleic acid DNA which was linear 
and double-stranded and approximately 45 kb. 
The study (Ophel et al.,  1993) concluded that the small 45 kb bacteriophage genome 
would be unlikely to encode genes for toxin production due to the complex nature of 
the glycolipid corynetoxin molecule, as well as those necessary for bacteriophage 
replication and survival.  It was suggested rather, that the bacteriophage may encode a 
regulatory gene that switches on toxin production in the bacteria or encode a gene 
product involved in the biosynthetic pathway for corynetoxin production.  
Alternatively, it was also suggested that bacteriophage infection makes cells more 
permeable to export of the toxin.  This study observed that phage carrier cells 
appeared morphologically altered, especially the bacterial cell membrane which 
appeared diffuse and disintegrated, possibly making the cells more permeable to toxin 
export.  It was demonstrated that corynetoxin was produced only by these infected 
cells and not by uninfected cells.  The study also noted that phage-infected cultures 
were somewhat unstable and grew more slowly than wild-type.  The mechanism by 
which this occurs is unknown.   
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Currently, little is known in regard to ecology of the bacteriophage or the role of 
corynetoxins.  DNA restriction pattern and host-range studies indicate that the same 
bacteriophage NCPPB 3778 is present in toxic galls from the two other plant species 
(A. avenacea and P. monspliensis) known to be responsible for flood plain staggers 
(McKay and Ophel, 1993).  It is possible other toxigenic bacteria/bacteriophage 
associations exist.  Bacteriophage associations have also been described for 
Clavibacter michagenese subsp. michiganese, C.m. subsp. Insidiosum, C.m. subsp. 
nebraskense, and C.m. subsp. sepedonicum (Vidaver, 1982).  These bacteria have 
been reported as having limited host ranges, are lytic and appear morphologically 
similar to bacteriophage NCPPB 3778.  However, there are no reports of these phage 
having a role in pathogenicity or toxin production. 
The role of bacteriophage as reservoirs of toxin genes and their involvement in 
bacterial virulence is well documented (Wagner and Waldor, 2002).  Since the 
discovery in 1951 that the diphtheria toxin is encoded on the β-phage genome from  
C. diptheriae (Freeman, 1951), bacteriophage-encoded toxins have been identified in 
a range of both Gram-negative and Gram-positive bacteria, including: E. coli, Shigella 
spp., P. aeruginosa, V. cholerae, C. tetani, C. botulinum (Boyd and Brussow, 2002).   
The selective advantage for the association between R. toxicus and the bacteriophage 
still remains unclear.  It is tempting to speculate that the bacteriophage may play a 
role in pathogenicity or survival of R. toxicus.  Production of toxin by these infected 
bacteria may be a reaction to infection, or alternatively, it may give these slow 
growing bacteria a competitive advantage in ryegrass galls.  It has been suggested that 
phage infection, demonstrated to make the bacteria unstable in culture, may facilitate 
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infection of plants, and therefore may play a role in pathogenicity (Ophel et al.,  
1993). 
1.2.5 Clinical signs of ARGT 
ARGT, also known as corynetoxin poisoning or tunicaminyl-uracil toxicosis (Bourke 
et al.,  1992) is an often highly fatal neurological disease characterised by convulsions 
(Berry et al.,  1980a; Jago and Culvenor, 1987).  ARGT is predominantly known to 
affect sheep, however stock losses in cattle can also be substantial (McIntosh et al.,  
1967).  Documented cases of ARGT have also been reported in pigs (Cockrum et al.,  
1987), goats (Stewart and May, 1994) and horses (Creeper et al.,  1996).  ARGT has 
also been reported to affect a range of laboratory animals including: nursling rats and 
guinea pigs (Jago et al.,  1983; Yeoh et al.,  1984).  Sheep appear particularly 
sensitive to corynetoxins, all ages are affected with high morbidity and mortality 
rates.  Early signs of toxicity can develop within four days or can take up to 12 weeks, 
depending on stocking rate, density of infected plants, and stress factors such as hot 
weather, mustering, shearing and transport. Animals may also continue to exhibit 
symptoms for up to 10 days after removal from a toxic paddock (Berry and Wise, 
1975; McIntosh et al.,  1967). 
The clinical signs displayed by intoxicated animals appear similar regardless of the 
species affected (McIntosh et al.,  1967; Berry and Wise, 1975).  Clinical signs often 
appear abruptly, usually following some external stimulation, with signs of toxicity 
more visible when the animals are under stress or excited. They include tremors, 
ataxia, adoption of a wide-based stance, incoordination, nystagmus, opisthotonus, 
convulsions while in lateral recumbency and finally death. Animals may appear to 
recover between episodes of ataxia and convulsions. Sheep often exhibit a high 
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stepping gait with their forelimbs, while the head is held high. When forced to run 
some sheep have a stiff-legged or “rocking horse” gait. Some cattle appear 
disorientated and wander aimlessly between episodes of convulsions. In the final 
stages, poisoned animals lie on the ground, unable to regain their feet. They may have 
nervous spasms or convulsions, often making paddling movements, sweeping the 
ground bare. Animals can remain in this state for up to two days prior to death (Berry 
and Wise, 1975). 
Testimonials from farmers experiencing the disease first hand explain that “ARGT is 
a cruel disease that strikes suddenly without warning, even when all precautions have 
been taken.  When it strikes there is no effective treatment for affected animals and it 
causes death in the most distressing way.  “I have experienced no other livestock 
disease that emotionally affects farmers the way this disease does” [(J. Allen, 
Department of Agriculture, Western Australia; personal communication).]. 
1.2.6 Sub-cl inical effects of ARGT 
Livestock have been reported to apparently ingest up to 75% of a lethal dose of toxin 
and still appear clinically unaffected.  Also, a lag time of approximately 3 to 4 days 
exists between ingestion of a lethal dose and the onset of clinical signs.  As a result, 
clinically “normal” but intoxicated livestock can remain within the toxic environment 
and continue to be exposed to corynetoxins without detection.  In addition, other 
unaffected livestock also risk exposure by unknowingly being introduced into the 
toxic field environment or may be fed contaminated hay/fodder. 
Sub-clinical cumulative effects of corynetoxin exposure have been reported to also 
affect livestock growth, productivity and reproduction as described above.  In 
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particular, ARGT has been reported to cause abortion in late pregnant ewes (Berry 
and Wise, 1975; McIntosh et al.,  1967; Schneider, 1981).  Schneider (Schneider, 
1981) reported a case in which 200 of 557 ewes aborted after an outbreak of ARGT.  
Anecdotal reports by farmers of low lambing rates (~50%) in the breeding season 
following an outbreak of annual ryegrass toxicity raised the question of a possible 
association between the ingestion of non-lethal amounts of corynetoxins and fertility 
(Peterson et al.,  1996).  These losses are likely to be underestimated as producers 
may not associate the losses with outbreaks of ARGT that occurred several months 
earlier.  Tunicamycin, a commercially available, structurally similar antibiotic used as 
an experimental substitute for corynetoxins (see Sect: 1.3.2) has been shown to 
interfere with embryonic development in a range of animal species (Marek et al.,  
1999; Mizoguchi et al.,  1981; Webb and Duksin, 1981).  Subsequent studies have 
since demonstrated that tunicamycins causes permanent infertility in male rats at 
levels that show no obvious clinical signs of poisoning (Peterson et al.,  1996) and 
abortion and maternal deaths in pregnant rats at doses well below those tolerated by 
non-pregnant rats (Stewart et al.,  2002). 
Production losses associated with prolonged exposure to low levels of corynetoxins 
have not been adequately investigated.  However, research in the 1990’s showed that 
sub-lethal intakes of corynetoxins by sheep reduced wool staple length and wool fiber 
diameter by 10% and 7% respectively, resulting in a 22% reduction in wool volume, 
and probably increasing the risk of tender wool (Davies et al.,  1996).  These were 
findings in experiments that lasted 11 weeks, and in which CT intake was so low, that 
it is probable that many sheep consume sub-lethal intakes of CT for up to 6 months of 
the year. Follow-up studies have shown that the suppression of wool growth was 
attributed to the direct affect that the toxin appears to have on the mitotic activity in 
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the bulb of the wool follicle (Davies et al.,  1997).  These findings suggest that 
cumulative, sub-lethal exposure of corynetoxins have a substantial impact on ewe 
development and production. 
Costs associated with sub-clinical cumulative exposure to corynetoxin have not yet 
been reported.  This is predominantly due to an incomplete understanding of the sub-
clinical effects associated with ARGT.  However, based on the low lambing rates and 
suppression of wool growth associated with corynetoxin exposure, the estimated costs 
are expected to be significant. 
1.2.7 Cumulative nature 
Corynetoxins are cumulative in action (Jago and Culvenor, 1987) in that the total 
lethal dose of corynetoxin is equivalent whether given as a single dose or as repeated 
smaller doses over an extended period.  The relatively hydrophobic nature of 
corynetoxins causes them to associate with cellular membranes (Stuart et al.,  1994) 
which are retained in tissue, persisting and remaining biologically active for up to 
several months.  Jago and Culvenor (1987) describes the cumulative effect of repeated 
doses of the toxin maintained over a wide range of dosages and over intervals of up to 
9 weeks between doses.  Therefore, corynetoxins consumption below levels that 
produce clinical signs may contribute to accumulating toxicity, resulting in later 
deaths with a small additional toxin exposure. This finding is important in the 
management of disease as repeated consumption of the toxin causes cumulative 
damage at least in the one season.  Thus, it is important to avoid subsequent exposure 
of animals to toxic ryegrass. 
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The cumulative nature of corynetoxins has rendered the capacity of current 
diagnostics, to detect and confirm corynetoxins exposure, severely limited. In 
particular, prolonged sub-lethal exposure (potentially causing irreversible damage 
before the manifestation of overt clinical symptoms) is completely undetectable based 
on current diagnostic strategies.  As discussed in Sect: 1.2.6, cumulative sub-clinical 
effects of corynetoxins appear to affect livestock growth, productivity and 
reproduction.  The effects of low-level cumulative exposure are likely to be latent, 
chronic, long-term rather than immediate and could be difficult to distinguish from 
common health problems such as infertility, abortion and neurological problems.  As 
such, further studies to examine the effects of cumulative long-term, low level 
exposure to these toxins are required [P.R. Giesecke, personal communication]. 
1.2.8 P athology 
It is the experience of diagnostic pathologists that the macroscopic and microscopic 
pathology of ARGT is neither significant nor consistent, nor necessarily specific 
(Finnie, 1991b).  Often several animals may need to be examined to see the range of 
pathological changes reported for this disease. Pathological changes include 
hemorrhages in various organs, vascular damage in the brain, particularly the 
cerebellum (Berry and Wise, 1975), as well as liver damage (McIntosh et al.,  1967; 
Schneider, 1981).   
Autopsies are more useful for eliminating other causes of death, rather than 
confirming diagnosis of corynetoxin poisoning (Purcell, 1985).  Nevertheless, autopsy 
findings often reveal the liver to be enlarged and pale tan to yellowish in colour. 
Affected cattle may have very pale fatty livers. Horses have similarly shown 
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extremely fatty livers with hemorrhagic anterior thoracic lymph nodes. There may be 
mild jaundice, with liver-specific enzymes increased in infected animals. 
Histopathology has been found to be extremely variable for field cases of ARGT. 
Observable changes appear to be generally associated with capillary damage.  
Perivascular cuffing may be seen in the brain, liver and lymph nodes.  Diffuse 
vacuolation of hepatocytes due to distension of endoplasmic reticulum is also often 
observed.  Necrosis of individual hepatocytes, fatty acid change, billary hyperplasia 
and hepatic regeneration (Finnie and Jago, 1985; Berry et al.,  1982) with vacuolation 
in the CNS may also be seen (Berry et al.,  1982).  
1.2.9 Detection and Diagnostic Strategies for ARGT 
1.2.9.1 Detection of ARGT 
Current methods to detect ARGT or predict the potential for a paddock or feed 
supplies to cause ARGT, are based on identification of either the bacterium or toxin 
as primary indicators.  The first and most extensively used method relies on the 
Enzyme-Linked Immunosorbent Assay (ELISA)-based detection of water-soluble 
antigens specific to R. toxicus (Masters et al.,  2006).  The second and third 
approaches indirectly or directly target corynetoxins rather than the bacterium.  A 
bacterial inhibition assay (Stynes and Vogel, 1983; Riley and Ophel, 1992b) 
indirectly estimates corynetoxin levels by assessment of the bioactivity of 
corynetoxins.  However, antibacterial activity is not specific to corynetoxins.  Direct 
assays for detection of the corynetoxins include high performance liquid 
chromatography (HPLC) with peak detection by UV absorption (Cockrum and Edgar, 
1985), mass spectrometry (Anderton et al.,  2004) and a corynetoxins ELISA (Than et 
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al.,  1998).  Analysis of extracts using HPCL are impractical for handling field 
samples routinely as the procedure is expensive, time-consuming allowing only 
relatively small numbers of samples to be processed and is non-reproducible when 
very low levels of toxin are present.  Further, mass spectrometry (Anderton et al.,  
2004)  is also a time consuming processes and expensive for routine screening use.  
The new direct test allows large numbers of feed samples to be tested at once, 
reducing the cost and time required for a result.  If evaluation demonstrates that the 
test is applicable and robust, the test may become commercially available to farmers 
through state analytical laboratories [P. Vogel, unpublished data].  
Whilst any of the current methods, in combination with clinical signs in livestock, can 
be used to confirm the presence of toxin or bacteria, the predictive application is still 
problematical [ARGT Workshop, El Cabello Blanco, Western Australia, November 
2002]. 
1.2.9.2 Diagnosis of ARGT  
The capacity of current diagnostics to detect and confirm Corynetoxin exposure in 
suspect livestock is severely limited, predominantly due to the cumulative nature of 
corynetoxins; wherein prolonged sub-lethal exposure (potentially causing irreversible 
damage before the manifestation of overt clinical symptoms) is completely 
undetectable based on current diagnostic strategies.  In particular, sheep and cattle can 
apparently ingest up to ¾ of a lethal dose and still appear clinically unaffected.  
Compounding the difficulty in diagnosis is the reported lag time between ingestion of 
a lethal dose and the onset of clinical signs [Meat and Livestock Australia, 2003]. 
There is no definitive test to diagnose ARGT in livestock.  Currently, diagnosis of 
ARGT is based on (1) characteristic clinical signs, (2) history of exposure to annual 
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ryegrass in pasture or hay, and (3) traditional toxicity endpoints including: clinical 
pathology, histopathology and clinical chemistry (Chapman, 1989; Stewart and May 
1995).  In addition, confirmation should also include demonstration of bacterial galls 
in the pasture or fodder to which stock had access to using the detection techniques 
described above.  Furthermore, a through history and evaluation of contents of the 
pastures often assists in differentiation of ARGT from other similar diseases.   
A presumptive diagnosis of ARGT can be sometimes made on the basis of the 
characteristic clinical signs.  However, clinical signs displayed as a result of ARGT 
exposure have proven to be often varied and not necessarily specific and/or sensitive 
for ARGT.  In particular, clinical signs exhibited by affected livestock such as 
convulsions, tachycardia and incoordination can be mistaken for other diseases that 
cause similar clinical signs, including: mycotoxicosis, ergot poisoning, phalaris and 
ryegrass staggers (McIntosh et al.,  1967).  Furthermore, the appearance of clinical 
signs is believed to manifest only after exposure reaches an acute level which often 
coincides with the onset of the terminal stages of disease progression (Richards, 
1982).  Therefore, diagnosis based on clinical signs is only of limited value. 
Pathological examination to identify evidence of liver and other organ damage post 
mortem has been routinely used to diagnose ARGT.  However (as described in Sect: 
1.2.8), it is the experience of diagnostic pathologists that often the macroscopic and 
microscopic pathology of ARGT is neither significant nor consistent, nor necessarily 
specific. Several animals may need to be examined to see the full range of changes 
reported for this disease and pathological damage is only usually evident with acute 
level exposure.   
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Alternatively, biochemical tests of liver function based on serum chemistry have also 
been used as diagnostic indicators of ARGT.  In clinically affected live animals, 
damage to the liver is often reflected in elevated levels of liver specific enzymes 
including: aspartate aminotransferase (AST), total bilirubin and bile acids.  A number 
of studies have evaluated the abovementioned serum chemistry for possible 
correlations with ARGT (Berry and Vogel, 1982; Davies et al.,  1995; Davies et al.,  
1993; Finnie and Jago, 1985; Jago and Culvenor, 1987; Stewart and May, 1994). It 
has been demonstrated however, that measuring the activities of these markers, are 
similarly problematic as they have been demonstrated to lack sensitivity, specificity 
and consistency (Jago and Culvenor, 1987; Stewart and May, 1995).  The direct 
inhibition of GPT by tunicaminyl-uracil toxins (as described in Sect: 1.3.4) has been 
reported as an effective and highly specific dose-dependent indicator of ARGT 
(Stewart and May, 1994).  Results have demonstrated that liver microsomal GPT is 
the most sensitive indicator of in vivo exposure to tunicamycins (Stewart et al.,  
1998).  Collection of a liver biopsy and assay for liver microsomal GlcNAC-P-1 
transferase provides a very specific diagnosis of TMU poisoning as the transferase is 
profoundly inhibited in ARGT and can be measured.  However, this approach is not 
practical as a useful diagnostic to be routinely applied in the field, as liver biopsies are 
required which are clearly difficult and expensive to perform, and stressful to animals 
involved (Stewart, 1998).  Further, once biopsy samples are collected they must be 
stored to prevent degradation due to autolysins in tissues which may prove a difficulty 
with in-field collection. 
As a result, both the cumulative nature and lethality of corynetoxins has significantly 
impeded diagnostic efforts and has proven a major challenge in the control and 
prevention of ARGT.  New, improved methods with enhanced sensitivity and 
Chapter 1 
  23 
specificity for detection and rapid screening of low level chronic Corynetoxin 
exposure are required. 
1.2.10 Treatments 
There appears to be currently no satisfactory treatment, practical vaccine against, nor 
antidote for the toxin for ryegrass toxicity in livestock.  Over the years, various 
chemotherapeutic agents have been investigated as a form of treatment for ARGT-
affected animals, without any success.  Oral cobalt administration was the first 
prophylactic treatment investigated for its ability to protect against ARGT.  The use of 
cobalt for treatment of ARGT was based on its previous use for prevention of the 
onset of clinical signs associate with Phalaris staggers (Lee and Kuchel, 1953).  A 
second study by Davies et al., (1995) reported that cobalt treatment enabled sheep to 
consume 30% more toxin prior to exhibiting clinical signs, however no outright 
protection against ARGT was achieved.  Several other experimental chemical 
treatments including: chlordiazepoxide (Richards et al.,  1979; Norris et al.,  1981) 
and magnesium sulphate (Epsom salts) (Richards, 1982) have also been tested in both 
pen and field trials, but none has proved sufficiently successful to warrant continued 
use. 
A study by May and Stewart (1998) reported using derivatives of beta-cyclodextrin as 
a toxin-binding antidote in protection studies as a potential treatment for ARGT.  The 
study evaluated the ability of hydroxypropyl-β-cyclodextride (HPβ-CD) to ameliorate 
the clinical condition of sheep exposed to tunicamycin.  Results indicated that a 
significant increase in survival was observed in sheep exposed to tunicamycin, 
suggesting that this formulation may have potential as an effective in-field treatment 
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for sheep and, as such, warrants further testing in field outbreaks of ARGT (May and 
Stewart, 1998).  A field evaluation of the formulation is yet to be published. 
The normal disease course of ARGT provides an opportunity for a treatment 
(antidote) to be administered during the movement of animals from toxic to non-toxic 
areas.  However, up until now no specific treatment has proven practical.  Currently, 
the best way to manage affected stock is their removal to a “safe” paddock with good 
water, safe feed and shade.  Affected and unaffected livestock should be maintained 
in separate paddocks, so that any further toxic paddock is quickly identified by a new 
outbreak.  Drenching 1-2L of water per day to affected sheep has proven beneficial as 
animals showing episodic convulsions tend not to drink and can become dehydrated.  
If they are carefully drenched with water to prevent dehydration their chances of 
survival will improve.   
1.2.11 Prevention Strategies 
There are three main strategies currently in practice for the prevention of ARGT.  
These include: biological control of the causative organisms, pasture and livestock 
management and regular sampling of pastures to assess their degree of toxicity. 
It has been suggested that the best long term "clean and green" method to prevent 
outbreaks of ARGT is to control the causative organisms by use of biological control 
agents.  The possible application of a biological agent for the control of ARGT was 
first proposed in 1981 (McKay et al.,  1981).  Several potential biological control 
agents have been identified, the most promising of which is a naturally occurring 
plant-parasitic organism known as the twist fungus (Dilophospora alopecuri) 
(Atanasoff, 1925; Bird and McKay, 1987; McKay et al.,  1981).  The twist fungus 
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presence was demonstrated to lead to a dramatic reduction in the number of 
nematodes present in the ryegrass seed heads (McKay et al.,  1981).  The twist fungus 
was shown to be able to invade the ryegrass seedhead via the production of spores 
that adhere to A. funesta, allowing it to be vectored into the plant (Bird and McKay, 
1987).  An inoculum of the fungus was developed by the Department of Agriculture 
and Food and was first used in 1997.  The twist fungus inoculum is now available 
through Biological and Resource Technology Pty Ltd under license from the 
Department of Agriculture.  Interestingly, D. alopecuri is now common near 
Gnowangerup in Western Australia [I.T. Riley, personal communication] where the 
incidence of ARGT has declined (Pink, 1989).  It is unclear at this stage, however 
whether the bacterial population has declined as a result of management strategies 
adopted by farmers or whether the fungus has displaced the bacterium. 
Pasture management procedures including: cropping, spraying, burning or grazing 
prior to maturation of the ryegrass has been used to reduce the numbers of bacterial 
galls and control seed-head set.  Stynes and Wise (Stynes and Wise, 1980) 
demonstrated that burning of pastures in autumn reduced the number of bacterial galls 
colonised by R. toxicus in subsequent pastures by up to 85 %.  Similarly Price (Price, 
1973) suggested that ryegrass may be controlled by hard grazing to reduce seed set 
and remove infected tillers.  Herbicides have also been used at or after anthesis to 
prevent seed set and gall development, as ARGT appears to only develop when 
sufficient infected ryegrass seed heads are allowed to approach maturity.  However, 
recent concerns with the widespread use of herbicides for this purpose have arisen as 
these herbicides have been shown to cause a reduction in pasture productivity and an 
emergence of herbicide-resistant ryegrass populations in the cropping belts of 
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Western Australia, with the numbers of farms affected increasing each year (Suzuki et 
al.,  1996).  A feature of these populations is that they can develop cross resistance to 
different chemical groups (Powles and Matthews, 1992). The ineffectiveness of 
selective herbicides on these populations will make control of ARGT more difficult 
with stockowners now encouraged not to rely on selective herbicides (McKay and 
Ophel, 1993).  Furthermore, regular monitoring of grazing animals between 
November and March, when pastures may be toxic, has also been recommended to 
ensure the number of affected livestock are kept to a minimum (McKay et al.,  1981) 
and removed as previously described.   
Regular sampling of pastures to identify infected fields and determine the risk of 
toxicity is also an integral practice in the prevention and management of ARGT.  
ARGT Diagnostic Services has been established to provide tests to assist stock 
owners manage ARGT (McKay and Riley, 1993).  The first available test (pre-
flowering test) is based on ELISA (enzyme linked immunosorbent assay) to detect the 
bacterium R. toxicus in ryegrass seed heads emerging from the boot when toxin 
concentrations are low.  The second test (mature ryegrass test) estimates the risk of 
stock being killed based on the concentration of both R. toxicus and A. funesta in dry 
ryegrass or hay (the mature ryegrass test).  Based on the results of these tests, farmers 
are able to make more informed decisions on where to allow stock to graze and take 
preventative measures to control the ryegrass.  A statistical study conducted by 
McKay and Riley (1993) demonstrated the utility of this test by revealing that 79% of 
sheep deaths occurred on pastures that were classified as “high risk.” 
Studies to develop a vaccine to prevent ARGT in livestock have also been reported 
(Than et al.,  1998).  There is no natural immunity to corynetoxins in the field, since 
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the glycolipid toxin is a poor immunogen.  To address this problem, Than et al., 
(1998) reported the coupling of tunicamycins as haptens to carrier proteins, thereby 
forming molecules capable of eliciting an immune response against the toxin.  It was 
identified that protection against clinical signs of toxicity correlated with antibody 
titre involving chronic and acute challenges with tunicamycin and parasitized ryegrass 
respectively.  Larger scale investigations of the efficacy of the ARGT vaccine are still 
to be investigated before this vaccine is available for therapeutic purposes. 
1.3 Corynetoxins 
1.3.1 Chemical structure and properties 
Corynetoxins are a series of glycolipid compounds (Vogel et al.,  1981) that belong to 
a subclass of nucleoside antibiotics, collectively referred to as tunic-aminyl-uracil 
(TMU) antibiotics (Figure 1.5) (Vogel et al.,  1981; Edgar et al.,  1982; Cockrum et 
al.,  1987). TMU-based compounds have very high mammalian toxicity, are 
cumulative in action and occur in nature as complexes of closely related compounds. 
The composition of each complex is characteristic of the micro-organism that 
produces it. There are currently five known naturally occurring complexes which 
include: corynetoxins produced by R. toxicus, tunicamycins, streptovirudin, 
mycospocidin and antibiotics 24010 and MM19290 produced by various different 
Streptomyces spp., (Cockrum and Edgar, 1983; Vogel et al.,  1982; Eckardt, 1983).   
Corynetoxins have molecular masses of 800-900 Daltons and have been reported as 
structurally, biochemically and toxicologically related to tunicamycins (Edgar et al.,  
1982; Vogel et al.,  1982) and to other tunicaminyl-uracil toxins (Cockrum et al.,  
1987).  Tunicaminyl-uracil antibiotics are characterised by a common structure of 
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uracil, tunicamine (a C11 amino sugar) and N-acetylglucosamine.  They differ from 
each other only in regard to the variable fatty acid chain length and terminal 
branching attached by an amide link to the amino group of the tunicamine unit (Edgar 
et al.,  1982; Frahn et al.,  1984).  A total of 16 corynetoxins have been identified with 
fatty acid chain lengths of 15 to 19 carbon atoms (Edgar et al.,  1982; Cockrum and 
Edgar, 1983; Payne et al.,  1983; Jago et al.,  1983; Frahn et al.,  1984).  TMU toxins 
are in themselves multi-component toxins, representing several toxin congeners.  
Hence, many studies have referred to the toxins in the plural form of the noun (i.e. 
corynetoxins, tunicamycins etc) as has been done in this thesis.   
1.3.2 Bi oequivalence of Corynetoxins and Tunicamycin 
Several studies have demonstrated corynetoxins and tunicamycins to have similar, if 
not identical mechanism of action (Finnie and Jago, 1985).  Much information on the 
toxicity of corynetoxins is derived from studies using tunicamycins as an 
experimental substitute.  Jago et al., (1983) reported both toxins to have similar 
antibiotic activity against Newcastle disease virus and a range of Gram-positive 
bacteria. It was also demonstrated that pretreatment of rats with both toxins resulted in 
similar dose- and time-related reduction in the level of activity of transferase in liver 
microsomal preparations (Jago et al.,  1983; Vogel et al.,  1986).  Further, 
corynetoxins and tunicamycins have also been reported to exhibit similar toxicities for 
nursling rats (Jago et al.,  1983) and cause similar similar clinical disease in sheep 
(Jago and Culvenor, 1987; Finnie and Jago, 1985). 
The effects of corynetoxins and tunicamycins on rat liver hepatocytes cultured in vitro 
have been reported separately (Finnie, 2001; Yeoh et al.,  1984).  Although 
similarities in cytopathic effects of both toxins have been described, a side-by-side 
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comparison of in vitro tunicaminyl-uracil exposure has not yet been published prior to 
studies reported in this thesis. 
1.3.3 Tunicamycins as an experimental model for ARGT 
The use of tunicamycins to experimentally model corynetoxins is based on the 
abovementioned experimental evidence suggesting both toxins are biologically 
equivalent and the routine accessibility of tunicamycins.  Tunicamycins are a 
commercially available antibiotic which is readily available through a laboratory-
based strain of Streptomyces lysosuperficus (Takatsuki et al.,  1971).  In contrast, the 
availability of corynetoxins is severely limited and attempts to induce significant in 
vitro production in R. toxicus were largely unsuccessful (Payne and Cockrum, 1988).  
Presently the only way to source corynetoxins, albeit in minute (μg) quantities is from 
toxic ryegrass seedheads from the field, or from contaminated fodder requiring a 
complex extraction procedure that is not only difficult and costly, but associated with 
significant health and safety risks (Yeoh et al.,  1984; Anderton et al.,  2004).  
1.3.4 Actions of Tunicaminyl-uracil Toxins 
1.3.4.1 Protein  N-glycosylation 
Tunicaminyl-uracil (TMU) toxins cause specific and potent inhibition of lipid-linked 
N-glycosylation of glycoproteins (Vogel et al.,  1981; Edgar et al.,  1982; Cockrum 
and Edgar, 1983; Jago et al.,  1983; Frahn et al.,  1984).  These toxins specifically 
inhibit the enzyme UDP-GlcNAc: dolichol-P-GlcNAc-1-P transferase, which 
catalyses the initial step in oligosaccharide assembly on dolichol phosphate, a lipid 
carrier involved in N-glycosylation of protein (Heifetz et al.,  1979).  In the presence 
of sufficient amounts of tunicaminyl-uracil toxin, this lipid-linked oligosaccharide 
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cannot be formed and consequently proteins are not glycosylated.  Inhibition of 
protein glycosylation has been suggested as the major factor in the biochemical 
pathogenesis of ARGT. 
Many proteins are glycosylated, that is they are covalently linked to oligosaccharide 
side chains as part of their molecular structure.  It has become increasingly clear that 
oligosaccharide side chains play a critical role in protein structure and function 
(Rademacher et al.,  1988).  Since glycoproteins are widely distributed in tissues, are 
involved in many important biological processes with a myriad of functions, the 
potential effects of TMU toxins in animals are diverse (Schwartz and Datema, 1982; 
Olden et al.,  1982; Elbein, 1987).  Potential targets of inhibition of glycoprotein 
synthesis include a wide range of enzymes, hormones, and membrane structural 
elements and receptors distributed throughout the body.  For many proteins, 
glycosylation is necessary for their secretion, membrane insertion, or maintenance of 
molecular conformation and stability (Peterson et al.,  1996).   
Approximately 90% of mammalian brain glycoproteins are comprised of the N-
asparagine type and it is possible that any change in their glycosylation pattern could 
lead to disruption of tight junctions between vascular endothelium allowing protein 
and erythrocyte leakage.  Tunicamycin has been demonstrated to cause apoptotic 
death of neurons from sympathetic ganglia (Chang and Korolev, 1996) and the 
cerebellar granular layer (Chang et al.,  1997), suggesting a vital role for N-
glycosylation in neuronal survival (Lin et al.,  1999).  Scattered vacuolation of 
neurons have also indicated a direct cytotoxic effect of corynetoxin (Berry et al.,  
1980b).  Therefore, the underlying basis of toxicity observed in ARGT, particularly 
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neurological effects, may be due to the lack of essential N-glycosylated glycoproteins 
(Jago et al.,  1983).   
1.4 Genomics 
The term “Genomics” is used to encompass many different technologies, all of which 
are related in some way to the information content of a cell (i.e. its DNA or RNA). 
This is based on the central dogma of molecular biology in which genes are encoded 
in DNA are copied into messenger RNA (mRNA), which is translated into functional 
proteins.  The study of genomics first emerged in the early 1980s, but became more 
prevalent in 1990s with the initiation of genome projects for several biological 
species.  Technological advancements combined with intensive DNA sequencing 
efforts have generated an enormous database of sequence information over the past 
decades.  Genome projects continue to produce gene sequence information at an 
accelerating rate.  As of September 2007, approximately 1879 viruses sequences were 
complete [The Viral Genomes Resource, NCBI Friday, 14 September 2007], 577 
bacterial species and approximately 23 eukaryote organisms, of which about half are 
fungi [Genome Project Statistic, NCBI Friday, 14 September, 2007].  The knowledge 
of complete genomes has created the possibility for the field of functional genomics, 
mainly concerned with patterns of gene expression during various conditions.   
To exploit more fully the wealth of new sequence information, it was necessary to 
develop novel methods for the high-throughput or parallel monitoring of gene 
expression.  Established methods such as northern blotting, RNAse protection assays, 
S1 nuclease analysis, plaque hybridization and slot blots, fail to provide sufficient 
throughput to effectively utilize the new genomics resources.  Gene microarray 
technology was developed as a way to simultaneously monitor the expression of large 
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numbers of genes within cells or tissues on a genome-wide scale presenting a possible 
solution to this bottleneck (Chee et al.,  1996; Schena et al.,  1995; Shalon et al.,  
1996).   
1.4.1 M icroarray Technology 
The rapid and highly publicised development of microarray technology during the 
past ten years has led to a proliferation of potential applications.  DNA microarray 
technology has already had and continues to have a major impact on many different 
areas, particularly toxicology.   
Almost without exception, gene expression is altered during toxicity, as either a direct 
or indirect result of toxicant exposure.  These changes can be detected and quantities 
of the relevant messenger RNAs (mRNAs) in cells measured to study toxicity.  
Alterations in gene expression can be seen earlier and at significantly lower doses 
before the development of a toxic pathological response (Harris et al.,  2004).  While 
it may take weeks, months, or even years before some traditional toxicological 
endpoints occur, specific changes in mRNA levels can occur within a few hours or 
days after exposure to chemical compounds.  In many cases, these changes in gene 
expression are a far more sensitive, characteristic and measurable endpoint than the 
toxicity itself (Nuwaysir et al.,  1999).   
Microarray technology offers an ideal platform for toxicological-based analysis and 
offers a new approach to identify novel candidates genes, biomarkers, stressor-
specific signatures, and stress modulated molecular pathways.  Various studies 
indicate that analysis of gene expression changes caused by toxic substances is a 
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highly sensitive method of toxicity analysis (Uehara et al.,  2006; Hirode et al.,  
2008).   
Generally, microarray approaches involve a solid phase platform (array) prepared 
with DNA sequences (targets) specific for the genes of interest to the study.  
Sequences can be a few genes for a specific pathway, organ, or whole genome.  The 
probes can be short sequences of nucleotides (oligonucleotides) or sections of 
complementary DNA (cDNA).  Routinely, a microarray assay involves extraction of 
RNA from the cells or organs of interest, amplification of RNA using PCR and 
labelling with, for example, biotin.  The amplified and labelled RNA is hybridised to 
a gene chip where the RNA molecules bind to the complementary DNA.  A tracer is 
then added that binds to the labelled RNA and this is quantified for each gene using, 
for example fluorescence.  Mathematical analysis is used to identify patterns in gene 
up regulation or suppression. 
1.4.1.1 Array  platforms 
Currently, there are two major platforms of nucleic acid microarrays.  The first, 
commonly referred to as the complementary deoxyribonucleic acid (cDNA) 
microarray, consists of probes (usually amplified cDNAs or PCR products) attached 
to a surface such as a nylon membrane or glass substrate (Schena et al.,  1995; Heller 
et al.,  1997; Brown and Bolstein, 1999; Duggan et al.,  1999; Gerhold et al.,  1999; 
Hu et al.,  2002).  The other platform, referred to as the oligonucleotide array, utilizes 
synthetically derived oligonucleotides (oligos) spotted onto a surface via in situ 
synthesis of oligos (Fodor et al.,  1991; Maskos and Southern, 1992; Nanthakumar et 
al.,  2000; Singh-Gasson et al.,  1999; Gao et al.,  2001; Butler et al.,  2001)  or 
deposition of prefabricated oligos (Iyer et al.,  1999; Perou et al.,  2000; Bittner et al.,  
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2000; Hughes et al.,  2001; Lockhart et al.,  2000; Wildsmith SE, 2000) onto the 
desired substrate.  In addition, CombiMatrix Custom Array™ Platforms are also 
available which use a unique system for the in situ synthesis of oligonucleotide 
probes directly on the chip made to your specifications. This allows changes to chip 
designs and layouts easily with sensitivity of microarray maximised (Nittler et al.,  
2005) and (Wells et al.,  2006). 
There are several advantages and disadvantages to both commonly used microarray 
platforms (Gabig and Wegrzyn, 2001; Schulze and Downward, 2001; Zarrinkar et al.,  
2001; Blohm and Guiseppi-Elie, 2001; Firestein and Pisetsky, 2002; Burgess, 2001; 
Gabig and Wegrzyn, 2001).  In general, cDNA microarrays use a multicolor strategy 
of labeling several different targets, allowing for comparison of relative expression 
changes among different samples to be performed on a single array (Heller et al.,  
1997; Brown and Bolstein, 1999; Duggan et al.,  1999; Gerhold et al.,  1999; Hu et 
al.,  2002).  This is a powerful advantage of being able to compare two different 
samples in the same hybridization without worrying about experimental variables 
such as differences among arrays and hybridization conditions (Shalon et al.,  1996).   
However, problems with the fluorescent labels arise, including different hybridization 
kinetics, different efficiencies of incorporation, different half-lives, and spectral 
overlap between dyes, all of which can affect differential expression results 
(Wildsmith and Elcock, 2000; Wang et al.,  2002; Cheung et al.,  1999).   Other issues 
with the cDNA platform include probe generation, quality control, and 
standardization. Clone generation and PCR amplification must be performed 
continually, as one has to conduct a new reaction and purification to replenish 
amplicon supply.  Furthermore, sources of DNA and clones require laborious tracking 
and quality checking (Hu et al.,  2002; Taylor et al.,  2001).  Lastly, cDNA arrays 
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require rigorous standardization methods, and even though universal references are 
used as controls, the search still continues for improved reference standards (Weil et 
al.,  2002). 
Oligonucleotide arrays are considered to be more reproducible and predictable than 
cDNA arrays (Huang et al.,  2001). Therefore, one can use single-color labeling 
techniques, whereby gene expression comparisons are made by performing ratio 
analysis between different samples run on independent arrays, with greater 
confidence.  Furthermore, several oligonucleotides can be designed to serve as 
internal standards used to compare expression results from different experiments.  
Oligonucleotide probes offer greater specificity than cDNAs or PCR products, in that 
they can distinguish between closely related members of gene families, discern splice 
variants, and allow for analysis of single nucleotide polymorphisms (SNPs) (Hughes 
et al.,  2001; Wildsmith and Elcock, 2001; Hu et al.,  2002; Guo et al.,  1994).  When 
sequence information is available, oligonucleotides can be designed to hybridize 
specifically to each gene in the target sample.  A major advantage of the deposition-
type oligonucleotide arrays is that stringent quality control measures, confirming the 
fidelity and purity of the synthesized oligos, can be performed prior to array 
manufacturing. 
Although these are the two most common types of microarrays, advancements 
continue to be made to all types of microarrays, including improvements to array 
surfaces (glass, silicon, gold, three-dimensional gel matrix), fluorescent labeling, 
detection methods, number of spots on the arrays (high-density arrays), printing 
technologies (non-contact and contact), and experimental hybridization procedures 
(Hughes et al.,  2001; Shalon et al.,  1996; Lipshutz et al.,  1999; Edman et al.,  1997; 
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Bowtell, 1999; Meiyanto et al.,  2001; Pividori et al.,  2000; Okamoto et al.,  2000; 
Meiyanto et al.,  2001). 
Gene expression profiling using DNA microarrays is a complex procedure with each 
single step in the entire process from RNA purification to data extraction potentially 
increasing the variability of the results.  Common sources of variation within 
microarray systems are varying RNA quality and cDNA synthesis efficiency, dye-bias 
in using two colour fluorescence dye labelling systems, inconsistent hybridisation 
conditions due to poor temperature control and inadequate mixing or distribution of 
the hybridisation solution.  Since the primary objective in microarray studies is to 
accurately detect differences in gene expression levels, variations due to the 
technology should be kept to a minimum.  
A variety of commercial array platforms are commonly available and have been 
extensively utilised in a range of microarray applications.  It has been reported that 
commercially available microarrays provide significant advantages in terms of 
offering superior quality arrays which can be purchased “ready to use”, are 
reproducible and optimized for detection having gone through extensive and stringent 
manufacturing quality control and combined with well-designed analysis control 
systems aimed to reduce these technical variations.   
Commercial arrays are available in high density and low density platforms. Low-
density (LD) array platforms generally comprise a few hundred genes, while high-
density (HD) arrays may contain probes specific for thousands of target genes 
potentially covering entire genomes.  High-density (HD) arrays have the advantage of 
studying thousands of genes simultaneously, giving a global view of the changes 
occurring in cells.  However, potential problems with cross-hybridisation and 
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background have been recognised with HD arrays (Nuwaysir et al.,  1999).  Other 
major drawbacks are related to the high cost and time taken for analysis and 
interpretation of data.  In general, in vivo studies using global gene expression 
profiling platforms are considered to have the highest chance of uncovering 
unexplained or uninterpretable toxicogenomic data (Castle et al.,  2002).   
Low-density (LD) commercial arrays are considered more suitable for routine 
applications due to their simplicity, good reproducibility, easy data management and 
low cost (Zammatteo et al.,  2002).  A variety of LD “toxicology arrays” are now 
available from several commercial vendors, consisting of genes with demonstrated or 
presumed relevance to toxic responses.  Several studies have demonstrated the high 
utility of LD arrays in toxicological studies, as they offer the ability to rapidly study 
gene expression changes following toxin exposure (de Longueville et al.,  2002).  
However, fewer studies have been carried out using LD arrays as compared to HD 
array platforms (de Longueville et al.,  2003).  Further, it has been suggested that 
limiting the number of genes represented on a DNA microarray yields more accurate 
and unambiguous results.  Castle et al., (2002) suggested that the least amount of risk 
is expected with in vitro studies, in vivo or in vitro systems that use a targeted 
approach in which only a few genes of known function are measured using low-
density platforms.  
1.4.2 T oxicogenomics 
Toxicogenomics is an emerging and evolving technology made possible by the advent 
of DNA microarray.  Toxicogenomics has been defined as the study of gene 
expression changes in biological samples exposed to toxic agents to discover specific 
expression patterns that can be related to toxicological endpoints (Lee et al.,  2005).  
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Toxicogenomics can also be defined as the measurement of global gene expression 
changes in biological samples exposed to toxicants (Orphanides, 2003) or as the study 
of the response of the genome to toxic agent exposure (Marchant, 2003) 
Toxicogenomics offers extreme sensitivity with the potential for detection of 
subclinical exposure (Nuwaysir et al.,  1999).  Application of toxicogenomics to 
toxicology as a diagnostic parameter for toxicity screening holds the promise of far 
surpassing traditional approaches in terms of predictive potential, sensitivity and 
speed (Burczynski et al.,  2000).  Toxicogenomics has been reported to provide more 
sensitive, immediate and comprehensive markers of toxicity than typical toxicological 
approaches (Marchant, 2003).  Gene expression analysis using toxicogenomics can 
allow for earlier detection of a toxic insult, at significantly lower doses which are 
insufficient to trigger obvious toxicity detectable by conventional endpoints.   
Toxicogenomics is reported as a powerful tool for compound classification, for 
mechanistic studies, and for the detection of toxicity markers.  Presently, there are 
many groups worldwide applying toxicogenomic studies on large scale.  In particular, 
the US National Institutes of Environmental Health Sciences Microarray Group has 
been using microarrays to analyze changing patterns of gene expression across the 
entire genome, studying thousands of affected genes at a time and revolutionizing the 
way that toxicological problems are investigated (The National Center for 
Toxicogenomics, 2004).  Furthermore, toxicogenomics has been used extensively to 
identify biomarkers of exposure to potentially toxic drugs and xenobiotics. 
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1.4.3 Liver   
The liver, or more specifically hepatocyte cultures, are a promising target and well 
suited to toxicogenomic studies.  The liver is often useful for toxicogenomic analysis 
as it is a major stage for toxic events and drug-induced hepatotoxicity and displays a 
certain level of metabolic activity (Waring and Ulrich, 2000). Further, the liver is 
often useful for gene expression analysis as whole-body toxic events can be detected 
by measuring gene expression changes in a single organ. 
The application of toxicogenomics to investigate hepatotoxicity, in particular, 
identification of gene expression profiles and/or biomarkers to detect early stage pre-
clinical toxicity is supported by many published studies (Harris et al.,  2004; Huang et 
al.,  2004; Heinloth et al.,  2004; Steiner et al.,  2004; Ulrich et al.,  2004).  In 
particular, a study by Waring et al., (2001) revealed a strong correlation between the 
histopathology, clinical chemistry and gene expression profile induced by 15 known 
hepatotoxicants on cultured primary rat hepatocytes.   
1.4.4 Bi omarkers 
Biomarker discovery holds much promise for providing important tools for the pre-
clinical detection of toxicity.  An ideal biomarker must have a degree of clinical 
sensitivity and specificity to be of greatest value and should provide an indication of 
potential toxicity at times or doses preceding overt tissue damage, toxicity, or disease 
initiation.   
Toxicogenomics, in particular DNA microarrays, is an extremely powerful tool for 
identifying potential biomarkers of toxicity.  Toxicogenomics with its enormous 
investigative power promises to be particularly useful in accelerating biomarker 
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discovery.  In particular identifying, characterizing and developing new biomarkers 
rapidly, leading to sensitive, specific, reproducible, predictive assays, to replace 
conventional methods (Gundert-Remy et al.,  2005).   
The utility and feasibility of toxicogenomics in biomarker discovery has been 
reported in many studies delineating chemical-induced toxicity, including 
hepatotoxicity leading to the identification of many promising biomarkers 
(Burczynski and Dorner, 2006; Heinloth et al.,  2004; Steiner et al.,  2004; Bushel et 
al.,  2007; Hegele, 2007; Pecheniuk et al.,  2008; Man et al.,  2008).  In particular, 
Bushel et al. (2007) published gene expression signatures that predict exposure to 
harmful levels of acetaminophen in the rat model and reported these gene-based 
measurements were more accurate than classical clinical pathology and 
histopathology assessments.   
The strength of toxicogenomics (as discussed above) is that it offers the potential to 
detect pre-clinical effects of toxicity in the form of marker genes for which traditional 
biochemical tests are incapable due to low sensitivity and specificity.  There are 
significant benefits associated with the identification of biomarkers specific to pre-
clinical exposure of corynetoxins.  Ultimately, the development of a detection test for 
pre-clinical exposure to corynetoxins may allow the development of early prediction 
tests for ARGT to alert farmers of subtle changes prior to organ dysfunction or 
damage and may facilitate improved control and prevention strategies for ARGT.  
Identification of pre-clinically exposed livestock may assist in reducing the risk of 
lethal toxicity by the immediate identification of pastures likely to be toxic which 
would enable direct action to be taken to prevent any continued or new exposure to 
those toxic areas. 
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1.4.5 In vitro models for Toxicogenomic studies 
A great deal of interest exists for the development of in vitro-based toxicogenomic 
methods.  In particular, there has been an increased demand for the development and 
refinement of predictive in vitro high-throughput toxicity screening assays that can be 
used as an alternative to traditional in vivo testing.  The development of in vitro 
systems for toxicological experimentation has been highlighted as a scientific priority 
as a result of considerable pressure from public and regulatory authorities to minimise 
the use of animals in testing and to facilitate acceptance of alternative testing methods 
(Abbot et al.,  2005).  
In vitro systems are recognised as providing significant advantages over traditional in 
vivo experiments for toxicological research.  In particular, in vitro systems are 
considered to be a cost effective alternative, amenable to high-throughput screening, 
are inherently more simplified and offer better controlled experimental conditions 
when compared to in vivo experiments (Dere et al.,  2006).  Furthermore, isolation of 
biopsies and other biological material (in particular liver cells) for toxicological 
investigations is not always feasible for ethical or practical reasons.  Moreover the 
biological material available can be insufficient to perform the required investigations 
and it may not always be possible to obtain or synthesise sufficient amounts of 
compounds to test.  As discussed (Sect 1.3.3), the problem of insufficient quantities of 
biological material to perform relevant investigations has been a significant difficulty 
when investigating corynetoxins and as such the development of an in vitro model to 
overcome this problem has been demonstrated in this thesis. 
Therefore, various in vitro hepatic models including perfuse liver, precision cut liver 
slices, isolated primary liver cells and a number of immortalised liver cell lines have 
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been used as animal alternatives for many early phase toxicological studies (Boess et 
al.,  2003).  
As discussed above, hepatocyte cultures are well suited for toxicogenomic studies 
because they display a certain level of metabolic activity and the liver is a major stage 
for toxic events (Waring and Ulrich, 2000).  Continuous hepatocyte cultures have 
been shown to retain many liver specific characteristics and have become a useful 
indicator of toxic exposure using toxicogenomics (Huang et al.,  2001).  In particular, 
continuous hepatic cell lines (HepG2, Clone-9 and BRL3A) (Burczynski et al.,  2000; 
Dere et al.,  2006) and isolated primary hepatocytes (Waring et al.,  2001; Harris et 
al.,  2004; Baker et al.,  2003) have been used extensively to identify gene expression 
changes in response to various toxin stimuli.  Some reports have demonstrated a good 
correlation in gene expression data between in vivo and in vitro models.  In particular, 
Baker et al., (2003) demonstrated that hepatocytes treated with PPARα agonist 
fenofibrate produced gene expression changes characteristic of the in vivo response in 
rat liver.  The data revealed remarkable similarities in both the affected biological 
pathways and the rank-order magnitude of the response.  Furthermore, rodent in vitro 
hepatic systems are currently the experimental model of choice for predictive 
toxicology, especially in early phase development. 
1.5 PROJECT AIMS 
As highlighted in the Introduction, the capacity of current diagnostic and detection 
systems to predict and effectively monitor ARGT potential both in the field and 
within livestock is severely limited by factors, including: the cumulative effect of the 
toxin sub-clinically; bacterial presence not necessarily indicative of toxicity; and 
molecular triggers for toxin production remaining largely undefined.  Furthermore, 
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current diagnostic and detection strategies have been primarily based on traditional 
toxicological approaches which do not offer the sensitivity or specificity required for 
effective detection and monitoring of ARGT, especially pre-clinical exposure.   
Molecular-based technologies offer improved strategies for detection and monitoring 
of ARGT with far greater sensitivity, specificity and speed, at significantly lower 
levels undetectable by conventional endpoints. 
The overall objective of this presented investigation was to develop new sensitive 
molecular approaches for improved detection, monitoring and prediction of ARGT 
(particularly low level exposure) in both the field and within livestock.  Two distinct 
strategies based on detection of molecular indicators of toxicity were applied to 
address this primary aim.   
The first strategy is addressed in Chapter 2 and involves molecular detection of 
known, or in the case of the phage, suspected, factors contributing to ARGT in the 
field.  The second strategy addressed in Chapters 3, 4 and 5 involve development of 
an in vitro toxicogenomic system for detection of molecular biomarkers of exposure 
to ARGT in livestock. 
The primary aim of the first strategy was to develop a rapid and comprehensive 
molecular-based detection system to identify the presence of R. toxicus and its 
associated phage in the field.  The initial step was to investigate the host-phage 
interaction and ecology of R. toxicus and phage by (1) screening pasture-derived 
samples of L. rigidum to determine if a relationship exists between phage, bacterium 
and toxin presence (2) partially characterise the phage sequence to identify associated 
“signature genes” to provide insight into its role in toxin production. 
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The second strategy was aimed at developing an in vitro toxicogenomic model to 
identify genomic biomarkers of low-level exposure to ARGT.  To address this 
objective, the studies aims were: (1) To develop and validate an in vitro 
toxicogenomic model using the Eppendorf DualChip™ rat hepato to examine the 
effects of low dose tunicamycins exposure on clone-9 hepatocytes at the molecular 
level, combined with cytotoxic and morphological assessment; (2) To apply the same 
combined in vitro toxicogenomic model to investigate the bioequivalence of 
tunicamycins and corynetoxins and to examine the suitability of using tunicamycins 
as an experimental substitute for corynetoxins; and (3) To identify potential 
biomarker candidates that may act as early predictors of pre-clinical exposure using 
the same combined in vitro toxicogenomic model. 
Ultimately, the presented investigation is aimed at developing rapid, molecular-based 
bio-assay strategies which may contribute to part of an early warning system prior to 
and during the ARGT season, alerting farmers to the first signs of threats to pastures 
and livestock and providing the information needed for more timely and effective 
prevention, control and management of ARGT. 
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Figure 1-1 The lifecycle of ARGT associated organisms   The lifecycle of ARGT associated 
organisms: Lolium rigidum, Anguina spp., Rathayibacter toxicus and possible involvement of 
bacteriophage NCPPB 3778 is not fully elucidated. Typically galls colonised by bacteria are 
bright yellow and galls containing nematodes are dark brown and significantly thicker [Bird 
et al., 1980]. 
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Figure 1-2 Phylogenetic tree derived from 16S rDNA sequences of actinomycetes containing 
DAB in their cell wall. Phylogenetic tree derived from 16S rDNA sequences of actinomycetes 
containing DAB in their cell wall . The tree was created by the neighbour-joining method and 
Knucvalues. The numbers on the tree indicate bootstrap values for the branch points [Sasaki 
et al., 1998]. 
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Figure 1-3  Colony morphology Rathayibacter toxicus Colony morphology 
Rathayibacter toxicus, characteristic flat, smooth, yellow colonies of R. toxicus grown in 
vitro on 523 M agar after 5 days culture at 26 ْC. 
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Figure 1-4  Electron micrograph of bacteriophage NCPPB 3778 associated with annual 
ryegrass toxicity. Scale bar 100 nm. 
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Figure 1-5  Generic structure of CTs including the N- acetylglucosaminyltunicaminyluracil 
core shared between the six naturally occurring tunicaminyluracil antibiotics. The fatty acid 
side chain is variable and determines the species of toxin 
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CHAPTER 2 
Development and preliminary application of molecular-
based assays for detection of Rathayibacter toxicus and a 
bacteriophage associated with Annual Ryegrass (Lolium 
rigidum) Toxicity 
2.1 Publications relating to Chapter 2 
Kowalski, M.C., Cahill, D., Doran, T.J. and Colegate, S.M. (2007)  Development and 
application of polymerase chain reaction-based assays for Rathayibacter toxicus and a 
bacteriophage associated with annual ryegrass (Lolium rigidum) toxicity.  Aus J Exp 
Agr  47, 177-183. 
Kowalski, M.C:- approximately 80 % contribution to the manuscript (performing all 
experiments and writing manuscript).  Cahill, D., Doran, T.J. and Colegate, S.M.:- all 
contributed with supervision of this work and assisted with the manuscript. 
2.2 Introduction 
Annual Ryegrass Toxicity (Stewart and May, 1994) is a severe and constant threat to 
the livestock and grain industry within Australia with outbreaks often unpredictable.  
Monitoring ARGT effectively within the field and in seed exports is vital to 
maintaining animal health and welfare, productivity and international trade.  The 
capacity of current diagnostic and detection systems to predict ARGT potential is 
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limited by a number of factors including: cumulative effect of the toxin sub-clinically; 
bacterial presence not necessarily indicative of toxicity; and molecular triggers for 
toxin production remaining largely undefined. 
Current methods to detect ARGT or predict the potential for a paddock or feed 
supplies to cause ARGT are based on identification of either the bacteria or toxin as 
primary indicators.  The first and most extensively used method relies on the Enzyme-
Linked Immunosorbent Assay (Than et al.,  2002)-based detection of water-soluble 
antigens specific to Rathayibacter toxicus (Masters et al.,  2006).  The second and 
third approaches indirectly or directly target corynetoxins rather than the bacterium.  
A bacterial inhibition assay (Stynes and Vogel, 1983; Riley and Ophel, 1992b) 
indirectly estimates corynetoxin levels by assessment of the bioactivity of 
corynetoxins.  However, antibacterial activity is not specific to corynetoxins.  Direct 
assays for detection of the corynetoxins include high performance liquid 
chromatography (HPLC) with peak detection by UV absorption (Cockrum and Edgar, 
1985) or mass spectrometry (Anderton et al.,  2004) and a corynetoxins ELISA (Than 
et al.,  1998).  Whilst any of the current methods, in combination with clinical signs in 
livestock can be used to confirm a diagnosis of ARGT, the predictive application is 
still problematical (ARGT Workshop, El Cabello Blanco, Western Australia, 
November 2002). 
Corynetoxins (as described in Chapter 1) are produced by the coryneform bacterium 
Rathayibacter toxicus (Masters et al.,  2006; Vogel et al.,  1981) which utilizes the 
nematode Anguina funesta as a vector to enable infection of the seedheads of Lolium 
rigidum (L. rigidum) (Price et al.,  1979).  Once translocated to the seedhead, the 
bacterium can outcompete its “galled” nematode vector and a “bacterial gall” results.  
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It has been established that toxin production within the bacterial gall coincides with 
the onset of senescence in Annual Ryegrass (Stynes and Bird, 1983) but the trigger 
for this switch to toxicity still remains unclear.  As previously discussed in Chapter 1, 
it has been speculated that a R. toxicus- specific bacteriophage isolated from R. 
toxicus-colonized nematode galls on L. rigidum is implicated based upon electron 
microscopic analysis, serology and anti-bacterial activity.  However, it is not clear 
how the phage potentially causes the production of the toxin, as the complicated 
glycolipid structure of corynetoxins would require an elaborate metabolic pathway to 
be expressed from the phage genome (Riley and Gooden, 1991; Ophel et al.,  1993).  
Stynes and Bird (1983) were the first to investigate a possible relationship between 
toxicity and the presence of phage particles.  They observed that phage particles 
present in galls were found only after anthesis.  The presence of particles in some 
galls but not others they believed was significant and that differences observed in 
toxicity may be reflective of the relative proportion of galls which contained these 
particles.  Riley and Gooden (1991) were the first to describe the isolation of 
bacteriophage specific to R. toxicus and suggested that this bacteriophage could serve 
as a tool for rapid identification of bacterial strains suspected of being toxigenic as 
traditional tests have not proven definitive.  In addition, Ophel et al. (1993) reported 
that R. toxicus produces corynetoxin in vitro when infected by bacteriophage NCPPB 
3778.  Ophel et al. (1993) concluded that bacteriophage presence was associated with 
the ability of R. toxicus to produce corynetoxins and suggested that toxin-producing 
strains of R. toxicus were in a phage-carrier state rather than a true lysogenic state. 
The role of bacteriophage as reservoirs of toxin genes and their involvement in 
bacterial virulence is well documented (Wagner and Waldor, 2002).  Since the 
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discovery in 1951 that the diphtheria toxin is encoded on the β-phage genome from  
C. diptheriae (Freeman, 1951), bacteriophage-encoded toxins have been found in a 
range of both Gram-negative and Gram-positive bacteria, including: E. coli, Shigella 
spp., P. aeruginosa, V. cholerae, C. tetani, C. botulinum (Boyd and Brussow, 2002).  
The mechanism for bacteriophage encoded toxicity in bacteria which leads to 
modification of bacterial phenotype has been called “lysogenic phage conversion” and 
results in expression of “prophage” genes over the lysogenic infection.  A “prophage” 
is a bacteriophage which has the ability to insert its genome as part of the linear 
structure of the DNA chromosome of a bacterium, thereby resulting in host 
acquisition of phage DNA together with genes governing toxin production (Oakey, 
2000; Boyd and Brussow, 2002; Faruque et al.,  1998; Freeman, 1975). 
Interestingly, tailed phage, in particular members of Siphoviridae are recognised 
prophage that cause toxin production in bacterial hosts.  For instance, the virulence of 
some pathogenic strains of E. coli is enhanced by the expression of Shiga toxin (stx) 
genes encoded on a resident lambdoid prophage of the Siphoviridae family (Friedman 
and Court, 2001).  Prophage in some instances can contribute ~3-10% of the 
chromosomal gene content of the host bacterium (Brussow and Hendrix, 2002).  The 
scientific value of these prophage sequences is potentially great however, detailed 
analysis in the literature is scarce.  Ultimately thorough analysis is still required to 
elucidate the role of prophage in the context of bacterial genomes. 
To date there have been no further investigations to examine the dynamics of bacterial 
and phage populations in annual ryegrass. Researchers in the past who may have 
considered developing molecular based assays to screen ryegrass for bacteriophage 
NCPPB 3778 may have been hindered through a lack of sequence analysis, gene 
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typing and/or characterisation available for this specific phage.  Further, the absence 
of conserved ribosomal regions such as 16s rRNA within bacteriophage to allow 
taxonomic characterization and identification may have also presented difficulties in 
the development of molecular based assays.  
Development of molecular based approaches to determine if a relationship exists 
between phage, bacterium and toxin presence is crucial for increasing our knowledge 
of the host-phage interaction and ecology of R. toxicus and phage in toxic fields, grain 
and livestock feed.  Furthermore, development of such assays is important for 
development of improved detection and prevention strategies, especially for sub-
clinical exposure.  
2.3 Aims  
This chapter describes the development of PCR-based assays to detect the presence of   
R. toxicus and its associated phage.  These assays were used in combination with the 
existing corynetoxin ELISA, to examine pasture-derived samples of L. rigidum for a 
correlation between the presence of phage, R. toxicus and corynetoxins. 
In order to detect the presence of the associated phage using the PCR based assay, the 
partial nucleotide sequence of bacteriophage NCPPB 3778 was determined.  Electron 
microscopy and partial characterization of this phage using comparative phage 
genomics to identify associated “signature genes” was also performed in an attempt to 
potentially elucidate the class of phage and to provide some insight into its role in 
toxin production. 
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2.4 Materials and methods 
2.4.1 Bacterial strains, bacteriophage, plasmids and growth media 
Bacterial strains, bacteriophage and plasmids used in this study are listed in  
Table 2.1.  
R. toxicus strain CS14 (NCPPB 3552) was grown and maintained on nutrient agar 
plates (523M) at 26°C according to the method of Riley and Ophel (Riley and Ophel, 
1992a).  This CS14 isolate was shown to be non-toxigenic since it was inactive in the 
antibacterial assay used to estimate levels of corynetoxins (Riley and Ophel, 1992b).   
Clavibacter tritici (C. tritici) and Curtobacterium sp. VKM Ac-1376 (gifted from Dr 
Ian Riley, University of Adelaide, South Australia) were grown and maintained also 
on nutrient agar plates (523M) at 26°C according to the method of Riley and Ophel 
(Riley and Ophel, 1992a). 
Escherichia coli (Boyd and Brussow, 2002) was cultivated in Luria-Bertani (LB) 
broth as described in Sambrook et al., (1989).  Ampicillin and tetracycline were used 
to select for E. coli transformants at concentrations of 100µg ml-1 and 12.5 µg ml-1, 
respectively. IPTG and X-Gal were used, where appropriate, at concentrations of 0.5 
mM and 40 µg ml-1, respectively. 
The bacteriophage isolate NCPPB 3778 (also gifted by Dr Ian Riley, University of 
Adelaide, South Australia) was stored at 4°C in SM buffer Sambrook et al. (1989) in 
the presence of 0.5% (v/v) chloroform.  A routine plaque assay of the phage isolate 
was used to determine the phage titre in plaque-forming units (pfu). 
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2.4.2 Transfection of R. toxicus with bacteriophage NCPPB 3778  
2.4.2.1 Liqu id culture 
A culture broth (523M media, 100 mL) of R. toxicus was maintained for 2 days at 
25°C resulting in a cellular density of approximately 108 cells/mL.  At this stage, 
approximately 1 x 105 pfu of bacteriophage isolate NCPPB 3778 were added.  The 
resultant cultures were incubated for a further 10-14 days at 25°C following the 
method of Ophel et al. (1993).  Visual inspection of the transfected cultures for signs 
of cellular debris and a clarification of the media, revealed phage-induced lysis of 
bacterial cells from 2-3 days of incubation.  
After removal of the cell debris the lysate was treated with RNase (10µg ml ml-1), 
DNase (10µg ml ml-1) and MgCl2 (10 mM) to ensure degradation of host nucleic 
acids.  NaCl (0.5 M) and PEG 6000 (10%) were added to the supernatant and phage 
particles were allowed to precipitate during overnight incubation at 4°C.  Phage 
particles were subsequently collected by centrifugation and concentrated by caesium 
chloride density-gradient centrifugation as described by Sambrook et al. (1989).  
The titre of each stock was determined by serial dilution in sterile broth and 10 µl 
drops of dilutions 10-1 to 10-8 were dispensed onto CS14 overlay plates and incubated 
for 4 days at 25  C. 
2.4.2.2 Plates 
Ten-fold serial dilutions of phage stocks were prepared.  100 µL of each phage 
dilution was dispensed into a sterile eppendorf tube and 100 µL of R. toxicus culture 
broth (approximately 108 cells/mL) was added to each tube.  The mixtures were then 
vortexed and incubated for 20 mins (min) at 26 C to allow the bacteriophage particles 
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to adsorb to the bacteria. 3 ml of 7% agarose at 47C was added to the first tube, 
vortexed gently, and immediately poured onto the centre of a labelled 523M agar 
plate.  The overlay plates were swirled gently to ensure an even distribution of 
bacteria on top of the agarose.  This was repeated with the second and subsequent 
tubes on fresh plates.   The plates were then left to stand for 5 mins at room 
temperature to allow the top agarose to harden.  The plates were then inverted and 
incubate for 2-5 days at 25 ْC.  The plates were examined for plaque development and, 
if not detected, returned to the incubator for later examination. 
2.4.3 Phage sensitivity test 
Phage stock (20 µl) was dripped onto the top middle point of a 523M agar plate.  The 
plate was immediately tilted to allow the phage stock to run down the middle of the 
plate.  Bacterial colonies of R. toxicus, C. tritici and Curotobacterium were then 
streaked separately across the phage line, moving in one direction only.  The plates 
were then incubated at 26 ْC for a further 5-7 days. 
2.4.4 Elect ron Microscopy 
Electron micrographs of the bacteriophage were taken on a bacteriophage suspension 
that had been cleared of bacterial cell debris by ultracentrifugation.  Bacteriophage 
NCPPB 3778 suspension was adsorbed onto carbon coated parlodion filmed 400mesh 
copper grids for 5 mins.  The suspension was wicked off and the grid stained for 1 
min with 2% Phosphotungstic Acid (pH 6.8), air dried and examined using Philips 
CM120 and Hitachi H7000 Transmission Electron Microscopes at 75 to 100kV. 
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2.4.5 DNA extraction and restriction analysis 
2.4.5.1 Bact eriophage 
Bacteriophage DNA was extracted from the phage-lysed R. toxicus cultures and 
purified from co-extracted R. toxicus DNA using the Mini Lambda DNA purification 
kit (Qiagen, Australia) and differential centrifugation as recommended by the 
manufacturer.  It was then tested with DNase and RNase.  It was also tested with 
various restriction enzymes including BamHI, EcoRI, HindIII and PstI using the 
conditions recommended by the supplier (Promega). 
2.4.5.2 Bact eria 
DNA was extracted from the non-toxigenic R. toxicus CS14 (NCPPB 3552) cultures 
and the closely related soil bacteria C. tritici and Curtobacterium sp. VKM Ac-1376, 
all harvested directly from agar culture plates.  A loop-full of the cultured bacterial 
cells was suspended in TE buffer (870 μL) containing Lysozyme (7.5 mg/mL; Sigma, 
Australia) and the mixture was then incubated at 37°C for 1-2 hr. The mixture was 
then briefly vortexed every 20-30 mins before the addition of 5M NaCl (20 μL), 10% 
SDS (100 μL) and proteinase K (250 μg/mL,10 μL; Sigma, Australia). Lysis was 
allowed to proceed by incubation at 50°C overnight.  Co-extracted RNA was 
degraded by treatment with RNaseA (50 μg/mL, 5µL; Sigma, Australia) for 30 min at 
room temperature.  The resultant mixture was extracted with an equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma, Australia) by vortexing the 
mixture briefly and centrifuging at 13,000 x g for 5 min.  The upper phase (ca. 200 
μL) was transferred to an eppendorf tube (1.5 mL) and the DNA was precipitated by 
addition of isopropanol (210 μL; BDH, USA).  After centrifugation (13,000 x g, 15 
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min) and removal of the supernatant, the DNA was resuspended in 70% ethanol (1ml; 
BDH, Australia) and centrifuged (13,000 x g, 5 min).  The resultant DNA pellet was 
air dried to remove residual ethanol and then dissolved in distilled water (Berry and 
Vogel, 1982).  
2.4.6 Assessment of DNA quality 
Aliquots (3 μL) of all DNA preparations were subjected to electrophoresis on 1% 
(w/v) agarose gels in 1 x TAE buffer.  After staining with ethidium bromide, DNA 
bands were visualized, for photographic recording or band-excision, on a UV 
transilluminator.  The integrity and concentrations of the DNA solutions were 
estimated spectrophotometrically at 260-280 nm (ND-1000 Spectrophotometer, 
Nanodrop Technologies, Wilmington, DE, USA). 
2.4.7 Cloning phage DNA for DNA sequence analysis 
The E. coli vector pUC19 (Progen, Australia) was used for shotgun cloning of a 
variety of restriction-enzyme-generated fragments of the bacteriophage NCPPB 3778 
genome.  Ligation mixtures were used to transform electrocompetent  
E. coli Top10F’ (Invitrogen, USA) using standard procedures (Sambrook, 1989).  
Positive selection of recombinant plasmids was performed using blue/white screening 
on plates containing X-gal and IPTG. 
2.4.8 DNA sequence analysis 
Successful recombinant plasmids were sequenced by Newcastle DNA Express 
Sequencing (Australia) using the universal M13 forward and reverse primer  
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(Table 2-2) and continued with synthetic oligonucleotides (18-mer) primers 
(GeneWorks, Australia). 
DNA sequence determination was performed with an Applied Biosystems 373A 
automated DNA sequencer.  Phage sequences were obtained by sequencing cloned 
phage DNA fragments and primer walking.  Assembly of sequences was performed 
using the Seqman program of the DNASTAR software package and CloneManager®.  
Putative open reading frames (ORF) from these sequences were determined using 
CloneManager® and compared to the GenBank database BLASTN and TBLASTN 
(Altschul et al.,  1990) programs.  Sequence alignments were performed using the 
Clustal method of the MEGALIGN program of the DNASTAR software package. 
2.4.9 P lant material 
Samples of harvest grain screenings collected in Western Australia in 1994 and stored 
at room temperature, were sieved to concentrate the L. rigidum seedheads.  Using a 
dissecting microscope to enhance the accurate identification of the characteristically, 
golden coloured bacterial galls, 72 bacterially-infected galls were selected from this 
seed concentrate. 
A collection of seventy-nine pasture-grab samples of L. rigidum was organized by  
Dr Jeremy Allen (Roberts and Bucat, 1992) in the summer of 2004/2005 from various 
areas of South West Western Australia (Figure 2-1).  These samples, each consisting 
of a random handful of ryegrass from a paddock, were collected into separate paper 
bags to avoid cross-contamination.  
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2.4.10 Extraction of Corynetoxins and DNA from plant material 
The 72 isolated galls were each steeped separately in 1% (w/v) aqueous methyl-β-
cyclodextrin solution (ca 0.5 mL) and gently shaken at room temperature for 16 h. 
Sample extracts were stored at 4ºC prior to Corynetoxin ELISA and PCR analysis for  
R. toxicus and the bacteriophage within 24 h. 
An entire seedhead was randomly selected from each of the 79 pasture-grab samples.  
Each seedhead was manually broken apart into a small container and covered with 1% 
(w/v) aqueous methyl-β-cyclodextrin solution (ca. 1 mL), shaken for 20 h at room 
temperature and stored at 4°C prior to ELISA and PCR analysis.   
2.4.11 PCR amplification  
Forward (F) and reverse (R) phage DNA primers were designed based upon a DNA 
sequence obtained from a shot-gun cloned 2.6 kb fragment derived from BamH1 
restriction enzyme digestion of the phage DNA.  The F and R primers for R. toxicus 
genomic DNA were designed based on the partial sequence of the R. toxicus 16S 
ribosomal RNA (16S rRNA) gene (Genbank accession number: D84127).  All 
primers were synthesised by Geneworks (Australia) (Table 2-2).  The PCR reactions, 
on aliquots (Berry and Vogel, 1982) of the aqueous solutions of phage and R. toxicus 
DNA, and the aqueous cyclodextrin extracts of the gall and plant material, utilized 
either a tube method or, for larger sample sets, a higher throughput 96 well plate 
(Eppendorf) method.  Thus, 50 µL of a solution containing 100µM of each primer (10 
µL), 5.5U/µL Taq (10 µL, Bioline), 10x Buffer (500µL Bioline), 25mM MgCl2 (400 
µL, Bioline), 25mM dNTPs (40µL, Bioline) in dH2O (4060) was added to the 
template (5µL) in each well.  The PCR conditions for all reactions involved 35 cycles 
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of: 94 °C for 1 min (denaturation); 55 °C for 1 min (annealing); and 72 °C for 2 min 
(extension) (Figure 2-2).  
In the application of the PCR assay to the plant sample extracts, positive control 
samples (R. toxicus and phage DNA) and negative controls (1% aqueous methyl-β-
cyclodextrin) were included with every assay.  DNA from C. tritici and 
Curtobacterium sp. VKM Ac-1376, soil bacteria both closely related to R. toxicus, 
were included as additional controls to monitor the specificity of the R. toxicus 
primers.  PCR products were examined for size against a standard DNA ladder (MBI 
Fermentas, USA) by electrophoresis on 1 % (w/v) agarose gels and stained with 
ethidium bromide (0.5 μg/mL) and viewed under UV light. 
2.4.12 PCR inhibition investigation  
Samples of L. rigidum, free of R. toxicus and phage, were extracted and extracts 
spiked with various amounts of bacterial and phage DNA.  These DNA-spiked 
extracts were PCR amplified along with control samples of DNA in water.  In 
addition, extracts of those samples shown to be phage-negative were serially diluted 
(10-1 to 10-8 etc) and spiked with 75 ng of phage DNA and reanalyzed using PCR 
amplification.   
2.4.13 Nested PCR 
Nested PCR primers (internal primers) were designed based on the internal sequence 
of the phage PCR product (Figure 2-3) obtained using the Phage (F) and Phage (R) 
primers (external primers) (Table 2-2).  Thus, in two successive PCRs, both 
conducted under the same conditions as previously for the phage and R. toxicus PCRs, 
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1µL of the product from the first amplification was used as the template in the second 
PCR amplification using the internal primers, Nested (F) and Nested (R).  The nested 
PCR product was analysed using agarose gel electrophoresis as previously described.  
2.4.14 Detection of Corynetoxins 
An ELISA was used to quantitatively analyse all gall and plant material for 
corynetoxins (Than et al.,  1998).  Briefly, aliquots of the 1% (w/v) aqueous methyl-
β-cyclodextrin extracts of the samples were analysed using an indirect ELISA in 
which the sample analytes in solution competed with a toxin-derived antigen, 
immobilized on the ELISA plate, for polyclonal corynetoxin antibodies present in 
diluted serum obtained from a sheep vaccinated with a corynetoxins-derived hapten 
conjugated to foetal calf serum.  After the reaction and washing phases the samples 
were mixed with donkey anti-sheep IgG coupled to peroxidase for 2 h at room 
temperature.  Subsequent washing and addition of 3, 3’, 5, 5’-tetramethylbenzidine 
(Sigma, Australia) produced a colour in inverse proportion to the amount of 
corynetoxins in the sample.  The concentrations of corynetoxins were subsequently 
calculated from the optical densities of the samples against a standard curve, 
measured at 450 nm using an ELISA plate reader (Than et al.,  1998). 
2.5 Results 
2.5.1 Phage sensitivity test and plaque morphology 
Bacteriophage NCPPB 3778 was tested for host specificity using bacterial R. toxicus 
CS14 strain, C. tritici and Curtobacterium.  Under the test conditions, only R. toxicus 
CS14 strain was susceptible to infection by phage NCPPB 3778 (Figure 2-4).  Phage 
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NCPPB 3778 specific to R. toxicus CS14 strain formed small circular clear plaques 
(0.8 and 0.7 mm, respectively) (Figure 2-5). 
2.5.2 El ectron microscopy  
Electron microscopy of intact bacteriophage NCPPB 3778 particles revealed an 
isometric capsid-headed phage ~61.6 nm in diameter, with a flexible, non-contractile 
tail approximately 185 nm long ending in a bulb like structure, which is presumably 
involved in attachment.  Based on the characteristics of possession of an isometric 
capsid (morphotype B1) of approximately 55-60 nm and a long non-contractile tail up 
to 570 nm without ornamentation tentatively places this phage in the family 
Siphoviridae.  The electron micrographs (Figures 2-6) depicting the morphological 
characteristics of the phage appeared consistent with that previously reported (Riley 
IT, 1991).  
2.5.3 Cloning phage DNA 
Phage double-stranded DNA was extracted and digested with a range of restriction 
enzymes including: BamHI, EcoRI, HindIII, and PstI to provide a restriction pattern 
Figure 2-7 depicts the restriction enzyme digest pattern of phage DNA with EcoRI 
(lane 4) as compared to the published EcoRI phage digest (Ophel et al.,  1993).  
Agarose electrophoresis of restriction endonuclease digests of phage DNA confirmed 
a linear genome of approximately 45 kb.  The restriction fragment pattern was 
consistent with the experimentally observed and published EcoRI restriction map of 
phage NCPPB 3778 (Ophel et al.,  1993), thus providing evidence that the extracted 
DNA was phage NCPPB 3778. 
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The partial sequence of the bacteriophage NCPPB 3778 genome was determined by a 
combination shotgun cloning strategy using BamHI, EcoRI and HindIII restriction 
enzyme fragments of phage genomic DNA into appropriately restricted E. coli 
cloning vector pUC19 followed by a limited walk strategy using primers designed 
based on the shotgun sequences.  
This involved randomly selecting clones for sequencing and then using the resulting 
sequence information to design primers in order to sequence the remaining gaps using 
either existing clones or genomic phage DNA as a template. 
Approximately 29-kb of the bacteriophage NCPPB 3778 was sequenced, 
corresponding to about 65% of the genome.  The total GC content of the phage is 
approximately  
53 %, which is lower than the 60.4 % of the host chromosome R. toxicus. 
Twenty eight potential open reading frames (ORFs) encoding proteins of 100 amino 
acids (aa) or more were identified (Table 2-3).  Most (25 of 28) are encoded by the 
same strand, as is typical for bacteriophages.  When putative open reading frames 
(ORFs) were tested for similarity to sequences in the GenBank database 19 of the 28 
potential ORFs showed expectation values of greater than 5e-05.  Further, 15 of the 
28 ORFs showed homology to bacteriophage related proteins, with 9 having 
expectation values of greater than 7e-20.  In addition, 6 of these 9 ORFs had 
significant homology to hypothetical proteins of Microbacterium phage Min1, 
including: gp42, gp45, gp46 and gp47.  In particular, ORF1 of contig 1 with 
significant homology to hypothetical protein MPMin_gp47 [Microbacterium phage 
Min1] had the highest expectation value of 1e-50 (see Appendices). 
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Four of the 28 ORFs are homologous with conserved hypothetical proteins.  In 
particular, ORF3 of contig 2 showed a high expectation value of 2e-32 with homology 
related to hypothetical protein Lxx03880 of bacterial species Leifsonia xyli subsp. 
xyli, but had no significant homology to any bacteriophage.  Finally, 7 of the 28 ORFs 
appear to be unique to phage NCPB3778, having no significant homologies identified 
in the GenBank databases 
2.5.4 PCR amplification products 
The forward and reverse primers specifically designed for the phage and R. toxicus 
PCRs (Table 2-2) resulted in amplified products of approximately 1 kb and 200 bp for 
the phage and R. toxicus respectively (Figure 2-8).  The same bands were observed 
with PCR amplification of the methyl-β-cyclodextrin extracts of the isolated bacterial 
galls but not with cyclodextrin solution alone.  No amplified products were obtained 
with either primer set when tested on their non-target DNA i.e., phage (for the R. 
toxicus-derived primers), R. toxicus (for the phage-derived primers), and  
C. tritici or Curtobacterium.  Furthermore, sequence analysis of the 1 kb and 200 bp 
PCR products revealed DNA sequences with exact homology to the 2.6 kb phage 
DNA fragment and the 16S rRNA partial sequence of R. toxicus respectively.  
2.5.5 Analysis of Annual Ryegrass (Lolium. rigidum)-related samples 
The 72 bacterially-infected galls selected from concentrated grain screenings were all 
strongly positive (in excess of about 6400 pg/0.1 mL extract) for corynetoxins by 
ELISA.  All of these samples were also PCR-positive for the presence of R. toxicus 
(Appendix Figure A I-1) However, only 49 of the 72 were PCR-positive for the 
bacteriophage (Appendix Figure I-II) (Table 2-4).  A random selection of 5 phage-
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positive and 5 phage-negative samples were diluted and reanalyzed for corynetoxins.  
The dilution step (up to 1:1000) aligned the corynetoxins concentration in the sample 
to the linear portion of the calibration curve allowing a more accurate estimation of 
content.  The concentrations of corynetoxins in the phage-positive samples were 10.5, 
7.1, 3.7, 3.2 and 0.5 μg/gall whilst the phage-negative samples returned levels of 5.0, 
3.2, 2.6, 2.1 and 0.6 μg/gall (Table 2-5). 
Out of the 79, recently collected pasture grab samples of L. rigidum, 68 were positive 
for R. toxicus and 32 of these were also positive for corynetoxins, 30 of which 
returned levels in excess of about 6400 pg/0.1 mL (Appendix Figure 1-III) (Table 2-
6).  Only 4 of the 79 pasture-grab samples were positive for phage (Appendix Figure 
I-IV).  The 4 phage-positive samples were also positive for R. toxicus and for 
corynetoxins.  Nine of the 32 corynetoxin-positive samples, including the 4 phage-
positive displayed the characteristic yellow bacterial slime associated with ARGT.  
None of the corynetoxin-negative samples displayed the characteristic yellow 
bacterial slime.  The results for the 79 pasture-grab samples were confirmed by repeat 
analyses.   
2.5.6 Spe cificity and sensitivity 
Neither the outer nor the inner primers cross-reacted with any of the samples tested, 
other than with the target phage samples used in this study.  The sensitivity of  the 
PCR’s was determined by spiking and serially diluting 50 ng of  phage and R. toxicus 
genomic DNA into Annual Ryegrass extracts known to be negative in both PCR’s.  
Sensitivity results are shown in Figure 2-9.  The conventional PCR’s detected both 
phage and R. toxicus DNA to a dilution of 10-7 or 5 fg.  Given that the phage genome 
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is approximately 45 kb (Ophel et al.,  1993), which is equivalent to 0.05 fg of DNA,  
5 fg represents approximately 100 phage particles.  The R. toxicus genome has been 
estimated to be 2,500 kb in size assuming that the total genome is 2,500 kb (USDA 
2005).  This is equivalent to 2.74 fg of DNA and therefore 5 fg represents 
approximately 2 R. toxicus organisms. 
A random selection of 5 phage-positive and 5 phage-negative samples were 
reanalysed to establish whether phage presence impacted upon the concentration of 
corynetoxins in the bacterially-infected gall. Results from the CT ELISA indicated 
that there was no difference between corynetoxins content in phage-positive or phage-
negative galls. 
2.5.7 PC R-inhibition and nested PCR 
The phage DNA-spiked samples all resulted in the expected phage amplification 
product.  There was no evidence of matrix-related inhibition of the PCR amplification 
of phage DNA.  
The nested PCR phage DNA amplification product was approximately 300 bp and 
enabled the detection of phage related DNA to a dilution of 10-12 of the primary phage 
template solution, representing > 1 phage particle (Figure 2-10).  This product was 
observed with the PCR phage-positive samples but not with any of the phage-negative 
samples tested. 
2.6 Discussion 
Bacteriophage NCPPB 3778 Sequence and Characterisation 
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In this study, the first partial genomic sequence and morphological description of 
bacteriophage NCPPB 3778 is presented.  Based on the morphological characteristics, 
phage NCPPB 3778 appears to belong to the order Caudorvirales, Siphoviridae 
family.  More specifically, as a tailed virus of bacteria, bacteriophage NCPPB 3778 
appears to fall within the order Caudovirales which contains three families of tailed 
viruses that infect Bacteria and Archaea (van Regenmortel et al.,  2000).  The 
possession of an isometric capsid (morphotype B1) of approximately 55-60 nm and a 
long non-contractile tail up to 570 nm without ornamentation would , tentatively place 
this phage in the family Siphoviridae comprising approximately 300-400 assigned and 
unassigned species (van Regenmortel et al.,  2000).  Siphoviridae are a family of 
double stranded linear DNA viruses infecting only bacteria.  The genomic size of 
Siphophages mostly ranges from 40-50 kb, thus the approximate size of phage 
NCPPB 3778 (45 kb) falls neatly within this range.  Therefore, based on the 
morphological characteristics of phage NCPPB 3778 it would appear to belong to the 
Siphoviridae family corresponding to group B1 as defined by (Bradley, 1967). 
In this study, approximately 29-kb of bacteriophage NCPB3778 has been sequenced, 
corresponding to about 65% of the genome.  Based on the partial phage sequence 
obtained, database searches have revealed putative functions for many identified 
ORFs and provided further evidence that phage NCPPB 3778 has significant 
homology to phage related proteins consistent with the order Caudorvirales, 
Siphoviridae family.  Analysis of the partial phage genome sequence revealed the 
presence of 28 putative ORFs (Table 3-3).  These were identified based on the 
adopted criteria that an ORF consists of at least 40 codons and the sequence begins 
with commonly used initiation codons (AUG, UUG, GUG) (Moran et al.,  1982); 
(Harley and Reynolds, 1987).  In particular, 6 of the 9 ORFs with expectation values 
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of 7e-20 or greater had significant homology to hypothetical proteins of 
Microbacterium phage Min1.  These included: gp42, gp45, gp46, gp47, Clp protease 
and a probable tape measure protein.  The predicted ATP-dependent Clp serine 
protease (COG0740) has been suggested to be involved in the maturation of the 
capsid protein of the phage (Akimkina et al.,  2007).  The predicted tape measure 
protein of Mycobacteriophage TM4 (Ford et al.,  1998) is believed to determine the 
length of phage tails (Ford et al.,  1998).  
Bacteriophage Min1 is a temperate phage which infects a coryneformspecies of 
bacteria Microbacterium nematophilum (M. nematophilum), an unusual coryneform 
pathogen of the nematode Caenorhabditis elegans and related soil nematodes 
(Akimkina et al.,  2006; Hodgkin et al.,  2000).  This temperate phage is normally 
integrated into a stable plasmid, pMN1, found in cells of M. nematophilum, but it can 
also grow lytically (Akimkina et al.,  2006).  Bacteriophage Min1 is lamboid in 
morphology and in sequence, belonging to the family Siphoviridae.   
The observation that significant sequence homology has been identified for 
bacteriophage NCPPB 3778 with Bacteriophage Min1 is not surprising given both 
phages are recognised as infecting coryneform-like soil-borne bacterial hosts (non-
motile, gram-positive organisms with a high GC content) and also interact with a soil 
nematode.  Furthermore, electron micrographs reveal that both phages are 
morphologically very similar in structure with both exhibiting conventional lamboid 
phage morphology.  These results provide further confidence with sequence data 
obtained for phage NCPPB 3778 given the close relationship ecologically between 
both phage and may suggest further evidence of NCPPB 3778 role as a prophage. 
Chapter 2 
  71 
Further analysis of phage sequence revealed 3 ORFs representing relatively high 
expectation values with homology to hypothetical protein Lxx03880 of Leifsonia xyli 
subsp. xyli (L. xyli), a gram-positive sugarcane pathogen.  Interestingly, homology to 
L. xyli was also observed for Bacteriophage Min1, which apparently had the greatest 
similarity to various proteins predicted from the complete genome sequence 
(Monteiro-Vitorello et al.,  2004).  Again, this is hardly surprising, given L. xyli is the 
closest relative of M. nematophilum, for which a complete genome has been 
published.  This observation provides further evidence of bacteriophage NCPPB 3778 
being closely related to Bacteriophage Min1. 
A number of other ORFs identified by phage sequence analysis revealed significant 
homology to mycobacteriophage-related hypothetical proteins, including:  gp74, 
gp51, gp60 and gp205.  Mycobacteriophage are also known to infect high GC Gram-
positive bacteria and are also members of the Siphoviridae family.  However, other 
identified ORFs possessed significant homology to phage related proteins belonging 
to phage known to infect low GC Gram-positive bacteria, including: E. coli and 
Clostridium acetobutylicum.  Despite these proteins being encoded by phage known 
to infect low GC Gram-positive bacteria, these phage are also members of the 
Siphoviridae family.  These identified ORFs encode proteins for which their functions 
can plausibly be proposed including: gp16, minor tail subunit protein and endolysin.  
For instance, gp16 is proposed to be involved as a small terminase protein which 
appears to play an important role in DNA recognition and in modulating the functions 
of the terminase/packaging complex (Basaveswara and Black, 1988; Powell et al.,  
1990).  With regard to the endolysin, many double-stranded DNA phage utilize a lytic 
system consisting of an enzyme known as “endolysin”, which possess muralytic 
activity to degrade the host cell (Young et al.,  2000).  Therefore, as suggested 
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previously, given phage NCPPB 3778 is a temperate phage which has been shown to 
have a lytic phase, pocession of lysin related genes would be expected. 
A number of ORFs displayed some similarity albeit low, to other phage related genes 
including a J-tail protein.  However, one quarter of the ORFs had no significant 
similarity to sequences in the databanks and therefore potential homologies cannot yet 
be identified.  The observation that a significant proportion of the phage sequence 
does not display any homologues in the database is perhaps to be expected since less 
than 0.0002% of the global phage metagenome has been sampled (Rohwer, 2003) 
with the majority of identified genes having no assigned function or matches in 
GenBank (Pedulla et al.,  2003).  This translates to merely an estimated 250 complete 
phage genomes, a tiny fraction of the estimated total number of phages in the world 
(~1030); (Bergh et al.,  1989; Whitman et al.,  1998; Bukovska et al.,  2006).  
Furthermore, most of the completed phage genome sequences are for phages that 
infect Gram-negative eubacteria or the A+T-rich Gram-positive bacteria such as 
Lactococci, Streptococci or Bacilli (Smith et al.,  1999).  
Detailed analysis of phage sequence using comparative phage genomics to effectively 
characterise and assign functions to new phage sequence is limited.  The phage 
population is very dynamic, exceptionally diverse with rapid population turnover 
occurring within a relatively short period of time (Breitbart et al.,  2002).  A large part 
of this diversity is due to mosaicism arising by homologous and illegitimate 
recombination between members of phage families (Casjens et al.,  1992). 
The partial sequence analysis determined for NCPPB 3778 has not revealed any 
obvious homologies for virulence or toxin related genes, despite morphological and 
genomic sequence analysis suggesting that this phage belongs to the large family of 
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Siphoviridae, recognised to comprise prophage known to cause toxin production in 
bacterial hosts (Friedman and Court, 2001).  Absence of obvious virulence 
determinants is probably not unexpecetd given the unusual and unique nature of the 
disease caused by R. toxicus.  In fact, it can be argued that ORFs which possess no 
similarity to genes in the databases are of most interest and warrant further 
investigation using both molecular genetics and bioinformatic approaches.  However, 
further molecular genetic investigations may pose some difficulty at this point as  
R. toxicus was discovered only recently and is still poorly charaterised, consequently 
molecular genetic approaches for R. toxicus are not yet properly developed. 
Future work to obtain the complete NCPPB 3778 genomic sequence annotated and 
completely characterised, in line with increased sequencing efforts for related phage 
and Rathayibacter/ Coryneform related bacterial species would represent a new 
source of sequence information which may reveal prospective virulence determinants 
and provide some elucidation of phages’ role in toxin production. 
PCR-based Assay 
In order to achieve PCR amplification of R. toxicus and phage DNA, specific 
sequence primers had to be developed using the partial phage sequence obtained. 
In the case of the phage, the specific sequence was obtained by first digesting the 
phage DNA and selecting a 2.6 kb fragment for insertion into a plasmid.  The 
nucleotide sequence of the cloned plasmid was compared to those existing in 
GenBank by performing a BLAST search (Altschul et al.,  1990).  The lack of any 
existing homology supported the uniqueness of the 2.6 kb fragment to this phage 
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isolate and increased confidence that the PCR primers designed from the derived 
sequence would be specific for phage NCPPB 3778.   
For PCR detection of bacteria, primers are often derived from the 16S ribosomal RNA 
(16S rRNA) gene target sequences (Deng and Hiruki, 1991; Lee et al.,  1993; Namba 
et al.,  1993).  This gene is highly conserved between species (Fox et al.,  1980), 
however it does contain variable regions that can be used to develop bacterial 
‘species-specific’ primers.  Consequently, analysis of 16S rRNA has proven to be 
very useful and reliable in the classification of micro-organisms and has allowed for 
rapid differentiation of phytopathogenic coryneform bacteria for diagnostic 
application (Drennan J et al.,  1993; Pallen et al.,  1994; Lee et al.,  1997).  Of 
particular relevance to this present study, R. toxicus, a known phytopathogenic 
coryneform, has previously been distinguished from other species in the same genus 
on the basis of 16S rRNA gene typing (Sasaki et al.,  1998).  Using the reported 
partial sequence of 16S rRNA gene (Genbank accession number D84127), primers for 
the PCR amplification of R. toxicus were designed to specifically amplify R. toxicus 
DNA and differentiate it from R. tritici.  Specifically, the reverse primer falls within 
the variable region 9 (V9) domain of 16S rRNA gene (Coenye and Vandamme, 
2003). 
The phage PCR did not amplify R. toxicus bacterial DNA used in this study, nor did 
the R. toxicus PCR amplify phage DNA or the DNA extracted from the non-target 
bacteria (R. tritici and Curtobacteria) used in this study.  This observation increased 
confidence in the specificity of the primers designed for PCR amplification of both 
phage and R. toxicus DNA.  The sensitivities of the PCRs were determined by spiking 
and serially diluting 50 ng of phage or R. toxicus genomic DNA into an extract of L. 
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rigidum already shown to be negative for both PCRs.  Both the R. toxicus and phage 
PCRs detected 5 fg (10-7 dilution) of DNA that correlates to approximately 2 R. 
toxicus and 100 phage particles assuming their total genome size of 2,500 kb (USDA 
2005) and 45 kb (Ophel et al.,  1993) respectively. 
For application of the new PCR-based assays, the samples were extracted with a 1% 
aqueous β-cyclodextrin solution that provided an extract that was compatible with the 
PCR assay and the corynetoxins ELISA.  Thus, each sample could be analyzed for the 
presence of R. toxicus, bacteriophage NCPPB 3778 and corynetoxins without the 
sampling issues associated with preparing separate samples for different analysis. 
The PCR assays and the corynetoxins ELISA were initially applied to extracts of 72 
bacterially-infected galls isolated from Annual Ryegrass-contaminated grain 
screenings obtained at harvest in Western Australia.  As expected, the selected galls 
were each positive for the presence of the bacterium and corynetoxins.  However, the 
observation that 23 of these bacterium and corynetoxin-positive samples were 
negative for the phage tended to contra-indicate a tripartite relationship between the 
bacterium, bacteriophage and corynetoxins.  Five randomly selected phage-positive 
extracts and 5 randomly selected phage-negative extracts were reanalyzed to establish 
whether phage presence impacted upon the concentration of corynetoxins in the 
bacterially-infected gall.  This reanalysis made optimum use of the quantitative 
capability of the corynetoxin ELISA (Than et al.,  1998) by applying sufficient 
dilution of the strongly corynetoxin-positive extracts to ensure that the final optical 
density was within the linear portion of the calibration standard curve included on 
each ELISA plate.  As expected, since the size of the galls varied, the results indicated 
a wide range of corynetoxin content (0.5-10 μg corynetoxin/gall).  However, there 
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was no difference between corynetoxin content in phage-positive or phage-negative 
galls.  
The analytical results from the 79 pasture-grab samples of L. rigidum clearly 
indicated two things: 1) the presence of bacterium does not imply the presence of 
corynetoxins, even though the samples were collected at a time of plant senescence 
and the bacterium is expected to produce the toxins (Stynes and Bird, 1983), and 2) 
the presence of corynetoxins and/or R. toxicus does not imply the presence of phage.  
The lack of a positive correlation between the presence of R. toxicus and corynetoxins 
supports the observation that, on average, only 1 in 5.75 bacterially-infected paddocks 
are toxic to sheep (Roberts D, ARGT Workshop, El Caballo Blanco, Western 
Australia, November 2002). 
These observations with the isolated galls and pasture-grab samples could indicate 
that phage is not required for the production of corynetoxins by R. toxicus.  The 
absence of corynetoxins in about 50% of those pasture-grab samples identified as 
positive for R. toxicus may indicate an as yet unknown or undefined stimulus required 
to initiate toxin production.  However, differential sensitivities of the assays leading to 
false negatives can not be discounted on this data.  
Although the corynetoxin ELISA can detect as little as 50 pg/100μL, the R. toxicus 
PCR is estimated to detect as few as 2 bacteria so it is conceivable that trace amounts 
of R. toxicus DNA may be amplified and detected without a corresponding detection 
of corynetoxins.  This could be addressed by developing a quantitative approach to 
the PCR assay (Real Time PCR) and correlating corynetoxins to R. toxicus in isolated 
bacteria-infected galls.  The derived correlation could then be applied to field samples 
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of pasture where R. toxicus was detected to produce an indication of the level of 
corynetoxins that should be expected.  
The potential for false negatives in the phage PCR assay was addressed in two ways: 
1) the elucidation of any inhibitory matrix effects in the PCR assay, and 2) by 
enhancing the specific sensitivity of the phage assay via a nested PCR approach. 
Thus, seven of the isolated bacterially-infected gall samples that failed to amplify 
phage DNA were serially diluted (to lessen any matrix-related inhibitory effect) and 
spiked with phage DNA.  All spiked samples were phage-positive in subsequent PCR 
reactions indicating that nothing inhibitory was present within the sample to prevent 
the phage PCR.  Application of the nested PCR approach enabled an approximately 
10,000-fold enhancement in the detection of phage ensuring detection of a single 
phage particle.  Nested PCR analysis of 8 gall samples, which included both PCR 
phage-positive and phage-negative samples, only produced an amplified product in 
those samples that were PCR phage-positive, thereby increasing the confidence that 
the negative phage results were real.  
In this preliminary application of the PCR assays in combination with the corynetoxin 
ELISA, neither the geographic location, presence of characteristic bacterial slime nor 
the level of corynetoxins could differentiate the 4 phage-positive samples from the 
other corynetoxin-positive samples.  
Since the proposed involvement of phage in corynetoxin production in the field is 
speculative, it is not known how much phage would be required and whether the 
current PCR assay is sensitive enough to detect a minor involvement.  It is also 
possible that unknown matrix effects might hinder the extraction and/or PCR 
amplification of phage DNA from Annual Ryegrass samples.  However, several 
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experiments in which methyl-β-cyclodextrin extracts of Annual Ryegrass were spiked 
with phage DNA did not identify problems with sample matrix effects (data not 
shown).  Additionally, the extraction and PCR amplification of R. toxicus DNA was 
not apparently hindered and it would require a significant difference in the 
biology/ecology of the bacterium and its putative associated phage if detection of one 
and not the other was so severely affected.  Another possibility is that more than one 
species or strain of phage, that was not identified in earlier research (Ophel et al.,  
1993) nor detected by the specific primers designed for phage NCPPB 3778, might be 
involved in the production of the corynetoxins.  For instance, (Kurtböke et al.,  1995) 
isolated two other bacteriophage phiCT1 and phiCT2 from toxic ryegrass seeds and 
demonstrated that both isolates were also able to infect R. toxicus. 
A thorough study investigating parameters which can affect a carrier-type 
lysogenicity of R. toxicus phage would also be important before the involvement of 
the phage can be discounted.  In particular, the capability of a temperate phage to 
lysogenise a sensitive host is controlled by a number of factors, including: the genetic 
composition of the phage; the genetic composition of the host; and the environment.   
Other factors which can affect a carrier-type lysogeny depend on conditions such as 
cation concentrations, changes in temperature and multiplicity of infection (Gold, 
1959).  . 
Combined with potential development of a PCR-based method of detection for the 
nematode vector (J. Allen, Department of Agriculture, Western Australia; personal 
communication) and the existing ELISA for corynetoxins, the PCR-based assays for 
R. toxicus and the bacteriophage NCPPB 3778 provides a method for assessing 
pasture and animal feed stocks for all known, or in the case of the phage, suspected, 
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factors contributing to ARGT.  Such a rapid and comprehensive detection system 
could be regularly used prior to and during the ARGT season (should the phage be 
shown to be associated with toxin production) to provide for more timely and 
effective control and management of ARGT.  
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Table 2-1 Bacterial strains, phage and plasmid 
 
 
(Progen, Australia)  pUC19 
Ian Riley (University of Adelaide)Bacteriophage NCPPB 3778
(Invitrogen, USA)Escherichia coli Top10F’ 
Ian Riley (University of Adelaide)Curtobacterium sp. VKM Ac-1376
Ian Riley (University of Adelaide)Clavibacter tritici 
Ian Riley (University of Adelaide)R. toxicus CS14 (NCPPB 3552)
Source Bacterium, bacteriophage or plasmid
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Table 2-2 Primer sequences used in the PCR based assay 
 
ACTTAGTCCTAATCACCGATC Rathayibacter toxicus (R) 
GTTGTAAAACGACGGCCAGT Universal M13 (F) 
CACAGGAAACAGCTATGACC Universal M13 (R) 
AGCGAATCCCAAAAAGCC Rathayibacter toxicus (F) 
AGCGAATCCCAAAAAGCC Nested phage (R)  
TACCACTCCGACAACATCAC Nested phage (F)  
CGTACAGCAGGAGGGTACTC Phage (R)  
ACCGCACATCTGCTCTATCC Phage (F)  
5’->3’ nucleotide sequencePrimer 
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Figure 2-1 Collection areas of the 79 pasture-grab samples of L. rigidum.  
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Figure 2-2 Overview of PCR-based assays for R. toxicus and bacteriophage NCPPB 
3778 
 
Soak individual galls 
O/N in 250μl
Cyclodetxtrane
Obtain galls from 
infected ryegrass
Boil, spike and 
dilute individual 
samples
PCR samples
Primer Sequence (5’-3’) 
pMK-1 5’-AGGCAGACGCGGAGAGAG-3’
pMK-2 5’-CCTTCCGTTCGTATTTCTCG-3’
pMK-3 5’-CTATGTTGCCAGCGGGTTAT-3’
pMK-4 5’-TTCATGAGGTCGAGTTGCAG-3’
Clone phage DNA and 
primer design
Detection PCR products 
using agarose gel 
electrophoresis
CT ELISA to verify CTs 
presence
1% Cyclodextrin
Figure 2-2  Overview of PCR-based assays for R. toxicus and bacteriophage NCPPB 3778
Prepare PCR 
mixture in 96-well 
plate format
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Figure 2-3 Bacteriophage NCPPB 3778 PCR product with nested PCR primers 
 
GTCCTCTATTCCATCCTCGAAAGAAGTAATACCATAAGT
GTTTGATGTAAGCGCCGAAATATTTAGTGAACTGTCTTCG
CTGGCCACCCGCTGTAACGCAGTGAATGTGTAGGTGAAT
ATCGCCGCCGTAGTCGCTGCCGTTTGCGGATGCCCCAGA
CCAGCCCAGTATCTCGCCCTGGTTATAGTGACGGCCGTTC
TCGCCAAAGCGCGACTGGTGCTGATATACCACTCCGACA
ACATCACCGATCGGCCTATCTAGCATAAGGATAGAACGA
CGCCCAGCAGANCCAATCTGCCCAGCAACAAGCTCACCA
CTCCCGCCGGAAGTTCTCAAGGTGCCCGCGGCANCACAG
GCAAAGGTGTGCCGAANCCTAAGGGATAATCCTCACCGC
CCANGCTGTAGCTCATATGATCCGCCCANGTGCCAGTNA
NTCGGTACCCNGCGAACGGGGTTGTATCCCCATAAGCCA
ATACCCCTTCCNAAAAAGTTCGNTTAATGGGATAAAAGG
GTGGAATAAGTTTGGGCGTTCTAACCCCGTTCTTACCNG
GCTTACCNAAAAACCGAANTTCCCNTTTGANGTTNTTTG
GGTTGGGGAATAAAGCCCCCAAAAGGGCNTTTTCCCCGN
CCCCNGTTGGTTCTTAAACAATTCCNTTGGAACCCGGGTT
Chapter 2 
  85 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-4 Phage sensitivity test:  Confirmed only R. toxicus to be sensitive to infection by 
bacteriophage NCPPB 3778 streaked down the centre of plate. 
 
R. toxicus 
C. tritici 
R. toxicus
Curtobacteriu
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Figure 2-5 Transfection of R. toxicus with bacteriophage NCPPB 3778 Transfection 
of R. toxicus with bacteriophage NCPPB 3778: Visual inspection of transfected 
plates 5-7 days after incubation show phage plaques on R. toxicus lawn. 
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Figure 2-6 Electron micrographs of bacteriophage NCPPB 3778  
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Figure 2-7  EcoRI Restriction enzyme pattern. Agarose electrophoresis of EcoRI restriction 
endonuclease digest of phage DNA confirmed a restriction pattern consistent with the 
experimentally observed pattern (Ophel et al. 1993) 
 
 
 
 
>12 kb 
doublet
>2 kb 
doublet
1.58 kb
0.9 kb
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Table 2-3 ORFs of partial phage sequence ORFs of the partial bacteriophage NCPPB 3778 
genome and presumed characteristics determined by similarity motif search. Sequences 
provided for Contigs 5 and 12 (See Appendices).  
 
Contig 
No
Length ORF Start End Homology E value GenBank Acc No.
1 7201 1 780 1163 Hypothetical protein MPMin_gp47 
[Microbacterium phage Min1]
1.00E-50 YP001294807
2 157 579 Hypothetical protein MPMin_gp46 
[Microbacterium phage Min1]
2.00E-30 YP001294806
3 4612 5211 Phage related protein Gp16 5.00E-30 NP346707
4 4219 5004 Probable tape measure protein 
[Microbacterium phage Min1]
1.00E-26 YP001294810
5 4225 5328 bacteriophage minor tail subunit (tape 
measure protein)
3.00E-23 NP 691134.1
6 2979 3602
p
(possible phage related tail length 
tape measure protein)
5.00E-20 YP001354469
2 2975 1 457 816 Hypothetical protein Lxx03880 4.00E-09
2 831 1244 Lxx03880 5.00E-05
3 1024 1749
Lxx03880
2.00E-32
3 2156 1 1797 1261 unknown
4 1812 1 593 1213 Gp60: Phage related protein
2 1449 1667 Gp74 [Mycobacteriophage Che9d]
5 1605 1 281 766 Endolysin putative 1.00E-06 YP181785
2 802 1239 Gp51 Mycobacteriophage 2.00E-19 AAN12695
3 988 1545 Gp51 Mycobacteriophage 5.00E-14 AAN12695
6 1333 1 365 592 Unknown
7 1331 1 450 692 Hypothetical protein MPMin_gp42 
[Microbaterium phage Min1]
8 1323 1 446 1267 M23 peptidase domain 3.00E-17 YP_629991.1
9 1310 1 - - Unknown
10 1304 1 - - Unknown
11 1300 1 473 718 Hypothetical protein MPMin_gp45 
[Microbaterium phage Min1]
7.00E-20 AAN12407
12 1257 1 467 6 Clp protease [Microbaterium phage 
Min1]
7.00E-23 YP_001294799.1
13 1203 3 258 515 Polyhedron envelope
14 1099 unknown
15 693 2 275 631 Gp205 Mycobacteriophage 1.2 AAN16839
16 607 Unknown
17 437 2 59 184 Conserved Hypothetical Protein 8.00E-05 ZP00369774
18 326 1 202 23 J-tail host specific protein 
[Enterobacterium phage lambda]
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Figure 2-8 PCR of positive and negative controls PCR amplified products resulting from 
testing gall material. Lane (M) 1 kb Plus DNA ladder (1) Positive control – 1 kb amplified 
product from phage genomic DNA (2) Positive control – 200 bp amplified product from R. 
toxicus genomic DNA (3) Negative control – Cyclodextrin solvent. 
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Table 2-4 Tabulated data of 72 gall samples 
 
Gall 
Sample
CTs R.toxicus Phage
Gall 
Sample
CTs R.toxicus Phage
Gall 
Sample
CTs R.toxicus Phage
1 + + + 25 + + - 49 + + -
2 + + - 26 + + + 50 + + +
3 + + + 27 + + + 51 + + -
4 + + + 28 + + - 52 + + +
5 + + - 29 + + + 53 + + +
6 + + + 30 + + + 54 + + +
7 + + + 31 + + + 55 + + +
8 + + + 32 + + - 56 + + +
9 + + - 33 + + + 57 + + +
10 + + + 34 + + + 58 + + -
11 + + + 35 + + + 59 + + -
12 + + + 36 + + + 60 + + +
13 + + + 37 + + - 61 + + +
14 + + - 38 + + + 62 + + +
15 + + + 39 + + + 63 + + +
16 + + + 40 + + + 64 + + +
17 + + + 41 + + + 65 + + +
18 + + - 42 + + - 66 + + -
19 + + + 43 + + + 67 + + +
20 + + - 44 + + - 68 + + +
21 + + + 45 + + + 69 + + +
22 + + + 46 + + - 70 + + +
23 + + + 47 + + + 71 + + -
24 + + + 48 + + + 72 + + +
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Table 2-5 Random selection of gall samples reanalysed for CTs 
 
 
 
NegativePositive 5.02 51 
NegativePositive 3.15 47 
NegativePositive 2.6 25 
NegativePositive 2.13 9 
NegativePositive 0.56 2 
Positive Positive 0.50 63 
Positive Positive 3.17 36 
Positive Positive 3.72 35 
Positive Positive 7.08 7 
Positive Positive 10.47 1 
Phage BacteriaCT ELISA 
Toxicity 
Gall 
Sample 
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Figure 2-9  Phage and R.toxicus PCR sensitivity Phage and R.toxicus PCR sensitivity (A) 
Ten-fold dilutions of the extracted Phage DNA (15ng/µL) from 10-1 to 10-7were used. 
Conventional PCR product was detected up to the 10-7 dilution, which corresponds to 100 
phage particles (B) Ten-fold dilutions of the extracted R.toxicus DNA (15ng/µL) from 10-1 to 
10-7 were also used. Conventional PCR product was detected up to the 10-7 dilution, which 
corresponds to 2 R.toxicus organisms. 
 
 
 M           N       -1        -2       -3        -4         -5       -6         -7       -8  
        M           -1             -2          -3           -4            -5           -6            -7
A 
B 
1000  
200 
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Figure 2-10  Conventional PCR and nested PCR sensitivity Conventional PCR and nested 
PCR sensitivity Ten-fold dilutions of phage DNA (75 ng/µL) from 10-1 to 10-7 were used; 
Phage DNA neat (N) and molecular mass marker 1 kb Plus ladder was also included. A. 
Conventional PCR. Product was detected up to 10-7 dilution, which corresponds to 100 phage 
particles. B. Nested PCR. Product was detected up to the dilution 10-12, which corresponds to 
>1 phage particle. 
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Table 2-6 Tabulated data from 79 ryegrass sample screening 
 
Sample Location Mean Toxin R. toxicus Phage Sample Location Mean Toxin R.toxicus Phage Sample Location Mean Toxin R. toxicus Phage
1 NE Grace > + + - 27 York > + + + 53 Walerbing > - + -
2 Wongon > + + - 28 York 48 - + - 54 Underoin 29 - + -
3 York > + + - 29 Kunnundpun 49 - + - 55 Marrow 16 - + -
4 York > + + - 30 Wongon 44 - + - 56 Carrigan 2 - + -
5 Wyachatchem 38 - - - 31 Ballidu > + + - 57 Gillingarra 0 - + -
6 Wongon* > + + - 32 Bywater > + + - 58 MRST7 0 - + -
7 Wongon 0 - - - 33 Wubin 22 - - - 59 MRS8CE 0 - + -
8 Bywater* > + + - 34 WHRS > - + - 60 WHRS* > + + -
9 Wongon* > + + - 35 WHRS 2 - - - 61 S. Wongon* 70 - + -
10 Bruce Rock 50 - - - 36 Koodra 6 - - - 62 York 0 - + -
11 Grace 40 - + - 37 Banaubbin 0 - + - 63 York 0 - + -
12 Narembeen 25 - + - 38 E. Northam 0 - + - 64 L. Grace > + + -
13 Narambeen 29 - + - 39 Marling > + + - 65 York 4 - + -
14 Grace 26 - + - 40 Kalannie 3 - + - 66 York > + + -
15 Grace 27 - + - 41 Kalannie 3 - + - 67 York > + + -
16 Kulin 27 - - - 42 Northam 4 - - - 68 York > + + -
17 W. Yearling 25 - + - 43 Walebing 7 - + - 69 York > + + -
18 W. Bullaring 27 - - - 44 Smarredin 4 - + - 70 York 10 + + -
19 Dangin 28 - + - 45 Babollein 16 - + - 71 York > + + -
20 Quairading 22 - + - 46 N. Wongon 17 - - - 72 York 68 + + -
21 Hastings 27 + + - 47 E. Wongon 24 - + - 73 York > + + -
22 Wongon* > + + + 48 E Yeaacoin 17 - + - 74 York 29 + + -
23 Kalannie* > + + + 49 Ardata 17 - + - 75 York 16 + + -
24 Wongon* > + + + 50 Miling 10 - + - 76 York 2 + + -
25 Traynning 36 - + - 51 Kalannie* > + + - 77 York 0 + + -
26 York 32 - + - 52 Miling 68 + + - 78 York 0 + + -
79 York 0 + + -
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CHAPTER 3 
Differential Gene Expression in cultured Rat Hepatocytes 
Exposed to low levels of Tunicamycins: A Model for Annual 
Ryegrass Toxicity 
3.1 Publications relating to Chapter 3 
Kowalski, M ., Cahill, D., Doran, T. and Colegate, S. (2007) Dose-related, 
Differential Gene Expression in Cultured Rat Hepatocytes Exposed to Tunicamycins: 
a Model for Annual Ryegrass Toxicity. In: Poisonous Plants: Global Research and 
Solutions (Eds K Panter, T Wierenga and J Pfister). pp 253-258. 
Part of the research presented in this chapter has been published:- Kowalski, M.C:- 
approximately 80 % contribution to the manuscript (performing all experiments and 
writing manuscript).  Cahill, D., Doran, T.J. and Colegate, S.M.:- all contributed with 
supervision of this work and assisted with the manuscript. 
3.2 Introduction 
Annual Ryegrass Toxicity (Stewart and May, 1994) is as an often fatal hepatocerebral 
disease of livestock caused by ingestion of corynetoxins produced by the bacterium  
R. toxicus which results in high morbidity, mortality and suffering.  Monitoring 
ARGT effectively in the field, in particular, diagnosis of non-clinical exposure of 
livestock to corynetoxins is important when considering animal health, welfare and 
productivity.  The capacity of current diagnostics to detect and confirm corynetoxin 
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exposure is severely limited due to the cumulative nature of corynetoxins; prolonged 
sub-lethal exposure (potentially causing irreversible damage before the manifestation 
of overt clinical symptoms) is completely undetectable based on current diagnostic 
strategies. 
Currently, diagnosis of ARGT is limited to clinical observations presented by affected 
livestock; history of access to annual ryegrass in pasture or hay; demonstration of 
bacterial galls in ryegrass and traditional toxicity endpoints such as histopathology, 
clinical pathology and chemistry brain (Giesecke, pers. comm. 1992).  While ARGT 
presents primarily (symptomatically) as a neurological disorder, the clinical signs 
displayed as a result of ARGT exposure are often varied and not necessarily specific 
for corynetoxicosis.  Furthermore, the appearance of clinical signs is believed to occur 
only after exposure reaches an acute level which often coincides with the onset of the 
final stages of disease progression.  Therefore, diagnosis based on clinical signs is 
only of limited value and subclinical exposure to corynetoxin is undetectable based on 
current diagnostic strategies. Thus, (as discussed in Chapter 1) these approaches are 
limited by a lack of specificity and inability to detect sub-lethal exposure prior to the 
onset of clinical signs.   
Diagnosis of ARGT is currently based on clinical signs; history of access to annual 
ryegrass in pasture or hay; demonstration of bacterial galls in ryegrass; and 
histological evidence of hepatotoxicity and vascular lesions in the brain (Giesecke, 
pers. comm. 1992).  As discussed in Chapter 1, these approaches are limited by a lack 
of specificity and inability to detect sub-lethal exposure prior to the onset of clinical 
signs.   
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In addition to ARGT presenting as a neurological disorder, concomitant liver damage 
is also associated with the disease (Berry et al.,  1982).  Pathological examination post 
mortem to identify evidence of liver and other organ damage has been used to 
diagnose ARGT.  However, pathological examination does not offer strict 
confirmation of corynetoxins exposure, as evidence of liver and other organ damage 
is not necessarily specific to ARGT.  Further, the pathological damage associated with 
ARGT is often varied and usually only evident with acute exposure. 
Alternatively, diagnostics based on serum chemistry (such as measurement of 
Aspartate transaminase (AST) enzyme levels) are similarly problematic as these tests 
are not necessarily specific to or diagnostic for liver damage associated with 
corynetoxins (Finnie and Jago, 1985; Berry et al.,  1982) and are not adequately 
sensitive to detect subclinical exposure.  As a result, both the cumulative nature and 
lethality of corynetoxins has significantly impeded diagnostic efforts and has proven a 
major challenge in the control and prevention of ARGT.  Therefore, new improved 
methods with enhanced sensitivity and specificity for detection/rapid screening of low 
level chronic corynetoxins exposure are required. 
As discussed previously, corynetoxins are known to be produced by the coryneform 
bacterium R. toxicus (Vogel et al.,  1981) and are among the more lethal natural 
toxins, with an oral median lethal dose of about 1 mg/kg Bodyweight (BW) for sheep, 
cattle and pigs (Bourke and Carrigan, 1993).  
The commercially available tunicamycins are a group of tunicaminyl-uracil 
glycolipids that are structurally very similar to corynetoxins and have been routinely 
used as a substitute to experimentally induce ARGT.  Tunicamycins are an inhibitor 
of N-linked glycosylation and the formation of N-glycosidic protein-carbohydrate 
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linkages (Mahoney and Duksin, 1979).  Tunicamycins specifically inhibit dolichol 
pyrophosphate-mediated glycosylation of asparaginyl residues of glycoproteins 
(Olden et al., 1978) and induce “ER stress”.  Tunicamycins appear to be a true or 
intrinsic hepatotoxin (Zimmerman and Ishak, 1994) as the toxin readily produces 
hepatic damage in a number of species in a seemingly dose-dependent manner 
(Finnie, 1994).  
Several in vivo studies based on acute exposure of tunicamycins and corynetoxins 
have shown both toxins to exhibit similar antibiotic and biochemical activities, 
toxicities and clinical disease (Jago et al.,  1983; Finnie and Jago, 1985; Jago and 
Culvenor, 1987).  Despite liver pathology not necessarily being diagnostic for ARGT, 
liver toxicity has been relatively well characterized using hepatocyte cultures and 
have provided an effective end-point to measure hepatoxicity in many studies (Berry 
et al.,  1982).  The in vitro effects of acute exposure to corynetoxins and tunicamycins 
on primary rat liver hepatocytes based on morphological analysis and conventional 
cytotoxic endpoints have been reported separately (Yeoh et al.,  1984; Finnie, 2001).  
In particular, Finnie and O’Shea (1989) demonstrated that tunicamycins doses of 20 
and 80µg/ml directly damage hepatocytes in vitro, producing morphological changes 
resembling those found in the liver of sheep and guinea-pigs given the toxin.  
Although traditional toxicity approaches provide valuable information in relation to 
the morphologic and cytotoxic effect of a toxin, they do not offer the sensitivity 
required for detection of low level sub-clinical exposure.  In particular, despite the 
morphologic and cytotoxic effects of acute exposure to corynetoxins and 
tunicamycins having been reported, detection of low level subclinical exposure has 
not been possible using these approaches.  Therefore, new approaches to examine the 
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effects of low level corynetoxins and tunicamycins exposure at the molecular level are 
required. 
It is now commonly accepted that toxicity is often preceded by and results in, 
alterations in gene expression.  Various studies indicate that analysis of gene 
expression changes caused by toxic substances is a highly sensitive method of toxicity 
analysis: wherein changes in gene expression can be seen earlier and at significantly 
lower doses before the development of a toxic pathological response (Harris et al.,  
2004).  While it may take weeks, months, or even years before some traditional 
toxicological endpoints occur, specific changes in mRNA levels can occur within a 
few hours (h) or days after exposure to chemical compounds.  In many cases, these 
changes in gene expression are a far more sensitive, characteristic and measurable 
endpoint than the toxicity itself (Nuwaysir et al.,  1999). 
Toxicogenomics is a valuable approach for toxicity analysis which utilizes microarray 
technology to analyse gene expression changes caused by a toxic substance, offering 
exquisite sensitivity and the potential for detection of subclinical exposure (Nuwaysir 
et al.,  1999).  As discussed in Chapter 1, application of toxicogenomics to toxicology 
as a diagnostic parameter for toxicity screening holds the promise of far surpassing 
traditional approaches in terms of predictive potential, sensitivity and speed 
(Burczynski et al.,  2000).  Gene expression analysis using toxicogenomics can allow 
for earlier detection of a toxic insult, at significantly lower doses insufficient to trigger 
obvious toxicity detectable by conventional endpoints.  The application of 
toxicogenomics to investigate hepatotoxicity, in particular, identification of gene 
expression profiles and/or biomarkers to detect early stage pre-clinical toxicity is 
supported by many published studies (Harris et al.,  2004; Huang et al.,  2004; 
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Heinloth et al.,  2004; Steiner et al.,  2004; Ulrich et al.,  2004).  In particular, a study 
by Waring et al., 2001 revealed a strong correlation between the histopathology, 
clinical chemistry and gene expression profile induced by 15 known hepatotoxicants.   
A great deal of interest exists for the development of in vitro-based toxicogenomic 
methods.  In particular, there has been an increased demand for the development and 
refinement of predictive in vitro high-throughput toxicity screening assays that can be 
used as an alternative to traditional in vivo testing.  The development of in vitro 
systems for toxicological experimentation has been highlighted as a scientific priority 
as a result of considerable pressure from public and regulatory authorities to minimise 
the use of animals in testing and to facilitate acceptance of alternative testing methods 
(Abbot et al.,  2005).  
In vitro systems are recognised as providing significant advantages over traditional in 
vivo experiments for toxicological research.  In particular, in vitro systems are 
considered to be a cost effective alternative, amenable to high-throughput screening, 
are inherently more simplified and offer better controlled experimental conditions 
when compared to in vivo experiments.  Furthermore, isolation of biopsies and other 
biological material (in particular liver cells) for toxicological investigations is not 
always feasible for ethical or practical reasons.  Moreover the biological material 
available can be insufficient to perform the required investigations and it may not 
always be possible to obtain or synthesise sufficient amounts of compounds to test.  
Therefore, various in vitro hepatic models including perfused liver, precision cut liver 
slices, isolated primary liver cells and a number of immortalised liver cell lines have 
been used as animal alternatives in many toxicological studies (Boess et al.,  2003).  
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Hepatocyte cultures are well suited for toxicogenomic studies because they display a 
certain level of metabolic activity and the liver is a major stage for toxic events 
(Waring and Ulrich, 2000).  Continuous hepatocyte cultures have been shown to 
retain many liver specific characteristics and have become a useful indicator of toxic 
exposure using toxicogenomics (Huang et al.,  2001).  In particular, continuous 
hepatic cell lines (HepG2, Clone-9 and BRL3A) (Burczynski et al.,  2000; Dere et al.,  
2006) and isolated primary hepatocytes (Waring et al.,  2001; Harris et al.,  2004), 
(Baker et al.,  2001) have been used extensively to identify gene expression changes 
in response to various toxin stimuli.  Some reports have demonstrated a good 
correlation in gene expression data between in vivo and in vitro models.  In particular, 
Baker et al., (2003) demonstrated that hepatocytes treated with PPARα agonist 
fenofibrate produced gene expression changes characteristic of the in vivo response in 
rat liver.  The data revealed remarkable similarities in both the affected biological 
pathways and the rank-order magnitude of the response.  Furthermore, rodent in vivo 
and in vitro systems are currently the experimental model of choice for predictve 
toxicology, especially in early phase development. 
Microarray technology (as discussed in Chapter 1) provides an powerful platform for 
the analysis of changes in gene expression levels.  The power of this technology lies 
in the ability for simultaneous analysis and monitoring of complex genetic changes at 
the mRNA level.  Recent applications of microarray technology include gene 
expression profiling with unprecedented precision for toxicogenomics studies (Uehara 
et al.,  2006; Hirode et al.,  2008).   
Gene expression profiling using DNA microarrays is a complex procedure with each 
single step in the entire process from RNA purification to data extraction potentially 
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increasing the variability of the results.  In particular, common sources of variation 
within microarray systems are varying RNA quality, varying cDNA synthesis 
efficiency, dye-bias in using two colour fluorescence dye labelling systems, 
inconsistent hybridisations conditions due to poor temperature control, inadequate 
mixing or distribution of the hybridisation solution.  Since the primary objective in 
microarray studies is to accurately detect differences in gene expression levels, 
variations due to the technology should be kept to a minimum.  
Generally, the least amount of risk is expected with in vitro studies, in vivo or in vitro 
systems that use a targeted approach in which only a few genes of known function are 
measured using low-density platforms (Castle et al.,  2002).  As discussed previously, 
low-density (LD) arrays comprise a few hundred genes, while high-density (HD) 
chips contain probes specific for thousands of target genes.  HD-arrays have the 
advantage of potentially studying thousands of genes simultaneously, giving a global 
view of the changes occurring in cells.  However, the major drawbacks are related to 
the high cost and the time taken for analysis and interpretation of data.  In general, in 
vivo studies using global gene expression profiling platforms are considered to have 
the highest risk of uncovering unexplained or uninterpretable toxicogenomic data.   
Low-density (LD) commercial arrays are considered to be more suitable for routine 
applications due to their simplicity, good reproducibility, easy data management and 
low cost (Zammatteo et al.,  2002).  Several studies suggest that LD arrays are highly 
useful in toxicological studies, as they offer the ability to rapidly study gene 
expression changes following toxin exposure (de Longueville et al.,  2002).  
However, fewer studies have been carried out using LD arrays.  Furthermore, it has 
been suggested in the literature that commercially available microarrays provide 
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significant advantages in terms of offering superior quality arrays, which are 
reproducible and optimised for detection, combined with well-designed analysis 
control systems aimed to reduce these technical variations.  A variety of LD 
“toxicology arrays” are now available from several commercial vendors, consisting of 
genes with demonstrated or presumed relevance to toxic responses.  
The DualChip™ rat hepato (Eppendorf, Germany) is a commercially available LD 
array platform which has been evaluated and validated in a number of toxicogenomic 
studies to identify genes associated with drug toxicity.  These studies have 
demonstrated a strong correlation between liver histopathology and the identified 
gene expression profiles for many hepatotoxins (de Longueville et al.,  2003) as 
already obtained with HD microarrays (Hamadeh et al., 2002; Morgan et al., 2002).  
Thus, the DualChip™ rat hepato is considered a fast and effective tool for assessing 
the toxicity profile of hepatotoxins. 
DualChip rat hepato consists of 149 genes spotted in triplicate which have been 
selected among potential toxic markers involved in basic cellular processes and drug 
metabolism related genes.  In addition, the DualChip includes 8 housekeeping genes 
and a subset of positive and negative hybridisation controls as well as a number of 
features for normalisation and internal calibration.   
DualChip technology (Eppendorf, Germany) offers a highly reproducible platform 
which provides an effective analysis control system aimed to reduce technical 
variation (de Longueville et al.,  2003).  For instance, each gene is spotted in triplicate 
in different areas of the array making the system less prone to bubbles or dust that 
may alter signal intensity of a spot and in addition enables statistical analysis and 
correction of the gene data within the single experiment.  As a result of the inclusion 
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of triplicate spots, the user is less vulnerable to irregularities on the array with these 
kinds of unusual or suspect spots ‘outliers’ can be removed.  Additionally, DualChip 
technology provides a specialised analysis control system, including a two step 
normalisation process involving internal standards as well as several hybridisation 
controls.  
DualChip technology has been designed to efficiently integrate a two-step 
normalisation procedure to take into account the abovementioned sources of 
experimental variation that may occur during the array process (de Longueville et al.,  
2002).  In the past, the expression level of housekeeping genes were considered to be 
constant and were used to normalise microarray expression data.  However, recent 
reports indicate that the expression levels of housekeeping genes may vary in many 
situations (Eickhoff et al., 1999; Savonet et al., 1997).  Therefore, using housekeeping 
genes alone to normalise expression data may potentially lead to erroneous 
conclusions.  For this reason, Eppendorf ® has developed the two step normalisation 
approach to allow for the elimination of technological-based differences between the 
reference and test experiments. 
The two step normalisation procedure involves the use of well quantified internal 
standards to normalise differences due to efficiency variation in reverse transcription 
(RT), hybridisation, microarray quality and indirect detection.  It is essential to 
normalise the data obtained from different hybridisations to allow the data from 
separate arrays to be compared within the one experiment and between different 
experiments.  The internal standard mixtures provided with the DualChip™ kits 
allows for a local correction of variability (CV) of hybridisation and sample 
preparation for normalisation.  However, since the internal control disregards the 
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purity and integrity of mRNA samples, a second adjustment of data is performed 
based on the set of 8 separate housekeeping gene probes spotted on each array to 
allow a correction of variability due to the purity, quality and amount of the analysed 
RNA.  The inclusion of more than one housekeeping gene appears to be crucial as 
previous studies indicate that any toxin may affect the expression of housekeeping 
genes. 
In summary, DualChip technology offers a highly reproducible LD array platform 
combined with a specialised analysis control system which features simplified data 
analysis with enhanced accuracy of signal detection. 
3.3 Aims of this chapter 
To develop and validate an in vitro toxicogenomic model using the Eppendorf 
DualChip™ rat hepato to examine the effects of low dose tunicamycins exposure on 
clone-9 hepatocytes at the molecular level, combined with cytotoxic and 
morphological assessment.  In addition, to identify the lowest tunicamycin dose rate 
to induce a no observable effect level for subsequent bioequivalence and biomarker 
investigations (Chapter 4). 
3.4 Materials and Methods 
3.4.1 Reagents, cell lines and media 
Tunicamycins (av. MW 840; Sigma-Aldrich, St Louis, Missouri, USA) were 
solubilised and serially diluted in 0.6 mM AnalaR grade sodium hydroxide (NaOH) 
(BDH Ltd., Merck, Darmstadt, Germany).  Clone-9 rat hepatocytes were purchased 
from the ATCC (Manassa, Virginia, USA- ATCC accession number CRL-1439).  
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F12K Nutrient Mixture media was obtained from Gibco™ (Invitrogen, Carlsbad, 
California, USA) and supplemented to contain 2 mM L-glutamine (MP Biomedicals, 
Irvine, California, USA), 0.25% w/v amphotericin B (Invitrogen, Carlsbad, 
California, USA), 100 units/mL penicillin (CSL Limited, Parkville, Victoria, 
Australia), 100 μg/mL streptomycin (Sigma-Aldrich, St Louis, Missouri, USA) and 
10% heat-inactivated fetal calf serum (Trace Biosciences, Sydney, New South Wales, 
Australia).  AnalaR grade sodium hydroxide (NaOH) was obtained from BDH Ltd. 
(Merck, Darmstadt, Germany). Tunicamycins were added to the media at 0.5% v/v 
such that the final concentrations in F-12K Nutrient Mixture Media (Invitrogen, 
Carlsbad, California, USA) were 0.05, 0.5, 5 and 50 µM. Reverse-phase high 
performance liquid chromatography (RP-HPLC) analysis of each solution was 
performed on a Shimadzu Class VP instrument with a 5 μm particle size C18 column 
(Phenomenex, Torrance, California, USA).  Samples were eluted in a linear gradient 
of 70-90% methanol + 0.1% TFA at a flow rate of 200 μL/min over 40 mins and 
detected at 260 nm.  Once the purities of the tunicamycin and corynetoxin solutions 
were established, their concentrations were adjusted using sterilised 0.6 mM NaOH. 
NaOH control samples consisting of 0.5% v/v toxin-free 0.6mM NaOH (pH 12) in F-
12K media were prepared in addition to the solvent-free F-12K media controls.  
3.4.2 Exposure of in vitro hepatocytes to tunicamycin 
3.4.2.1 OptiCells ™ 
The OptiCell™ cell culture system was utilized for morphological analysis of the in 
vitro effects of tunicamycin on clone-9 hepatocytes.  Opticell™ provides a unique cell 
culture system for growing, monitoring and transporting cells.  OptiCell™ consists of 
two parallel gas-permeable, cell culture treated polystyrene membranes attached to a 
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standard microtiter plate-sized frame (Figure 3-1).  The OptiCell™ system is 
particularly well suited for combined approaches such as this investigation involving 
both morphological assessment of cells over time, as well as culturing and harvesting 
of cells.  The OptiCell™ system offers the unique ability of protecting cells at all 
times by remaining sterile with use inside or outside of the incubator.  For instance, 
the user has the ability to remove the OptiCell™ from an incubator and place it on a 
microscope stage for high quality imaging without contaminating the cell culture 
process.  Further, the OptiCell™ system offered a number of additional advantages 
which were attractive to this study, including: saving time and money by minimising 
the steps and equipment needed for cell culture, reducing space and media 
requirements, i.e. OptiCell™ takes less than one-fifth the bench-top, incubator or 
storage space, provides one-third more growth surface in vitro and generates one-third 
less solid waste by weight than a traditional culture flask.  
3.4.3 Exposure of cells 
Cells were grown using the OptiCell™ culture system (BioCrystal, Westerville, Ohio, 
USA).  Twelve cells™ (BioCrystal, Westerville, Ohio, USA) were seeded with clone-
9 rat hepatocytes (ATCC, Manassas, Virginia, USA; accession number CRL-1439) at 
a density of 1 x 105 cells mL-1 in toxin free F-12K media.  Briefly, a syringe with an 
attached tip was used to inject 10 mL of cell suspension into the chamber through one 
of the self-sealing ports before inverting the OptiCell™ and withdrawing an equal 
volume of air.  The cells were left to grow until 80 to 90% confluent (4 x 106 to 5 x 
106 cells approximately 48 h).  Cells were adherent to one of the 50-cm2 100-μm-thick 
membranes enclosing the 2-mm-deep OptiCell™ chamber.  The clone-9 cell line is an 
epithelial cell line isolated in 1968 from normal rat liver (NRL) taken from a young 
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male rat and has mainly been used for studies of in vitro carcinogenesis (Weinstein et 
al.,  1975).  This provided 4 groups of triplicate samples representing the solvent-free 
control (F-12K media alone), NaOH control (F-12K media with toxin-free NaOH 
added), 0.05 µM and 50 µM tunicamycin in F-12K media.  After 48 h post-seeding 
incubation at 37 ºC in a 5% CO2 in air atmosphere, the media was removed from all 
OptiCell™ and replaced with the various test media and incubation continued for a 
further 24 h (Figure 3-2). 
3.4.4 Bioassay: Viability and cytotoxicity assessment of toxin-exposed cells 
Fifteen Nunclon™ Delta Surface 24-well plates (Nunc, Roskilde, Denmark) were 
seeded with clone-9 hepatocytes at a density of 1 × 104 cells/cm2 in toxin-free F-12K 
media (2.5 × 104 cells/mL).  Forty-eight hours post-seeding, all plates were checked 
under low-power microscopy to ensure adequate cellular adhesion and the presence of 
apparently healthy cells.  The media was then removed from each well and replaced 
with toxin-containing media, NaOH media or control F-12K such that each of the four 
dose groups were represented by two wells per plate.  At the 12 pre-determined time 
points: 0, 4, 8, 22, 26, 30, 46, 50, 54, 70, 74 and 78 h following toxin-exposure, two 
randomly selected plates were assessed for cellular viability and proliferation rates 
using the trypan blue dye exclusion staining method (i.e. n = 2 for each dose at each 
time point).  Trypan blue dye exclusion was used to determine cell membrane 
integrity.  In this protocol, cells were trypsinised for five mins at 37°C, mixed in a 
ratio of 1:1 with 0.2% trypan blue and preparations were mounted immediately in the 
counting chamber of a hemocytometer and viewed at 100x with a standard light 
microscope.  It is generally accepted that a viable cell will exclude an acid dye such as 
trypan blue, and that its uptake is indicative of irreversible membrane damage 
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preceding cell death.  The number ratio of live to dead cells (cell viability) was then 
determined.  
3.4.5 Stati stical Analysis 
An unpaired Student's t-test (Student, 1908) was used to analyze most data to 
determine whether two population means were significantly different.  The 
application of Student’s t-tests to cell viability data generated from trypan blue dye 
exclusion Assay are demonstrated in many publications (Jauregui et al.,  1981).  A 
correlation coefficient was determined for the scatter plot together with the P-value by 
a regression analysis.  Significant differences were defined at a confidence level 
where P was < 0.05. All statistics were evaluated using Prism Software (Graph Pad, 
San Diego, CA). 
3.4.6 M orphological analysis of toxin-exposed cells 
Five OptiCell™ (BioCrystal, Westerville, Ohio, USA) were seeded at a density of  
1 × 104 cells/cm2 in toxin-free F-12K media (1 × 105 cells/mL).  As with the 24-well 
plates, every OptiCell™ was examined under low-power microscopy at 48-h post-
seeding.  The media was then removed from the OptiCells™ using the specifically 
designed OptiCell™ tips and replaced with toxin-containing F-12K, NaOH F-12K or 
control F-12K.  At the 12 pre-determined time points (described above), digital 
microphotograms of the live, unstained cells within the OptiCells™ were captured 
and examined in ‘real-time’ using a Leica DMLB Microscope attached to a DC300F 
digital camera (Leica Microsystems, Bannockburn, Illinois, USA). 
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3.4.7 Ge ne expression analysis 
In order to evaluate the reliability of microarray experiments and to obtain an accurate 
gene expression profile for each compound, three independent hepatocyte 
preparations were carried out for each treatment group.  However, the array 
experiments were performed on a pooled preparation of the three triplicate samples.  
The microarray experiment included the following steps: mRNA extraction; labelled 
cDNA synthesis; and microarray hybridisation with the pooled sample for each 
treatment group (Figure 3-3). 
3.4.8 Cel l treatment and RNA extraction 
After incubation the test medium was removed from each OptiCell™ and the residual 
cells still adhering to the OptiCell™ membrane were washed twice with phosphate-
buffered saline (PBS).  Cells were recovered from the OptiCell™ following treatment 
with trypsin for five mins at 37°C, pelleted by centrifugation and total RNA extracted 
(RNeasy® Mini Kit, Qiagen).  The integrity and the concentration of extracted RNA 
was assessed spectrophotometrically at 260/280 nm (Nanodrop Spectrophotometer, 
Nanodrop Technologies).  Denaturing agarose gel electrophoresis was also carried out 
to assess the integrity and relative contamination of mRNA in the total RNA sample. 
3.4.9 Reverse transcription 
Total RNA (8µg) was used in a reverse transcription reaction with indirect labelling 
(the incorporation of a biotin-11-dCTP mixture indirectly during cDNA synthesis).  
All reverse transcription reactions were performed separately for control and treated 
samples and then replicate samples pooled to minimise variability according to the 
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DualChip™ instruction manual.  One-colour gene expression analysis was performed, 
whereby the same labelled nucleotide (biotin-11-dCTP) used in all reactions with all 
resulting cDNAs are labelled identically (Figure 3-4).  An internal standard mixture 
was used for quantification/normalisation and estimation of experimental variation 
(de Longueville et al.,  2002).  This included three synthetic poly(A)+ tailed RNA 
standards which were spiked at three different amounts (10 ng, 1 ng, and 0.1 ng per 
reaction) into the purified mRNA in accordance with the manufacturers instructions 
(Eppendorf, Hamburg, Germany).  The RNA standards were used for quantification 
and estimation of experimental variation introduced during labelling and analysis.  
The cDNA replicates were then pooled prior to hybridisation to reduce the reverse 
transcription reaction variability. 
3.4.10 Microarray design and hybridisation 
The DualChip™ rat hepato (v 1.0) (Eppendorf, Germany) consists of two separate 
arrays per slide enclosed within separate hybridisation frames.  The DualChip™ rat 
hepato (v. 1.0) contains 149 specific rat hepatocyte genes (see Appendices) designed 
to efficiently target toxicology–relevant gene expression patterns comprising of and 
with a range of genes and toxic-specific markers involved in basic cellular processes 
such as drug metabolism, stress responses, cell proliferation, cell cycle activation, 
transcription, inflammation and apoptosis (de Longueville et al.,  2002).  Table 3-1 
presents an overview of the gene content of the DualChip™ rat hepato (v. 1.0).  All 
genes selected are marker genes for hepatotoxicity; therefore any changes in the 
expression of these genes are indicative of toxic effects on liver cells.  Further, the 
DualChip™ rat hepato (v. 1.0) can be used to address a number of key toxicological 
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issues including: mechanism of action; dose response relationships; and chemical 
interactions.   
To evaluate the reliability of the experimental data, several positive and negative 
hybridisation and detection controls are included on the microarray.  For 
normalisation, six internal standard control probes and eight housekeeping genes are 
arrayed on the slides (Table 3-1).  Furthermore, positive hybridisation/orientation 
control probes are included to monitor the hybridisation step and determine the 
orientation of the array.  Also, negative hybridisation control probes (non-specific 
DNA) and negative detection control spots (spotting solution) are present as 
additional controls to check for non-specific background.  The Rat HepatoChips are 
composed of single stranded DNA probes attached to a glass support by a covalent 
link.  Each DNA probe is presented in triplicate.  Figure 3-5 presents the array design 
of the DualChip™ rat hepato (v. 1.0).  The length of the DNA probes has been 
optimised using advanced probe technology.  The lengths are the same for all genes 
and are located near the 3’ end of the transcript (Figure 3-7).  All probes have been 
designed to be gene specific and have been prepared using rat cDNAs.  Appendix 
Figures A II-1, II-II, II-III display the hybridisation data of control, 0.05 and 50 μM 
treated samples on DualChip™ rat hepato at 24 h.   
3.4.11 Hybridisation using biotinylated-labelled cDNA 
The DualChip™ rat hepato hybridisation was carried out according to the 
manufacturers instructions (de Longueville et al.,  2002) using one-colour indirect 
labeling protocol.  In brief, hybridisation of the arrays with the biotin labelled cDNA 
was completed in 16 h at 60ºC and 1400 rpm using a Thermomixer comfort 
(Eppendorf, Germany).  Hybridisation conditions were kept consistent by utilising a 
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specially designed Thermomixer™ (Eppendorf) to increase or control factors 
contributing to hybridisation quality.  Hybridised products were detected indirectly 
using a fluorescent streptavidin conjugate (Cy™3-conjugated IgG Fractional 
Monoclonal Mouse Anti-Biotin) (Jackson Immuno Research laboratories, USA).  To 
minimise variation associated with individual slide handling and treatment, 
hybridisation of samples from treatment groups were designated to the right array and 
the untreated samples were performed on the left side to allow for direct comparison.  
Hybridisation conditions were kept consistent by utilising a specially designed 
Thermomixer™ (Eppendorf) to increase or control factors contributing to 
hybridisation quality. 
 
3.4.12 Detection and data analysis 
3.4.12.1 Raw data transformation 
The detection and quantification of hybridisation events were carried out with a 
microarray scanner (ArrayWoRxe, Applied Precision, USA) using a 565 nm emission 
filter for the Cy3 signal.  To maximise the dynamic range of the microarrays and 
allow quantification of both high and low copy expressed genes, arrays were scanned 
using three different exposure times [0.7, 1 and 1.5 sec].  After image acquisition, the 
scanned 16-bit image was used to quantify the signal intensities (ImaGene® 4.1 
software, BioDiscovery®, USA).  It is essential in microarray image analysis to adjust 
for background, as the measured intensity of each spot includes a contribution of non-
specific binding and fluorescence emitted from other chemicals on the glass.  Thus, 
the fluorescent intensity of each DNA spot (average intensity of each pixel present 
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within the spot) was calculated by subtraction of both the local mean background and 
the mean of the negative hybridisation controls from the total signal intensity of each 
spot.  
3.4.13 Data selection and replicates data merging 
All genes of the DualChip rat HepatoChip microarrays are spotted in triplicate to 
provide valuable information and allow the performance of statistical analysis and the 
correction of the gene expression data for each single experiment.  As a result, the 
coefficient of variation (CV) of the replicate signal intensities was determined after 
the image had been quantified.  Spots representing an abnormal variation of signal 
intensity within a replicate were marked or flagged automatically with the mean of the 
remaining replicates computed.  For the determination of acceptable genes, very 
bright element intensities (saturated signals, highly expressed genes) and very low (≤ 
2.5 times the local background) signal intensities were deemed unsuitable for accurate 
quantitation and were excluded from further analysis.  All genes not labelled as 
saturated or low were considered acceptable for reliable ratio data generation.  The 
three intensity values of triplicate DNA spots were then averaged and used to 
determine the intensity ratio between the reference (control) and the treated samples.  
3.4.14 Normalisation and data analysis 
In accordance with the manufactures recommendations, a two-step normalisation 
procedure was performed prior to data analysis to account for potential sources of 
experimental variation.  The DualChip™ Kit includes an internal standard mixture (a 
dilution series of in vitro-transcribed polyadenylated RNA of six Lycopersicon 
esculentum genes) selected specifically for their involvement in plant-specific 
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processes and have no known mammalian homologues in the NIH sequence database.  
As well as the corresponding capture probes already printed on the array.  
Additionally, capture probes corresponding to numerous housekeeping genes had 
been spotted throughout the array to allow a reliable two-step normalisation.  
Firstly, a correction of values was carried out by using a local normalisation factor 
calculated from the intensity ratios of the internal standards in both the reference and 
test samples.  The corresponding probes of the internal standards were located in 6 
different areas on each array to determine the local background and to evaluate the 
microarray homogeneity.  Secondly, to reflect the purity, quality and amount of the 
analysed RNA, a correction of values was carried out by using a global normalisation 
factor calculated from the mean intensity ratios of housekeeping genes.  Only those 
housekeeping genes for which the expression was not changed after treatment with 
toxin were taken into account for the normalisation. 
3.4.15 Statistical significance of gene expression ratios 
To test the significance of the ratios obtained (Chen et al., 1997; de Longueville et al., 
2002) the variance of the normalised set of housekeeping genes (excluding those 
affected by the tested condition) was used to generate an estimate of expected 
variance, leading to a predicted confidence interval (CI).  Gene ratios inside the 0.95 
confidence interval can not be considered statistically different from 1.  They are 
flagged as unchanged.  Ratios outside the 0.95 confidence interval were determined to 
be ‘significantly different’; ratios outside the 0.99 confidence interval were 
statistically ‘highly significant’ following the treatment.  Furthermore, the ratios of 
analysed genes were then divided into two groups: (semi-) quantitative and 
qualitative.  In general, ratios involving two acceptable signal intensities were 
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considered quantitative.  Ratios involving one low and/or one saturated intensity were 
considered qualitative.  Ratios resulting from two low or two saturated intensities 
were considered unusable. 
3.4.16 Multiple scanning data 
Quantitative data analysis could only be performed on the signal intensities of the 
reference and test experiments in the acceptable range (corresponding to the linear 
part of the scanning curve).  Thus, only genes that were not saturated or very low 
(lower than 2.5 times the local background) were used for quantitative data analysis.  
As mentioned previously, in order to increase the number of acceptable genes the 
arrays were scanned with multiple exposure times to increase the dynamic range of 
the system and therefore a higher number of reliable ratios.  To achieve this, an 
intermediate exposure time was first chosen to analyse medium expressed genes.  
Highly expressed genes were accurately quantified at a low PMT setting, and low 
expressed genes at a high PMT setting. 
3.5 Results  
3.5.1 Cell viability and Cytotoxicity 
The cellular viability of clone-9 cells treated with tunicamycin was evaluated by 
determining the cells ability to exclude trypan blue after exposure to tunicamycin at 
various dose rates over time.   
The trypan blue dye exclusion method was successfully used to evaluate cellular 
viability and cytotoxicity of clone-9 hepatocytes exposed to tunicamycin.  RP-HPLC 
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analysis indicated that the purities of the tunicamycin solutions were > 90% (Figure 3-
6).  
Tunicamycins exposure at all four doses (0.05, 0.5, 5 and 50 µM) was shown to be 
hepatotoxic in effect on clone-9 rat hepatocytes as measured by trypan blue dye 
exclusion staining.  Figure 3-7 illustrates the live cell count data with increasing 
tunicamycin concentrations over 78 h.  The average number of live cells after 
treatment with tunicamycin is presented in Appendix Table AII-I.  Initially, there 
appeared to be no significant increase in cell numbers in any of the treatment groups.  
However, after t = 30 h the average number of live cells in the control treatment 
appeared to increase dramatically and continued to exponentially increase over all 
remaining time points as depicted in Figure 3-7.  Thus, based on this figure, only cells 
present in the untreated ‘control’ cultures appeared to proliferate.   
To determine the time points at which the number of live control cells and cells 
exposed to tunicamycin became ‘significantly’ different, a Student’s t-test comparing 
the number of cells within the control samples to the four toxin-treated cultures was 
performed.  The trendlines plotted for the 0.05, 0.5, 5 and 50 µM tunicamycin treated 
samples exhibited p-values of 0.05 at the same time of ~74 h following toxin 
exposure (data not shown).  Based on this result it can be assumed that the number of 
live cells in all cultures is indistinguishable from control cultures until ~74 h after 
toxin exposure.  A Student’s t-test was also used to compare the number of live cells 
between the four toxin treatments to determine if the difference in live cell numbers 
was statistically significant.  Results indicate that the number of live cells (based on 
the resulting p-values) in all tunicamycin treated cells were not significantly different.  
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The relative cytotoxicity of each dose expressed as a percentage of cellular death is 
presented in Appendix Table AII-II.  Figure 3-8 illustrates the percentage of cellular 
death within each treatment with increasing tunicamycin concentrations over 78 h.  
After 30 h of toxin-exposure, cellular death within toxin treated cultures was as high 
as ~40-70%, with numbers of cellular death continuing to increase over time.  The 5 
and 50µM dose groups appeared more similar in their time-dependent decline of cell 
numbers than both lower doses.  Over time, the percentage of cellular death appeared 
similar between the 5 and 50 µM doses with ultimately all cells in both samples dead 
at t = 78 h.  However, at the earliest time point (t = 4), the 50µM tunicamycin sample 
had a higher percentage of cellular death, with ~50% of highest dosed cells dead, 
versus less than 20% in all other tunicamycin treated groups.   
The overall percentage of cellular death within the lower dosed cells (0.05 and 0.50 
µM) appeared markedly lower than the higher doses.  Only 70 and 64% of cells had 
died at t = 78 h in the 0.5 µM and 0.05 µM samples respectively.  Surprisingly, the 
percentage of dead cells appeared to be higher in the 0.05 µM tunicamycin samples 
over time than the 0.5 µM.  In contrast, only 5% cellular death was measured within 
the control samples.   
Whilst the trendlines shown in Figure 3-7 indicate that the 5 and 50 tunicamycin 
samples exhibited a higher percentage of cellular death over time than the lower 
dosed 0.05 and 0.5 µM tunicamycin treatments, the apparent differences in cell 
numbers are shown only to be statistically significant when compared to the highest 
50µM tunicamycin sample (as assessed by Students t-test- results not shown).  Results 
indicate that the percentage of cellular death in the 50 µM treatment was statistically 
significant when compared to 0.05 and 0.5 µM dose groups.  The percentage of 
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cellular death between 0.05, 0.5 and 5 µM dose groups were shown not to be 
statistically significant from each other.  Despite the percentage of cellular death 
appearing consistently higher in the 0.05 µM tunicamycin samples over time, 
statistical testing demonstrated that the difference in cell numbers between the 0.05 
and 0.5 µM tunicamycin doses was not statistically significant.  Therefore, the 
percentage of cellular death of tunicamycin treated samples based on the Students t –
test, has demonstrated that only the percentage of dead cells in the 50 µM 
tunicamycin treatment was significantly different as compared to the two lowest 0.05 
and 0.5 µM treatments. 
3.5.2 M icroscopy 
Exposure of cultures to 0.05, 0.5, 5 and 50 µM tunicamycin for 78 h resulted in 
marked morphological changes at the light microscope level in all doses. 
Each treatment was examined at the twelve pre-determined time points (sect 3.2.3) 
with digital microphotograms of the live, unstained cells within each OptiCell™ 
captured and examined in ‘real-time’.   
All five cultures representing the various treatments were indistinguishable from each 
other until the 22 h time point following toxin exposure (Figure 3-9 and 3-10). Prior 
to this time, the cultures consisted of broad sheets of hepatocytes through which 
scattered holes were rapidly being filled by new cells rising via mitosis.  Mitosis and 
normal cellular enlargement were obvious throughout the 8 h period.   
After 22 h it became possible to differentiate between two groups of treatments: 
Cultures exposed to ≥ 0.5 µM tunicamycin (including control) and cultures exposed to 
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≥ 0.5 µM tunicamycin.  The distinction between these two groups was evident until 
the 48 h time point.  
Cytopathic effect (CPE) observed within all cultures exposed to tunicamycin could be 
broadly divided into: vacuolation of the cytoplasm with other degenerate changes; 
separation and shrinkage of cells to form small, amorphic or round bodies; disruption 
and disintegration of the sheets of hepatocytes due to loss of cells from the OptiCell 
surface; and overall cellular shrinkage to form small spherical-shaped cells. Each of 
CPE observed led to disruption of the cell monolayer through detachment of 
hepatocytes from the culture surface. 
Vacuolation of the cytoplasm first appeared at 22 h in samples ≥ 0.5 µM tunicamycin 
doses (Figure 3-10).  The most significant vacuolation was evident in the 50 µM 
treatment with cells developing many vacuoles large in size.  The 50 µM treatment 
demonstrated the most significant effect on cells which was consistent throughout all 
remaining time points.  However, toxic effects were also significant and increased 
over time for 0.5 and 5 µM tunicamycin doses. 
At 26 and 30 h, significantly more cells in ≥ 0.5µM tunicamycin treatments developed 
vacuolation and with time the nuclei in these vacuolated cells displayed a number of 
changes (Figures 3-11 and 3-12).  Slight vacuolation had appeared for the first time in 
the 0.05 µM treatment, however no nucleic changes had yet appeared with cells still 
indistinct from controls.  
At 46 h (Figure 3-13) the first signs of vacuolation appeared in the lowest (0.05 µM) 
treatment.  However, changes in the nucleus in the lowest dose were not yet apparent.  
Vacuolation of the cytoplasm with degenerate changes in the nucleus was most severe 
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in ≥ 0.5µM tunicamycin treatments at 46 and 51 h (Figure 3-14) wherein cell 
shrinkage and detachment from adjacent cells first became obvious.  In addition, the 
proportion of vacuolated cells attached to the OptiCellTM membrane decreased from 
51 h onwards.  It was interpreted that these cells had died and had fallen from the 
culture surface. 
Over time, the severity of changes consistent with apoptosis increased in all dose 
groups, including 0.05 µM.  Ultimately, at the last time point (78 h) visible cells were 
identified only in the two lowest dose groups (0.05 and 0.5 µM) and control (Figure 
3-15).  Overall, the control cells showed comparatively few changes throughout the 
experiment, consisting of continuous sheets of normal appearing cells and exhibiting 
changes consistent with effects of time and normal cellular turn-over. 
3.5.3 Ge ne Expression Analysis 
A low-density DualChip™ rat hepatochip containing 149 rat liver genes was used to 
analyse the gene expression profiles generated in continuous cultures of rat 
hepatocytes (clone-9) exposed to 0.05 and 50 µM of tunicamycin at 24 h. 
In order to characterise changes in gene expression in response to tunicamycin 
treatment, mRNA was extracted from all tunicamycin treated and control samples 
after 24 h.  Biotinylated labelled cDNA was prepared from 8 µg mRNA by reverse 
transcription and hybridised on separate arrays Rat (Dual chips) spotted on the same 
slide (Appendix Figure 1-5).  To increase the reliability of the microarray 
hybridisation and reduce inter sample variability all arrays used originated from the 
same batch.  Furthermore, separate reverse transcription reactions were performed and 
pooled to also minimise variability.  The arrays were then washed at high stringency 
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and scanned with a confocal laser scanner.  To maximise the dynamic range of 
microarrays and by consequence, to facilitate detection of the complete gene 
expression spectrum, the same arrays were scanned at low, medium and high 
exposure times.  The data was then normalised in a two step approach, first using the 
internal standards (local normalisation factor) and then with the housekeeping genes 
(global normalisation factor). 
The results of gene expression analysis using the DualChip™ demonstrated for the 
first time that treatment of in vitro cultured rat hepatocytes (clone-9) with 0.05 µM 
and 50 µM tunicamycin for 24 h results in differential gene expression when 
compared to control untreated cells.  In particular, exposure of in vitro cultured rat 
hepatocytes to 0.05 µM and 50 µM tunicamycin for 24 h resulted in 9 and 8 genes 
respectively that were expressed at significantly different levels compared to 
untreated hepatocyte controls.   
As a result of the stringent DualChip analysis control system only ratios which had 
two acceptable signal intensities were considered ‘quantitative’ and therefore 
identified as differentially regulated.  The remaining analysed genes were either 
unchanged, or had ratios involving one low and/or one saturated signal intensity and 
were thus considered ‘qualitative’.  All quantitative ratios identified were determined 
to be outside the 99% confidence interval and were considered statistically ‘highly 
significant’ (Tables 3-4 and 3-5). Appendix Figures 1-6 and 1-7 display the 
hybridisation data of control, 0.05 µM and 50 µM treated samples on DualChip™ rat 
hepato at 24 h. Figure 3-16 and 3-17 shows the corresponding scatter plot. 
Overall, the differential gene expression observed between 0.05 µM and 50 µM 
tunicamycin doses was very similar (Figures 3-18, 3-19 and 3-20).  The most highly 
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induced genes consistent within both treatments compared to untreated cells were 
JNK3 and APOE.  JNK3 was the most significantly up-regulated gene which 
functions as a protein kinase activated as part of a stress response.  APOE functions as 
a lipid transport protein.  Both APOE and JNK3 were significantly more up-regulated 
in the 50 µM dose.  The most significantly down regulated genes within both 
treatments compared to controls were: FN, ecoa, MnSOD, mt_Co1 and Osteon.  Their 
functions, include oxidative metabolism and detoxification of free radicals which are 
toxic to biological systems (MnSOD- superoxide dismutase), drug metabolism 
(mt_Co1 – cytochrome c oxidase), lyase activity/ β oxidation (ecoa-enoyl CoA) and 
maintaining the integrity of the extracellular matrix (FN-fibronectin and Osteon-
Osteonectin.  Overall, the levels of repression were fairly similar between both dose 
groups.  Differences in gene expression between the 0.05 µM and 50 µM treatment 
were restricted to only three genes which included c-jun, Bclx and BAD.  Within the 
lowest dose 0.05 µM treatment c-jun was significantly upregulated, with this gene 
unchanged in the highest dose 50 µM.  The function of c-jun is as a kinase involved in 
signal transduction.  In the highest 50 µM treatment Bclx and BAD were both shown 
to be significantly down regulated compared to the 0.05 µM treatment.  Bclx and BAD 
belong to the Bcl-2 family which govern mitochondrial outer membrane 
permeabilisation and can be either pro-apoptotic or anti-apoptotic. Table 3-6  provides 
a summary of the functions of all genes identified as quantitatively significant.  
3.5.4 Sensitivity of the assay- Detection limit for low abundance genes 
To evaluate the sensitivity of the microarray experiments the internal standard 
mixture was used.  The sensitivity of the microarray assay is based on the lowest 
detectable amount of internal standard.  Known amounts of the exogenous poly (A) + 
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tailed RNA (ranging from 10,000 to 5 pg) were spiked into a background of 8 µg rat 
hepatocyte mRNA.  The labelled cDNA synthesis and hybridisations were processed 
and intensities of internal standard control spots were used to create a standard curve.  
Hybridisations of rat hepatocyte mRNA (without an internal standard transcript) did 
not result in detectable signals for any probe designed to detect the internal standard 
(data not shown).  The presence of the internal standard was reproducibly detected 2-
fold above the local background for an amount of 5 pg of synthetic RNA.  The lower 
detection limit for the internal standard using an indirect fluorescence method was at a 
dilution of < 1:1,000000 (w/W) in rat hepatocyte mRNA.  This detection limit 
corresponds approximately with 107 molecules or 5 pg of specific RNA.  If we 
assume a homogenous population of cells and 300,000-500,000 molecules of mRNA 
per single mammalian cell (Gerhold et al.,  1999), a detection level of 1:1,000000 
corresponds to a detection limit of less than one copy per cell.  We found that the 
lower detection limit of this indirect fluorescence method was obtained at a dilution of 
1:1,000000 (w/w) of the synthetic poly 9(A)+ spiked into rat liver mRNA.  This 
dilution correlates with 2 pg or 107 molecules of specific mRNA in the reaction.  
Therefore, this protocol could detect transcripts that constitute 0.0001% of the total 
mRNA in a sample. 
3.5.5 RNA Integrity 
The integrity of the total RNA was assessed by visualisation of intact ribosomal RNA 
bands using gel electrophoresis.  The 18S and 28S ribosomal RNA (Deng and Hiruki, 
1991) bands appeared as fairly sharp, intense bands.  Nanodrop also checked purity 
ratio of absorbance for all samples with the ratio A260/A280 ranging from 1.9 to 2.1.  
No degradation was evident. 
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3.6 Discussion 
The principal aim of this study was to develop and validate an in vitro toxicogenomic 
model using Eppendorf DualChip™ rat hepato arrays to investigate the genomic 
effects of low level tunicamycin exposure on clone-9 hepatocytes.  In particular, to 
determine whether differential gene expression could be observed based on levels of 
tunicamycins significantly lower than previous studies utilising traditional 
toxicological approaches.  This study involved a combined toxicogenomic approach 
using microarray technology, coupled with conventional toxic parameters i.e. 
cytotoxic and morphological assessment.  A further aim was to identify the lowest 
tunicamycin dose rate to induce differential gene expression without causing overt 
toxicity (no observable effect level), as defined by conventional criteria to apply to 
subsequent bioequivalence and biomarker studies (Chapter 4). 
The in vitro toxicogenomic strategy developed in this study provided a valid and 
useful approach for analysing low level tunicamycin exposure.  Tunicamyin exposure 
at all four doses was shown to be hepatotoxic in effect on clone-9 rat hepatocytes as 
measured by trypan blue dye exclusion staining and microscopy.  With the 
demonstration that low level tunicamycin could affect the viability of hepatoctytes in 
vitro, it followed to examine the molecular basis for these changes. The results of 
gene expression analysis using the DualChip™ demonstrated for the first time that 
treatment of in vitro cultured rat hepatocytes (clone-9) with 0.05µM and 50µM 
tunicamycin for 24 h results in differential gene expression when compared to control 
untreated cells.  Based on these results, in particular the overt toxicity observed in all 
treatments, significantly lower levels of tunicamycin are required for subsequent 
tunicamycin investigations of low level/ pre-clinical exposure. 
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3.6.1 Ce ll viability -Trypan blue dyes exclusion assay 
Tunicamycins exposure at all four doses (0.05, 0.5, 5 and 50 µM) was hepatotoxic in 
effect on clone-9 rat hepatocytes as measured by trypan blue dye exclusion staining.  
Trypan blue dye exclusion represented a useful and quantitative method to assess the 
toxic effect of tunicamycins on hepatocytes at the macroscopic level (King et al.,  
1959).  The trypan blue assay is based on the principle that cells with compromised 
plasma membranes will allow trypan blue dye to penetrate into the cell and strongly 
stains the nucleus blue, which then can be visualized and assessed by light 
microscopy.   
Initially, no significant change in live cell numbers in any treatment group were 
observed using the trypan blue assay until after 30 h post exposure.  This may have 
been due to cells experiencing a lag phase as a result of media being removed and 
replaced with various test media 48 h post-seeding.  After 30 h, control cell cultures 
continued to proliferate and appeared to enter an exponential phase of growth.  In 
contrast, inhibition of cellular proliferation was apparent in all tunicamycin-treated 
cultures (0.05, 0.5, 5 and 50 µM) demonstrating a marked decline in live cell 
numbers. Previous in vivo and in vitro studies examining the effects of tunicamycins 
have reported similar observations.  In general, tunicamycins have been shown to 
cause interference in the cell cycle and cell division (Hemming, 1982) owing to a lack 
of the correct cell surface glycoproteins for divison to occur successfully (Frisch et 
al.,  1976).  Tunicamycins have also been demonstarted to impair DNA, RNA, and 
protein syntheis (Takatsuki et al., 1971, 1972).  In vivo studies have reported that 
direct infusion of tunicamycins into the abdomen of sheep significantly reduced the 
number of cells in metaphase (Davies et al.,  1997).  Also in vitro studies of 
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tunicamycins have shown inhibition of mitosis in cultures of bovine aortic endothelial 
cells (Finnie and O'Shea, 1990b). 
Prior to this study, the lowest dose of tunicamycins applied to cultured cells was 0.05 
ug/ml (Savage and Baur 1983).  Interestingly, Savage and Baur (1983) demonstrated 
an effect of 0.05 ug/ml tunicamycin on cell viability of a rat hepatoma cell line only 
after 72 h. This observation appears remarkably consistent with this study that has 
demonstrated that after 74 h, a significant effect on cell viability was evident in all 
tunicamycins doses.  In particular, the number of live control cells exposed to 
tunicamycins became significantly different from each tunicamycin-treated dose 
group.  Furthermore, this study has demonstrated for the first time an effect on cell 
viability using a significantly lower dose of 50 nM (0.05 µM) tunicamycin.  
The highest 50 µM tunicamycin treatment appeared to have a higher overall cellular 
death rate with approximately 50% of the 50 µM tunicamycin treated cells dead 
versus less than 20% in all other treatment groups at t = 4h.  This result is consistent 
with the results derived from further statistical analysis which indicate that the 
percentage cellular death in the 50 µM tunicamycin treatment was significantly 
different as compared to the two lowest 0.05 and 0.5 µM treatments.  This observation 
is perhaps not surprising given the increased potency of the 50 µM dose (i.e. 10-fold 
higher concentration than the next closest dose group).  
The cytotoxic cell count data provided a somewhat quantitative assessment of the 
effect of tunicamycin exposure on cells at the various doses.  Qualitative 
measurement of the morphological effect of tunicamycin on cells was also performed 
at the various time points to provide a combined approach. 
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3.6.2 M orphology 
Tunicamycins at all four doses were shown to have a discrete and damaging 
morphological effect on clone-9 hepatocytes in vitro.   
The morphological effects of tunicaminyl-uracil toxin exposure observed in this 
investigation are consistent with those reported in previous studies (Yeoh et al.,  
1984; Finnie and O'Shea, 1989; Finnie, 2001). In general terms, tunicamycin treated 
hepatocytes in this study displayed cytopathic effects including: vacuolatation; 
degenerate changes of the nucleus; and/or cellular shrinkage to form round cells. 
Hepatic changes characterised by severe vacuolation of hepatocytes due to dilation of 
the RER (Finnie and O'Shea, 1990b) and lipid accumulation, bile-ductile hyperplasia 
are the most frequently described observations in cellular morphology both in vivo 
and in vitro associated with tunicaminyl-uracil toxicity (Berry et al.,  1982; Finnie, 
1991a; Finnie and Hajduk, 1992; Finnie et al.,  2004; Finnie and Mukherjee, 1987; 
Finnie and O'Shea, 1990b; Glassy and Ferrone, 1981; Hickman et al.,  1977; Lin et 
al.,  1998; Olden et al.,  1978; Seiberg and Duksin, 1983; Tiganis et al.,  1992; Yeoh 
et al.,  1984).  As tunicamycins are a potent inhibitor of protein glycosylation 
(Takatsuki and Tamura, 1982), a biochemical process which is located in RER 
(Struck and Lennarz, 1980), insoluble aggregates of unglycosylated proteins have 
been attributed to the effect of swelling and dilation of the RER. In particular, 
inhibition of protein glycosylation resulting in the absence of carbohydrate side chains 
have also been suggested to impact or alter the physiochemical properties of certain 
proteins contributing to the aggregation and impaired mobility through the 
intracellular membrane system (Finnie and O'Shea, 1990b; Hickman et al.,  1977; 
Yoshimi et al.,  2000). 
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Cellular shrinkage and rounding has also been identified in previous studies to be 
linked to a reduction in N-linked glycosylation of cell surface adhesion and 
attachment proteins, including fibronectin, collagen and integrins (Ekblom et al.,  
1986; Hou et al.,  2001; Krasteva et al.,  2002; Vleminckx and Kemler, 1999).  In 
particular, Duksin & Bornstein (1977) suggest that tunicamycins exposure results in 
morphological changes that may be attributed to the production of a carbohydrate-
depleted fibronectin and an inability to convert procollagen to collagen. Further, 
previous studies have demonstrated that unglycosylated forms of fibronectin and 
specific integrins have altered binding efficiencies towards certain solid phase 
matrices (Jones et al.,  1986; Lehmann et al.,  1996). This may account for the 
disruption of cellular sheets and detachment of cells from the OptiCell™ surface as a 
result of tunicamycins exposure observed in this study.  
Morphological changes consistent with apoptosis were observed in all tunicamycins 
treatments used in this study.  However, apoptosis was not definitively confirmed as 
the mechanism of cell death.  Numerous previous experiments have reported 
apoptosis-related mechanism of cell death resulting from tunicamycins exposure in 
vitro and in vivo in various cell types (Calle et al.,  2000; Carlberg et al.,  1996; 
Chang and Korolev, 1996; Chang et al.,  1997; Dricu et al.,  1997; Leist and Wendel, 
1995; Martinez et al.,  2000; Noda et al.,  1999; Perez-Sala and Mollinedo, 1995; 
Finnie et al.,  2004).  In particular, Finnie et al., (2004) recently reported that in vivo 
derived liver tissue from guinea pigs treated with tunicamycins demonstrated 
morphological evidence consistent with apoptosis utilizing terminal deoxynucleotidyl 
transferase mediated dUTP-biotin nick-end labeling (TUNEL) and DNA laddering 
techniques.  Therefore, further experiments using techniques such as those mentioned 
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above would be necessary to definitively distinguish apoptosis from necrosis as the 
mechanism of cell death in this study. 
The OptiCell™ system offered a valuable technique for monitoring cellular 
morphology and was vital to the success of this study.  As mentioned in Section 3.4.1, 
the OptiCell™ system offers the unique ability of protecting cells at all times by 
remaining sterile with use inside or outside of the incubator.  This feature was 
invaluable to this study as it allowed each OptiCell™ treatment to be examined 
microscopically and then returned to the incubator following observation at each of 
the 12 time points.  Therefore, ensuring the sterility of the cellular environment was 
maintained within each treatment across the 78 h duration of the study.  This 
OptiCell™ feature allowed a significant reduction in resources as only six OptiCells 
i.e. one per treatment for morphological analysis was required.  Alternatively, to 
perform this same experiment using a traditional chamber slide system would require 
at least one well per time point.  This equates to a large number of samples which can 
obviously be difficult to handle, expensive and cells must be fixed and stained when 
processing chamber slides for microscopic examination.  Further, the chamber slide 
system doesn’t offer microscopic examination of cells in real-time as they take 
considerable time to be processed and must be fixed and stained.  Various 
applications of the OptiCellTM system utilized in previous studies have been reported 
including an in vitro model for studying oral cancer cell invasion (Duong et al.,  
2005) and gene delivery technology (Vandenbroucke et al.,  2007; Rahim et al.,  
2006). 
Interestingly, the most severe morphological effects consistent throughout all 
remaining time points identified in the 50 µM dose is supported by the cell viability 
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data (3.5.1).  In particular, the cell viability data demonstrated the percentage rate of 
cellular death was most significant over time in the 50 µM dose, closely followed by 
5 µM.  However, the observation of treatments 0.5 µM or greater showing similar 
dramatic morphological effects over time and the lowest dose toxin treatment (0.05 
µM) showing comparatively few morphological changes (up until 46 h) with cells 
appearing indistinct from controls was not reflected in the cell count data.   
Differences in observed results between the cytotoxic cell count data and the recorded 
morphological observations is perhaps to be expected as two separate parameters 
(quantitative vs qualitative) are being measured with obviously seperate variables at 
play.  As mentioned previously, variables in cell count data collection may include: 
errors with cell counts due to ineffective tryptinisation and human error with cell 
counts etc.  With regard to morphological observations, interpretation and descripton 
of the morphological images may not have been as precise given this was a 
preliminary study and resources were not initially available for microscopy to be 
performed by a skilled molecular epidemiologist.  For instance, identifying an area 
which was representative of the entire cell population within a particular treatment to 
later use for assessing cellular morphology was extremely difficult.  Ultimately, 
assessment of each set of data (cytotoxic and morphologic) against the corresponding 
controls within each experiment is what is relevant and is what needs to be the focus 
for interpretation. 
In general, the results of both the cell viability assay and morphological assessment 
have demonstrated a hepatotoxic effect on clone-9 hepatocytes in vitro at all four 
doses of tunicamycins, including the lowest dose of 0.05 µM which is a significantly 
lower concentration than used previously.  As a result, significantly lower doses are 
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required for future studies investigating low level subclinical and no observable effect 
level exposure.  
3.6.3 Toxicogenomic - Microarray 
With the demonstration that tunicamycins and corynetoxins affected the viability and 
morphology of hepatocytes in vitro, it followed to examine the molecular basis for 
these changes through the combined in vitro toxicogenomic approach.   
The in vitro toxicogenomic model using Eppendorf DualChip™ rat hepato arrays 
demonstrated for the first time that treatment of in vitro cultured rat hepatocytes 
(clone-9) with levels of tunicamcyins as low as 0.05 µM and 50 µM tunicamycin for 
24 h resulted in differential gene expression when compared to control untreated cells. 
The commercial low-density DualChip™ rat hepato was selected as the array 
platform for this in vitro toxicogenomic model in an attempt to minimise the inherent 
variability associated with microarray studies (i.e. non-commercial HD array 
platforms) and to extract more reliable data from array experiments.  The DualChip 
system offers a highly reproducible array platform which provides an effective 
analysis control system aimed to reduce technical variations.  
The DualChip array system offers the opportunity to perform one-colour labelling 
using the same labelled nucleotide dCTP for both the reference and test samples.  It is 
widely accepted that Cy3 and Cy5 (two commonly used fluorochromes) differ in their 
chemical stability, quantum yields and incorporation rates (Worley, 2000).  The one-
colour protocol avoids these problems associated with unequal properties of uisng two 
different labels and significantly enhances the efficiency of hybridisation and 
consequently improves detection of less abundant transcripts.  In addition, the layout 
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and quality of Eppendorf DualChip™ is optimised for one colour gene expression 
protocols.  Firstly, two arrays per DualChip™ allow a direct comparison of two RNA 
samples on the one slide.  Secondly, one colour gene expression analysis allows the 
possibility of carrying out a comparison of several RNA samples with only one 
control.  Despite, the one-colour labelling protocol involving at least two independent 
hybridisation reactions which may be perceived as constituting certain technical 
variations between experiments, the DualChip analysis control system has the ability 
to compensate for most of these problems.  
Although the DualChip system is equally suited for either direct or indirect labelling, 
noticeably better results, particularly in terms of sensitivity, have been observed when 
using the indirect one-colour protocol (de Longueville et al.,  2002).  This is reflected 
in the amount of RNA recommended for use in the given protocol: i.e. 5 to 10 µg of 
total RNA for one-colour labelling using indirect labelling protocol and 20 to 25 µg of 
total RNA is required for our two colour direct labelling protocol, respectively.  For 
the abovementioned reasons, the DualChip indirect one-colour protocol was utilised 
for all array experiments.   
Separate RT reactions were also carried out on each of the three biological replicates 
as inherent variability is expected in gene transcription that may be found in two so-
called “identical” samples (Arfin et al.,  2000; Baldi and Long, 2001).  These separate 
RT reactions were then pooled to minimise variability between samples for 
hybridisation.  The use of replicate samples and separate RT reactions has been shown 
to increase the statistical significance of the findings generated by microarrays (Lee et 
al.,  2000). 
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A single time-point of 24 h after tunicamcyins treatment was selected for analysis of 
gene expression.  Twenty four hours has been frequently selected as an appropriate 
time point to sample after exposure for analysing gene expression modifications under 
in vitro conditions.  It has been suggested that sampling at 24 h provides a more 
complete gene response in hepatocytes without the interference of adaptive responses 
that may be encountered at earlier time points or secondary responses that may be 
encountered later (Baker et al.,  2001; Waring et al.,  2001).  Furthermore, previous 
studies have shown that early in vitro responses may accurately model early in vivo 
gene expression effects (Dere et al.,  2006).  
Exposure of in vitro cultured rat hepatocytes to 0.05 µM and 50 µM tunicamcyins for 
24 h resulted in 8 and 9 genes respectively that were expressed at significantly 
different quantitative levels compared to untreated hepatocyte controls.  Of the 
quantitative ratios identified, all ratios were considered statistically ‘highly 
significant’ as they fell outside the 99% confidence interval.  The remaining analysed 
genes were either unchanged or had ratios involving one low and/or one saturated 
signal intensity and were considered “qualitative” or had two unacceptable signal 
intensities and were considered “not in linear range”.  Upon further inspection of the 
listed “qualitative” genes for each of the three separate gains in the ratio table, it 
appeared that the majority of “qualitative” ratios had an associated “low signal mean” 
for the “experimental” signal with the reference signal acceptable “ok”.  This 
indicates that there may have been detection problems associated with the reference 
array.  
The signal intensity values used to calculate ratios (reference/treatment) was 
automatically set at least 2.5 times the background signal.  This cut-off was applied to 
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each experiment and selects preferentially genes that are moderate to strongly 
expressed.  However, a disadvantage of this stringent cut-off is the tendency to 
disregard weakly expressed genes.  Therefore, it would appear that many genes did 
not reach a high and stable enough signal-to-background ratio in these experiments.  
The presence of many highly abundant transcripts has a dilution effect on low 
abundance transcripts.  It should be noted that current microarray technology 
continues to have some difficulty in reliable detection of low copy genes.  It is unclear 
whether this provides an explanation for the associated low signal mean of the 
reference sample.  Subsequent RNA amplification steps have been suggested to 
circumvent this limitation (Eberwine et al.,  1992). 
Analysis of the genes which had statistically significant expression (qualitative and 
quantitative) revealed similar differential gene expression levels between 0.05µM and 
50µM tunicamycin doses.  In general, gene expression changes were identified that 
were indicative of toxic stress with cell membrane disruption, detoxification and 
apoptosis.  
Interestingly, the majority of differentially transcribed genes in both treatments were 
down regulated.  In particular, the 0.05 and 50 µM treatments identified 51 and 46% 
respectively of the statistically significant genes as down-regulated.  The most 
significantly down regulated genes within both treatments compared to controls were: 
FN, ecoa, Osteon, MnSOD and mt_Co1.  Generally, the functions of these repressed 
genes include: maintaining the integrity of the extracellular matrix (FN-fibronectin 
and Osteon-Osteonectin); lyase activity/ β oxidation (ecoa-enoyl CoA); oxidative 
metabolism and detoxification of radicals which are toxic to biological systems 
(MnSOD- superoxide dismutase); and drug metabolism (mt_Co1 – cytochrome c 
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oxidase).  Overall, the levels of repression were fairly similar between both dose 
groups. 
The most significantly down regulated gene was Fibronectin (FN). Fibronectin (FN) 
is a glycoprotein important in cell to cell and cell to substrate adhesion and 
maintaining the integrity of the extracellular matrix (Grinnell and Feld 1979; Yamada 
et al.,, 1976).  Fibronectin is synthesised by diverse cell types, including hepatocytes, 
which are known to secrete plasma FN and are the major source of this protein in vivo 
(Tamkun and Hynes, 1983).  Interestingly, the repression of FN as a result of 
tunicamycins treatment is consistent with previous reports (Jago, 1984).  It has been 
previously shown that the absence of FN impairs cardiovascular function and 
modulates vascular permeability by causing decreased peripheral circulation and 
oxygen utilization, culminating in organ collapse and death (Jago, 1984).  Thus, the 
inhibition of FN by tunicamycins has been suggested to play a role in the associated 
vascular effects of tunicamcyins by favouring an increase in capillary permeability 
and thrombus formation.  By electron microscopy evidence of endothelial damage and 
associated thrombosis has been evident in some cerebral capillaries (Finnie and 
O'Shea, 1988; Finnie and Mukherjee, 1987).  Should the expression and protein 
synthesis of FN be affected by tunicaminyl-uracil toxicity, the subsequent effect may 
explain the breached blood-brain barrier and potentially the associated liver damage 
caused by corynetoxins and tunicamcyins (Jago et al.,  1983).  However, further 
studies to confirm FN repression may be required as FN synthesis and FN receptor 
expression is frequently found to be present at very low levels or completely absent in 
transformed and neoplastic cells (Schwarzbauer, 1991). 
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Osteonectin (Osteon)/SPARC (secreted protein acidic and rich in cysteine) was also 
shown to be down regulated as a result of tunicamycins exposure.  Osteon, like 
fibronectin (FN), is a glycoprotein involved in maintenance of the extracellular 
matrix.  In particular, osteon is specifically involved in the regulation of cell shape, 
adhesion, migration and proliferation.  Osteon has been demonstrated to have effects 
on extracellular matrix synthesis and degradation and it has also been found to affect 
FN and lamin synthesis (Kamihagi et al.,  1994).  Therefore, the identification of both 
FN and Osteon as differentially regulated is perhaps to be expected given there 
relationship as evidenced by previous studies. 
Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A (ecoa) is a bifunctional 
enzyme involved in the β-oxidation cycle of peroxisomes.  This gene is involved in 
fatty acid degradation, and has been shown to have intrinsic hydratase activity 
(Nakagawa et al.,  1995).  Previous studies have identified strong repression of 
transcript levels of multiple genes in energy demanding biochemical pathways as a 
result of hepatotoxin treatment.  In particular, genes involved in microsomal (or 
peroxisomal) β-oxidation were found to be down regulated following administration 
of acetaminophen (APAP) (a known model hepatotoxin) to rats in vivo (Heinloth et 
al.,  2004).  Since microsomal/peroxisomal β-oxidation is not directly coupled to an 
energy producing electron transport system and the initial step in this pathway is an 
ATP requiring reaction, negative regulation of this pathway via repression of ‘ecoa’ 
(the second enzyme in the peroxisomal β-oxidation pathway) is consistent with the 
negative regulation of other energy consuming pathways.  Interestingly, acyl-CoA 
oxidase (ACO), the first enzyme (precursor) in the β-oxidation cascade was not shown 
to be differentially regulated.  However, upon closer inspection this gene in both 
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treatments had an experimental low signal mean and low signal to noise ratio (SNR), 
reference OK.  This rendered the overall value “qualitative”.  
Superoxide dismutase 2, mitochondrial / Manganese-containing superoxide dismutase 
(MnSOD) is an intramitochondrial free radical scavenging enzyme.  MnSOD has been 
identified as a highly inducible enzyme (Davies et al.,  1993) and is involved in the 
primary antioxidant defence whereby it acts to destroy toxic free radicals within the 
cells by transforming superoxide anion into hydrogen peroxide.  A balance between 
the activity of MnSOD and the Glutathione (GSH) redox cycle must exist to ensure 
the efficient disposal of hydrogen peroxide (Fernandez-Checa et al.,  1997).  Previous 
studies have shown that exposure of rat hepatocyte cultures to acute doses of 
particular hepatotoxins results in a sharp decrease in MnSOD and catalase enzyme 
activities and mRNAs.  Thus, despite MnSOD perhaps being expected to be induced 
in response to toxic stress, previous studies have suggested that oxidative stress 
induced by particular hepatotoxins may in fact occur because of the down-regulation 
of primary antioxidant defence genes and as such the oxidative stress participates in 
the signalling pathways responsible for inducing cell death (Sanz et al.,  1999). 
mt_Co1 -cytochrome c oxidase subunit 1 is a large transmembrane protein complex 
invoved in the fatty acid beta-oxidation (KEGG) pathway (Liu et al.,  1996).  It is the 
last enzyme in the respiratory electron transport chain whereby it catalyzes the 
reduction of oxygen to water.  The activity of this protein has been implicated in 
controlling cell growth and differentiation.  Various toxins including cyanide (CN), 
sulphide and carbon monoxide are potent inhibitors of mt_Co1 (Dorman et al.,  2002; 
Khan et al.,  1990; Way, 1984).  In particular, CN attaches to the iron within this 
protein.  The binding of CN to this cytochrome prevents transport of electrons from 
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cytochrome c oxidase to oxygen.  As a result, the electron transport chain is disrupted 
and the cell can no longer aerobically produce ATP for energy (Chen and Chen, 2003; 
Gunasekar et al.,  1998; Jones et al.,  2000).  Tissues that mainly depend on aerobic 
respiration, such as the central nervous system and the heart, are particularly affected.  
It is unknown whether tunicamcyins have the ability to bind to mt_Co1.  However, it 
would be expected that the evident repression of mt_Co1 would occur prior to any 
binding event. 
The most highly induced genes consistent within both treatments compared to 
untreated cells were APOE and JNK3.  
JNK3 – (MAPK10) c-jun N-terminal kinase gene was the most significantly 
up-regulated gene and is consistent with expected induction following a toxic insult.  
JNK3 functions as a stress-activated protein kinase and is activated as part of the pro-
apoptotic stress response.  JNK3 activity is required for c-jun phosphorylation and 
promoter activation, as well as the pro-apoptotic signalling pathway (Eilers et al., 
2001).  JNK3 is involved in a wide variety of cellular responses including: cell 
growth, oncogenic transformation, cell differentiation and cell death (Leppa and 
Bohmann, 1999; Ip and Davis, 1998).  JNK3 plays a critical role in activation of c-jun 
and apoptosis in a classical model of cell-autonomous programmed neuron death 
(Bruckner et al.,  2001).  In particular, JNK3 regulates gene expression by 
phosphorylating transcription factors, such as c-Jun within the stress activated protein 
kinase pathway.  Therefore, the observed induction of JNK3 (known to play a critical 
role in promoting apoptosis (Jarpe et al.,  1998) is consistent with previous studies 
demonstrating that apoptosis contributes to hepatocytes loss in tunicamycins 
poisoning (Finnie et al.,  2004).  Furthermore, these results suggest that the MAPK 
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pathway may be involved in the mechanism of tunicamycins-induced apoptosis as 
increased expression of the JNK3 gene was consistently observed in these tissues, 
suggesting that JNK3 may be a key factor. 
Apolipoprotein E (ApoE) is a lipid transport protein primarily produced by the liver 
with expanded functions in cellular response to tissue injury, immune regulation and 
cell growth.  More specifically, ApoE is involved in both lipid metabolism and 
neuroprotection (Pearson et al.,  2005).  In addition, ApoE has been shown to direct 
vascular changes that contribute to arterial protection (Bocksch et al.,  2007). This 
would seem to be in direct contrast to FN previously identified to be down-regulated 
as a result of tunicamycins exposure and suggested to be involved in increasing 
capillary permeability and thrombus formation.  Given ApoE has been shown to 
possess anti-inflammatory properties and contribute to neuro and arterial protection it 
would then perhaps be expected to be induced as a result of toxic insult to potentially 
counter the effects of tunicamycins, a known neurotoxin and vasodilator.  
APOE and JNK3 were significantly more up-regulated in the 50 µM dose compared to 
0.05 µM which suggests that these genes may be in fact dose dependent.  
Furthermore, FN and ecoa (two of the five most highly expressed genes) were shown 
to be significantly more repressed in the 50 µM dose compared to 0.05 µM sample.  
This may indicate that the induction of Bclx, FN and ecoa is a dose-dependent cellular 
response to tunicamycins. 
Differences in gene expression between 0.05 µM and 50 µM treatment involved three 
genes c-jun, Bclx and BAD.  Within the lowest 0.05 µM treatment, c-jun was 
significantly upregulated; however this gene was unchanged in the highest 50 µM 
dose.  As mentioned previously, c-jun functions as a kinase involved in signal 
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transduction, mediating a stress response activated as a result of the JNK pathway and 
is thought to play a role in induction of apoptosis.  Therefore, c-jun would be 
expected to be induced given JNK was shown to be up-regulated in both treatments.  
Alterations in apoptosis-related genes Bclx and BAD were both shown to be 
significantly down regulated in the 50 µM treatment compared to the 0.05 µM 
treatment.  Both genes belong to the Bcl-2 family which govern mitochondrial outer 
membrane permeabilisation and can be either pro-apoptotic or anti-apoptotic.  Bclx (B 
cell lymphoma 2-like 1) is an anti-apoptosis inhibitor of programmed cell death and 
mitochondrial dysfunction.  BAD (Bcl-2 associated death agonist) is involved in 
growth factor receptor signalling and in promotion of apoptotic pathways.  Studies 
have identified BAD and Bclx regulation as early events linking endoplasmic 
reticulum (ER) stress to mitochondria-mediated apoptosis.  In particular, treating 
neuronal cells with ER stressors (NDGA and BFA) induced a rapid 
dephosphorylation of BAD and decrease expression of Bclx which is associated with 
an apoptotic cascade involving the mitochondria (Elyaman et al.,  2002).  TM is 
recognised as an ER stressor also and may trigger a similar response in hepatocytes 
given both BAD and Bclx were shown to be down-regulated in the high dose 50 µM 
treatment. 
The results clearly demonstrate that treatment of in vitro cultured hepatocytes with 
tunicamycins causes differential gene expression when compared to control untreated 
cells.  As there was very little difference in gene expression patterns between 0.05 and 
50 µM tunicamycin doses, a preliminary signature profile of tunicamycin exposure 
has been established.  The expression profile includes genes related to oxidative 
stress, apoptosis, lipid metabolism and drug metabolism.  Ultimately, combining 
microarray data with other biochemical and anatomical measurements of toxicity has 
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proven to be valuable in providing more direct linkages between a change in gene 
expression and the toxic end result.   
Overall, it was a surprising result that differential gene expression between both the 
high (50 µM) and low (0.05 µM) tunicamycin treatments was very similar and 
reflected overt toxicity (cytotoxic and morphologically) despite the 1000-fold 
difference in dose concentrations.  This observation was not expected since 0.05 µM 
tunicamycin is significantly lower than any dose previously reported to produce overt 
toxicity as reflected by traditional clinical chemistry and histopathology parameters.  
It would appear from this investigation that gene expression changes are a far more 
sensitive indicator of potential adverse effects than traditional measurements of 
toxicity.  In particular, the range of concentrations tested in the combined 
toxicogenomic approach was based on preliminary assays (data not shown) using 
doses of tunicamycin/corynetoxin equal to or 10-fold lower than concentrations 
reported from previous studies.  As overt toxicity was observed in all treatments, 
identification of the lowest tunicamycin dose to induce gene expression changes 
without causing overt toxicity was not identified.  Therefore, these results suggest that 
significantly lower doses of tunicamycins are required for subsequent investigations 
of low level/ sub-toxic exposure.  
The in vitro toxicogenomic strategy developed in this study provides a valid and 
useful approach for analysing low level tunicamycin exposure.  The in vitro based 
model offers a number of significant advantages for early phase developmental 
studies such as this, including: simplicity, cost effectiveness, reproducibility (i.e. 
small focussed array and continuous cells) and is amenable to high-throughput 
screening.  In addition, this strategy offers other significant benefits for early stage 
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toxicogenomic investigations, including: avoiding the use of animal models, allowing 
the maintenance and better control of experimental conditions and reduces the need 
for acquiring large amounts of toxin for testing (Baker et al.,  2001).  This last point is 
a significant issue with regard to studying corynetoxin and was a major factor behind 
the development of the in vitro model for this and subsequent studies (Chapters 4 and 
5). 
Although the in vitro toxicogenomic strategy developed in this study constitutes an 
effective tool for gene expression analysis and has the potential to provide a valid and 
useful system for further toxicogenomic investigations of low level 
tunicamycin/corynetoxin exposure, amenable to the development of high-throughput 
toxicity screening assays, there are a number of limitations in using in vitro 
approaches.  These include: functional differences observed in primary hepatocytes 
relative to the intact liver; the absence of interactions with biological entities (e.g., 
organs, blood) under in vitro conditions; and the difficulty to select doses and time 
points which are representative of an in vivo situation.  Despite these differences, 
immortalised cells as well as other emerging in vitro systems (e.g., primary cells, stem 
cells, and 3D culture systems) provide valuable alternatives in early phase 
developmental studies.  However, it is critical to keep in mind the inherent limitations 
in the ability of in vitro system to model in vivo or whole organism gene responses 
which must be eventually identified and appropriately considered in later clinical 
phase studies.  
Furthermore, it should also be kept in mind that this in vitro toxicogenomic strategy 
developed in this study remains a complex method that always needs validation with 
more sensitive methods such as real-time PCR, western blotting or verification of 
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protein function.  Therefore, subsequent toxicogenomic investigations of low level 
tunicamycin exposure should be coupled with real-time PCR analysis to further 
validate the resultant gene expression data obtained.   
3.7 Conclusion 
This combined toxicogenomic approach to defining the effect of exposure of in vitro 
rat hepatocytes to low level tunicamycin will complement previous work that has 
focussed primarily in toxicology, pathology and pathogenesis associated with acute 
exposure to tunicamycins.  Furthermore, this approach represents a useful surrogate to 
primary hepatocytes and in vivo models (especially in early developmental stage) for 
future toxicity studies. 
Future work is required using this validated in vitro toxicogenomic model to 
investigate the effects of corynetoxin and tunicamycin at significantly lower dose 
rates to potentially identify sub-clinical genomic effects of corynetoxin exposure and 
to assess the specificity of the gene regulation changes for tunicaminyl-uracil toxicity.  
In particular, further studies to examine the bioequivalence of corynetoxin and 
tunicamycins are important to assess the suitability and validity of using tunicamycin 
as a substitute for corynetoxin for experimentally modeling ARGT.  This work forms 
the basis for the bioequivalence and biomarker study described in Chapter 4. 
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Figure 3-1 OptiCell™ OptiCell™ is a unique cell culture format for growing, monitoring, 
and transporting cells. OptiCell™ consists of a 2mm thick culture chamber providing a 
sterile, sealed cell culture environment between two optically clear 100 cm2 gas-permeable 
growth surfaces. OptiCell™ has a standard microtiter plate-sized plastic frame with specially 
designed ports for access to the contents. 
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Figure 3-2 OptiCell ™ procedure Twelve Opticells™ (BioCrystal, Westerville, Ohio, USA) 
were seeded with clone-9 rat hepatocytes (ATCC, Manassas, Virginia, USA; accession 
number CRL-1439) at a density of 1 x 105 cells mL-1 in toxin free F-12K media.  After 48h 
post-seeding incubation at 37 ºC in a 5% CO2 in air atmosphere, the media was removed 
from all Opticells™ and replaced with the various test media and incubation continued for a 
further 24 h. 
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Figure 3-3 Overview of array experiment: After cell treatment, mRNA is extracted, reverse-
transcribed and labelled with biotin.  Hybridisation of the DNA microarrays is then 
performed. Fluorescence readout allows detection of genes expressed in the cells. Analysis is 
performed by quantification of the cellular mRNA: comparison between reference cells and 
treated cells allows analysing differentially expressed genes in response to the toxin 
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Figure 3-4 Overview of one-colour gene expression (a) One-colour gene expression 
involves two RNA sets (1) Test and (2) Reference to be analysed. (b) RNA is labelled in two 
separate reverse transcription reactions that employ the same kind of labelled nucleotide (e.g. 
biotin-11-dCTP) in both reactions. Resulting in both cDNAs labelled identically. (c) cDNA 1 
(derived from RNA1) is then hybridised against microarray 1, whereas in parallel cDNA2 
(derived from RNA2) is hybridised against microarray 2. 
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Figure 3-5 Design of the DualChip rat hepato version 1.0 Internal Standards (yellow; 
contain 6 differently concentrated plant sequences) and house keeping genes (blue) are 
distributed over the array. All probes on the DualChip microarrays are spotted in triplicate. 
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Figure 3-6 RP-HPLC analysis of ~1 mg/mL solutions of tunicamycins RP-HPLC analysis of 
~1 mg/mL solutions of tunicamycin prepared in 0.6 mM NaOH.  5 mL of each was applied to 
a C18 column and eluted using a methanol + 0.1% TFA gradient of 70-90% over 40 minutes.  
The assignment of components in based on the results of Cockrum and Edgar (1983). 
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Figure 3-7 Average number of live cells A graphical representation of the average numbers 
of live cells present within each dose group (Table 3-4). Exponential trend lines were plotted 
using Microsoft Excel. 
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Figure 3-8 Percentage of dead cells:  The percentage of dead cells within each culture by 
Trypan blue dye exclusion staining. This was generated based upon the results presented in 
Table 3-5. 
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Figure 3-9 Photomicrographs of cells exposed to various treatments at 12 h Morphological 
differences were not observed in any of the treatments up to 22 h following toxin exposure. 
(a) 0.05 μM TMs (b) 0.5 μM TMs (c) 5 μM TMs (d) 50 μM TMs (e) and  
(f) Control (untreated) cells at 8 h. All images 100 x magnification. Scale bar is 100um. 
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Figure 3-10 Photomicrographs of cell treatments at 22 h Morphological changes including 
vacuolation of cytoplasm first appeared at 22 h in samples ≥ 0.5 μM TMs. (a) 0.05 μM TMs 
(b) 0.5 μM TMs (c) 5 μM TMs (d) 50 μM TMs (e) and (f) Control (untreated) cells at 22 h. 
All images 100 x magnification. Scale bar is 100um. 
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Figure 3-11 Photomicrographs of clone 9 cells exposed to various treatments at 26 h 
Morphological changes including vacuolation of cytoplasm continued and nucleic changes 
first appeared at 26 h in samples ≥ 0.5 μM TMs. (a) 0.05 μM TMs (b) 0.5 μM TMs (c) 5 μM 
TMs (d) 50 μM TMs (e) and (f) Control (untreated). All images 100 x magnification. 
Scale bar is 100um. 
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Figure 3-12 Photomicrographs of clone 9 cells exposed to various treatments at 30 h 
Morphological changes including vacuolation of cytoplasm and nucleic changes continued at 
in samples ≥ 0.5 μM TMs. First signs of vacuolation appeared in the 0.05 μM TMs sample. 
(a) 0.05 μM TMs (b) 0.5 μM TMs (c) 5 μM TMs (d) 50 μM TMs (e) and (f) Control 
(untreated). All images 100 x magnification. 
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Figure 3-13 Photomicrographs of clone 9 cells exposed to various treatments at 46 h. 
Vacuolation of cytoplasm and degenerate nucleic changes were most severe in samples ≥ 0.5 
μM TMs at 46 and 51 h. Vacuolation was evident in the 0.05 μM TMs sample, however 
nucleic changes had not yet appeared. (a) 0.05 μM TMs (b) 0.5 μM TMs (c) 5 μM TMs (d) 50 
μM TMs (e) and (f) Control (untreated). All images 100 x magnification. 
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Figure 3-14 Photomicrographs of clone 9 cells exposed to various treatments at 51 h. 
Cellular shrinkage and detachment from adjacent cells were observed in samples  
≥ 0.5 μM TMs at 51 h (a) 0.05 μM TMs (b) 0.5 μM TMs (c) 5 μM TMs (d) 50 μM TMs (e) 
and (f) Control (untreated). All images 100 x magnification. 
 
 
a b  
c d  
e f  
100 um100 um 
100 um 100 um
100 um 100 um
Chapter 3 
  160 
 
 
 
 
 
 
 
 
 
Figure 3-1 5 Photomicrographs of clone 9 cells exposed to various treatments at 78 h 
Visible live cells were observed only in the 0.05 and 0.5 μM TMs treatments. Control cells 
consisted of continuous sheets of normal appearing cells showing comparatively few changes 
(a) 0.05 μM TMs (b) 0.5 μM TMs (c) 5 μM TMs (d) 50 μM TMs (e) and (f) Control 
(untreated). All images 100 x magnification 
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Figure 3-16 Scatter plot of normalised fluorescent intensity values 0.05 µM Tunicamycins 
treatment DualChip™ rat hepato hybridised with cDNA obtained from mRNA extracted from 
hepatocytes untreated and hepatocytes treated with 0.05 µM TMs at a medium PMT setting. 
Control values (x-axis) were plotted against TMs dosed values (y-axis). The arrows represent 
the most highly up-regulated and down-regulated genes consistent between all 3 PMT settings 
and both TMs doses. 
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Figure 3-17 Scatter plot of normalised fluorescent intensity values 50 µM Tunicamycins 
treatment DualChip™ rat hepato hybridised with cDNA obtained from mRNA extracted from 
hepatocytes untreated and hepatocytes treated with 50 µM TMs at a medium PMT setting. 
Control values (x-axis) were plotted against TMs dosed values (y-axis). The arrows represent 
the most highly up-regulated and down-regulated genes consistent between all 3 PMT settings 
and both TMs doses. 
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Figure 3-18 Differential gene expression 0.05 µM Tunicamycins treatment Changes in gene 
expression observed after 24 h treatment of clone 9 cells with 0.05 µM TMs 
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Figure 3-19 Differential gene expression 50 µM Tunicamycins treatment. Changes in gene 
expression observed after 24 h treatment of clone 9 cells with 50 µM TMs 
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Figure 3-20 Comparison of changes in gene expression 0.05 and 50 µM Tunicamycins 
Comparison of changes in gene expression observed after 24 h treatment shared between 
Clone 9 cells with 0.05 and 50 µM TMs. 
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Table 3-1 DualChip hepato series content overview 
 
Functional group Genes
Cell cycle Cyclins, JNK's, Telomerase
Drug metabolism P450s, GSTs UGTs
Oncogenes c-jun, c-myc, elk-1
Inflammation IL-6, Cox2
Apoptosis Bax, Bcl-2, TNF, Smp30
Stress response ApoJ, Hsp70, Ho-2, SOD, TGFBRII
Transcription factors C/EBPα, κB-α, NFκB, erk-1, p388, 
HGF
Peroxisome Proliferators Enoyl coA hydratase, PPARα, ACO
Transport MDRs, albumin, transferrin
DNA damage GADD45, GADD153
DNA repair MGMT
Housekeeping genes α-tubulin, S29, myr, HGT, GAPDH, 
Polyubiquitin, PA2, β-actin
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Table 3-2  List of quantitative highly significant genes differentially expressed in Array 2 
(0.05 µM) vs. control. 
 
 
Time Control 0.05 µM TMs 0.5 µM TMs 5 µM TMs 50 µM TMs
0 4.63 5.56 5.19 4.63 5.56
4 7.41 7.41 9.44 11.94 2.04
8 3.15 2.04 5.37 5.56 1.30
22 8.89 2.59 3.70 9.26 2.59
26 6.48 3.52 6.85 5.00 1.67
30 2.04 0.83 2.59 4.81 3.70
46 27.04 6.11 6.85 2.22 5.74
50 37.78 9.81 16.48 2.59 3.52
54 67.22 3.70 15.74 4.26 3.89
70 40.93 5.00 10.74 4.07 0.00
74 69.58 0.74 8.15 2.04 0.69
78 107.96 6.11 12.41 0.19 0.00
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Table 3-3 List of quantitative, highly significant genes differentially expressed in Array 3 (50 
µM) vs. control. 
 
Time Control 0.05 µM TMs 0.5 µM TMs 5 µM TMs 50 µM TMs
0 11.47 9.74 3.71 4.14 0.00
4 5.12 14.93 15.26 12.46 48.22
8 32.25 38.92 24.04 26.45 64.86
22 50.28 58.82 66.00 26.27 64.95
26 28.63 32.56 21.71 38.27 67.69
30 48.22 70.07 37.59 65.91 47.14
46 11.00 31.42 31.15 72.66 41.66
50 15.44 32.85 27.65 80.51 69.70
54 3.72 71.53 30.47 67.12 70.72
70 41.93 58.33 47.19 71.87 100.00
74 10.66 0.97 48.10 88.43 95.54
78 5.51 75.95 64.20 98.31 100.00
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Table 3-4 Functions of identified differentially regulated genes 
 
 
Gene ID Ratio Status Significance Genbank SwissProt
JNK3 2.64 Quantitative Highly 
Significant
NM_012806 P49187
c-jun 1.74 Quantitative Highly 
Significant
X17163 P17325
APOE 1.52 Quantitative Significant J00705 P02650
FN 0.22 Quantitative Highly 
Significant
X15096 P04937
ecoa 0.36 Quantitative Highly 
Significant
K03249 P07896
MnSOD 0.44 Quantitative Highly 
Significant
Y00497 P07895
mt_Co1 0.45 Quantitative Highly 
Significant
M27315 P00406
Osteon 0.5 Quantitative Significant NM_012656 P16975
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Table 3-5 List of quantitative, highly significant genes differentially expressed in Array 3 (50 
µM) vs. control. 
 
 
Gene ID Ratio Status Significance Genbank SwissProt
JNK3 4.54 Quantitative Highly 
Significant
NM_012806 P49187
APOE 3.40 Quantitative Highly 
Significant
J00705 P02650
BAD 1.59 Quantitative Significant NM_022698 O35147
FN 0.20 Quantitative Highly 
Significant
X15096 P04937
Ecoa 0.30 Quantitative Highly 
Significant
K03249 P07896
Osteon 0.49 Quantitative Highly 
Significant
NM_012656 P16975
Bclx 0.55 Quantitative Highly 
Significant
NM_031535 P53563
MnSOD 0.56 Quantitative Highly 
Significant
Y00497 P07895
mt_Co1 0.57 Quantitative Highly 
Significant
M27315 P00406
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Table 3-6  Functions and Genbank accession numbers of identified differentially regulated 
genes 
 
 
Gene name Gene Function Genbank
JNK3 (MAPK-10) JNK3 Stress response NM_012806
Apolipoprotein E APOE Lipidprotein transport J00705
Fibronectin FN Extracellular matrix X15096
enoyl coA ecoa Lyase activity K03249
Superoxide dismutase 2 MnSOD Oxidative metabolism Y00497
Cytochrome c oxidase subumt_Co1 Drug metabolism M27315
Osteonectin osteon Extracellular matrix NM 012656
c-jun c-jun Stress response X17163
B cell lymphoma 2-like 1 Bclx Anti-apoptosis NM 031535
Bcl-2 associated death agnBAD Bcl-2 associateed death agoni NM 022698
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CHAPTER 4 
An In Vitro Study of the Bioequivalence of Corynetoxins and 
Tunicamycins and Investigation of Biomarkers of 
Corynetoxins Exposure 
4.1 Publications relating to Chapter 4 
Allen JG, Retallick MAS, Kowalski M , Colegate SM, Speijers EJ, Doran T, 
Michalski WP (2007) A Study of the Bioequivalence of Corynetoxins and 
Tunicamycins: The effect of these toxins on the viability and morphology of rat 
hepatocytes in tissue culture.  In: Poisonous Plants: Global Research and Solutions 
(Eds K panter, T Wierenga and JP Pfister). pp 588-595. 
Part of the research presented in this chapter (bioequivalence only) has been 
published: - Allen JG:- responsible for the morphological analysis and descriptions of 
toxin exposed cells in vitro. Kowalski M  and Retallick MAS: - responsible for 
experimental design and performing experiments.  Kowalski, M.C, Retallick MAS 
Cahill, D., Doran, T.J. and Colegate, S.M.:- all contributed and assisted with the 
manuscript. 
4.2 Introduction 
Corynetoxins are poisonous natural chemicals produced by the bacterium  
R. toxicus and have proven extremely difficult to obtain in sufficient amounts and 
purity for experimental purposes and have significantly impeded studies attempting to 
Chapter 4 
  173 
investigate corynetoxin in the past (as discussed previously Chapter 1). Tunicamycins 
are a commercially available group of tunicaminyl-uracil glycolipids that have been 
routinely used as a substitute for corynetoxin to experimentally induce ARGT due to 
their similar structure, mechanism of action and accessibility (Edgar et al.,  1982; 
Payne et al.,  1983; Jago et al.,  1983).   
As described in Chapter 1, tunicamycins and corynetoxin share a common N-acetyl 
glucosamine-tunicaminyl-uracil (GTU) core structure and differ only in the length, 
hydroxylation state and terminal branching structure of the fatty acid chain attached 
via an amide link to the amino group of the central C11 aminosugar (tunicamine) unit 
(Cockrum and Edgar, 1983).  It has not been investigated as yet whether these 
differences in molecular structure may influence the biological activities of these 
toxins. 
Previous studies of ARGT have been based on acute exposure of tunicamycins and 
corynetoxin and have shown both toxins to exhibit similar antibiotic and biochemical 
activities, toxicities and clinical disease (Jago et al.,  1983; Finnie and Jago, 1985; 
Jago and Culvenor, 1987).  These published studies have described effects of acute 
exposure to support the bioequivalence of tunicamycins and corynetoxin.  The effects 
of corynetoxin and tunicamycins on rat liver hepatocytes cultured in vitro have been 
reported separately (Finnie, 2001; Yeoh et al.,  1984).  Although similarities in 
cytopathic effects of both toxins have been described, a side-by-side comparison of 
low level in vitro tunicaminyl-uracil exposure has not yet been published prior to 
studies reported in this thesis. 
A direct comparison of the molecular effects of low level tunicamycin and 
corynetoxin exposure is vital to further developing the current understanding of the 
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bioequivalence of these two toxins and assessing the suitability of tunicamycins as an 
experimental substitute for corynetoxin in future toxicity studies, in particular 
bioequivalence discovery.   
Biomarker discovery holds much promise for providing important tools for the pre-
clinical detection of toxicity (as discussed, Chapter 1).  Toxicogenomics provides an 
extremely powerful tool for identifying toxicity biomarkers, offering the potential to 
detect pre-clinical effects of toxicity for which traditional biochemical tests are 
incapable due to low sensitivity and specificity. The utility and feasibility of 
toxicogenomics in biomarker discovery has been demonstrated in a number of reports 
delineating chemical-induced toxicity, including hepatotoxicity leading to the 
identification of many promising biomarkers (Burczynski and Dorner, 2006; Heinloth 
et al.,  2004; Steiner et al.,  2004; Bushel et al.,  2007).  In addition, previous studies 
(Chapter 3) using the combined in vitro toxicogenomic model have also identified 
differential gene expression based on low level tunicamycin and corynetoxin exposure 
at doses undetectable by conventional endpoints including: cytotoxic and 
morphological analysis.  
As discussed (Chapters 1 and 3), the cumulative nature and lethality of corynetoxin 
has significantly impeded diagnostic efforts, with current approaches limited by a lack 
of specificity and inability to detect sub-lethal exposure prior to the onset of clinical 
signs.  The inability of current diagnostics to detect pre-clinical exposure has 
potentially important implications for long-term animal health, welfare and 
productivity and reinforces the urgent need to establish improved diagnostics for 
detection of low level pre-clinical exposure to corynetoxin.  
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As reported, livestock can apparently ingest up to 75% of a lethal dose of toxin and 
still appear clinically unaffected.  Also, a lag time of approximately 3 to 4 days exists 
between ingestion of a lethal dose and the onset of clinical signs.  As a result, 
clinically “normal” but intoxicated livestock can remain within the toxic environment 
and continue to be exposed to corynetoxin without detection.  In addition, other 
unaffected livestock also risk exposure by unknowingly being introduced into the 
toxic field environment or may be fed contaminated hay/fodder.  Furthermore, 
although the effect of chronic low level corynetoxin exposure currently remains 
unclear, there has been preliminary evidence to suggest that long term low level 
exposure can affect animal productivity (Davies et al.,  1996).  As such, effective 
detection and diagnostic approaches have proven a major challenge in the control and 
prevention of ARGT.   
Consequently, a more effective approach with enhanced specificity for detection of 
corynetoxicosis and enhanced sensitivity capable of identifying low level sub-clinical 
corynetoxin exposure is urgently required. 
Biomarker discovery offers the potential to provide important tools for the pre-clinical 
detection of corynetoxin.  Identification of biomarkers specific to pre-clinical 
exposure of corynetoxin may allow the development of early prediction tests for 
ARGT to alert farmers of subtle changes prior to organ dysfunction or damage and 
may facilitate improved control and prevention strategies for ARGT.  In particular, 
identification of pre-clinically exposed livestock may assist in reducing the risk of 
lethal toxicity by the immediate identification of pastures likely to be toxic.  Direct 
action could be then taken to prevent any continued or new exposure of stock to those 
areas. 
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This chapter describes the first reported comparative bioequivalence and biomarker 
study investigating exposure at the microscopic (cytotoxic and morphological) and 
genomic level of an in vitro rat hepatocytes cell line to equivalent low level doses of 
tunicamycin and corynetoxin.  
To investigate the bioequivalence of tunicamycins and corynetoxins in parallel and 
identification of biomarkers, the combined in vitro toxicogenomic approach 
developed and validated previously (Chapter 3) has been applied.   
This strategy (as discussed in Chapter 3) provides an effective and adaptable approach 
for analyzing low level tunicamycin exposure.  Furthermore, this strategy offers 
enhanced maintenance and improved control of experimental conditions by avoiding 
the use of in vivo animal models and global gene expression profiling platforms and 
importantly reduces the need for acquiring large amounts of toxin for testing (Baker et 
al.,  2001).  As discussed, reduced levels of corynetoxin for experimental testing is 
crucial when investigating ARGT and was a major factor behind the development of 
the in vitro model for this and subsequent studies.  Thus, this model has facilitated for 
the first time a parallel investigation of equivalent doses of corynetoxin and 
tunicamycin and identification of biomarkers of corynetoxin exposure.  
4.3 Aims of this Chapter 
This study aims to apply the combined in vitro toxicogenomic model to investigate 
the bioequivalence of tunicamycins and corynetoxins based on genomic, 
morphological and cytotoxic effects using an in vitro clone-9 hepatocytes exposed to 
equivalent low concentrations of toxin. 
Chapter 4 
  177 
A further aim was to utilise toxin at significantly lower concentrations to identify the 
lowest tunicamycin/ corynetoxin dose rate to induce no observable effect based on 
conventional morphological, cytotoxic measurement for the subsequent biomarker 
study. 
Ultimately, the results of this study aim to contribute to a better understanding of the 
suitability and validity of using tunicamycins as a substitute for corynetoxin for 
experimentally modeling ARGT. 
Based on the results of the bioequivalence study, the second aim was to apply the 
combined in vitro toxicogenomic model to examine gene expression changes caused 
by the exposure of clone-9 hepatocytes to corynetoxin to identify potential biomarkers 
that may act as early predictors of pre-clinical exposure to ARGT. 
4.4 Materials and Methods  
4.4.1 Reagents, cell lines and media 
Tunicamycins (av. MW 840; Sigma-Aldrich, St Louis, Missouri, USA) was obtained 
from Sigma-Aldrich (St Louis, Missouri, USA).  Corynetoxins (MW 860) was 
isolated from toxic annual ryegrass (Lolium rigidum) by Mr Neil Anderton of the 
Plant Associated Toxins Groups, AAHL, using the purification protocol described by 
Anderton et al.,, 2004. Clone 9 rat hepatocytes were purchased from the ATCC 
(Manassas, Virginia, USA – ATCC accession number CRL-1439).  F-12K Nutrient 
Mixture media was obtained from Gibco™ (Invitrogen, Carlsbad, California, USA) 
and supplemented to contain 2 mM L-glutamine (MP Biomedicals, Irvine, California, 
USA), 0.25% w/v amphotericin B (Invitrogen, Carlsbad, California, USA), 100 
units/mL penicillin (CSL Limited, Parkville, Victoria, Australia), 100 μg/mL 
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streptomycin (Sigma-Aldrich, St Louis, Missouri, USA) and 10% heat-inactivated 
fetal calf serum (Trace Biosciences, Sydney, New South Wales, Australia).  AnalaR 
grade sodium hydroxide (NaOH) was obtained from BDH Ltd. (Merck, Darmstadt, 
Germany). 
4.4.2 Preparation of toxin-containing media 
One mg/mL solutions of tunicamycin and corynetoxin were prepared in 0.6 mM 
NaOH (pH 12) and sterilised using a 0.22 μm filter within a laminar flow cabinet.  
Reverse-phase high performance liquid chromatography (RP-HPLC) analysis of each 
solution was performed (Shimadzu Class VP instrument, 5 μm particle size C18 
column) (Phenomenex, Torrance, California, USA).  Samples were eluted using a 
linear gradient of 70-90% methanol + 0.1% TFA at a flow rate of 200 μL/min over 40 
minutes and the eluate absorption at 260 nm determined.  The pure tunicamycin and 
corynetoxin solutions were then adjusted with sterilised 0.6 mM NaOH to 
concentrations of 0.84 mg/mL and 0.86 mg/mL, respectively.  From these stocks, 10-
fold serial dilutions in sterilised 0.6 mM NaOH were prepared down to 0.00084 
mg/mL and 0.00086 mg/mL for the tunicamycin and corynetoxin solutions 
respectively.  To create the toxin-containing media with the final concentrations of 5 
nM, 50 nM, 500 nM and 5000 nM tunicamycin or corynetoxin, ten-fold serial 
dilutions were then prepared to a final concentration from 5000 nM  to 5 nM.  NaOH 
control sample consisting of 0.5 mL of toxin-free 0.6 mM NaOH added to 99.5 mL of 
media was also prepared. 
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4.4.3 Exposure of clone-9 hepatocytes to toxins 
A cell culture system (OptiCell™ BioCrystal, Westerville, Ohio, USA) as described 
in Sect: 3.4.1 was also utilised for this bioequivalence study.  Thirty six OptiCell™ 
were seeded with clone-9 rat hepatocytes at a density of 1 x 105 cells mL-1 in toxin 
free F-12K media.  This provided 6 groups of triplicate samples of corynetoxin and 
tunicamycin representing: solvent-free control (F-12K media alone); NaOH control 
(F-12K media with toxin-free NaOH added); 5 nM (de Longueville et al.,  2003); 
5000 nM (high dose) in F-12K media.  After 48 h post-seeding incubation at 37 ºC in 
a 5% CO2 in air atmosphere, the media was removed from all OptiCell™ and replaced 
with the various test media.  Incubation continued for either a further 24 or 48 h 
depending on the treatment group. 
4.4.4 Viability and cytotoxicity assessment of toxin-exposed cells 
Thirty 24-well plates (Nunclon™ Delta Surface, Roskilde, Denmark) were seeded 
with clone-9 hepatocytes at a density of 1 × 104 cells/cm2 in toxin-free F-12K media 
(2.5 × 104 cells/mL).  Twenty wells per plate were used.  Forty-eight h post-seeding, 
all plates were checked under low-power microscopy to ensure adequate cellular 
adhesion and presence of apparently healthy cells.  The media was then removed from 
each well and replaced with toxin-containing media, NaOH media or control F-12K 
such that each of the ten dose groups were represented by four wells per plate.  At the 
14 pre-determined time points from 0 to 108 h following toxin-exposure, two 
randomly selected plates were assessed for cellular viability and proliferation rates 
using the trypan blue dye exclusion staining method (King et al.,  1959) (i.e. n = 4 for 
each dose at each time point).  In this protocol, cells were trypsinised for five minutes 
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at 37°C and then mixed vol/vol with 0.2% trypan blue.  The numbers of stained and 
unstained cells per cells/cm2 were then determined using a haemocytometer. 
4.4.5 M orphological analysis of toxin-exposed cells 
Ten OptiCell™ plates were seeded at a density of 1 × 104 cells/cm2 in toxin-free F-
12K media (1 × 105 cells/mL).  Each OptiCell™ was examined for cell growth under 
a microscope at low-power 48-h post-seeding.  The media was then removed from 
each plate using the specifically designed OptiCell™ tips and replaced with toxin-
containing F-12K, NaOH F-12K or control F-12K.  Toxin-containing F-12K media 
provided 8 separate treatment groups representing: 5 nM, 50 nM, 500 and 5000 nM 
for each toxin.  The OptiCell™ were then randomised to facilitate a blind 
morphological assessment of the effects of toxin-exposure.  At the 14 pre-determined 
time points as used in the cell viability experiment, the “real-time” morphology of the 
unstained cells within the OptiCell™ was examined and recorded using 
photomicrography. 
4.4.6 St atistical analysis - hepatocyte viability study 
Statistical testing was carried out using a software program (GenStat 8th Edition – 
VSN International Ltd., Hemel Hempstead, HERTS, UK) by Ms Jane Speijers of the 
Western Australian Department of Agriculture.  A generalized linear mixed model 
(GLMM) was fitted to the percentages of dead cells within the cultures.   
In the fixed model, the following functions were taken into consideration: 
   Fixed model:  [Control+ (Toxin*Dose)]*Time 
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Applying Wald statistics to assess the fixed effects, this model gave powerful tests of 
the effects of Toxin as a main effect and as an interaction with Dose and Time. 
Further, the fixed model enabled the variables of control, Toxin, Dose and Time to be 
independently examined and assessed alone and against other variables where 
appropriate. 
In the random model, the following functions were taken into consideration: 
 Random model: Plate.Time 
The random model allowed for a variance between plates to be taken into 
consideration.  Further, the binomial variance expected when each cell in an aliquot 
was assessed as live or dead was also considered.  
Numbers of live cells in all treatments were adjusted and plotted in logistic curves to 
compensate for the effect of live cell numbers that were changing rather than the 
number of dead cells initially. Proportions of dead cells within each treatment group 
were adjusted according to the number of live cells within the control treatment.  This 
was performed by estimating the average number of live cells in control samples from 
the 54 h time point onwards, then calculating the ratio between this value and the 
average number of live cells counted at each time point between 0 and 48 h for the 
control treatment. These ratios were then applied to the live cell counts for all 
treatments for the time points between 0 and 48 h. Numbers of live cells and total 
cells were subsequently adjusted upwards for these time points.  Logistic regressions 
were fitted to the treatments for which the numbers of dead cells were changing over 
time. 
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4.4.7 Ge ne expression analysis 
In order to evaluate the reliability of microarray experiments and to obtain an accurate 
gene expression profile for each compound, three independent hepatocyte 
preparations (triplicates) representing both biological and technical replicates were 
carried out for each treatment group.  In contrast to the previous study (Chapter 3), 
wherein independent replicate samples were pooled in an attempt to minimise the 
biological variance, array experiments were performed on each separate RNA 
preparation derived from each of the three independent experimental replicates. 
As discussed in Sect: 3.4.5 , the microarray experiment included the following steps: 
mRNA extraction; labeled cDNA synthesis; and microarray hybridisation which were 
carried out separately for each triplicate sample in all treatment groups. 
4.4.8 Cel l treatment and RNA extraction 
After incubation the test medium was removed from each OptiCell™ and the residual 
cells still adhering to the OptiCell™ membrane were washed twice with phosphate-
buffered saline (PBS).  Cells were recovered from the OptiCell™ following treatment 
with trypsin for five mins at 37°C, pelleted by centrifugation and total RNA extracted 
(RNeasy® Mini Kit, Qiagen).  The integrity and the concentration of extracted RNA 
was assessed spectrophotometrically at 260/280 nm (Nanodrop Spectrophotometer, 
Nanodrop Technologies).  Denaturing agarose gel electrophoresis was also carried out 
to assess the integrity and relative contamination of mRNA in the total RNA sample. 
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4.4.9 Reverse transcription 
All reverse transcription reactions were performed separately for each triplicate 
sample. Total RNA (8µg) was used in a reverse transcription reaction with indirect 
labelling (the incorporation of a biotin-11-dCTP mixture indirectly during cDNA 
synthesis).  All reverse transcription reactions were performed separately for control 
and treated samples and then replicate samples pooled to minimise variability 
according to the DualChip™ instruction manual.  One-colour gene expression 
analysis was performed, whereby the same labelled nucleotide (biotin-11-dCTP) used 
in all reactions with all resulting cDNAs are labelled identically.  An internal standard 
mixture was used for quantification/normalisation and estimation of experimental 
variation (de Longueville et al.,  2002).  This included three synthetic poly(A)+ tailed 
RNA standards which were spiked at three different amounts (10 ng, 1 ng, and 0.1 ng 
per reaction) into the purified mRNA in accordance with the manufacturers 
instructions (Eppendorf, Hamburg, Germany).  RNA standards were used for 
quantification and estimation of experimental variation introduced during labelling 
and analysis.  The cDNA replicates were then pooled prior to hybridisation to reduce 
the reverse transcription reaction variability. 
 
4.4.10 Microarray design and hybridisation 
A targeted microarray (DualChip™ rat hepato (v 1.0) (Eppendorf, Germany) was 
used to examine differential gene expression in this bioequivalence study. As 
described in 3.4.10,   DualChip™ rat hepato (v 1.0) contains 149 specific rat 
hepatocyte genes designed to efficiently target toxicologically-relevant gene 
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expression patterns.  All genes selected in the DualChip array are marker genes for 
hepatotoxicity.  Therefore, theoretically any changes in the expression of these genes 
should be indicative of toxic effects on liver cells.  
4.4.11 Hybridisation using biotinylated-labelled cDNA 
The DualChip™ rat hepato hybridisation was carried out according to the 
manufacturers instructions (de Longueville et al.,  2002) using the one-colour indirect 
labelling protocol as detailed Section 3.5.11.  To minimise variation associated with 
individual slide handling and treatment, each independent triplicate sample from each 
treatment group was hybridised on separate arrays.  Samples from tunicamycin 
treatment groups were designated to the right array on the DualChip and the 
corynetoxin treated samples were hybridised on the left side to allow for direct 
comparison.  
4.4.12 Detection and data analysis 
4.4.12.1 Raw data transformation 
The detection and quantification of hybridisation events were carried out with a 
microarray scanner (ArrayWoRxe, Applied Precision, USA) using a 565 nm emission 
filter for the Cy3 signal.  To maximise the dynamic range of the microarrays and 
allow quantification of both high and low copy expressed genes, arrays were scanned 
using three different exposure times [0.7, 1 and 1.5 sec].  After image acquisition, the 
scanned 16-bit image was used to quantify the signal intensities (ImaGene® 4.1’ 
software, BioDiscovery®, USA).  It is essential in microarray image analysis to adjust 
for background, as the measured intensity of each spot includes a contribution of non-
specific binding and fluorescence emitted from other chemicals on the glass.  Thus, 
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the fluorescent intensity of each DNA spot (average intensity of each pixel present 
within the spot) was calculated by subtraction of both the local mean background and 
the mean of the negative hybridisation controls from the total signal intensity of each 
spot.  
4.4.13 Data selection and replicates data merging 
As described in Chapter 3, all genes of the DualChip rat HepatoChip microarrays are 
spotted in triplicate to allow statistical analysis and correction of the gene expression 
data for each single experiment.  As a result, the coefficient of variation (CV) of the 
replicate signal intensities was determined after the image had been quantified.  Spots 
representing an abnormal variation of signal intensity within a replicate were marked 
or flagged automatically with the mean of the remaining replicates computed.  For the 
determination of acceptable genes, very bright element intensities (saturated signals, 
highly expressed genes) and very low (≤ 2.5 times the local background) signal 
intensities were deemed unsuitable for accurate quantitation and were excluded from 
further analysis.  All genes not labelled as saturated or low were considered 
acceptable for reliable ratio data generation.  The three intensity values of triplicate 
DNA spots were then averaged and used to determine the intensity ratio between the 
reference and  treated samples.  
4.4.14 Normalisation and data analysis 
In accordance with the manufactures recommendations, a two-step normalisation 
procedure was performed prior to data analysis to account for potential sources of 
experimental variation.  The DualChip™ Kit includes an internal standard mixture (a 
dilution series of in vitro-transcribed polyadenylated RNA of six Lycopersicon 
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esculentum genes) selected specifically for their involvement in plant-specific 
processes and have no known mammalian homologues in the NIH sequence database.  
As well as the corresponding capture probes already printed on the array.  
Additionally, capture probes corresponding to numerous housekeeping genes had 
been spotted throughout the array to allow a reliable two-step normalisation.  
Firstly, a correction of values was carried out by using a local normalisation factor 
calculated from the intensity ratios of the internal standards in both the reference and 
test samples.  The corresponding probes of the internal standards were located in 6 
different areas on each array to determine the local background and to evaluate the 
microarray homogeneity.  Secondly, to reflect the purity, quality and amount of the 
analysed RNA, a correction of values was carried out by using a global normalisation 
factor calculated from the mean intensity ratios of housekeeping genes.  Only those 
housekeeping genes for which the expression was not changed after treatment with 
toxin were taken into account for the normalisation. 
4.4.15 Statistical significance of gene expression ratios 
The gene expression ratios for each treatment were analysed as described previously 
in Section: 3.4.15. 
4.4.16 Multiple scanning data 
As described in Section 3.5.16, each individual array was scanned with multiple 
exposure times to increase the dynamic range of the system and therefore provide a 
higher number of reliable ratios and acceptable genes.  
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The entire data analysis procedure was performed independently for each scanner 
setting.  Both normalization factors, the value of internal standards and the value of 
house keeping genes were calculated for each scanner setting using quantifiable data 
from all scans.  Finally, each gene produced as many ratios as exposure times/separate 
gains used.  A reliable overall ratio for each gene based on the combined gains was 
then established and used as the overall gene expression ratio for that particular array.  
If ratios generated from quantifiable intensities were available, the means were used 
in order to provide quantitative data.  If no quantitative ratio was available, qualitative 
ratios were used.  To summarise, quantitative results overrule qualitative results and 
qualitative results overrule “not in linear range” results. 
4.4.17 Replicate data merge  
To obtain relevant mean ratios for each gene based on all independent replicates of 
the same gene profile experiment, ratios of all experimental replicates were combined 
based on the multiple gains overall ratio.  This provided an ultimate combined ratio 
for each gene based on all independent experimental replicates.  This mode also 
enabled the evaluation of the variability between replicates of the same experiment. 
4.4.18 Experimental Design 
Overviews of the experimental design for the bioequivalence and biomarker studies 
are presented in Figures 4-1 and 4-2.  
4.4.19 Preparation of RNA for Quantitative Real Time PCR  
Total RNA (10 ug) was extracted from each hepatocyte sample exposed to 
tunicamycin and corynetoxin, treated with DNase1 (3 units) (Ambion, USA) in the 
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buffer provided by the manufacturer at a concentration of 0.1 µg/µl and then 
incubated at 37  ْC for 10 mins.  The DNase1 enzyme was activated by treatment with 
a DNase inactivation solution as described by the manufacturer.  Reverse transcription 
was performed on 1 µg/µl samples (Multiscribe reverse transcriptase enzyme, 
Applied Biosystems, UK) according to the manufacturer’s protocol in a total volume 
of 50 µl.  Reverse transcription was performed at 25°C for 10 mins, 48°C for 40 mins 
and 95°C for 5 mins (Hybaid OmniGene Thermocycler).   
4.4.20 Real-time PCR 
Real-Time PCR (Morgan et al.,  2002) was performed on genes, mtCO1, CEBPA, FN, 
JNK3, GSTαA, GA45, GAPDH  and S29.  Forward and reverse primers for real-time 
PCR amplification were designed by Eppendorf™ based on the gene oligonucleotide 
sequences printed on the HepatoChip using the Primer express Software (PE Applied 
Biosystem, Foster City, CA). Table 4-1 outlines all oligonucleotide primers used in 
this study.   
Reactions were performed in triplicate using a SYBR-green master mix (Applied 
biosystems, UK) of 25µl final volume.  Primers were used at a final concentration of  
50 nM per reaction. Template, including the control template were either 10 ng of 
reverse transcribed RNA template per reaction (+RT), an identical amount (10 ng) of 
RNA reverse transcribed in the absence of the reverse transcription enzyme (-RT), or 
a no template control (NTC) where water was substituted for the template.  Real time 
PCR was performed (ABI prism 7700 Sequence Detector, Applied BIOSYSTEMS, 
UK), with an initial run consisting of 80°C for 2 mins and 95°C for 10 mins, followed 
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by 40 cycles of 95°C for 15 secs and 60°C for 1 min.  Dissociation curves were also 
assessed to confirm the validity of each PCR signal. 
 
4.4.21 Data Analysis 
The ABI PRISM 7700 sequence detection system (Applied Biosystems, UK) software 
(version 1.6) was used for data analysis according to the manufacturer’s instructions 
(PE Applied Biosystem, Foster City, CA). 
All RT-PCR experiments were performed in duplicate.  Data from individual 
experiments were analysed using the comparative CT method of analysis (Equation 4-
1) (Livak KJ , 1997).  Fluorescence emission was detected for each PCR cycle and the 
threshold cycle (CT) values were determined.  The CT value is defined as the PCR 
cycle when the fluorescence signal increased above the background threshold.  
Average CT values from duplicate PCR reactions were normalised to average CT 
values for housekeeping genes from the same cDNA preparations. The ratio of 
expression of each gene in hepatotoxicants treated vs. vehicle sample was calculated 
as 2-(ΔΔCT) of that treatment where CT is the ΔΔCT is the difference CT (test gene) – 
CT (Savonet et al.,  1997) for treated sample minus vehicle sample.  Values were 
reported as an average of triplicate analyses. 
Equation 4-1: Applied Biosystems Comparative CT equation (Livak, 1997) 
2-ΔΔCT= 2–[(CT target gene- CT standard gene) – (CT normalised gene –CT standard gene)] 
For the above equation, data from individual samples were standardised against the 
average of the two independent (house keeping) genes GAPDH and S29.  GAPDH 
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(glyceraldehyde 3-phosphate dehydrogenase) is a house-keeping gene commonly used 
to standardise data in qRT-PCR experiments (Rockbi et al., 2001; Griscelli et al., 
2001; Leutenegger et al., 1999).  The gene designated as “S29” is a ribosomal protein 
Rps29 shown to be constitutively expressed and commonly used as an internal control 
(Kraniou et al.,  2001).  These studies have shown GAPDH and S29 to be 
constitutively expressed in the array experiments performed and, therefore, good 
candidates for an internal control.  To eliminate inter-assay variation, data was 
normalised against the average of three samples, independently RNA purified and 
independently analysed by RT-PCR. 
Statistical analysis utilised a one-way analysis of variance (ANOVA) that compared 
numerical ΔΔCT values for tunicamycin derived samples with ΔΔCT values for 
corynetoxin samples. 
4.5 Results 
4.5.1 RP-HPLC – Toxin characterisation 
RP-HPLC analysis confirmed the identity and purity of the tunicamycin and 
corynetoxin solutions.  RP-HPLC analysis indicated that the purities of the 
tunicamycin and corynetoxin solutions were > 90%.  The RP-HPLC chromatograms 
obtained for the 1 mg/mL tunicamycin and corynetoxin solutions in 0.6 mM NaOH 
are presented in Figure 4-2.  Based on the results of a previously published study 
(Cockrum and Edgar, 1983) the major components of the tunicamycin solution were 
assigned as U15i (35%), U16i (30%) and U17 (15%).  The predominant corynetoxin 
components identified by RP-HPLC were: H17a (30%); U17a (30%); S17a (9%); 
U18i (10%); and U19a (6%).  These component ratios were shown to be similar to 
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those previously reported by Cockrum and Edgar [1983].  Smaller peaks representing 
less common toxin species could also be recognised in this chromatogram.   
4.5.2 Bi oequivalence 
4.5.2.1 Cyt otoxicity 
Two control cultures were also prepared in which cells were treated with either 0.6 
mM NaOH in F12-K, or with F-12K medium alone.  Relative to the medium control, 
there were no treatment-related effects on cell morphology or viability when the cells 
were exposed to 5 nM of either tunicamycin or corynetoxin, or to 0.6 mM NaOH.  
However treatment-related effects were observed in cultures exposed to ≥ 50 nM of 
tunicamycin or corynetoxin in an apparent dose dependent manner. 
Live and dead cell counts, averaged from the four samples (i.e. n = 4) at each time 
point (except t = 60, where n = 2 due to an incomplete trypsinisation step) are 
presented in Appendices Tables A III-I and III-II respectively.  A graphical 
representation of the live cell count data is presented in Figure 4-3.  Exponential 
trendlines representing the average growth-patterns of the cultures were plotted for 
the 10 datasets (Microsoft Excel).   The relative cytotoxicity of each dose was 
assessed by calculating the percentage of dead cells within the cultures at each time 
point as graphically presented in Figure 4-4.  As depicted in Figure 4-4, the 
percentage of dead cells in the control, NaOH and 5 nM tunicamycin and corynetoxin 
appeared identical with very low cellular mortality. In contrast, close to 100 per cent 
cellular mortality was observed in all other treatment groups (≥ 50 nM tunicamycin 
and corynetoxin). 
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The trendlines shown in Figure 4-3 indicate that the 5 nM tunicamycin and 
corynetoxin samples exhibited slower growth rates than the controls; the apparent 
differences in live cell numbers are not statistically significant.   
The results of the generalised linear mixed model (GLMM) fitted to the percentages 
of dead cells within the cultures is outlined in (Table 4-2).  The results of GLMM 
revealed that the effects of the two toxin treatments (corynetoxin or tunicamycin) 
were not significantly different as the p-value was > 0.05 for all functions involving 
Toxin.  In particular, the main effect of Toxin, averaged over dose levels and times 
amounted to 46.2 % and 40.9 % of cells dead treated with corynetoxin and 
tunicamycin respectively, with a p-value of 0.092.  Therefore based on GLMM, 
tunicamycin and corynetoxin appear to be bioequivalent in their effects as measured 
by trypan blue dye exclusion staining.  Factors that were identified as significant 
using GLMM included the control (as compared to NaOH control and to the average 
of the toxin treatments), Dose (various doses of the toxins) and the effect of time 
(Time).  The variance between plates of the random model was significantly greater 
than zero and has therefore been retained in GLMM. 
In this study the proportion of dead cells was high initially in the majority of 
treatments but then became less throughout the experiment.  This was particularly 
evident for the control treatment: an initially high proportion (~70%) was reduced to 
close to zero after 24 h of exposure (Figure 4-5).  This observation suggests that 
initially it was the number of live cells that were changing, rather than the number of 
dead cells as depicted in Figure 4-6.  To take account of this effect, the numbers of 
live cells in all treatments were statistically adjusted and plotted in logistic curves.  
This was performed by estimating the average number of live cells in the control 
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treatment from 54 h onwards and then calculating the ratio between this value and the 
average number of live cells counted at each of the time points 0 to 48 h for the 
control treatment.  Fifty four hours was used as the time point from which the average 
number of live cells in control treatments was estimated because up until that time 
point, there was no difference in the live: dead cell ratio for any of the cultures.  These 
ratios were then applied to live cell counts for all treatments for the time points 0 to 
48 h.  Numbers of live cells and total cells were adjusted upwards for these time 
points, and logistic regressions have been fitted to the treatments for which the 
number of dead cells change over time.  Figure 4-7 demonstrates that adjusting the 
proportions of dead cells divided the treatments into two distinct groups.  The first 
group was statistically indistinguishable from one another and consisted of the 
control, NaOH control and 5 nM doses of corynetoxin and tunicamycin.  The second 
group consisted of corynetoxin and tunicamycin treatments ≥ 50 nM and had very 
similar cytotoxic effects.  In particular, after 60 h of ≥ 50 nM toxin exposure, cellular 
mortality was greater than 50%.  All cells exposed to ≥ 50 nM of either toxin had died 
completely by t=108 h. 
Therefore based on these results, it would appear that doses ≤ 5 nM tunicamycin and 
corynetoxin are non-cytotoxic and have a limited or no effect on clone-9 hepatocyte 
growth and proliferation based on trypan blue dye exclusion staining.  Thus, ≤ 5 nM 
tunicamycin and corynetoxin appear to be a no observed effect level (NOEL) for 
tunicamycin and corynetoxin in vitro. 
4.5.2.2 Morphology of toxin-exposed cells 
There was no apparent morphological difference in the ten cultures representing the 
various treatments up to 24 h following toxin exposure.  The cultures consisted of 
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broad sheets of hepatocytes through which were scattered holes that appeared to be 
rapidly being filled by new cells being formed by mitosis.  Mitosis was obvious 
throughout this period and all the cells were becoming larger as shown in Figure 4-8. 
After 24 h it first became possible to distinguish between two groups of treatments 
based on morphological effects.  The first group consisted of both controls, 5 nM 
corynetoxin and tunicamycin treatments (Figures 4-9 and 4-10).  The second group 
consisted of the remaining corynetoxin and tunic 
Tunicamycins treatments (≥ 50 nM) (Figure 4-11).  The distinction of these two 
groups was apparent for the remaining 84 h of the experiment.  At no stage during this 
study was it possible to distinguish between the morphological effects of either 
tunicamycin or corynetoxin at any dose.  Therefore, based on morphological analysis, 
tunicamycin and corynetoxin appear to be bioequivalent. 
This first group showed comparatively few morphological changes throughout the 
experiment.  The cultures consisted of continuous sheets of cells that had normal 
morphology and reached maximum size at approximately 48 h.  Mitotic changes were 
obvious throughout the experiment, and changes consistent with apoptosis first 
appeared at 36 h and gradually increased in prevalence throughout the experiment.  
Mild vacuolation of cytoplasm was present in some cells at 93 and 109 h (Figure 4-
10).  It was not possible to distinguish between the separate treatments within the first 
group (control and 5 nM toxin) at any stage. 
There were dramatic morphological changes in cells in toxin treatments ≥ 50 nM 
(second group).  These can be broadly divided into vacuolation of cytoplasm with 
other degenerative changes; separation and shrinkage of cells to form small, round 
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bodies; and disruption and/or disintegration of the sheets of hepatocytes due to loss of 
cells from the OptiCells™ surface.  In general terms hepatocytes either became 
vacuolated with degenerate changes of the nucleus, or shrunk down to form small 
rounded cells.  A small number of cells appeared to remain reasonably normal but 
were reduced in size. 
Vacuolation of the cytoplasm first became apparent in toxin treatments ≥ 50 nM at 24 
h as depicted in Figures 4-11 and 4-12.  Large numbers of cells were vacuolated, 
however initially the vacuoles were not large in size.  As time progressed the 
vacuolation became more widespread.  The nuclei in these cells showed a number of 
changes including: increased density of the karyoplasms; angular morphology; 
margination of chromatin; nuclear membrane becoming indistinct with loss of clear 
nuclear definition; and disappearance of nucleoli.  Vacuolation of the cytoplasm with 
degenerate changes of the nucleus was most severe at 48 and 54 h (Figures 4-11 and 
4-12).  The proportion of vacuolated cells attached to the OptiCell™ surface also 
decreased from 54 h onwards and it was interpreted that this was due to cell death and 
loss of cell adhesion from the culture surface. 
Cell shrinkage and detachment from adjacent cells first became apparent at 30 h 
(Figure 4-13).  This predominantly affected non-vacuolated or only mildly vacuolated 
cells.  Cells undergoing this shrinkage change attained their smallest size between 
approximately 48 to 54 h and appeared as small round bodies of dense cytoplasm 
surrounded by a thick membrane, occasionally with a small indistinct nucleus, but 
often with no distinct nucleus or nucleolus.  Numbers of these affected cells decreased 
with time, and it was interpreted also that this was due to cellular death and loss of 
cell adhesion from the culture surface.  However, it was observed that many cells 
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appeared to still be viable and remained attached, and the proportion of these 
increased relative to vacuolated cells. 
Disruption of the sheets of hepatocytes first became obvious at 34 h when small holes 
in the monolayer started to appear as shown in Figure 4-13.  As cell loss, shrinkage 
and separation increased, changes became more severe with sheets being disrupted 
completely by 72 h.  After 72 h, cultures consisted of a few islands of several adjacent 
cells with individual round cells scattered over the remainder of the culture surface.  
Cell loss appeared to peak at 96 h. 
Regenerative changes first appeared in the second group (≥ 50 nM tunicamycin and 
corynetoxin) at 78 h.  As depicted in Figure 4-14, rounded cells extruded the dense 
body within their thick plasma membrane, and the empty membrane was discarded.  
This change became more prevalent through the remaining 30 h of the experiment, 
and the extruded round bodies were seen to elongate to form small mobile, spindle 
shaped cells with a small nucleus.  Some round cells developed into these spindle 
cells apparently without the extrusion process.  The regenerative process became 
more obvious from 78 h onwards and these spindle cells were observed joining 
together with other remnant cells to start reforming sheets.  Eventually the cells in the 
monolayer became larger and appeared to possess hepatocytes-like features. 
4.5.2.3 Gene Expression Analysis- Bioequivalence 
The DualChip™ rat hepatochip was again utilised as the array platform to 
characterise changes in gene expression in response to tunicamycin and corynetoxin 
at low (5 nM) and high dose (5000 nM) exposure.  In order to characterise changes in 
gene expression in response to tunicamycin and corynetoxin treatment, mRNA was 
extracted from clone-9 cells at 24 and 48 h.   
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Gene expression analysis using the DualChip™ has demonstrated for the first time 
that treatment of in vitro cultured rat hepatocytes (clone-9) with 5 nM and 5000 nM 
corynetoxin and tunicamycin resulted in a number of differences in gene expression 
profiles across each time point and dose.  Therefore, these results demonstrate non-
equivalence of these toxins at the genomic level.   
The importance of statistical and comprehensive data analysis cannot be overstated 
when applying microarray technology.  In this current study, genes identified as 
differentially regulated for each treatment are derived from each of the triplicate 
arrays representing separately tunicamycin and corynetoxin through a rigorous and 
comprehensive data selection and replicate data merge procedure.  Figure 4-15 depicts 
a schematic of the experimental work-flow.  Each individual triplicate array (as 
described in 4.3.16) was scanned with multiple exposure times which provided 
separate gain values to increase the dynamic range of the system and therefore 
provide a higher number of reliable ratios and acceptable gene expression values.  
Ratios (based on separate gains) obtained for each array replicate combination are 
then merged to obtain an overall ratio value.  The overall ratio values from each array 
combination are then merged to provide an ultimate overall ratio value based on all 
combined replicates for that treatment. 
5nM (LD)Tunicamycins and Corynetoxins 24 h  
Exposure of in vitro cultured rat hepatocytes to 5 nM tunicamycin and corynetoxin 
treatments for 24 h revealed 13 genes that were expressed at significantly different 
levels.  In particular, 7 genes were identified as down-regulated in tunicamycin 
compared to corynetoxin and 6 genes identified as up-regulated (Figure 4-16).  Down-
regulated genes included: FN, NaOx, mt_Co1, p53, PCNA, ferritin and Hdac.  Of 
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these seven down-regulated genes, four were involved in cell cycle regulation (p53, 
PCNA, Hdac and NaOx).  Genes identified as up-regulated in tunicamycin included: 
CEBPA, ACO, APOE, Bclx, p38 and HOX2.  Of these six up-regulated genes, three 
were involved in stress response (HOX2, p38 and Bclx).  Further, two of these up-
regulated genes were specifically involved in lipid metabolism (ACO and APOE).  
The results of the data selection and replicate data merge procedure for the 5 nM 
tunicamycin and corynetoxin 24 h treatments are presented in detail below.                               
Scatter plots based on the four separate gains measured for the first 5 nM tunicamycin 
experimental triplicate (Array 1.1) vs. each of the other 5 nM corynetoxin treated 
triplicates (Arrays 2.1, 2.2 and 2.3) are present in the Appendices (Figures III-I, III-II, 
III-III).  Appendices Table A III-IV (a) presents data ratio values (Ratios 1 to 3) based 
on the separate gains measured for each of the triplicate array combinations (i.e. 
Array 1.1 v Arrays 2.1, 2.2, 2.3).  A reliable overall ratio based on combined ratios of 
the replicate array combination (Ratio1 to 3) was then established and used as the 
overall gene expression ratios for the first array triplicate combination (Appendix 
Table A III-IV (b)).  As mentioned previously, quantifiable significant intensities 
(yellow) are preferentially used to generate ratios ahead of qualitative unchanged 
intensities (grey) wherein the means of these ratios are used in order to provide 
quantitative data.  
This same data selection and replicate data merge procedure was performed for the 
other independent triplicate array samples.  In particular, Appendices Table A III-IV 
(a) present the overall data ratio values (Ratio 1, 2, 3) based on the separate gains 
measured for the second 5 nM tunicamycin array (1.2) vs. each of the 5 nM 
corynetoxin treated triplicates arrays (2.1, 2.2, 2.3).  Overall ratios based on the 
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combined ratios of the second triplicate array combinations is presented in 
Appendices Table A III-IV (b).   
It should be noted that due to one of the triplicate 5 nM tunicamycin 12 h treated 
arrays (Array 1.3) being unquantifiable, analysis was based on the two viable 
tunicamycin treated arrays (Array 1.1 and 1.2), i.e. N=2 and three viable triplicate 
corynetoxin samples. 
Finally, to ultimately obtain relevant mean ratios for each gene based on all 
independent replicates of the same gene profile experiment, all experimental replicate 
ratios (ratios 1 to 6) need to be combined (Appendices Table III-V, III-VI).  
Appendices Table III-VII represents the ultimate combined ratios for each gene based 
on all independent experimental replicates of the 5 nM tunicamycin (1.1, 1.2) vs. 5 
nM corynetoxin (2.1, 2.2, 2.3) experiment.  Figure 4-16 represents the bar plot scale 
for the overall combined values.  This mode also enables the evaluation of the 
variability between replicates of the same experiment.   
Tunicamycins and Corynetoxins 5000 nM (HD) 24 h  
Analysis of the high dose 5000 nM tunicamycin and corynetoxin treatments at 24 h 
revealed only five genes that were expressed at significantly different levels.  Four of 
the five genes were identified as up-regulated in tunicamycin and included FN, 
MDH1, mt_Co1 and HSP40.  ApoE was the only down-regulated gene, however, the 
differential expression was very close to 1 (Figure 4-17). 
Appendices Tables A III-VIII, A III-IX, A III-X present the overall data ratio values 
(ratios 1 to 3) based on the separate gains measured for each of the replicate array 
combinations (Array 4.1, 5.1, 6.1 v Arrays 4.2, 5.2 and 6.2).  A reliable overall ratio 
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for each identified differentially regulated gene, based on all combined ratios of Array 
4.1, 5.1, 6.1 vs. the 4.2, 5.2 and 6.2 replicates were then established and used as the 
overall gene expression ratio for these particular arrays. 
Appendices Table A III-XI presents the ultimate combined ratio for each gene based 
on all independent replicates of the same gene profile experiment, all experimental 
replicate ratios (ratios 1 to 9) need to be combined.  Appendices Table A III-XI 
represents the ultimate combined ratios for each gene based on all independent 
experimental replicates of the 5000 nM tunicamycin (4.1, 5.1, 6.1) vs. 5000 nM 
corynetoxin (4.2, 5.2 and 6.2) experiment.  Figure 4-17 represents the bar plot for the 
overall combined values of all independent experimental replicates.  This mode also 
enables the evaluation of the variability between replicates of the same experiment.   
Gene expression observed between the 5 nM and 5000 nM tunicamycin and 
corynetoxin treatments at 24 h appeared to quite dissimilar.  In particular, of the 
eighteen genes identified as differentially regulated in total from both treatments at 24 
h, only two of the 18 were identified as differentially regulated in both treatments.  
The two genes identified as differentially regulated in both treatments were mt_Co1 
and FN.  However, both genes were shown to be oppositely regulated in the 5 nM 
dose and 5000 nM doses.  The function of mt_Co1 as discussed previously (Chapter 
3) is as a cytochrome c oxidase in oxidative metabolism and FN functions include 
maintaining the integrity of the extracellular matrix.   
Tunicamycins and Corynetoxins 5nM (LD) 48 h  
Gene expression analysis of 5 nM tunicamycin and corynetoxin treatments at 48 h 
resulted in 9 genes that were expressed at significantly different levels.  Differentially 
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expressed genes included 3 down-regulated genes in tunicamycin compared to 
corynetoxin and 6 genes identified as up-regulated in tunicamycin (Figure 4-18).  
Down-regulated genes in tunicamycin treatment compared to corynetoxin included: 
ecoa, PEPT1 and FN.  Genes identified as up-regulated in tunicamycin included 
MAO_A, mt_Co1, GSTP, GSS, GA45 and HMG.  Four of the six up-regulated genes 
are involved in drug metabolism and detoxification including: MAO_A, mt_Co1, 
GSTP and GSS. 
Appendices Tables A III-XII, III-XIII and III-XIV represent the reliable overall ratio 
values based on the combined ratios (derived previously from separate gains-data not 
shown) measured for each of the replicate array combinations of the 5 nM 
tunicamycin at 48 h (Arrays 7.1, 8.1, 9.1) vs. each of the 5 nM corynetoxin 48 h 
treated triplicates (Arrays 7.2, 8.2, 9.2).  Appendices A III-XV represents the ultimate 
combined ratio for each gene based on all independent experimental replicates of the 
5 nM tunicamycin vs. 5 nM corynetoxin at 48 h experiment.  Figure 4-18 represents 
the bar plot scale for the overall combined values.   
Gene expression profiles identified for the 5 nM tunicamycin and corynetoxin doses 
at both 24 and 48 h also appeared to be quite dissimilar.  In particular, of the 22 genes 
identified as differentially regulated (13 genes at 24 h; and 9 genes at 48 h).  Only two 
were differentially regulated in both treatments.  FN was the most highly repressed 
gene in tunicamycin treatment at 24 and 48 h.  The function of FN (as discussed in 
Chapter 3) includes maintaining the integrity of the extracellular matrix.  mt_Co1 was 
also identified as differentially regulated in both treatements.  However, mt_Co1 was 
shown to be down-regulated in 5 nM tunicamycin at 24 h and induced in 5000 nM 
dose at 24 and 48 h.  Figure 4-19 presents bar plots of ultimate combined 
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quantitatively significant values for each of the three treatments.  Table 4-3 represents 
a list of the functions of all differentially regulated genes identified in this study.  
Overall, differential gene expression observed between the low 5 nM tunicamycin and 
corynetoxin doses at both 24 and 48 h appeared most significant, as compared to the 
5000 nM treatment at 24 h.   
4.5.2.4 Rea l-time PCR- Bioequivalence 
To validate the microarray data obtained on the DualChip rat hepato, real-time PCR 
(Morgan et al.,  2002) was performed with three genes FN, mt_Co1 and CEBPA 
identified as differentially regulated in tunicamycin and corynetoxin using the 
microarrays.  The expression profiles were determined by RT-PCR.  Figure 4-21 
represents the relative expression levels of the three differentially regulated genes as 
determined by microarray and real-time PCR.  The RT-PCR results validated the 
microarray and showed good correspondence between the two expression profiles. 
Real time PCR (Morgan et al.,  2002) results have confirmed the differential gene 
transcription of three genes assessed to be non bioequivalent in tunicamycin and 
corynetoxin.  The gene expression measured by DNA microarray followed the same 
trend for the three genes measured.   
Real time PCR results were standardised against mRNA encoding house-keeping 
genes GAPDH and S29.  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is 
one of the most commonly used housekeeping genes used in comparisons of gene 
expression data.  Gene S29 has been named arbitrarily as it appeared to be 
constitutively expressed in the array data obtained.  Both GAPDH and S29 gene were 
shown to be constitutively expressed in the array experiments performed and as such 
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appeared to be a good candidate for an internal control in RT-PCR analysis.  RT-PCR 
demonstrated that expression of GAPDH and S29 was not affected by tunicamycin/ 
corynetoxin as the ratios were quite close to 1 (data not shown).   
4.5.3 Bi omarker 
4.5.3.1 Gene Expression Analysis- Biomarker 
The DualChip™ rat hepatochip was again utilised as the array platform to examine 
changes in gene expression in response to corynetoxin at low (5 nM) and high dose 
(5000 nM) exposure to identify potential biomarkers that may act as early predictors 
of pre-clinical exposure to ARGT.  In order to characterise changes in gene 
expression in response to corynetoxin treatment, mRNA was extracted from each 
experimental triplicate treatment at 24 and 48 h.   
Gene expression analysis using the DualChip™ demonstrated that treatment of in 
vitro cultured rat hepatocytes (clone-9) with 5 nM and 5000 nM corynetoxin for 24 h 
resulted in a significant number of differentially regulated genes as compared to 
control (untreated) cells.  In particular, 5 nM and 5000 nM corynetoxin treated 
samples revealed 41 and 28 genes respectively whose expression was differentially 
regulated compared to controls.  In contrast, the 5 nM corynetoxin treatment at 48 h 
revealed significantly less differential gene expression with only 4 genes identified as 
differentially regulated.   
Table 4-7 presents the ultimate combined ratios for each gene based on all 
independent replicates (ratios 1 to 9) combined for the same gene profile experiment. 
All tabulated data ratio values based on each of the separate gains measured for each 
of the triplicate array combinations are presented in Appendices.   
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24 h Corynetoxins 5nM (LD) treatment  
Exposure of in vitro clone-9 rat hepatocytes to 5 nM corynetoxin revealed 41 genes 
that were expressed at significantly different levels at 24 h.  Genes affected by 
corynetoxin treatment are detailed in Figure 4-21 and Table 4-4.  Analysis of the 
genomic data indicated that the majority of genes were induced as a result of the low 
dose 5 nM treatment.  In particular, 35 of the 41 genes were shown to be induced as a 
result of corynetoxin treatment, with only 6 identified as repressed.   
Analysis of differential gene expression revealed induction of genes involved in 
various functions, including: stress response (JNK3, HSP40 and HSP70), drug 
metabolism (cyp1b1, UGT, MAO-A, GSTP), cell cycle (CND3, p53, cnb1, cna2) and 
detoxification (GSTM5, GSTα, GSTM, GST01 and GSS).  The most highly induced 
genes included glutathione based genes involved in detoxification, along with JNK3 
involved in stress response.  The six genes identified as down-regulated included: 
mt_Co1, APOE, FN, ACO, HSP27 and cdk4.  Two of the six genes (ACO and APOE) 
are specifically involved in lipid metabolism.  Heat shock protein 27 (HSP27) is 
involved in stress response.  mt_Co1 is a cytochrome c oxidase involved in oxidative 
metabolism and fibronetcin (FN) is involved in maintaining the integrity of the 
extracellular matrix as described previously (Chapter 3).  Table 4-5 presents the 
ultimate combined ratios for each gene based on all independent replicates (ratios 1 to 
9) combined for the 5 nM corynetoxin 24 h treatment. 
 
24 h Corynetoxins 5000 nM (HD) treatment  
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Exposure of in vitro clone-9 rat hepatocytes to 5000 nM corynetoxin revealed 
significantly less differential gene expression compared to the 5 nM corynetoxin 
treatment.  In particular, 28 genes were identified as expressed at significantly 
different levels in the high dose 5000 nM corynetoxin treatment at 24 h.  Genes 
affected by corynetoxin treatment are detailed in Figure 4-22 and Table 4-6.  Analysis 
of the genomic data indicated that the numbers of genes repressed and induced in the 
high dose treatment were very similar.  In particular, 14 genes were identified as 
repressed, with the remaining 13 induced as a result of the high dose 5000 nM 
corynetoxin treatment. 
Interestingly, many of the highly induced genes identified in the previous low 5 nM 
corynetoxin treatment were shown to be repressed in the high dose treatment.  These 
genes included: HMG, cnd1, CND3, PCNA, MnSOD, HSP27, cna2 and cnb1.  The 
only genes identified as consistently down-regulated in both the low and high dose 
corynetoxin treatments were mt_Co1 and FN.  The majority of induced genes in the 
low dose treatment were also identified as up-regulated in the high dose treatment.  
These included ferritin, ecoa, MDHI, CEBPA, FMO5, cyp1b1, MAO-A, GSTα, JNK3 
and GA45.  In particular, GA45 was identified as the most highly induced gene.  
However, two of the most highly induced glutathione based genes (GSTP and 
GSTM5) in the low dose treatment were only identified as moderately induced in the 
high dose treatment.  Only two genes were identified as differentially regulated in the 
high dose treatment only and were repressed (TNFR and APOE). 
Table 4-7 presents the ultimate combined ratios for each gene based on all 
independent replicates (ratios 1 to 9) combined for the 5000 nM corynetoxin 24 h 
treatment. 
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48 h Corynetoxins 5 nM (LD) treatment  
The low dose 5 nM corynetoxin treatment at 48 h revealed minimal differential gene 
expression.  Genes affected by corynetoxin treatment are detailed in Figure 4-23 and 
Table 4-8.  Only 4 genes were identified as differentially regulated in the corynetoxin 
treatment compared to untreated controls.  These included two repressed (PCNA and 
mt_Co1) and two induced genes (PEPT1 and HMG).  Both PEPT1 and HMG were 
also identified as induced, and PCNA also identified as repressed in the low dose 5 
nM treatments.  However, in contrast to the up-regulation observed in this treatment 
for HMG, this gene was identified as the most down-regulated gene in the high dose 
5000 nM treatment.  In addition, PEPT1 was not identified as differentially regulated 
in the 5000 nM treatment.  There was only one gene identified which was shown to be 
consistently down-regulated in all treatments.  This gene was mt_Co1 which was also 
shown to be down-regulated in the low dose 5 nM corynetoxin treatment at 48 h.  
Table 4-9 presents the ultimate combined ratios for each gene based on all 
independent replicates (ratios 1 to 9) combined for the 5 nM corynetoxin 48 h 
treatment. 
 
4.5.3.2 Rea l-Time PCR- Biomarker 
RT-PCR has confirmed differential gene transcription of five biomarker candidate 
genes selected from microarray analysis for both the 5 and 5000 nM corynetoxin 
treatment at 24 h (Figures 4-24 and 4-25).  These genes included: mt_CO1, FN, JNK3, 
GSTα and GA45.  Further, the expression of the two independently constitutively 
expressed genes GAPDH and S29 were shown not to be affected by tunicamycin/ 
corynetoxin. 
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Therefore, given that RT-PCR has confirmed that expression of all selected genes 
followed the same tendency for microarray, these genes may be potentially useful as 
biomarkers of exposure. 
 
4.6 Discussion 
This chapter presents the first side-by-side comparative study that has investigated the 
effect of in vitro rat hepatocytes cell line to equivalent doses of tunicamycin and 
corynetoxin at the microscopic and molecular level, in an attempt to further the 
current understanding of the bioequivalence of these two toxins and the suitability of 
tunicamycin as an experimental substitute for corynetoxin. 
4.6.1 Bi oequivalence 
In order to investigate the bioequivalence of tunicamycin and corynetoxin in parallel, 
the combined toxicogenomic approach developed and validated previously (Chapter 
3) was applied.  This study involved using significantly lower dose rates of toxin in an 
attempt to identify the effect of low level tunicaminyl-uracil exposure and potentially 
identify the lowest tunicamycin/corynetoxin dose to induce no observable effect on 
cells at the genomic level based on microarray technology, coupled with conventional 
toxic cytotoxic and morphological parameters.   
The low level toxin concentrations used in this bioequivalence study was based on 
previous published investigations of tunicaminyl-uracil toxicity.  In particular, the 
preliminary study (chapter 3) which demonstrated an effect for the first time on cell 
viability, morphology and gene expression using significantly lower levels of 
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tunicamycin (50 nM) than those previously published. As a result, significantly lower 
levels of tunicamycin were applied in the investigation of the bioequivalence of 
tunicamycin and corynetoxin.  The first part of this investigation involved examining 
the bioequivalence of tunicamycin and corynetoxin on cell viability and morphology. 
A comparative assessment based on these two parameters was essential to 
understanding whether both toxins share similar mechanisms of action on clone-9 
hepatocytes in vitro.The second part of this study involved examining the 
bioequivalence of tunicamycin and corynetoxin using microarray technology.  In 
particular, Eppendorf DualChip™ rat hepato was again utilised to investigate the 
effects of low level tunicamycin exposure on clone-9 hepatocytes at the genomic 
level. 
The in vitro toxicogenomic strategy used provided an effective approach for 
examination of bioequivalence.  Cell viability and morphological assessment were 
used to examine the impact of equivalent doses of tunicamycin and corynetoxin on an 
in vitro rat hepatocyte cell line.  There were no cytopathic and cytotoxic effects or 
differences observed between the two.  Therefore, based on cell viability and 
morphology, tunicamycin and corynetoxin appear to be bioequivalent.  Furthermore, 
relative to the medium control, there were no treatment-related effects on cell 
morphology or viability when the cells were exposed to 5 nM of either tunicamycin or 
corynetoxin, or to 0.6 mM NaOH.  However treatment-related effects were observed 
in cultures exposed to ≥ 50 nM of tunicamycin or corynetoxin in a dose dependent 
manner. In contrast, statistically significant differences between the effects of 
tunicamycin and corynetoxin exposure on an in vitro biological system were 
identified for the first time at the genomic level.  The results of gene expression 
analysis using the DualChip™ have demonstrated for the first time that treatment of 
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in vitro cultured rat hepatocytes (clone-9) with equivalent doses of tunicamycin and 
corynetoxin (0.05 nM and 5000 nM) produced differential gene expression.  Based on 
these observed results, it appears that tunicamycin and corynetoxin are non-equivalent 
at the genomic level. 
4.6.1.1 Cyt otoxicity 
Cell viability studies that examined the impact of equivalent doses of tunicamycin and 
corynetoxin on an in vitro rat hepatocyte cell line produced indistinguishable 
cytopathic and cytotoxic effects.  This research supports the findings of several in vivo 
studies, which have demonstrated acute exposure to tunicamycin results in an ARGT-
like syndrome (Finnie and Jago, 1985; Jago and Culvenor, 1987; Jago et al.,  1983).  
The trypan blue dye exclusion was used to successfully evaluate cellular viability of 
clone-9 hepatocytes exposed to various doses of tunicamycin and corynetoxin.  
Tunicamycins and corynetoxin appear to be bioequivalent in their effect at the various 
toxin doses as measured by trypan blue dye exclusion staining. 
Initially, no significant differences were observed in the live: dead cell ratio for any of 
the treatments (including controls) up until 54 h post toxin exposure.  This was 
similarly observed in Chapter 3, whereby there was also no significant difference 
initially in live: dead cell ratio for any of the treatments.  A possible explanation for 
these observations (as suggested in Chapter 3),  may be that all cells experience a lag 
phase as a result of media being removed and replaced with various test media 48 h 
post seeding.  Thus, it may take some time for the cultured cells to acclimatize to the 
new media environment; especially given the new media is combined with a toxin 
component. 
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After 54 h post toxin exposure treatments appeared to demonstrate either proliferation 
or marked inhibition of cellular proliferation.  Cells exposed to ≤ 5 nM toxin (control, 
NaOH, 5 nM tunicamycin and corynetoxin) displayed proliferation and appeared to 
enter an exponential phase of growth.  In contrast, cells exposed to ≥ 50 nM (50 nM, 
500 nM and 5000 nM treatments) failed to proliferate with inhibition of cellular 
proliferation evident.  These cytotoxic observations also reflect the previous in vivo 
and in vitro studies which have reported exposing various cell types to tunicamycin 
(Davies et al.,  1997; Finnie and O'Shea, 1990b; Savage and Baur, 1983).  In 
particular, Savage and Baur demonstrated that 0.05 ug/ml of tunicamycin blocks the 
G1 phase of the cell cycle in rat hepatoma cell lines.  Furthermore, Savage and Baur 
(1983) also observed an apparent delay in the effect of tunicamycin on cell viability 
and cellular division.  They observed that this “delay” effect was apparent once cells 
had depleted their intracellular glycoprotein reserves and hypothesized that this delay 
may be related to glycoprotein turnover.  The explanation of Savage and Baur (1983) 
appears to be valid for the delayed toxic effect of tunicamycin as Tunicaminyl-uracil 
toxins are known to specifically and irreversibly inhibit the GPT enzyme required for 
synthesis of N-linked glycoproteins (Heifetz et al.,  1979; Jago et al.,  1983; Takatsuki 
and Tamura G, 1982; Tkacz and Lampen, 1975) (detailed in Sect: 1.3.4). 
The observed dramatic toxic effect of cells exposed to ≥ 50 nM tunicamycin and 
corynetoxin are consistent also with the cell viability data described in the previous 
Chapter 3.  In particular, tunicamycin doses of ≥ 50 nM) were also identified as 
cytotoxic in the previous study using trypan blue dye exclusion.  Further, this study 
found that at 60 h post toxin-exposure, greater than 50% of the cells counted within ≥ 
50 nM (50 nM, 500 nM and 5000 nM) treatments had died.  In contrast, a previous 
study by Yeoh et al., (1984) reported that in vitro exposure of foetal rat hepatocytes to 
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145 nM corynetoxin for 72 h had no impact on cell viability. However, after 72 h 
corynetoxin concentrations of 290 and 580 nM resulted in 2 and 43% reduction in cell 
numbers, respectively. The reduction in cell numbers of the study conducted by Yeoh 
et al., (1984) appears to be considerably lower than that observed in the present study. 
This may be due to differences in sensitivity associated with primary cells (foetal rat 
hepatocytes- (Yeoh et al.,  1984)) vs. secondary/continuous cells (clone-9 
hepatocytes- this study). There are several reports of secondary cell lines that are 
more sensitive to tunicaminyl-uracil toxins than primary cultures directly isolated 
from tissues (Olden et al.,  1978; Seiberg and Duksin, 1983). 
The lowest tunicamycin and corynetoxin dose used in this current study was 5 nM, 
ten-fold less in concentration than the previously used dose (Chapter 3) appeared to 
be non-cytotoxic in clone-9 hepatocytes in vitro.  In particular, the 5 nM tunicamycin 
and corynetoxin dose were statistically indistinguishable based on cytotoxicity data 
from both control and NaOH control.  Based on the cytotoxicity data obtained from 
this study, 5 nM tunicamycin and corynetoxin treatment appear to be consistent with a 
no observable effect level based on cytotoxic assessment. 
4.6.1.2 Morphology 
Morphological studies that examined the impact of equivalent doses of tunicamycin 
and corynetoxin on the clone-9 cell line showed no difference in cytopathic effects.  
This investigation support the findings of several previous in vivo and in vitro studies, 
which have demonstrated acute exposure to tunicamycin results in an ARGT-like 
syndrome (Finnie and Jago, 1985; Jago and Culvenor, 1987; Jago et al.,  1983).  
Tunicaminyl-uracil exposure, in particular tunicamycin and corynetoxin doses ≥ 50 
nM were shown to have a discrete and damaging morphological effect on clone-9 
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hepatocytes in vitro consistent with the morphological effects described in Chapter 3 
(with the exception of regenerative changes) and reported in previous studies (Yeoh et 
al.,  1984; Finnie and O'Shea, 1989; Finnie, 2001).  The lowest doses were shown to 
have no observed morphological effect on clone-9 hepatocytes in vitro which was 
reflected also with cytotoxic data.  In particular, the lowest 5 nM tunicamycin and 
corynetoxin doses were indistinguishable from both controls at all stages during the 
experiment.  Therefore, based on the morphologic and cytotoxic observations of this 
study, 5 nM tunicamycin and corynetoxin appear consistent with a no observable 
effect level (NOEL).   
Based on both morphological and cytotoxic analysis, tunicamycin and corynetoxin 
appear to be bioequivalent.  Morphological effects observed in hepatocytes treated 
with ≥ 50 nM tunicamycin and corynetoxin included the most frequently described 
references CPE features of Tunicaminyl-uracil exposure (as previously discussed 
Sect: 3.6.2), including: vacuolation and dilation of the RER; degenerate changes of 
the nucleus; and/or cellular shrinkage to form round cells.  Morphological changes 
consistent with apoptosis were also observed in ≥ 50 nM tunicamycin and corynetoxin 
treatments used in this study.  However, as discussed in 3.6.2, apoptosis cannot be 
confirmed as the mechanism of cell death.  Additional experiments using techniques 
such as TUNEL and DNA laddering used in previous studies (Gavrieli et al.,  1992) 
would be required to definitively distinguish apoptosis from necrosis. 
The observed dramatic morphological effects present in treatments ≥ 50 nM and the 
lowest dose toxin treatment (5 nM) appearing indistinct from controls is closely 
reflected also in the cell viability data from this study.  In particular, the observation 
of all treatments falling within two distinct group is supported by the cytotoxic data, 
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i.e. treatments ≥ 50 nM displayed similar dramatic morphological and cytotoxic 
effects over time (group 1) and the lowest dose toxin treatment (5 nM) appearing non-
cytotoxic and morphologically indistinct from controls (group 2).  Further, the 
apparent no observed effect level (NOEL) evident in treatments ≤ 5 nM tunicamycin 
and corynetoxin and the bioequivalence of corynetoxin and tunicamycin in vitro 
observed in both cytotoxic and morphological results serve to strengthen confidence 
with the observations and data obtained.   
The observed “regenerative changes” of cells exposed to ≥ 50 nM Tunicaminyl-uracil 
toxins in vitro has not been previously reported.  However, hepatocyte regeneration 
has been previously observed in affected livers of sheep suffering ARGT (McKay and 
Ophel, 1993).  Further, regenerative proliferation, subsequent to liver damage, is 
considered the carcinogenic mechanism of other hepatotoxins including furan and 
methapyrilene (Steinmetz et al.,  1988; Fransson-Steen et al.,  1997).  The present 
study identified apparent regenerative changes in clone-9 hepatocytes after 78 h 
exposure, wherein shrunken, rounded cells began to elongate and form spindle-shaped 
cells with a small nucleus.  Spindle cells were observed joining together with other 
remnant cells to start reforming sheets, eventually the cells in the monolayer became 
larger and appeared to possess hepatocytes-like features.  The development of 
elongated or spindle-like cellular morphology in response to tunicamycin treatment 
has been previously reported in a variety of different cell types including: embryonic 
fibroblasts (Duksin and Bornstein, 1977; Olden et al.,  1978; Seiberg and Duksin, 
1983), human embryonic lung cells (Olden et al.,  1978) and bovine aortic endothelial 
cells (Tiganis et al.,  1992).  Regenerative changes were not evident in the previous 
study (Chapter 3).  However, this is likely to be due to morphological observations 
Chapter 4 
  214 
not continuing past 78 h (the final time point of the previous study) which coincides 
with the time regenerative changes first appear in this study. 
4.6.1.3 Gene expression 
With the demonstration that equivalent doses of tunicamycin and corynetoxin 
produced indistinguishable morphological and cytotoxic effects in hepatocytes in 
vitro, it was important to examine the molecular basis for these observations through 
the combined in vitro toxicogenomic approach.   
The in vitro toxicogenomic model developed previously facilitated this first genomic 
based study of the bioequivalence of tunicamycin and corynetoxin.  The model 
offered several key features that were critical for the parallel investigation of 
equivalent doses that included: enhanced maintenance, reproducibility and improved 
control of experimental conditions. The use of animal models and high density array 
platforms was thus avoided.  Further, of paramount importance is the ability of this 
system to allow reduced levels of corynetoxin to be used for experimental testing.  
This feature was critical to the execution of this study as other strategies would have 
required significantly higher amounts of corynetoxin.  Furthermore, coupling this 
model with the OptiCell™ cell culture system provided several benefits including 
reduced media requirements, reduced cost, storage space and improved control of 
experimental conditions, thereby allowing more effective correlation with the 
morphological data obtained (Neely, 2008).   
To evaluate the bioequivalence of tunicamycin and corynetoxin at the genomic level, 
accurate and reliable data from each array experiment was critical to obtaining precise 
and reproducible gene expression ratios for meaningful comparison of the toxins.  As 
previously discussed, the commercial low-density DualChip rat hepato offered a 
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highly reproducible array platform that delivered a specialised analysis control system 
aimed to reduce technical variation (de Longueville et al.,  2002).  In particular, each 
gene is spotted in triplicate in different areas on the array platform to enable statistical 
analysis and correction of the gene data within the single experiment.  Additionally, 
the DualChip system utilises a rigorous and comprehensive data selection procedure 
to obtaining precise and reproducible gene expression ratios for each treatment.  
These features of the DualChip microarrays allow differential gene expression 
analysis of the highest quality to be performed quickly, simply and very reproducible 
(Marcq et al., 2006). 
DualChip rat hepatochip was again selecte as the array platform using the one-colour 
indirect labeling protocol to characterise changes in gene expression and for the first 
time investigate the bioequivalence of tunicamycin and corynetoxin at low (5 nM) and 
high dose (5000nM) exposure.   
In contrast to the previous study, whereby individual sample treatments were pooled 
then screened, this study used individual experimental triplicates group (N=3) from 
each treatment screened independently using separate arrays.  In particular, each 
individual triplicate array was scanned with multiple exposure times to increase the 
dynamic range of the system and therefore provide a higher number of reliable ratios 
and acceptable genes.  For each array, a reliable overall ratio based on the combined 
ratios of the separate gains was then established for each identified differentially 
regulated gene.  Finally, to obtain relevant mean ratios for each gene based on all 
independent replicates of the same gene profile experiment, ratios of all experimental 
replicates were combined based on the multiple gains overall ratio in a replicate data 
merging procedure.  Detailed results of the data selection and replicate data merge 
Chapter 4 
  216 
procedure were presented for the 24 h 5 nM tunicamycin / corynetoxin treatment 
(Sect: 4.4.5) to provide insight and an appreciation of the comprehensive data analysis 
procedure used to obtain the ultimate differential gene expression data derived from 
all replicates for each treatment. 
A time-point of 24 and 48 h after toxin treatment was selected for analysis of gene 
expression. As previously mentioned (Chpt 3.7.3), 24 h has been frequently selected 
as an appropriate time point to sample after exposure for analysing gene expression 
modifications under in vitro conditions.  Further, this time point also seemed 
appropriate given it coincided with the first signs of vacuolation observed in both 
studies and it became possible to differentiate between two groups of treatments 
morphologically and cytotoxicologically in both this study and that of the previous 
chapter. Furthermore, using the same time point as the previous study could 
potentially allow genomic data collected for this study to be compared with data 
collected previously (Chapter 3) using different doses of tunicamycin.   In addition, 
48 h was also selected as a time point based on cytotoxic and morphological changes 
that occurred at this time in both studies. In particular, vacuolation of cytoplasm with 
degenerate changes of the nucleus was most severe between 48 and 54 h.  Therefore, 
it seemed an appropriate time point in which to investigate the molecular effects of 
both toxins given the severe morphological changes that occurred in cells observed at 
that time.  
Exposure of in vitro hepatocytes to tunicamycin and corynetoxin at 5 nM and 5000 
nM for 24 and 48 h revealed a number of differences in their respective gene 
expression profiles across each time point and dose, thereby demonstrating the 
apparent non-equivalence of these toxins.   
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The highest number of differentially expressed genes was observed in the 5 nM 
tunicamycin and corynetoxin treatment at 24 h.  Thirteen genes in total were 
identified as differentially regulated of which 7 were identified as down-regulated in 
tunicamycin.  Of these seven genes, four appear to be involved in cell cycle 
regulation.  These genes included: p53 (tumour protein) (Abbas et al.,  2002), PCNA 
(Uehara et al.,  2006; Savio et al.,  1998),  Hdac (Histone D-acetylase) (Lin et al.,  
2000) and NaOx (NADPH) (Berasi et al.,  2004).  This result suggests that the 
differences in molecular structure of both tunicamycin and corynetoxin may directly 
influence the biological activities of each toxin and in turn may cause different effects 
on the cell cycle. 
Of the six remaining genes up-regulated in tunicamycin, three are involved in stress 
response.  These include HOX2 (Heme Oxygenase 2) (Vile et al.,  1994), p38 (p38 
mitogen activated kinase) (Kawasaki et al.,  1997) and Bclx (B cell lymphoma 2- like 
1).  Again, this result suggests that the mechanism by which the cell may be 
responding to the two toxins is potentially different given these stress response genes 
are differentially regulated.  Also, two of the up-regulated genes in tunicamycin are 
specifically involved in lipid metabolism, in particular, metabolism of long chain fatty 
acids and lipid protein transport.  As the molecular structure of tunicamycin and 
corynetoxin differ in the length, hydroxylation state and terminal branching structure 
of the fatty acid chain attached via to the tunicamine unit (Cockrum and Edgar, 1983) 
it is not be surprising that these differences in molecular structure may result in 
differential regulation of genes specifically involved in metabolism of long chain fatty 
acids.  Further, it is likely that the different fatty acid side lengths and configurations 
of these toxins could be affecting their ability to permeate membranes and their 
accessibility or affinity to certain biomolecules within the cell. 
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A significant number of genes were also identified as differentially regulated in the 5 
nM tunicamycin and corynetoxin treatment at 48 h.  Of the 9 genes identified as 
differentially regulated, 3 were down-regulated in tunicamycin treated sample and 
included FN (fibronectin), ecoa (ecoa-enoyl CoA); and PEPT1 (solute carrier family 
15 oligopeptide).  FN was also identified as significantly down-regulated in the 5 nM 
tunicamycin 24 h treatment in this study.  It is well documented (Berry et al.,  1980a)   
that reduced FN levels is a likely cause of the breached blood-brain barrier, impaired 
cardiovascular function and decreased peripheral circulation and oxygen utilisation 
seen in corynetoxin poisoned animals.  Interestingly, reduced levels of both FN and 
ecoa expression were also found in the previous study (Chapter 3) whereby FN and 
ecoa were the most significantly down- regulated genes within both 0.05 and 50 µM 
tunicamycin treatments.  In the present study, down-regulation of FN in samples 
treated with tunicamycin rather than corynetoxin suggests that FN and its role in 
maintaining the extracellular matrix may be affected to a greater extent as a result of 
tunicamycin exposure.  However, as this study is comparing differential gene 
regulation only between the two toxins, FN is likely to be still down-regulated in 
corynetoxin treated samples when compared to untreated control cells (Finnie and 
Jago, 1985).  Ecoa is another gene that is differentially regulated by tunicamycin and 
is thought to be involved in lipid metabolism.  In particular, ecoa is a bifunctional 
enzyme involved in fatty acid degradation and has been shown to have intrinsic 
hydratase activity (Nakagawa et al.,  1995).  As discussed above, it may not be 
surprising that differences in the molecular structure of the fatty acid side chain of the 
two toxins may result in differential regulation of genes specifically involved in 
metabolism of long chain fatty acids.   
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In addition, 6 genes were shown to be up-regulated in tunicamycin-treated sample.  
Interestingly, four of the six up-regulated genes are involved in drug metabolism and 
detoxification including: MAO_A, (mono amide oxidase) mt_Co1, (cytochrome 
oxidase subunit 1) GSTP, (Glutathione S-transferase Pi) GSS (Glutathione 
synthatase).  This suggests that tunicamycin and corynetoxin have potentially 
different drug metabolism and detoxification mechanisms at play.  Another possible 
explanation may be that observed differences in gene expression may be an artefact of 
the two toxins causing a different effect on cells as a result of time over time which 
was apparent at the late 48 h time point and not evident at 24 h. 
In contrast, only five genes were identified as differentially regulated in the high dose 
(5000 nM) tunicamycin and corynetoxin treatment at 24 h.  Four genes were up-
regulated in tunicamycin and down-regulated in corynetoxin.  Interestingly, one of 
these three genes ‘mt_Co1’ was identified as differentially regulated in all treatments.  
This gene is of particular interest as its function in drug metabolism and cytochrome c 
oxidation (Chen and Chen, 2003; Gunasekar et al.,  1998; Jones et al.,  2000; Way, 
1984) appears to vary in cells when exposed to either tunicamycin or corynetoxin.  As 
the regulation of this gene at first instance appears non-equivalent in tunicamycin and 
corynetoxin, mt_Co1 may possess the necessary requisite qualities for future 
biomarker studies its regulation warrants further investigation.  
The higher degree of differential gene expression observed between tunicamycin and 
corynetoxin at the low (5 nM) toxin dose compared to high (5000 nM) dose was 
unexpected.  One explanation may be related to the dose and the associated 
mechanism cells use to respond to the toxin insult.  The initial cellular response to 
high level exposure of tunicamycin and corynetoxin may overwhelm the cell and 
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trigger similar extreme cell suicide or apoptotic pathways, thus resulting in very 
similar gene expression between the treatments.  In contrast, low level exposure of 
cells to both toxins may cause the cell to initiate a more specific and directed genomic 
response.  This may involve induction of a cascade of xenobiotic pathways related 
specifically to the molecular chemistry of the individual toxins and thus are 
influenced by their differences in molecular structure.  As such, a variety of types of 
genes may be potentially involved, resulting in increased differential gene expression 
observed between the two toxin treatments, as opposed to a non-specific, all-
encompassing apoptotic cascade effect observed in high dose treatments.  
The apparent non-equivalence of these toxins at the genomic level observed in this 
study is substantiated by the findings of a proteomic based study carried out under 
similar conditions to those reported here (Retallick et al., 2006).  Retallick et al., 
(2006) demonstrated that changes in serum protein profiles were evident for the first 
18 h of toxin exposure in the low dose 5 nM treatments of tunicamycin and 
corynetoxin and furthermore time-dependent secretome changes were observed in the 
5000 nM dose from 18 to 30 h onwards.  Secretome changes suggest adaption to the 
toxin-containing environment.  The relatively large number of genes differentially 
regulated in the 5 nM treatments at 48 h is similar to that reported by Retallick et al., 
(2006).  PCA analysis of expressed proteins showed cells that were differentially 
expressing certain proteins between 42-54 h based on distributions of samples using 
PCA analysis. 
In contrast to the morphological and cytological studies, gene expression analysis 
using the DualChip™ demonstrated for the first time an apparent non-equivalence of 
these toxins at the genomic level.  Further, these results, combined with the findings 
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of a proteomic study carried out under similar conditions (Retallick et al., 2006) 
suggest an apparent non-equivalence of these toxins at the proteomic level.  This 
observed non-equivalence of tunicamycin and corynetoxin at the molecular level 
suggests that the effects of tunicaminyl-uracil toxins may vary as a result of their 
differences in molecular structure.  The nature of their influence on other signalling 
and biochemical pathways is yet to be determined. 
The in vitro toxicogenomic strategy utilised in this study has proven an impressive 
tool for gene expression analysis but it remains a complex method that requires 
validation with real-time PCR, western blotting or verification of protein function.  In 
particular, real-time PCR has been used to further validate the relative gene 
expression data obtained using the DualChip hepato (see Sect: 4.6.4 below).  
4.6.1.4 Rea l-Time PCR 
Real-time PCR (Morgan et al.,  2002) was performed to evaluate the reliability of the 
microarray technology used and validate the results obtained.   
Real time PCR results are often standardised against mRNA encoding GAPDH.  
However, recent evidence suggests that GAPDH is not constitutively expressed under 
all conditions and GAPDH was shown to be up-regulated (Ullmannova and Haskovec, 
2003).  In this study, however, there was no indication of differential transcription of 
GAPDH (results not shown) and in this report RT-PCR results were standardised 
against the average of two independently constitutively expressed genes GAPDH and 
S29.  The expression of the two independently constitutively expressed genes GAPDH 
and S29 were shown not affected by tunicamycin / corynetoxin as the ratios were 
quite close to 1.   
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DNA microarray analysis and real-time PCR demonstrate reliable methods for 
identifying differentially regulated genes. Therefore, subsequent toxicogenomic 
investigations should be coupled with real-time PCR analysis to further validate the 
resultant gene expression data obtained.   
4.6.2 Bi omarker 
4.6.2.1 Gene Expression 
The in vitro toxicogenomic model developed previously (Chapters 3 and 4) has 
facilitated this first genomic based investigation of low level corynetoxin on hepatic 
gene expression in an attempt to elucidate preliminary biomarkers of exposure. 
This study has utilised the same time points and doses used previously in Chapter 4 to 
to allow a direct comparison of the genomic data obtained in this investigation with 
the previously observed morphologic and cytotoxic effects (Chapter 4).  In particular, 
the 5 nM corynetoxin dose previously demonstrated as non-cytotoxic based on 
cellular morphology and trypan blue dye exclusion (Chapter 4) was of particular 
interest to examine further in this study at the genomic level. 
Gene expression analysis using the DualChip™ demonstrated that treatment of in 
vitro cultured rat hepatocytes (clone-9) with 5 nM and 5000 nM corynetoxin for 24 h 
resulted in a significant number of differentially regulated genes as compared to 
control (untreated) cells.  In particular, 5 nM and 5000 nM corynetoxin treated 
samples revealed 41 and 27 genes respectively whose expression was differentially 
regulated as compared to controls.  In contrast, the 5 nM corynetoxin treatment at 48 
h revealed significantly less differential gene expression with only 4 genes identified 
as differentially regulated.   
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Initial changes in drug-dependent gene expression have been shown to occur within 
24 h after exposure to many toxicants.  This may provide an explanation for the low 
level of differential gene expression observed at the 48 h time point between 5 nM 
corynetoxin treated sample and controls. 
The 5 nM corynetoxin treatment at 24 h revealed the highest number of differentially 
expressed genes.  The apparent higher degree of differential gene expression was also 
observed between tunicamycin and corynetoxin at the low (5 nM) treatment compared 
to high (5000 nM) treatment in the previous bioequivalence study (Chapter 4).  As 
previously discussed, a possible explanation for the higher number of differentially 
expressed genes in the low dose treatment may be related to the dose and the 
associated mechanism cells use to respond to the toxic insult.  In particular, the low 
level exposure of cells to toxin may cause the cell to initiate a more specific and 
directed genomic response to the particular toxic insult, as opposed to a non-specific, 
all-encompassing apoptotic cascade effect observed in high dose treatments.   
Further, thirty-five of the 41 differentially expressed genes were up-regulated in 
response to 5 nM corynetoxin treatment at 24 h.  The observed induction of many 
genes in response to the low dose corynetoxin treatment at 24 h may represent an 
early phase cellular compensatory response to low level toxin in order to minimise 
further damage.  The functional role of genes identified as up-regulated include:  
stress response; drug metabolism; cell cycle; and detoxification.  The functions 
identified for these genes appear to reflect the suggested explanation above for the 
observed induction in providing an early compensatory response to minimize further 
adverse effects.   
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Genes identified as consistently differentially regulated in both low and high dose 
toxin treatments have been reported to provide good preliminary biomarker 
candidates for further investigations (Van Leeuwen et al., 2006).  Genes identified as 
significantly induced in both the treatments included: ferritin (Ferritin-H subunit), 
ecoa (Nakagawa et al.,  1995), MDHI (Malate Dehydrogenase), CEBPA 
(CCAAT/enhancer binding protein), FMO5 (Flavin containing monooxygenase 5), 
cyp1b1 (Cytochrome P450), MAO-A (MAO-A), GSTα (GSTα cons) JNK3 
(MAPK10) and GA45 (Growth arrest and damage inducer).  In particular, JNK3, 
GSTα and GA45 were identified as the most highly induced genes.  The only genes 
identified as consistently down-regulated in both the low and high dose corynetoxin 
treatments were mt_Co1 (cytochrome oxidase subunit 1) and FN (fibronectin).  
Furthermore, mt_Co1 was also identified as differentially regulated in the 5 nM 
corynetoxin treatment at 48 h. 
Interestingly, mt_Co1 and FN have consistently been found as down-regulated in 
previous studies.  In particular, mt_Co1 and FN have been identified as the most 
significantly down-regulated genes in 0.05 and 50 μM tunicamycin treatments 
(Chapter 3).  In addition, both, mt_Co1 and FN were identified as non-equivalent 
between tunicamycin and corynetoxin in both the 5 nM and 5000 nM treatments 
(Chapter 4).  The function of mt_Co1 as discussed previously (Chapter 3) is as a large 
transmembrane protein complex involved in the fatty acid beta-oxidation (KEGG) 
pathway.  It is the last enzyme in the respiratory electron transport chain whereby it 
catalyzes the reduction of oxygen to water.  The activity of this protein has been 
implicated in controlling cell growth and differentiation.  As discussed in Sect 3.7.3, 
various toxins including cyanide, sulphide and carbon monoxide are potent inhibitors 
of mt_Co1 (Dorman et al.  2002; Khan et al.  1990).  Repression of mt_Co1 is 
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recognised as disrupting the electron transport chain and the cell can no longer 
aerobically produce ATP for energy.  FN is a glycoprotein important in cell to cell 
and cell to substrate adhesion and maintaining the integrity of the extracellular matrix 
(Yamada et al.  1976).  As discussed in Sect: 3.7.3, the repression of FN as a result of 
tunicamycin treatment is consistent with previous reports and has been suggested to 
play a role in the associated vascular effects of tunicamycin by favouring an increase 
in capillary permeability and thrombus formation (Jago, 1984); (Finnie and Jago, 
1985).  In particular, the repression of FN has been suggested as a possible 
explanation for the breached blood-brain barrier and associated liver damage caused 
by corynetoxin and tunicamycin (Jago et al.  1983).   
Both mt_Co1 and FN represent particularly interesting candidates for further 
investigation as biomarkers of exposure.  As observed in this study, not only are both 
genes consistently down-regulated as result of corynetoxin exposure, but their gene 
regulation appears to be non-equivalent in both corynetoxin and tunicamycin.   
There are numerous reports of use of FN and mt_Co1 as a useful and effective 
biomarker.  Fibronectin has been reported in the past as a useful biomarker in 
prostatic cancer (Webb and Lin, 1980).  More recently, FN has been reported as an 
useful and effective biomarker in renal and cell carcinoma (Webb and Lin 1980; 
Hegele et al., 2007), venous thromboembolism (VTE) and thromobosis (Pecheniuk1 
et al., 2008) and as a promising biomarker in chronic obstructive pulmonary disease 
(Man et al.,  2008).  Furthermore, FN has been utilised as a highly sensitive serum 
plasma biomarker in a commercially available enzyme linked immunoassay 
(Fibronectin (rat) ELISA) (Alpco™, Salem USA).  In addition, mt_Co1 has been 
identified as an established and reliable biomarker for a number of diseases, including 
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assessing colon cancer risk (Payne et al.,  2005).  Thus, mt_Co1 and FN may possess 
the necessary requisite qualities for detection of corynetoxin exposure in future 
biomarker studies.  
Genes displaying the highest up-regulation consistent between the 5 and 5000 nM 
treatments were also chosen as potential biomarker candidates.  Genes identified as 
induced in both the 5 nM and 5000 nM treatments appear to be involved in various 
different areas and functions including: drug metabolism (GSTP, cyp1b1, MAO-A, 
FMO5); stress response (Bruckner et al.,  2001); detoxification (GSTM5, GSTα); 
DNA synthesis (GA45 and CEBPA); iron stock (Finnie and O'Shea, 1990a); lyase 
activity (ecoa); and the citric acid cycle (MDH1).  It has been suggested that protein-
coding genes whose transcription is differentially up-regulated in the setting of tissue 
injury are considered effective candidate biomarkers (Hubank and Schatz, 1994).  
Among the existing data set, the genes displaying the highest up-regulation in both 
treatments were JNK3, GSTα and GA45.  Generally, genes displaying the highest 
level of differential regulation potentially represent good biomarker candidates and 
may warrant further investigation. 
JNK3 (MAPK10) N-terminal kinase gene is involved in a wide variety of cellular 
responses including: cell growth, oncogenic transformation, cell differentiation and 
cell death (Leppa and Bohmann 1999; IP and Davis 1998).  As discussed in Sect 
3.7.3, JNK3 functions as a stress-activated protein kinase and is induced as part of the 
pro-apoptotic stress response (Jarpe et al.,  1998).  The observed induction of JNK3 is 
consistent with previous studies demonstrating that apoptosis contributes to 
hepatocyte loss in tunicamycin poisoning (Finnie et al.,  2004).  Therefore, the up-
regulation of JNK3 is consistent with expected induction following a toxic insult.  
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Further, it has been reported in a number of publications that kinases and other 
immune system molecules can be reliable indicators or biomarkers of disease or 
physiologic state  (Griffin et al.,  1993; Hacker et al.,  2006; Sato et al.,  2005; 
Takahashi et al.,  2006). 
GSTα (Glutathione transferase α) is an enzyme consisting of two subunits (dimer) 
involved in the detoxification of electrophilic compounds, including: carcinogens, 
therapeutic drugs, environmental toxins and products of oxidative stress.  GSTα 
belongs to the Glutathione transferases (GST) multigene family of phase II drug-
metabolising enzymes that catalyse the conjugation of glutathione with a range of 
endogenous and exogenous substrates (Armstrong, 1997); (Salinas and Wong, 1999).  
Induction of GST synthesis is a protective mechanism that occurs in response to 
xenobiotic exposure.  This action reduces toxicity and facilitates urinary excretion 
(Beckett et al.,  1987).  There are four isozymes of GST (alpha, pi, mu, and theta), 
which are expressed in human and other mammals in soluble and membrane-bound 
GSTs form.  In particular, three genes encoding GST-related enzymes, GSTM5 
(Glutathione S-transferase, Mu5), GSTP (Glutathione S-transferase, Pi) GSTO1 
(Glutathione S-transferase, omega 1) were also identified as differentially expressed 
in the 5 nM and 5000 nM corynetoxin treatments of this study.  Liver is a major 
GSTα expressing tissue which is indicative of the role of GSTs in the 
biotransformation of xenobiotics (Pabst et al.,  1973; Armstrong, 1997).  In particular, 
GSTα is expressed in hepatocytes where it accounts for approximately 5% of soluble 
protein (Coles and Kadlubar, 2005).  Several previous studies have demonstrated the 
diagnostic utility of GSTα to assess acute hepatotoxicity.  A study by Giffen et al.,, 
2002 involved rats being given a single oral dose of either alpha-
naphthylisothiocynate (ANIT), bromobenzene (BrB) or thioacetamide (TAA) that 
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induce marked hepatotoxicity and GSTα elevations in serum corresponded to liver 
histopathological findings.  In addition, El-Sayed et al., 2007 demonstrated that that 
toxic selenazolidines induced expression of GSTα in a murine hepatoma (Dere et al.,  
2006) in vitro system.  Thus, the abundant and distinct localisation of GSTα in 
hepatocytes supports it use as a serum biomarker for determining liver damage 
(Lantum et al.,  2002). 
GA45 (GADD45a) is involved in growth arrest playing an important role in the 
maintenance of genomic stability by controlling cell cycle checkpoints, DNA repair 
and apoptosis (Duong et al.,  2005).  Generally, the induction of GA45 transcription is 
rapid, transient, and dose-dependent   GA45 gene induction has been observed in 
response to a wide range of genotoxic stresses including: mitomycin C (Abbas et al.,  
2002) and cisplatin (Shalon et al.,  1996) taxol, a spindle poison (Mullan et al.,  2001) 
hydrogen peroxide (Fornace et al.,  1988) and hypoxia (Price and Calderwood, 1992).  
Cell types tested include rodent cells in vivo (Abcouwer et al.,  1999) and rodent cell 
lines (Hollander et al.,  1999) and human lymphoblasts and fibroblasts (Lin et al.,  
1999; Papathanasiou et al.,  1991).  
GA45 appears to be a clearly conserved and important gene which has been 
investigated in several studies monitoring global gene expression using 
toxicogenomic.  The robust induction of GA45 expression was repeatedly observed 
with a wide range of genotoxins at various concentrations (Hu et al.,  2002; Newton et 
al.,  2004).  Further, GA45 has been reported as a potential key biomarker in blood for 
genomic stress (Amundson and Fornace, 2004).  In particular, GA45 has been 
identified as a successful biomarker for high throughput genotoxicity screening 
(Hastwell et al.,  2006).   
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Not all alterations in gene expression should be viewed as deleterious or have the 
potential as a predictive biomarker of toxin exposure.  Careful analysis of the types of 
changes occurring is essential to distinguish between responses representing harmful 
effects and those representing benign homeostatic adjustments (Heinloth et al.,  
2004).  For instance, changes in gene expression indicating a cellular stress responses, 
and interruption or repression of vital cellular functions may effectively serve as early 
markers of potential or impending toxicity.  However, changes associated with a need 
to increase the capacity to metabolise and excrete a chemical would not be considered 
to be an adverse effect and as such genes that are increasing metabolic capacity are 
unlikely to be specific and unique early markers.   
The five biomarker candidates identified in this study appear to all be regulated in 
response to toxic effect and several have previously been identified in various studies 
as important biomarkers of exposure to various toxicants.  Furthermore, from a 
biomarker discovery perspective, an ideal biomarker should be consistent in every 
case of the disease.  Thus, the differential gene changes observed in the five 
biomarker candidates identified in this study may prove effective in diagnosing low 
level of exposure and useful in predicting potentially adverse effects.   
Predictive biomarkers however, are not necessarily accessible biomarkers.  The best 
biomarker is of no use if it cannot be accessed in the least invasive manner possible.  
A general limitation of technologies based on genomics relates to accessibility and the 
absolute requirement for biological samples that are physically available for analysis.  
Although various biological samples might be readily available and easy to obtain, a 
potential biomarker of interest might be expressed in tissue that is difficult or 
inaccessible to sample preparation.  In particular, based on the biomarkers identified 
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in this study using hepatocytes, obtaining liver cells for testing would be extremely 
difficult to obtain for testing in order to diagnose pre-clinical exposure of livestock in 
the field.   
The need for accessible biomarkers has highlighted the need to extend our knowledge 
of genomic biomarkers of toxicity in whole blood RNA or other readily available 
sources.  In particular, it is relatively easy to obtain blood samples for testing.  Thus 
for clinical use it is prudent to investigate if changes in gene expression in peripheral 
blood cells or alterations in protein biomarkers in body fluids could serve to identify 
toxicity of extra hematological organs and tissues.  
The use of gene expression changes in peripheral blood cells as sentinels of tissue 
damage and dysfunction due to exposure and disease processes is showing great 
promise in many areas although there have been limited reports of success in toxicity 
detection (Baird, 2007; Burczynski and Dorner 2006; McHale et al., 2007).  A recent 
publication has identified gene expression signatures in the peripheral blood that 
predict exposure to harmful levels of acetaminophen in the rat and reported that these 
gene based measurements are more accurate than classical clinical pathology and 
histopathology assessments (Bushel et al.,  2007). They translated these rat genes into 
their human orthologs and found that they could separate acetaminophen-intoxicated 
patients from control humans. Such interesting results should spur the discovery and 
subsequent qualification of biomarkers that cross species barriers and prove useful in 
non-clinical and clinical arenas. 
The in vitro toxicogenomic approach utilized in this study therefore represents a 
useful and robust molecular approach to identify candidate biomarkers of pre-clinical 
disease.  Future studies are still required to compare these biomarkers identified in 
Chapter 4 
  231 
clone-9 cells to other in vivo systems to determine if response patterns to both toxins 
are similar across different systems.  In particular, investigation of corynetoxin-
exposed animals will be ultimately required as the capacity of these biomarkers to act 
as diagnostic indicators must be confirmed by experimental trials involving 
corynetoxin exposure.  Finally, extensive validation across different samples, doses 
and time points will also be required.   
4.6.2.2 Rea l-time PCR 
Real-time PCR (Morgan et al.,  2002) was performed to evaluate the reliability of the 
microarray technology used and validate the biomarker candidates identified.   
Based on the putative functional association with ARGT and the magnitude of gene 
expression, five biomarker candidate genes were selected from microarray analysis.  
Genes chosen to be analysed by RT-PCR included: mt_CO1, FN, JNK3, GSTα and 
GA45.  Comparison of the expression changes of these selected genes confirmed that 
all selected genes followed the same tendency for gene expression using RT-PCR and 
indicated that these genes may be potentially useful as biomarkers of exposure.  The 
expression of the two independently constitutively expressed genes GAPDH and S29 
were also shown not to be affected by treatment. 
Chapter 4 
  232 
Conclusion 
Bioequivalence 
A direct comparison of the effects of low level tunicamycin and corynetoxin exposure 
is vital to further developing the current understanding of the bioequivalence of these 
two toxins and assessing the suitability of tunicamycin as an experimental substitute 
for corynetoxin in future toxicity studies.  This study has demonstrated the effects of 
equivalent levels of tunicamycin and corynetoxin on hepatocyte viability and 
morphology to be indistinguishable, providing further evidence that these two related 
toxins have equivalent bioactivity at macroscopic level.  However, examining the 
bioequivalence of tunicamycin and corynetoxin using microarray technology has 
demonstrated for the first time an apparent non-equivalence of these toxins at the 
genomic level.   
Ultimately, it will be important to compare these and other responses in clone-9 cells 
to other cellular and in vivo systems to determine whether response patterns to both 
toxins are similar across different systems.  Investigating the bioequivalence of gene 
responses of both toxins across a variety of systems will be useful to confirm and to 
substantiate the observed non-equivalence of tunicamycin and corynetoxin at the 
genomic level.  
Identifying molecular indicators of non-equivalence of tunicaminyl-uracil toxicity in 
vitro has potentially important implications for future studies of ARGT.  The 
observed non-equivalence of these toxins at the genomic level may have significant 
implications for future molecular based studies of ARGT, particularly in the field of 
biomarker discovery.  In particular, the potential utility of the tunicamycin -based 
experimental model and associated tunicaminyl-uracil gene profile as an early 
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biomarker of exposure to corynetoxin may no longer be appropriate.  Based on the 
findings of this study, the long-standing use of tunicamycin as a substitute to 
experimentally model ARGT has been brought into question.  
Biomarker 
This study reports an initial biomarker discovery strategy using an in vitro 
toxicogenomic approach to identify potential candidate biomarkers of pre-clinical 
corynetoxin exposure.  The present study has identified five candidate genomic 
biomarkers of corynetoxicity (mt_CO1, FN, JNK3, GSTα and GA45).  Preliminary 
results suggest that these candidate biomarkers appear predictive of cell stress or 
subtle cell injury indicative of pre-clinical exposure to corynetoxin.  However, 
extensive biomarker validation is still required using additional systems (as discussed 
above) to assess the utility of these candidate biomarkers as diagnostic indicators of 
pre-clinical exposure to ARGT.  Ultimately, these preliminary candidates may offer 
the opportunity for the development of future diagnostic or prognostic tools in early 
prediction tests for ARGT.    
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Figure 4-1 Experimental design for the direct comparison of Tunicamycins (TMs) and 
Corynetoxins (CTs). Boxes representing mRNA samples are labelled as A (TMs) or B (CTs). 
Subscripts indicate the number of independent biological replicates of the same treatment. 
Arrows represent each of the triplicate samples which are designated to one of the arrays on 
the Dual Chip which are then compared with each of the other triplicates (designated to the 
other array) via a one-colour direct comparison protocol. 
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Figure 4-1 (b) Experimental design for the direct comparison of Corynetoxins (A2) and 
Control (B2). 
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Figure 4-2 RP-HPLC analysis of toxins of ~1 mg/mL solutions of (A) Tunicamycin (TMs) 
and (B) Corynetoxins (CTs) prepared in 0.6 mM NaOH.  5 mL of each was applied to a C18 
column and eluted using a methanol + 0.1% TFA gradient of 70-90% over 40 minutes.  The 
assignment of components in based on the results of Cockrum and Edgar (1983).  
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Table 4-1 Oligonucleotide primers used for RT-PCR 
 
Primer Gene symbol Gene name Genbank # Size of amplicon Primer sequence (5'-3') Tm
1 GCATTGTGAGAGCAGTTCCTTAGA 59°C
CCAGGAGAAAGGTTAAGGCTTGT 59°C
2 GCGGGAACGCAACAACAT 59°C
TGGTCAACTCCAACACCTTCTG 59°C
8 GCCAACCAAGATGCAAATGTTT 60°C
GTATTGCGGGCCAGACACTTA 59°C
3 GACCCTCGCATCCGACACT 60°C
TGTGTTCTATCATGGCGTCATCT 58°C
4 GCGGGAACGCAACAACAT 59°C
TGGTCAACTCCAACACCTTCTG 58°C
5 GA45 Growth arrest and DNA damage Mm81855 105 bp GACCCTCGCATCCGACACT 59°C
CTCCAGCCTGAACCATCGA 58°C
6 TCTAACCGCCACGGTCTGAT 59°C
AGGTCGCTTAGTCCAACTTAATGAA 58°C
7 ACTAAAGGGCATCCTGGGCTAC 59°C
CAGGAAATGAGCTTCACAATGTTG 60°C
GSTA GSTA cons X12752 94 bp
JNK3 Mitogen activated protein kinase10 NM_012806 128  bp
CEBPA CCAAT/enhancer-binding protein alpha 
(C/EBP-alpha; CEBPA)
X12752 94 bp
GAPDH Glyceraldehyde-3-phosphate-
dehydrogenase 
X02231 135 bp
S29 Ribosomal protein S29 X59051 108 bp
mtCO1 cytochrome c oxidase subunit 1 M27315 130 bp
FN Fibronectin X027 61 102 bp
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Table 4-2  Significance of the main treatment effects following GLMM analysis of data 
presented in Tables 4-2 and 4-3 
 
Fixed term Degrees of 
freedom
P value
Time 13 <0.001
Contol 2 <0.001
Time Control 26 <0.001
Dose 3 <0.001
Time Dose Toxin 39 <0.001
Time Toxin 1 0.999
Dose Toxin 13 0.558
Time Dose Toxin 39 0.819
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Figure 4-3 Live cell counts based on Trypan Blue dye exclusion. A graphical representation 
of the average numbers of live cells present within each dose group (Table 4-2).  Exponential 
trendlines were plotted using Microsoft Excel. 
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Figure 4-4 Percentage of dead cells. The percentage of dead cells within each culture as 
determined by Trypan blue dye exclusion staining based upon the results presented in Tables 
4-2 and 4-3.  
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Figure 4-5  Proportion of dead cell (adjusted). Proportion of dead cells for the various 
treatment groups across time based on the data presented in Tables 4-2 and 4-3. 
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Figure 4-6 Cell viability resultsCounts for live and dead cells in the Control treatment across 
time based on the data presented on Tables 4-2 and 4-3. 
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Figure 4-7 Adjusted proportion of dead cells. Logistic regressions have been fitted to the 
various treatments for which the proportion of dead cells change over time. 
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Figure 4- 8 Mitosis was observed in various treatments up to 24 hrs. Morphological 
difference were not observed in the ten cultures representing the various treatments up to 24 
hrs following toxin exposure. Cultures consisted of broad sheets of hepatocytes through 
which were scattered holes that were rapidly being filled by new cells being formed by 
mitosis. (a) Cells at 0 hrs prior to change of media (b) Control cells at 4 hrs (c) 5 nM CTs at 
11 hrs (d) 50 nM TMs at  22 hrs.  All images at 400x magnification 
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Figure 4-9 Cellular changes after 24 hours in Control culturesCellular changes after 24 hrs 
in controls, 5 nM CTs and TMs treatments were indistinguishable. (a) control at 24 hrs (b) 
control 35 hrs (c) control 49 hrs (d) control 71 hrs (e) control 96 hrs (f) control 109 hrs. All 
images at 400x magnification. 
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Figure 4-10  Cellular changes after 24 hrs in 5 nM CTs/TMs exposed cultures Cellular 
changes after 24 hrs in controls, 5 nM CTs and TMs treatments were indistinguishable. (a) 5 
nM TMs at 27 hrs (b) 5 nM TMs at 33 hrs (c) 5 nM CTs at 49 hrs (d) 5 nM CTs at 76 hrs.  
Mild vacuolation was present in some cells at 93 and 109 hrs (e) 5 nM TMs at 93 hrs (f) 5 nM 
CTs at 109 hrs. All images at 400x magnification. 
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Figure 4-11 Cellular changes after 24 hrs in ≥ 50 nM CTs or TMs. Progression of cellular 
changes after 24 hrs in  ≥ 50 nM TMs and CTs samples: (a) 50 nM TMs at 27 hrs (b) 50 nM 
TMs at 35 hrs (c) 5000 nM CTs at 54 hrs (d) 500 nM CTs at 76 hrs (e) 50 nM TMs at 93 hrs 
(f) 5000 nM CTs at 109 hrs. All images at 400x magnification. 
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Figure 4-12  Vacuolation in cultures exposed to ≥50 nM Corynetoxins or 
TunicamycinsVacuolation in cultures exposed to ≥50 nM CTs or TMs. Vacuolation became 
first observable (highlighted by arrows) from 24 hrs onwards in samples ≥ 50 nM CTs or 
TMs. (a) 5000 nM TMs at 28 hrs [1,000x magnification] (b) 50 nM TMs at 46 hrs [1,000x 
mag] (c) 500 nM CTs at 48 hrs [400x mag] (d) 5000 nM CTs at 54 hrs [400x mag]. 
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Figure 4-13 Cell shrinkage, detachment and disruption in cultures exposed to 5000 nM 
toxinCell shrinkage, detachment and disruption of sheets in cultures exposed to 5000 nM CTs 
or TMs. Cell shrinkage, detachment of cells and detachment from monolayer exposed to  
5000 nM CTs or TMs was first observable (highlighted by arrows) from 30 hrs onwards. (a) 
5000 nM TMs at 34 hrs (b) 5000 nM CTs at 49 hrs (c) 5000 nM CTs at 54 hrs (d) 5000 nM 
TMs at 70 hrs (e) 5000 nM CTs at 96 hrs.  All images at 400x magnification. 
 
 
a 
b c
d e
Chapter 4 
  250 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 4 Regenerative changes in cultures exposed to ≥ 50 nM toxinRegenerative 
changes in cultures exposed to ≥ 50 nM CTs or TMs first appeared at 78 hrs. Apparent 
regenerative changes exposed to ≥ 50 nM CTs or TMs were first observable (highlighted by 
arrows) from 78 hrs onwards. (a) 50 nM TMs at 78 hrs. (b) 50nM TMs at 81 hrs. (c) 500 nM 
CTs at 95 hrs. (d) 50 nM TMs at 106 hrs. All images at 400x magnification. 
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Figure 4-15 Experimental work flow for microarray experiments. Schematic representation 
of experimental work flow for microarray experiments. (a) Each triplicate sample from each 
of the two toxin treatments (b) Hybridised on separate arrays and screened using at least three 
different PMT settings (c) An overall ratio for each triplicate is obtained based on a 
comparison of the three separate gains for each triplicate treatment (d) Replicate data merge 
is used based on each of the combined overall ratios of the individual replicates (e) An 
ultimate overall ratio based on all combined replicates is obtained for the two treatment is 
obtained.   
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Figure 4-16 Differential gene expression 5 nM Tunicamycins (TMs) and Corynetoxins (CTs) 
24 h. Bar plot representing overall combined quantitatively significant values for TMs LD 
24h (Array 1.1, 1.2) vs. CTs (Arrays 2.1, 2.2, 2.3) 
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Figure 4-17 Combined quantitatively significant values for Tunicamycins (TMs) and 
Corynetoxins (CTs) HD 24h. Bar plot representing ultimate combined quantitatively 
significant values for TMs HD 24h (Array 4.1, 5.1 and 6.1) vs. CTs (Arrays 4.2, 5.2, 6.2) 
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Figure 4-18 Ultimate combined quantitatively significant values for Tunicamycins (TMs) LD 
48h. Bar plot representing ultimate combined quantitatively significant values for TMs LD 
48h(Array 7.1, 8.1 and 9.1) vs. CTs (Arrays 7.2, 8.2, 9.2) 
 
 
TMs vs CTs 5 nM (LD) 48h
0.1
1
10
ecoa
PEPTI
FN MA
O
-A
m
t_co1
G
STP
G
SS
G
A
45
H
M
G
Le
ve
l o
f g
en
e 
ex
pr
es
si
on
Chapter 4 
  255 
 
 
Table 4-3 List of differentially regulated genes identified 
Gene name Symbol Accession 
#
General function 
acyl-coenzyme A oxidase ACO J02752 Lipid metabolism
apolipoprotein E APOE J00705 Lipidprotein 
transport
B cell lymphoma 2-like 1 Bclx NM_031535 Anti-apoptosis
CCAAT/enhancer binding 
protein, alpha
CEBPA X12752 DNA binding
enoyl CoA ecoa K03249 Lyase activity
Ferritin-H subunit ferritin U58829 Iron stock
Fibronectin FN X15096 Extracellular 
matrix
Growth arrest and DNA-
damage-inducible 45 alpha
GA45 L32591 DNA repair / 
synthesis
Glutathione synthetase GSS NM_012962 Protection/ 
Detoxification/ 
membrane 
transport
Glutathione S-transferase Pi GSTP NM_012577 Drug metabolism
Histone D-acetylase Hdac NM_008228 DNA transcription
3-hydroxy 3-methylglutaryl-
Coenzyme A synthase 1
HMG X52625 Cholesterol 
Metabolism
Heme Oxygenase 2 HOX2 J05405 Stress response
HSP40 HSP40 NM_032079 Stress response
MAO-A MAO-A XM_343764 Drug metabolism
Malate Dehydrogenase 1 MDHI NM_033235 Citric acid cycle
cytochrome c oxidase subunit 
1
mt_Co1 M27315 Drug metabolism
NADPH N aOX NM_012985 Respiratory chain
p38 mitogen activated protein 
kinase
p38 U73142 Transcription 
factor
Proliferating cell nuclear 
antigen
PCNA Y00047 Cell cycle
Solute carrier family 15 
(oligopeptide transporter) 
member 1
PEPT1 NM_057121 Transport
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Figure 4-19 Differentially expressed genes identified in each treatment A) Overall combined 
A) Overall combined quantitatively significant values for TMs LD 24h (Array 1.1, 1.2) vs. 
CTs (Arrays 2.1, 2.2, 2.3); B) Overall combined quantitatively significant values for TMs HD 
24h (Array 4.1, 5.1 and 6.1) vs. CTs (Arrays 4.2, 5.2, 6.2); C) Overall combined 
quantitatively significant values for TMs LD 48h (Array 7.1, 8.1 and 9.1) vs. CTs (Arrays 7.2, 
8.2, 9.2). 
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Figure 4-20 Real-time PCR versus microarray data. Correlation of the ratios of induced and 
repressed genes determined by DualChip™ rat hepato and real-time PCR.  The data is 
expressed as ratio of the TMs versus the CTs sample. 
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Figure 4-21 Differential gene expression at 24 hours for 5 nM CTs vs. Controls. Bar plot 
representing overall combined quantitatively significant values for CTs LD 5 nM 24 h 
(Array 1.2, 2.2, 3.2) vs. Controls (Arrays 10.1, 10.2, 11.1) 
CTs LD (0.05 nM) vs Controls 24 hrs
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Table 4-4 Differentially regulated genes identified in Low Dose (LD) CTs (5 nM) vs. 
Controls at 24 hours 
 
Gene name Gene Overall 
ratio
Function Genbank
Cytochrome c oxidase subunit1 mt_Co1 0.338 Drug metabolism M27315
Apolipoprotein E APOE 0.500 Lipidprotein transport J00705
Fibronectin FN 0.697 Extracellular matrix X15096
Acyl-coenzyme A oxidase ACO 0.799 Lipid metabolism J02752
Heat Shock Protein 27 HSP27 0.847 Stress response M86389
Cyclin- dependent kinase 4 cdk4 0.901 Cell Cycle NM_053593
Cyclin D1 cnd1 1.025 Cell Cycle D14014
NADPH NaOx 1.217 Respiratory chain NM_012985
Malate Dehydrogenase 1 MDH1 1.324 Citric acid cycle NM_033235
Cytochrome P450 cyp1b1 1.335 Drug metabolism U09540
Heat Shock Protein 40 HSP40 1.394 Stress response NM_032079
Enoyl CoA ecoa 1.408 Lyase activity K03249
Cyclin D3 CND3 1.421 Cell Cycle NM_012766
P38 mitogen activated protein kinase p38 1.514 Transcription factor U73142
Heat Shock Protein 70 HSP70 1.520 Stress response L16764
GPX1 GPX1 1.554 Glutathione peroxidase NM_030826
UDP glucuronosyltransferase 1A UGT 1.556 Drug metabolism J05132
Histone D-acetylase Hdac 1.605 DNA transcription NM_008228
Osteonectin Osteon 1.606 Extracellular matrix NM_012656
Proliferating cell nuclear antigen PCNA 1.632 Cell Cycle Y00047
MAO-A MAO-A 1.643 Drug metabolism XM_343764
Aryl hydrocarbon receptor Ahr 1.695 Transcription factor NM_013149
Superoxide dismutase 2 MnSOD 1.706 Oxidative metabolism Y00497
Tumour protein p53 p53 1.756 Cell Cycle X13058
Insulin-like growth factor 1 receptor IGF1R 1.852 Cell signalling/receptor NM_052807
IGF-binding protein 2 IGF2 1.874 Growth factor/cytokines NM_031511
Cyclin B1 cnb1 1.898 Cell c ycle NM_171991
CCAAT/enhancer binding protein CEBPA 1.969 DNA binding X12752
Solute carrier family protein 15 PEPT1 1.926 Transport NM_057121
Glutathione S-transferase Pi GSTP 2.050 Drug metabolism NM_012577
Flavin containing monooxygenase 5 FMO5 2.140 Xenobiotic metabolism NM_144739
cyclin A2 cna2 2.218 Cell Cycle XM_342229
GSTM cons GSTM 2.383 Detoxification NM_017014
Growth arrest and DNA-damage 
inducer
GA45 2.347 DNA repair/synthesis L32591
GSTA cons GSTA 2.410 Detoxification NM_031509
Ferritin-H subunit ferritin 2.658 Iron stock U58829
Glutathione S-transferase, Mu5 GSTM5 2.779 Detoxification NM_172038
3-hydroxy 3-methylglutaryl- 
Coenzyme A synthase 1
HMG 2.894 Cholesterol metabolism X52625
JNK3 (MAPK-10) JNK3 3.090 Stress response NM_012806
Glutatthione S-transferase omega 1 GSTO1 3.320 Glutathione transferase XM_342062
Glutathione synthatase GSS 3.447 Protection/detoxification NM_012962
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Table 4-5  Differentially regulated genes identified in Low Dose (LD) CTs (5 nM) vs. 
Controls at 24 hours 
 
 
Gene Ratio 1R2 R3 R4 R5 R6 R7 R8 R9
Overall 
ratio Category
mt_Co1 0.434 0.374 0.346 0.285 0.313 0.267 0.305 0.331 0.388 0.338 Quant. Significant
APOE 0.478 1.284 0.422 0.380 0.427 0.473 0.252 0.349 0.432 0.500 Quant. Significant
FN 0.32459 2.009 0.365 0.474 1.227 0.415 0.443 0.519 0.504 0.697 Quant. Significant
ACO 0.500 1.966 0.348 1.111 1.726 1.111 0.280 0.396 0.378 0.799 Quant. Significant
HSP27 2.107 1.841 0.326 0.467 1.350 0.450 0.338 0.393 0.349 0.847 Quant. Significant
cdk4 1.970 2.304 0.333 0.483 1.400 0.384 0.369 0.493 0.370 0.901 Quant. Significant
cnd1 2.170 2.502 0.362 0.435 2.003 0.420 0.396 0.534 0.401 1.025 Quant. Significant
NaOx 1.867 2.053 0.476 0.439 1.854 0.525 0.405 1.404 1.927 1.217 Quant. Significant
MDH1 2.297 2.293 0.383 1.924 2.393 0.412 0.448 1.357 0.410 1.324 Quant. Significant
cyp1b1 2.268 2.339 0.461 1.841 2.387 1.783 0.423 0.507 0.531 1.335 Quant. Significant
HSP40 2.416 2.509 1.414 0.514 2.116 1.400 0.350 0.456 1.291 1.394 Quant. Significant
ecoa 1.176 2.749 1.770 0.443 2.269 1.146 0.312 1.383 1.422 1.408 Quant. Significant
CND3 2.351 2.641 0.998 1.381 1.938 1.346 0.403 1.123 0.494 1.421 Quant. Significant
p38 2.650 2.282 0.427 1.882 2.013 0.448 1.668 1.783 0.475 1.514 Quant. Significant
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 Table 4-5 (cont) Differentially regulated genes identified in Low Dose (LD) CTs (5 nM) vs. 
Controls at 24 hours 
Gene Ratio 1 R2 R3 R4 R5 R6 R7 R8 R9
Overall 
ratio Category
HSP70 2.715 3.305 0.323 1.382 1.470 0.301 1.523 2.265 0.974 1.520 Quant. Significant
GPX1 2.587 2.801 0.406 0.387 0.526 0.343 2.126 2.896 1.913 1.554 Quant. Significant
UGT 3.147 2.558 1.092 1.357 1.378 0.460 1.508 2.030 0.473 1.556 Quant. Significant
Hdac 2.990 3.039 0.492 1.916 2.427 0.464 0.515 2.073 0.528 1.605 Quant. Significant
Osteon 2.831 2.657 1.079 1.413 2.163 0.470 0.486 1.978 1.377 1.606 Quant. Significant
PCNA 2.538 2.304 1.771 1.441 2.119 1.464 0.458 1.124 1.466 1.632 Quant. Significant
MAO-A 3.333 2.537 0.426 2.663 2.526 0.504 1.742 0.568 0.488 1.643 Quant. Significant
Ahr 1.646 2.094 1.394 1.192 1.887 1.507 0.923 1.502 1.535 1.695 Quant. Significant
MnSOD 2.717 3.008 1.654 2.084 2.863 1.903 1.356 2.472 0.522 1.706 Quant. Significant
p53 3.726 2.942 1.129 2.122 2.081 0.457 1.439 1.419 0.491 1.756 Quant. Significant
IGF1R 2.782 2.620 0.453 2.245 2.635 0.539 1.420 2.157 1.822 1.852 Quant. Significant
IGF2 2.458 3.579 1.269 1.400 2.540 1.058 1.574 2.851 1.590 1.874 Quant. Significant
cnb1 2.869 3.455 0.417 2.163 3.253 0.467 1.416 2.551 0.489 1.898 Quant. Significant
CEBPA 2.190 3.147 2.069 0.442 2.398 1.897 0.382 2.566 2.626 1.969 Quant. Significant
PEPT1 3.012 2.800 2.111 1.384 2.085 1.865 0.478 1.472 2.126 1.926 Quant. Significant
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Table 4-5 (cont) Differentially regulated genes identified in Low Dose (LD) CTs (5 nM) vs. 
Controls at 24 hours 
Gene Ratio 1R2 R3 R4 R5 R6 R7 R8 R9
Overall 
ratio Category
HSP70 2.715 3.305 0.323 1.382 1.470 0.301 1.523 2.265 0.974 1.520 Quant. Significant
GPX1 2.587 2.801 0.406 0.387 0.526 0.343 2.126 2.896 1.913 1.554 Quant. Significant
UGT 3.147 2.558 1.092 1.357 1.378 0.460 1.508 2.030 0.473 1.556 Quant. Significant
Hdac 2.990 3.039 0.492 1.916 2.427 0.464 0.515 2.073 0.528 1.605 Quant. Significant
Osteon 2.831 2.657 1.079 1.413 2.163 0.470 0.486 1.978 1.377 1.606 Quant. Significant
PCNA 2.538 2.304 1.771 1.441 2.119 1.464 0.458 1.124 1.466 1.632 Quant. Significant
MAO-A 3.333 2.537 0.426 2.663 2.526 0.504 1.742 0.568 0.488 1.643 Quant. Significant
Ahr 1.646 2.094 1.394 1.192 1.887 1.507 0.923 1.502 1.535 1.695 Quant. Significant
MnSOD 2.717 3.008 1.654 2.084 2.863 1.903 1.356 2.472 0.522 1.706 Quant. Significant
p53 3.726 2.942 1.129 2.122 2.081 0.457 1.439 1.419 0.491 1.756 Quant. Significant
IGF1R 2.782 2.620 0.453 2.245 2.635 0.539 1.420 2.157 1.822 1.852 Quant. Significant
IGF2 2.458 3.579 1.269 1.400 2.540 1.058 1.574 2.851 1.590 1.874 Quant. Significant
cnb1 2.869 3.455 0.417 2.163 3.253 0.467 1.416 2.551 0.489 1.898 Quant. Significant
CEBPA 2.190 3.147 2.069 0.442 2.398 1.897 0.382 2.566 2.626 1.969 Quant. Significant
PEPT1 3.012 2.800 2.111 1.384 2.085 1.865 0.478 1.472 2.126 1.926 Quant. Significant
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Figure 4-5 (cont) Differentially regulated genes identified in Low Dose (LD) CTs (5 nM) 
vs. Controls at 24 hours 
Gene Ratio 1 R2 R3 R4 R5 R6 R7 R8 R9
Overall 
ratio Category
GSTP 3.473 2.953 0.349 0.963 1.386 0.292 3.254 3.478 2.303 2.050 Quant. Significant
FMO5 3.145 2.665 0.463 1.923 2.043 0.406 2.946 3.140 2.529 2.140 Quant. Significant
cna2 3.150 2.923 1.066 2.300 2.666 1.358 2.152 2.293 2.057 2.218 Quant. Significant
GSTM 3.699 3.296 2.326 0.389 0.537 0.357 3.018 4.148 3.674 2.383 Quant. Significant
GA45 3.258 3.187 1.731 0.520 2.000 0.479 3.049 3.752 3.150 2.347 Quant. Significant
GSTA 3.508 4.170 1.746 0.472 2.220 0.347 2.810 4.221 2.194 2.410 Quant. Significant
ferritin 3.541 3.107 2.126 1.463 2.038 0.400 3.879 4.097 3.276 2.658 Quant. Significant
GSTM5 4.479 4.297 0.417 1.812 2.624 0.279 4.183 4.680 2.242 2.779 Quant. Significant
HMG 3.706 4.870 0.474 1.250 2.060 0.698 2.685 4.437 2.028 2.894 Quant. Significant
JNK3 4.274 5.079 2.569 2.963 3.779 1.406 2.501 3.184 2.057 3.090 Quant. Significant
GSTO1 6.191 5.805 1.590 1.968 3.000 0.734 4.551 6.958 2.298 3.320 Quant. Significant
GSS 4.668 5.195 1.903 1.467 2.046 0.871 3.219 4.506 2.589 3.447 Quant. Significant
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Figure 4-22 Differential gene expression at 24 hrs 5000 nM CTs vs. Controls. Bar plot 
representing overall combined quantitatively significant values for CTs LD 5 nM 24h (Array 
4.2, 5.2, 6.2) vs. Controls (Arrays 10.1, 10.2, 11.1). 
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Table 4-6 Differentially regulated genes identified in High Dose (HD) Corynetoxins (5000 
nM) vs. Controls at 24 hours 
 
 
 
 
 
 
 
 
 
 
Gene name Gene Overall 
ratio
Function Genbank
3-hydroxy 3-methylglutaryl- 
Coenzyme A synthase 1
HMG 0.384 Cholesterol metabolism X52625
Fibronectin FN 0.451 Extracellular matrix D14014
Cytochrome c oxidase subunit1 mt_Co1 0.455 Drug metabolism M27315
Cyclin D3 CND3 0.464 Cell Cycle NM_012766
Proliferating cell nuclear antigen PCNA 0.514 Cell Cycle Y00047
Superoxide dismutase 2 MnSOD 0.516 Oxidative metabolism Y00497
Heat Shock Protein 27 HSP27 0.547 Stress response M86389
cyclin A2 cna2 0.576 Cell Cycle XM_342229
Transferrin receptor TNFR 0.645 Glycoprotein receptor X66539
Apolipoprotein E APOE 0.696 Lipidprotein transport J00705
Cyclin- dependent kinase 4 cdk4 0.790 Cell Cycle NM_053593
JNK3 (MAPK-10) JNK3 0.811 Stress response NM_012806
Glutatthione S-transferase omega 1 GSTO1 0.883 Glutathione transferase XM_342062
Cyclin B1 cnb1 0.946 Cell cycle NM_171991
Glutathione S-transferase Pi GSTP 1.22923 Drug metabolism NM_012577
Glutathione S-transferase, Mu5 GSTM5 1.2973 Detoxification NM_172038
Ferritin-H subunit ferritin 1.30679 Iron stock U58829
Enoyl CoA ecoa 1.31056 Lyase activity K03249
Malate Dehydrogenase 1 MDH1 1.47754 Citric acid cycle NM_033235
Acyl-coenzyme A oxidase ACO 1.61473 Lipid metabolism J02752
CCAAT/enhancer binding protein CEBPA 1.66143 DNA binding X12752
Flavin containing monooxygenase 5 FMO5 1.76676 Xenobiotic metabolism NM_144739
Cytochrome P450 cyp1b1 1.84148 Drug metabolism U09540
MAO-A MAO-A 1.94084 Drug metabolism XM_343764
GSTA cons GSTA 2.16515 Detoxification NM_031509
Multidrug resistance 1/P-glycoprotein MDR1 2.25348 Drug resistance M81855
Growth arrest and DNA-damage 
inducer
GA45 5.3709 DNA repair/synthesis L32591
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Table 4-7 Differentially regulated genes identified in High Dose (HD) Corynetoxins (5000 
nM) vs. Controls at 24 hours 
 
Gene R1 R2 R3 R4 R5 R6 R7 R8 R9
Overall 
ratio Category
HMG 0.689 1.094 0.373 0.443 0.761 0.257 0.380 0.599 0.255 0.384 Quant. 
Significant
FN 0.424 0.428 0.299 0.699 1.137 0.541 0.459 0.605 0.402 0.451 Quant. 
Significant
mt_Co1 0.479 0.469 0.522 0.327 0.337 0.410 0.759 0.638 0.831 0.455 Quant. 
Significant
CND3 0.452 0.567 0.380 0.414 0.662 0.397 0.413 0.526 0.448 0.464 Quant. 
Significant
PCNA 0.522 0.460 0.493 0.384 0.465 0.375 0.606 0.657 0.664 0.514 Quant. 
Significant
MnSOD 0.585 1.046 0.542 0.464 0.659 0.473 0.829 1.082 0.953 0.516 Quant. 
Significant
HSP27 0.583 0.659 0.420 0.492 0.601 0.527 0.975 1.059 0.841 0.547 Quant. 
Significant
cna2 0.638 0.689 0.447 0.821 1.040 0.602 0.635 0.698 0.556 0.576 Quant. 
Significant
TNFR 0.677 0.912 0.627 0.656 0.952 0.652 0.723 0.974 0.875 0.645 Quant. 
Significant
APOE 0.451 0.563 0.549 0.484 0.651 0.640 1.044 1.255 1.536 0.696 Quant. 
Significant
Gene Ratio 1R2 R3 R4 R5 R6 R7 R8 R9
Overall 
ratio Category
cdk4 0.534 0.884 0.485 0.973 1.632 0.662 0.823 1.060 0.639 0.790
Quant. 
Significant
JNK3 0.633 1.192 0.374 1.249 1.883 0.515 0.999 1.189 0.651 0.811
Quant. 
Significant
GSTO1 1.746 2.482 0.611 1.480 2.354 0.573 1.366 1.961 0.600 0.883
Quant. 
Significant
cnb1 0.644 1.101 0.499 1.256 2.365 0.657 0.733 0.912 0.564 0.946
Quant. 
Significant
GSTP 1.852 1.649 0.502 0.578 1.214 0.502 1.861 1.660 0.953 1.229
Quant. 
Significant
GSTM5 1.546 2.133 0.489 1.342 1.992 0.524 1.299 1.774 0.623 1.297
Quant. 
Significant
ferritin 1.529 1.622 0.529 1.248 1.799 0.615 1.523 1.529 1.027 1.307
Quant. 
Significant
ecoa 0.517 1.244 0.648 0.991 2.248 1.552 0.859 1.587 1.330 1.311
Quant. 
Significant
MDH1 1.589 1.903 0.653 1.235 1.762 0.618 1.775 2.042 1.320 1.478
Quant. 
Significant
ACO 1.742 2.492 1.624 0.668 1.547 0.931 1.046 1.397 1.206 1.615
Quant. 
Significant
CEBPA 1.500 1.607 1.935 0.797 1.523 1.230 1.013 1.655 1.749 1.661
Quant. 
Significant
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Figure 4-23 Differential gene expression 5 nM CTs vs. Controls at 48 hrs Bar plot 
representing overall combined quantitatively significant values for CTs LD 5 nM 24h (Array 
4.2, 5.2, 6.2) vs. Controls (Arrays 10.1, 10.2, 11.1). 
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Table 4-8  Differentially regulated genes identified in Low Dose Corynetoxins (5 nM) vs. 
Controls at 24 hours 
 
Gene name Gene 
Symbol
Overall 
ratio
Function Genbank
Solute carrier family protein 15 PEPT1 2.240 Transport NM_057121
Proliferating cell nuclear antigen PCNA 0.529 Cell Cycle Y00047
3-hydroxy 3-methylglutaryl- Coenzyme 
A synthase 1
HMG 0.527 Cholesterol metabolism X52625
Cytochrome c oxidase subunit1 mt_Co1 2.649 Drug metabolism M27315
Chapter 4 
  270 
 
Table 4-9  Differentially regulated genes identified in Low Dose Corynetoxins (5 nM) vs. 
Controls at 24 hours 
 
Gene Ratio 1R2 R3 R4 R5 R6 R7 R8 R9 Overall Category
PEPT1 1.610 1.183 1.171 4.117 3.351 3.134 1.058 0.576 0.654 2.240 Quant. 
Significant
PCNA 0.425 0.828 0.544 0.110 0.226 0.166 0.617 1.234 0.954 0.529 Quant. 
Significant
mt_Co1 0.567 0.484 0.530 0.397 0.342 0.406 1.123 0.943 1.013 0.527 Quant. 
Significant
HMG 10.098 4.483 2.422 0.482 0.229 0.128 2.723 1.225 0.629 2.649 Quant. 
Significant
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Figure 4-24 RT-PCR versus microarray data for 5 nM CTs treatment at 12 h. Correlation of 
the ratios of induced and repressed genes determined by DualChip™ rat hepato and real-time 
PCR.  The data is expressed as ratio of the TMs versus the CTs sample. 
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CHAPTER 5 
General Discussion 
The overall objective of this investigation was to develop new sensitive molecular 
approaches for improved detection of ARGT (particularly low level exposure) in both 
the field ‘causal agents’ and within livestock ‘corynetoxin exposure’.  As discussed 
previously, the capacity of current diagnostics and detection systems to predict ARGT 
potential in pastures, grain and livestock is limited.  Further, current strategies do not 
offer the sensitivity or specificity for effective early detection, especially pre-clinical 
exposure.  The investigation presented in this thesis represents preliminary data 
utilising molecular-based technologies, more specifically genomic technologies, to 
assist in the development of improved strategies for detection and monitoring of 
ARGT with greater sensitivity and specificity at significantly lower levels 
undetectable by traditional detection strategies. 
In order to address the overall objective of this thesis, two distinct strategies based on 
detection of molecular indicators of toxicity in (1) the field and (2) within livestock 
were examined.  The first strategy involved molecular detection of known, or in the 
case of the phage, suspected factors contributing to ARGT in the field.  The second 
strategy involved detection of molecular biomarkers of exposure to ARGT within 
livestock. 
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5.1 Strategy 1- Detection  of  molecular in dicators o f t oxicity in  th e 
field 
The first strategy was primarily aimed at developing a rapid, sensitive and specific 
molecular-based detection system to identify the presence of R. toxicus and its 
associated phage in the field.  In particular, a polymerase chain reaction (PCR)-based 
assay, compatible with an existing enzyme-linked immunoassay for corynetoxin was 
developed and used to screen L. rigidum for the presence of both R. toxicus and 
bacteriophage isolate NCPPB 3778.  Firstly, PCR based primers specific for  
R. toxicus were designed from the reported 16S ribosomal RNA sequence (Deng and 
Hiruki, 1991) (Genbank accession number D84127), (Deng and Hiruki, 1991; Lee et 
al.,  1993; Namba et al.,  1993).  In order to design primers for phage isolate NCPPB 
3778, phage DNA sequence had to be firstly identified, as no previously published 
phage sequence was available.  Phage DNA was firstly isolated, digested, cloned into 
a suitable vector and then sequenced.  The resultant phage-derived nucleotide 
sequence was then compared to those pre-existing sequences in GenBank to identify 
areas of the phage sequence with unique homology.  The lack of any existing 
homology within GenBank supported the uniqueness of the phage sequence obtained 
and as a result this sequence was utilised to design primers specific for phage NCPPB 
3778.   
Two further aims were also addressed by the development and application of the 
PCR-based assays.  These involved investigating the host-phage interaction and 
ecology of R. toxicus and phage by 1) screening pasture-derived samples of annual 
ryegrass (L. rigidum) to determine if a relationship exists between phage, bacterium 
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and toxin presence, and 2) partially characterising the phage sequence to identify 
associated “signature genes” to provide an insight into its role in toxin production. 
5.1.1 Screening L. rigidum samples  
The PCR-based assay developed in this study was used to successfully screen pasture-
derived and isolated bacterially-infected gall samples of L. rigidum.  Results of 
screening bacterially-infected galls from toxic grain screenings demonstrated a 
positive correlation between the presence of bacterium and corynetoxin.  However, a 
definite correlation between bacteria, phage and toxin presence was not established.  
Analysis of pasture-derived samples of L. rigidum also failed to reveal a positive 
correlation between bacterium, phage and toxin presence. This may suggest that the 
phage is not responsible for toxin production and/or the phage may be present at 
extremely low levels and there may be issues of temporal and spatial variability. 
The potential involvement of the phage in toxin production cannot be completely 
discounted based on the results of this preliminary survey using the developed PCR-
based assay.  Several possible explanations for the lack of correlation observed 
between bacteria, phage and toxin have been considered.  The first possible 
explanation is that inhibition of the assay or a matrix effect was present in samples 
which may have hindered detection.  However, subsequent PCR inhibition 
experiments carried out to investigate this possibility failed to identify sample matrix 
effects which may have hindered the extraction/amplification of bacterial DNA and/or 
phage DNA.  Another possible explanation considered was that the developed PCR-
based assay was not sensitive enough to detect a minor phage or bacterial 
involvement.  However, subsequent sensitivity experiments using nested PCR to 
investigate this possibility demonstrated extremely high levels of sensitivity, i.e. R. 
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toxicus detection ≥ 2 bacterial cells and phage detection to approximately ≥ 100 
particles.  Therefore, inhibitory effects or lack of sensitivity associated with this assay 
do not appear to be likely explanations for the lack of correlation observed between 
bacteria, phage and toxin.  Another possibility that may be considered, but was not 
investigated in the present study due to time constraints, is the possibility that more 
than one species or strain of phage exists that was not identified in earlier research 
(Ophel et al.,  1993) nor detected by the specific primers designed for phage NCPPB 
3778, may be involved in the production of corynetoxin.  As discussed, Kurtboke 
(1994) isolated two other bacteriophage phiCT1 and phiCT2 from toxic ryegrass 
seeds and demonstrated that both isolates were also able to infect R. toxicus.  Future 
studies to investigate the potential involvement of other strains or species of 
bacteriophage with ARGT may be warranted.  Such an investigation would require 
the generation of new specific PCR primers based on these unique phage sequences 
using the same PCR-based assay developed in this study, screening either the same 
pasture-derived and infected gall samples or new ryegrass material.  Ultimately, a 
wider survey using a far greater number and wider range of pasture-derived and 
bacterial gall samples may assist in providing more robust results and a greater 
understanding of a potential relationship between phage, bacteria and toxin.  Further 
studies also to investigate parameters which may affect a carrier-type lysogenicity of 
R. toxicus phage would also be important to consider before the involvement of the 
phage can be entirely discounted, including: the genetic composition of the phage; the 
genetic composition of the host; and the environment (Gold, 1959).   
Combined with potential development of a PCR-based method of detection for the 
nematode vector (J. Allen, Department of Agriculture, Western Australia; personal 
communication) and the existing ELISA for corynetoxin, the PCR-based assays for R. 
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toxicus and the bacteriophage NCPPB 3778 provides a method for assessing pasture 
and animal feed stocks for all known, or in the case of the phage, suspected, factors 
contributing to ARGT.  The observations of this preliminary study support the 
potential application of the PCR-based assays in providing a useful, complementary 
tool in the assessment of the likelihood of pasture and feed to cause ARGT and to 
enable a better understanding of the complex aetiology of ARGT.  Such a rapid and 
comprehensive detection system could be regularly used prior to and during the 
ARGT season to provide for more timely and effective control and management of 
ARGT.  
5.1.2 Partial characterisation of the phage sequence 
With regard to the second aim of the first strategy, the first partial genomic 
sequencing of phage isolate NCPPB 3778 was also undertaken in an attempt to 
identify associated phage “signature genes” to provide potential insight into its 
suspected role in toxin production.  Based on the morphological characteristics 
observed using electron microscopy,  phage NCPPB 3778 appears to belong to the 
order Caudorvirales, Siphoviridae family of Franciki et al. (1991) corresponding to 
group B1 as defined by Bradley (Bradley, 1967). 
Approximately 29-kb of the bacteriophage NCPPB 3778 genome was sequenced 
(corresponding to about 65% of the genome).  Phage sequence was obtained by 
sequencing cloned phage DNA fragments and performing a primer walking strategy 
to assemble sequences using the Seqman program of the DNASTAR software 
package and CloneManager®.  Comparative phage genomics using database BLAST 
searches (Altschul et al.,  1990) to identify and assign functions indicated that a 
significant proportion of the phage sequence did not display any homologues in the 
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database.  However, the majority of putative functions for ORFs shown to have 
significant homology to sequences in the database were consistent with the order 
Caudorvirales, Siphoviridae family.    
The partial sequence analysis determined for NCPPB 3778 did not reveal any obvious 
homologies for virulence or toxin related genes, despite both morphologic and 
genomic analysis indicating that this phage belongs to the large family of 
Siphoviridae. As discussed (Chapter 2), Siphoviridae family consists of a number of 
prophage viruses known to cause toxin production in bacterial hosts (Friedman and 
Court, 2001).  In particular, significant sequence homology was identified for 
bacteriophage NCPPB 3778 with Bacteriophage Min1 and a range of 
mycobacteriophage.  Interestingly, Bacteriophage Min1 appears to share a number of 
similar characteristics with its bacterial host association as phage NCPPB 3778.  In 
particular, both Bacteriophage Min1 and phage NCPPB3778 infect coryneform-like 
soil bacterial hosts non-motile, gram-positive with high GC content) which appear to 
also have an association with soil nematodes.   
Absence of obvious virulence determinants in the identified phage sequence is 
probably not entirely unexpected given the unusual and unique nature of ARGT.  In 
fact, it can be argued that ORFs which possess no similarity to genes present in the 
databases may be of most interest and as such may warrant further investigation using 
both molecular genetics and bioinformatic approaches.  However, at the present time 
detailed analysis of phage sequence using comparative genomics to effectively 
characterise and assign functions to new phage sequence may be limited.  This is 
primarily due to the exceptionally diverse and dynamic phage population which has 
such a rapid population turnover occurring within a relatively short period of time 
Chapter 5 
  278 
(Breitbart et al.,  2002).  Furthermore, molecular investigations of R. toxicus may pose 
some difficulty at this point as R. toxicus was discovered only recently and is still 
poorly characterised, consequently molecular genetic approaches for R. toxicus are 
not yet properly developed.   
Future work to obtain the complete NCPPB 3778 phage genomic sequence annotated 
and characterised, in line with increased sequencing efforts for related phage and 
Rathayibacter/Coryneform bacterial species would represent a source of novel 
sequence information which may contribute to revealing prospective virulence 
determinants/ toxin related genes to provide some elucidation of phages NCPPB 3778 
potential role in toxin production.  Furthermore, the complete annotated sequence of 
Bacteriophage Min1 may also serve as a useful resource to further characterise new 
phage NCPPB3778 sequence given their high sequence homology and similar phage 
associated characteristics.` 
5.2 Strategy 2: Detecti on of m olecular in dicators of  exp osure t o 
ARGT within livestock 
The second strategy was primarily aimed at developing an in vitro toxicogenomic 
model to identify genomic biomarkers of low-level exposure to ARGT.  To address 
this primary objective, the study involved the following sub-aims: (1) Develop and 
validate an in vitro toxicogenomic model using the Eppendorf DualChip™ rat hepato 
to examine the effects of low level tunicamycin exposure on clone-9 hepatocytes at 
the genomic level, combined with cytotoxic and morphological assessment; 2) Apply 
the combined in vitro toxicogenomic model to investigate the bioequivalence of  
corynetoxin with the commercially available tunicamycin, to examine the suitability 
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of using tunicamycin as an experimental substitute for corynetoxin; and 3) Identify 
potential biomarker candidates that may act as early predictors of pre-clinical 
exposure using the developed combined in vitro toxicogenomic model. 
5.2.1 Development and validation of an in vitro toxicogenomic model  
To address the first sub-aim of the second strategy, an in vitro toxicogenomic model 
was developed using the Eppendorf DualChip™ rat hepato to examine the genomic 
effects of clone-9 hepatocytes exposed to tunicamycin treatments at significantly 
lower levels than previously reported in the literature.  The in vitro toxicogenomic 
strategy provided a valid and effective approach for analysing low level tunicamycin 
exposure at the molecular level.  In particular, the in vitro toxicogenomic strategy 
demonstrated for the first time that treatment of cultured rat hepatocytes (clone-9) 
with 0.05 µM and 50 µM tunicamycin for 24 h resulted in significant changes in gene 
expression when compared to control untreated cells.  Interestingly, the gene 
expression observed for genes on the DualChip in both 0.05 and 50 μM tunicamycin 
treatments appeared very similar with both doses demonstrating an overtly toxic 
effect on clone-9 cells.  This was quite unexpected given the tunicamycin treatments 
examined were 10-fold lower than previously reported.  A preliminary signature 
profile of tunicamycin exposure was established based on differential gene expression 
consistent between 0.05 µM and 50 µM tunicamycin treatments.  This comprised of 
the most significantly differentially regulated genes which included: Fibronectin (FN), 
ecoa (Nakagawa et al.,  1995), superoxide dismutase (MnSOD) and cytochrome c 
oxidase (mt_Co1) (down-regulated); and JNK3 (MAPK10 N-terminal kinase) and 
APOE (Apolipoprotein E) (up-regulated).   
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This in vitro toxicogenomic strategy was also combined with conventional 
toxicological parameters, i.e. cytotoxicity and cellular morphology to examine the 
effects of the same low level tunicamycin exposure.  As expected, overt 
hepatotoxicity was observed in all treatments as measured by trypan blue dye 
exclusion staining and microscopy.  Thus, based on the overt toxicity observed in all 
treatments at the genomic, cytotoxic and morphological level, it was determined that 
significantly lower levels of tunicamycin were required for the subsequent 
investigations. 
Therefore, with the demonstration that the in vitro toxicogenomic strategy developed 
in this study provided a highly effective and sensitive system for identification of 
differential gene expression associated with low level tunicamycin exposure, this 
strategy was then applied to further investigations of low level toxin exposure using 
significantly lower levels of toxin. 
5.2.2 Bi oequivalence of Corynetoxins and Tunicamycins 
To address the second aim, the same combined in vitro toxicogenomic strategy 
developed in Chapter 3 was applied to investigate the bioequivalence of corynetoxin 
and tunicamycin.  Based on the abovementioned results, significantly lower levels of 
both tunicamycin and corynetoxin were examined.  The effects of equivalent doses of 
both toxins were monitored based on observed cellular morphology, viability and 
differential gene expression.  Results of the cellular morphology and viability studies 
indicated that both toxins were bioequivalent (Chapter 4).  However, comparative 
gene expression analysis of the various treatments revealed for the first time that 
exposure to 5 nM and 5000 nM doses of tunicamycin and corynetoxin produced non-
identical changes in gene expression between the two toxins (Chapter 4).  Therefore, 
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based on the non-equivalence observed only at the genomic level, it appears that gene 
expression changes are a far more sensitive indicator of potential adverse effects than 
traditional measurements of toxicity. 
The differential gene expression observed in clone 9 hepatocytes in response to both 
tunicamycin and corynetoxin treatments suggests that the mechanisms by which the 
cells are responding to each of the toxins is different.  This may be indicative of the 
cell employing different drug metabolism and detoxification mechanisms in response 
to each of the toxins.  All things being equal in relation to experimental 
protocol/conditions we therefore assume that the molecular effects of tunicaminyl-
uracil toxins appear to vary as a result of their differences in molecular structure.  
These differences in molecular structure, i.e. length, hydroxylation state and terminal 
branching structure of the fatty acids, may directly or indirectly influence a range of 
unidentified molecules and/or pathways in the cell resulting in differential gene 
expression.   
The observed non-equivalence of tunicamycin and corynetoxin at the genomic level 
and the potential identification of these molecular indicators of non-equivalence may 
have significant implications for future studies of ARGT.  In particular, the potential 
utility of tunicamycin as an experimental substitute for corynetoxin in future studies is 
largely dependent on the objective of the particular study.  For instance, when 
investigating cell viability related effects (i.e. morphologic and cytotoxic) associated 
with ARGT, it may be appropriate to still use tunicamycin as an experimental 
substitute initially based on the results presented in Chapter 4.  However, studies 
aiming to identify genomic-based effects, such as candidate biomarkers of exposure 
(clinical and sub-clinical) should be verified with corynetoxin-exposed animals based 
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on the non-equivalence observed between tunicamycin and corynetoxin at the 
genomic level (Chapter 4).  Therefore, based on the findings of this study, the long-
standing use of tunicamycin as a substitute to experimentally model ARGT may be in 
question.  In particular, the potential utility of the tunicamycin-based experimental 
model and associated tunicaminyl-uracil gene profile as an early biomarker of 
exposure to corynetoxin may no longer be appropriate.   
Ultimately, future studies aimed at investigating the bioequivalence of gene responses 
of both toxins across a variety of systems both in vitro and in vivo will be useful to 
confirm and to substantiate the observed non-equivalence of tunicamycin and 
corynetoxin at the genomic level.  
5.2.3 Identification of  biomarker c andidates predictive of pre-clinic al 
exposure to ARGT 
To address the third aim, the in vitro toxicogenomic model developed and validated in 
Chapters 3 and 4 was applied to identify biomarker candidates that may be predictive 
of pre-clinical exposure to ARGT.  With the previous demonstration that low level 
tunicamycin and corynetoxin exposure produced non-equivalent and identifiable gene 
expression profiles at levels insufficient to trigger overt morphological/cytotoxic 
effects (Chapter 4), it followed to investigate these corynetoxin based genomic effects 
specifically using this same in vitro toxicogenomic approach.   
Many genes were identified as differentially regulated in response to corynetoxin 
compared to control (untreated) cells, particularly within the 5 nM treatment 
(previously shown to have no observed cytotoxic or morphological effect).  However, 
this initial biomarker discovery strategy selected only those genes as potential 
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candidate biomarkers which demonstrated the highest level of differential regulation 
consistent between all treatments.   
Five candidate genomic markers were identified using this strategy, each consistently 
highly differentially regulated in both the low and high dose treatments.  These 
candidate biomarkers included: cytochrome c oxidase (mt_Co1), fibronectin (FN), 
MAPK10 N-terminal kinase (Bruckner et al.,  2001), Glutathione transferase α 
(GSTα) and GADD45a (GA45).  As discussed (Chapter 4), the functions of these five 
biomarkers appear to be predictive of exposure to cell stress or subtle cellular injury 
which may be reflective of the early gene response consistent with pre-clinical 
exposure to corynetoxin.  Furthermore, all five biomarker candidates identified in this 
study have been previously reported as differentially regulated in response to toxin 
exposure and each has been reported as potentially useful biomarkers in a range of 
diseases.  
Fibronectin (FN) and Cytochrome c oxidase (mt_Co1) represented particularly 
interesting candidates for further investigation as biomarkers of ARGT.  Not only 
were both genes consistently down-regulated as a result of corynetoxin exposure in all 
treatments, but their gene regulation also appeared non-equivalent in both corynetoxin 
and tunicamycin in the bioequivalence studies (Chapter 4).  As described previously 
(Chapters 3 and 4), Fibronectin (FN) is a multifunctional protein that binds to both 
membrane spanning receptor proteins and extracellular matrix components.  
Fibronectin (FN) is involved in many cellular processes, including: tissue repair; 
blood clotting; and cell migration/adhesion.  There are numerous reports of use of FN 
as a useful and predictive biomarker in a variety of diseases (Webb and Lin, 1980; 
Hegele, 2007; Pecheniuk et al.,  2008; Man et al.,  2008).  Furthermore, FN has also 
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been utilised as a highly sensitive serum plasma biomarker in a commercially 
available enzyme linked immunoassay (Fibronectin (rat) ELISA) (Alpco™, Salem 
USA).  Cytochrome c oxidase subunit 1 (mt_Co1) is a critical enzyme that controls 
mitochondrial respiration and is central to apoptosis.  Cytochrome c oxidase subunit 1 
(mt_Co1) has also been reported as a reliable and effective biomarker for a number of 
diseases, including assessing the risk of colon cancer in patients (Payne et al.,  2005) 
and detecting copper deficiency in tissues and blood cells (Milne, 1994).   
MAPK10 N-terminal kinase gene (Bruckner et al.,  2001), Glutathione transferase α 
(GSTα) and GADD45a (GA45) displayed the highest level of up-regulation in the 
corynetoxin treatments.  Previous reports have suggested that protein-coding genes 
whose transcription is differentially up-regulated in the setting of tissue injury are 
considered particularly effective candidate biomarkers (Hubank and Schatz, 1994).  
Furthermore, each of these genes have been previously reported in several studies as 
useful biomarker candidates.  As such, these three genes were selected as potentially 
representing important gene biomarker candidates for further investigation.  
MAPK10 (Bruckner et al.,  2001) represents an N-terminal kinase with its observed 
induction consistent with previous studies demonstrating that apoptosis contributes to 
hepatocyte loss in Tunicamycin poisoning (Finnie et al.,  2004).  Furthermore, it has 
also been reported in many studies that kinases and other immune system molecules 
can provide reliable indicators or biomarkers of disease or physiologic state (Griffin et 
al.,  1993; Hacker et al.,  2006; Sato et al.,  2005; Takahashi et al.,  2006).   
Glutathione transferase α (GSTα) is an enzyme involved in the detoxification of a 
variety of electrophilic compounds.  Previous studies have demonstrated the 
diagnostic utility of GSTα elevations in serum to assess acute induction of GSTα in 
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hepatocytes in response to toxicity (Giffen et al.,  2003; El-Sayed et al.,  2007).  
Furthermore, it has also been reported that the abundant and distinct localisation of 
GSTα in hepatocytes supports its use as a biomarker for detecting liver damage 
(Lantum et al.,  2002).   
GADD45a (GA45) is involved in growth arrest, playing an important role in the 
maintenance of genomic stability by controlling cell cycle checkpoints, DNA repair 
and apoptosis (Duong et al.,  2005).  The robust induction of GA45 expression has 
repeatedly been observed with a wide range of genotoxins at various concentrations 
(Hu et al.,  2004; Newton et al.,  2004).  GADD45a (GA45) has also been reported as 
a potential key protein biomarker in blood for genomic stress (Amundson and 
Fornace, 2004) and high throughput genotoxicity screening and (Hastwell et al.,  
2006). 
The five candidate biomarkers mt_Co1, FN, JNK3, GSTα and GA45 appear at first 
instance to possess the necessary requisite qualities to contribute to pre-clinical 
diagnosis of ARGT.  However, this study constitutes merely the first Biomarker 
Discovery Phase involving an initial toxicity evaluation of genomic profiles following 
administration of a single dose of toxin.  As such, many considerations and limitations 
need to be addressed in future work to determine if these identified biomarkers may 
ultimately prove useful for pre-clinical diagnosis of ARGT.  
5.2.4 Ge nomic approaches for biomarke r discove ry: considerati ons and 
limitations 
Biomarker discovery holds much promise for providing important tools for the pre-
clinical detection of toxicity.  As discussed, toxicogenomics is an extremely powerful 
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tool for accelerating biomarker discovery (Gundert-Remy et al.,  2005).  Furthermore, 
the strength of toxicogenomics is that it offers the potential to detect pre-clinical 
effects of toxicity for which traditional biochemical tests are incapable due to low 
sensitivity and specificity.  The utility and feasibility of toxicogenomics in biomarker 
discovery has been demonstrated in a number of reports delineating chemical-induced 
toxicity, including hepatotoxicity leading to the identification of many promising 
biomarkers (Burczynski and Dorner, 2006; Heinloth et al.,  2004; Steiner et al.,  2004; 
Bushel et al.,  2007).   
Despite genomics offering great potential for providing powerful new biomarkers 
with unprecedented specificity and sensitivity, many considerations and limitations 
need to be addressed.  A general limitation of biomarker candidates derived from 
genomic expression analysis relates to accessibility.  In particular, the absolute 
requirement for biological samples that are physically available for analysis.  
Although various biological samples might be readily available and easy to obtain, a 
potential biomarker of interest might be expressed in tissue that is difficult or 
inaccessible for testing.  For instance, this study has focused on using genomics to 
identify hepatic biomarkers of toxicity, which may ultimately prove problematic in 
later down-stream validation studies due to accessibility.  As a result, these candidate 
hepatic biomarkers may prove inaccessible for testing due to difficulties associated 
with obtaining non-invasive pre-clinical samples from suspect livestock. 
The requirement for accessible biomarkers has highlighted the need to extend our 
knowledge of genomic biomarkers of toxicity to other readily available sources, 
including peripheral blood cells and protein.  In particular, the use of gene expression 
changes in peripheral blood cells as effective sentinels of tissue damage and 
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dysfunction is showing great promise in many areas.  However, there have been 
limited reports of success in toxicity detection (Baird, 2007; Burczynski and Dorner, 
2006; McHale et al.,  2007). 
It has been suggested that biomarker candidates derived from expression analysis 
should be triaged according to their tractability for protein assessment (Lewin and 
Weiner, 2004).  In many situations, particularly preclinical diagnosis, testing protein 
biomarkers in body fluids (blood, urine etc) may be more amenable to the clinical 
environment when immediate information is required for effective and decisive 
livestock management.  In particular, identification of serum proteins are a valuable 
diagnostic tool to monitor clinical progress and for protemoic biomarker discovery. 
Examples of serum proteins which may be useful to monitor clinical progress include: 
alpha2-macroglobulin, other globulins (alpha, beta and gamma), Lipoproteins, 
Transferrin and Prothrombin (Jacobs et al., 2005). 
Many reports have used genomic approaches to identify genes that encode proteins 
secreted from cells or cleaved from their surfaces while undergoing disease processes 
and following exposure to toxicants.  Examples of genomics used to identify potential 
protein biomarkers include kidney injury molecule-1 (Kim-1, HAVCR1), adipsin and 
fetuin-B (Denecke et al.,  2003; Mendrick and Daniels, 2007; Pennie et al.,  2000; 
Searfoss et al.,  2003; Vaidya and Bonventre, 2006). Furthermore, this study has 
identified genes differentially regulated as a result of CTs exposure encoding serum 
proteins including Apolipoprotein E (ApoE) and Transferrin (TNFR) (see Table 4-6). 
There are limitations associated with using only genomic data in the search for protein 
biomarkers of toxicity.  These limitations lie in the difficulty of associating a change 
in transcript profile with an actual change in protein abundance (Tugwood et al.,  
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2003).  Gene expression profiling detects only stably-expressed mRNA transcripts, 
which does not necessarily inform the presence of a candidate protein biomarker.  As 
a result, there has been skepticism regarding the usefulness of measuring mRNA 
levels to infer expression at the protein level with some studies having identified 
discordance between genomic and proteomic data (Gygi et al.,  1999).  Therefore, it 
has been suggested that genomic biomarker studies should be coupled with semi-
quantitative assays (including: immunoblot and immunostaining) or parallel 
toxicoproteomic-based studies to confirm the presence of candidate protein 
biomarkers.    
Several of the candidate biomarkers identified using this genomic approach (i.e. FN, 
GSTα and GA45) have been previously reported as encoding proteins shown to be 
secreted from cells or cleaved from their surface while undergoing disease processes 
following exposure to toxicants.  However, it still remains unclear based on the results 
of this study whether these candidate biomarkers encode proteins that will be 
ultimately secreted following exposure to corynetoxin specifically and be readily 
present and accessible in bodily fluids such as serum for testing.  As discussed above, 
this genomic based study should be ultimately coupled in future studies with semi-
quantitative assays or parallel toxicoproteomic-based studies to confirm the presence 
of candidate protein biomarkers.    
Development of proteomic techniques for biomarker discovery is tightly linked to the 
groundbreaking efforts of genomic studies.  Toxicoproteomics which compliments the 
field of toxicogenomics seeks to identify critical proteins and pathways in biological 
systems that are affected by and respond to adverse chemical and environmental 
exposures using global expression technologies (Wetmore and Merrick, 2004).  
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Several studies have used both genomic and protein analyses to assess potential 
biomarkers (Chen et al.,  2002, 2003; Orntoft et al.,  2002).  The results of the 
combined data appear to be far superior to those obtained with only one technical 
approach.   
Further, potential combinatorial biomarkers based on these candidates and possibly 
others (unidentified at this stage) may also warrant investigation.  Although a sole 
biomarker is appealing as it can be easier to understand, there are few examples in 
pre-clinical testing or in clinical practice wherein a single measurement is considered 
definitive (Mendrick, 2008). Multiple markers are often desired to capture biological 
heterogeneity of organs involved, individual variations and disease or toxicity 
processes.  As such, a combinatorial biomarker may ultimately be more effective as a 
diagnostic indicator of corynetoxin-exposure. 
Ultimately, the integration and interfacing of different technologies and approaches, 
including bioinformatics with genomic and proteomic technologies would represent 
exemplified value in the quest to identify, characterise and validate effective 
biomarkers of toxicity for ARGT (Ilyin et al.,  2004).  Ideally, it would be 
advantageous to have the ability to assay a biomarker as a nucleic acid and a protein 
for pre-clinical diagnosis of ARGT.  Thus, whether the biomarker(s) for ARGT is 
ultimately a gene, a variant of such or a protein, it will only prove useful to serve as 
an effective and flexible biomarker if extensive further validation is performed in 
order to demonstrate its validity from the research context to practical or regulatory 
applications in pre-clinical testing.  
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5.2.5 Bi omarker validation 
Biomarker validation is a process aimed to provide objective information regarding a 
new assay/test to confirm its specificity, sensitivity and robustness between 
laboratories and to demonstrate that the generated data is reliable in practical 
application for decision making purposes.  
Extensive biomarker validation of these five candidates for practical application in a 
commercial assay format or an in-field adaptable test would involve overcoming 
many obstacles and uncertainties.  Firstly, the toxicological significance of the five 
candidate biomarkers must be validated by confirming their consistency and 
reproducibility in further tests involving multiple low dose treatments of corynetoxin 
over longer periods of time.   
Further validation of these candidate biomarkers would also include an evaluation of 
the robustness of microarray results in order to assess the suitability of these 
biomarkers as diagnostic indicators of corynetoxin exposure.  This would involve 
evaluating the results across different cell lines, from in vitro to in vivo experiments, 
across different species, individuals, tissues and time periods and across different 
laboratories (Hamadeh et al.,  2002).   
As discussed in Section 3.7.3, the in vitro based strategy developed in this study 
constituted a valid and useful system for gene expression analysis of low level 
tunicaminyl-uracil exposure and offered a number of significant advantages for early 
phase developmental studies.  Advantages of the in vitro based strategy included: 
simplicity, cost effectiveness, reproducibility (i.e. small focused array and continuous 
cells) and amenability for high-throughput screening.  In addition, this strategy 
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offered other significant benefits for early stage toxicogenomic investigations, 
including: avoiding the use of animal models, allowing the maintenance and better 
control of experimental conditions and reducing the need for acquiring large amounts 
of toxin for testing (Baker et al.,  2001).  This last point is a significant issue with 
regard to studying corynetoxin and was a major factor behind the development of the 
in vitro model for this and subsequent studies (Chapters 4 and 5).  However, despite 
the abovementioned significant advantages, it is critical to keep in mind the inherent 
limitations in the ability of using an in vitro system to model in vivo or whole 
organism gene responses.  These include: functional differences observed in primary 
hepatocytes relative to the intact liver; the absence of interactions with biological 
entities (e.g., organs, blood) under in vitro conditions; and the difficulty to select 
doses and time points which are representative of an in vivo situation.  Despite these 
differences, immortalised cells as well as other emerging in vitro systems (e.g., 
primary cells, stem cells, and 3D culture systems) provide valuable alternatives in 
early phase developmental studies.  Ultimately, however to identify valid and useful 
biomarker candidates, in vivo based validatory clinical phase studies in order to assess 
the suitability of candidate biomarkers must be eventually undertaken.   
The subset of gene expression changes that will predict the development of ARGT-
related effects needs to be identified in sensitive animal models and with study 
protocols at realistic dose levels and dosing periods in particular long term low level 
exposure.  Genomic markers with expression level changes that are predictive and 
determinative of pre-clinical exposure which may intensify in conjunction with the 
development of lesions are particularly useful, as they may also measure the level of 
tissue damage.  Finally, extensive validation is needed across samples from studies 
run with compounds having a broad spectrum of hepatotoxicity. 
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In addition, with regard to time periods, it will be important to understand the time 
course of gene expression changes following toxic exposure because some alterations 
may be transient and others may lead to permanent changes.  In particular, one of the 
most difficult issues will be in differentiating gene expression changes that represent 
the adaptive response of cells to external stimuli that have no toxicological 
significance or increased risk from those gene expression changes that truly represent 
the early stages of disease progression (Pennie et al.,  2000). For instance, some 
changes in gene expression might simply represent a non-specific and fully reversible 
response of the cell to stress or a response with no biological consequence.   
Further, given the massive quantity of data produced by a DNA microarray (albeit 
reduced with LD) there may be false positives results.  There may also be difficulties 
associated with quality control and consistency issues with respect to data collection, 
storage, interpretation and display (Hu et al.,  2004; Hamadeh et al.,  2002). 
As discussed, this study constitutes the first phase of Biomarker Discovery involving 
the initial toxicity evaluation using genomic profiling following administration of a 
single dose of corynetoxin.  Despite these five genomic biomarker candidates 
demonstrating consistent and robust differential gene expression in all corynetoxin 
treatments and previous reports suggesting that each of these genes has value as a 
biomarker in a variety of biological settings, extensive further validatory studies are 
still required using additional systems (as discussed above) to assess the utility of 
these candidate biomarkers as diagnostic indicators of pre-clinical exposure to ARGT.  
Future work will be essential in order to validate the biomarker candidates identified 
above before these or other candidates may be utilised outside the research context for 
practical or regulatory applications.  Ultimately, these preliminary candidates may 
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offer the opportunity for the development of future commercial in-field diagnostic or 
prognostic tools for exposure of livestock to corynetoxin which may prove invaluable 
in risk assessment and long-term management of ARGT. 
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Fig A I-I    Rathayibacter toxicus screening of 72 gall samples. PCR results of bacterially-
infected galls selected from concentrated grain screenings were all strongly bacterial and 
corynetoxin positive. Lane (M) 1 kb Plus DNA ladder (C) Positive control – 200 bp amplified 
product from Rathayibacter toxicus genomic DNA (NC) Negative control – Cyclodextrin 
solvent. 
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C   C 
FigureA I-I I Bacteriophage screening of 72 gall samples. Only 49 of the 72 toxic
bacterially-infected galls were  PCR-positive for the bacteriophage. Lane (M) 1 kb Plus
DNA ladder (C) Positive control – 200 bp amplified product from Rathayibacter toxicus
genomic DNA. 
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Figure A I-III  Rathayibacter toxicus screening 79 ryegrass samples. Of the 79
pasture grab samples,  68 were positive for Rathayibacter toxicus with only 32
positive for toxin. Lane (M) 1 kb Plus DNA ladder (C) Positive control – 200 bp
amplified product from Rathayibacter toxicus genomic DNA (NC) Negative
control – Cyclodextrin solvent. 
C    C     N C 
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Figure A I-IV  Bacteriophage screening of 79 ryegrass samples.
Four of the seventy nine ryegrass pasture grab samples indicated a
positive phage amplified product. These 4 phage positive were
also positive for Rathayibacter toxicus and Corynetoxins. Lane
(M) 1 kb Plus DNA ladder. 
22  23  24                 27 
Appendix I 
M      1     2      3     4     5     6      7     8      9   10   11   12
M    15  16   17   18   19   20   21   22  23  24      25  26
M    29  30   31   32   33   34   35   36  37  38   39   40
M    43  44   45   46   47   48   49   50  51  52   53   54
M    57  58   59   60   61   62   63   64  65  66   67   68
M   71  72   73   74   75   76   77
   354 
  
 
Time Control 0.05 µM TMs 0.5 µM TMs 5 µM TMs 50 µM TMs
0 4.63 5.56 5.19 4.63 5.56
4 7.41 7.41 9.44 11.94 2.04
8 3.15 2.04 5.37 5.56 1.30
22 8.89 2.59 3.70 9.26 2.59
26 6.48 3.52 6.85 5.00 1.67
30 2.04 0.83 2.59 4.81 3.70
46 27.04 6.11 6.85 2.22 5.74
50 37.78 9.81 16.48 2.59 3.52
54 67.22 3.70 15.74 4.26 3.89
70 40.93 5.00 10.74 4.07 0.00
74 69.58 0.74 8.15 2.04 0.69
78 107.96 6.11 12.41 0.19 0.00
Table A II-I 
The average number of live cells (x 104) per cm2 determined via Trypan blue
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Time Control 0.05 µM TMs 0.5 µM TMs 5 µM TMs 50 µM TMs
0 11.47 9.74 3.71 4.14 0.00
4 5.12 14.93 15.26 12.46 48.22
8 32.25 38.92 24.04 26.45 64.86
22 50.28 58.82 66.00 26.27 64.95
26 28.63 32.56 21.71 38.27 67.69
30 48.22 70.07 37.59 65.91 47.14
46 11.00 31.42 31.15 72.66 41.66
50 15.44 32.85 27.65 80.51 69.70
54 3.72 71.53 30.47 67.12 70.72
70 41.93 58.33 47.19 71.87 100.00
74 10.66 0.97 48.10 88.43 95.54
78 5.51 75.95 64.20 98.31 100.00
TableAII-II 
The percentage of dead cells (x104) per cm2 determined via Trypan blue dye
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A B C
Fluorescent intensity level
Figure A II-I Hybridisation of DualChip™ rat hepato. DualChip™ rat hepato
hybridised with cDNA obtained from total RNA extracted from untreated rat
hepatocytes (A), hepatocytes treated with 0.05 Tunicamycins at 24 hours (B) and 50
µM Tunicamycins at 24 hours (C). Fluorescence is represented in false colour scale
and corresponds to the gene expression levels. 
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A B
Figure A II-II   Microarray hybridised with treated and untreated mRNA.
Microarray probed with untreated (A) and 0.05 µM Tunicamycins at 24 hours (B) 50
µM Tunicamycins at 24 hours. Cells were harvested after 12 hours treatment and the
mRNA extracted using the RNeasy mRNA isolation kit (Qiagen). Examples of visible
differences in gene expression are circled. 
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B C
Figure A II-III  Microarray hybridised with treated and untreated mRNA. An example of 
microarrays probed with 0.05 µM (B) and 50 µM (C) Tunicamycins treated Clone 9-labelled 
probe. Cells were treated for 12 hours and the mRNA extracted using the RNeasy mRNA 
isolation kit (Qiagen). Examples of visible differences in gene expression are circled.
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Time (h) Control NaOH 5nM CT 50nM CT 500nM CT 5000nM CT 5nM TM 50nM TM 500nM TM 5000nM TM
0 0.69 2.22 0.69 2.22 2.5 0.69 0.97 3.06 0.28 0.97
6 2.64 1.94 1.53 1.53 0.42 1.39 1.39 1.67 0.69 1.81
12 9.72 1.67 1.25 2.64 2.78 3.19 2.36 1.11 3.33 1.11
24 8.33 8.06 2.22 3.47 2.22 2.92 4.31 5.14 2.64 2.5
30 13.61 3.75 5.42 0.97 2.36 0.69 6.25 2.92 2.64 2.92
36 13.19 11.11 7.22 4.17 3.75 2.64 4.03 2.78 0.97 2.5
48 14.44 14.86 4.86 3.47 3.06 0.69 6.67 3.47 1.53 0.69
54 31.94 14.86 34.58 6.11 3.06 0.97 34.44 4.03 6.11 1.81
60 10.28 10.28 5.28 2.78 1.39 0.56 6.11 2.5 1.39 1.94
72 25.56 18.33 12.78 1.94 0.69 0.28 16.67 1.11 0.83 0.83
78 20.42 24.72 19.58 0.83 0.14 0.14 18.61 0.28 0.42 0.14
84 42.64 35.42 8.19 0.56 0 0 24.31 0 0.14 0
96 31.53 31.67 10.56 0.69 0 0 17.22 0.28 0.14 0.14
108 32.08 27.08 17.92 0.14 0 0 21.81 0 0 0
Appendix III 
Table A III-I  Trypan blue dye exclusion test 
The average number of live cells (× 104 cm-2) determined via trypan blue dye
exclusion staining. All samples had an n of 4 except at the 60 hour time point
where n = 2. 
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Table A I II-1I The average number of dead cells (× 104 cm-2) per cm2 determined via
trypan blue dye exclusion staining.  All samples had an n of 4 except at the 60 hour time
point where n = 2  
Time (h) Control NaOH 5nM CT 50nM CT 500nM CT 5000nM CT 5nM TM 50nM TM 500nM TM 5000nM TM
0 1.67 1.53 1.25 0.69 0.56 1.11 0.69 1.39 0.56 1.11
6 1.67 0.83 0.42 1.53 0 0.69 1.25 0.28 0 0.56
12 3.06 0.97 1.11 0.69 0.56 0.69 0.69 0.42 0.83 0.56
24 0.56 0.97 1.39 0.42 0.42 0.42 0.14 0.97 0.69 1.39
30 1.25 0.97 0.69 0.42 1.25 0.69 1.11 1.25 0.69 0.83
36 0.42 1.67 0.42 1.11 0.97 1.25 0.42 0.42 0.14 1.11
48 1.11 0.69 1.25 1.81 1.81 2.64 0.69 2.08 2.36 1.67
54 1.39 1.67 2.92 4.86 5.83 5 2.78 3.75 6.53 6.25
60 1.67 2.5 0.83 5.56 5.56 5.83 1.39 2.5 4.72 7.78
72 3.89 1.67 2.5 5.97 7.22 5 2.08 6.25 6.25 8.61
78 3.06 3.33 3.47 6.39 6.53 4.58 1.81 5.28 4.17 4.58
84 1.81 3.47 1.25 7.08 6.94 7.92 2.92 6.81 6.39 6.11
96 2.36 3.19 1.81 9.31 7.36 8.19 2.78 5.14 5.97 7.36
108 3.61 4.03 2.08 9.17 5.97 4.86 2.22 7.22 7.22 5.42
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Figure A III-III  Scatter plots representing Array 1.1 (Tunicamycins Low Dose 24
hours) vs. Array 2.1 (Corynetoxins Low Dose 24 hours): Scatter plots of normalised
fluorescence intensity values based on 4 separate gains (i to iv)  measured for array 1.1
(Tunicamycins Low Dose 24 hours) vs. array 2.1 (Corynetoxins Low Dose 24 hours).
Reference = Tunicamycins values (x-axis) were plotted against Normalised Experiment
= Corynetoxins values.  
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i i
ii i
Figure A  II I-IV  Scatter plots representing Array 1.1 (Tunicamycins Low Dose 24
hours) vs. Array 2.2 (Corynetoxins Low Dose 24 hours): Scatter plots of normalised
fluorescence intensity values based on 4 separate gains (i.e. i to iv) measured for array
1.1 (Tunicamycins Low Dose 24 hours) vs. array 2.2 (Corynetoxins Low Dose 24
hours). Reference= Tunicamycins values (x-axis) were plotted against Normalised
Experiment = Corynetoxins values.  
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Figure A I II-V  Scatter plots representing Array 1.1 (Tunicamycins Low Dose 24
hours) vs. Array 2.3 (Corynetoxins Low Dose 24 hours). Scatter plots of normalised
fluorescence intensity values based on 4 separate gains (i.e. i to iv) measured for array
1.1 (Tunicamycins Low Dose 24 hours) vs. array 2.3 (Corynetoxins Low Dose 24
hours). Reference = Tunicamycins values (x-axis) were plotted against Normalised
Experiment = Corynetoxins values  
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TableAIII-VI(a)  Ratio values based on the separate gains measured for each of the
replicate array combinations: i) Array 1.1 (Tunicamycins Low Dose 24 hours) vs. Array 2.1
(Corynetoxins Low Dose 24 hours); ii) Array 1.1 (Tunicamycins Low Dose 24 hours) vs.
Array 2.2 (Corynetoxins Low Dose 24 hours); iii) Array 1.1 (Tunicamycins Low Dose 24
hours) vs. Array 2.3 (Corynetoxins Low Dose 24 hours) . Note: Yellow indicates
quantitatively significant ratio values which take precedence over the grey quantitative
unchanged values.  
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4  RATIO 1
CEBPA 0.644 0.724 0.728 0.726 CEBPA 0.644 Quantitative Significant
c-jun 0.701 0.675 0.644 0.637 c-jun 0.641 Quantitative Significant
Ferritin 0.666 0.671 0.675 0.698 Ferritin 0.643 Quantitative Significant
JNK3 0.639 0.598 0.595 0.591 JNK3 0.606 Quantitative Significant
Gene GAIN1 GAIN 2 GAIN 3 GAIN 4 RATIO 2
CEBPA 0.884 0.904 0.893 0.882 CEBPA 0.891 Quantitative Unchanged
c-jun 0.948 0.954 0.931 0.948 c-jun 0.94 Quantitative Unchanged
Ferritin 0.914 0.906 0.891 0.896 Ferritin 0.902 Quantitative Unchanged
JNK3 0.974 0.982 0.915 0.909 JNK3 0.946 Quantitative Unchanged
Gene GAIN1 GAIN 2 GAIN 3 GAIN 4 RATIO 3
CEBPA 0.657 0.746 0.714 0.698 CEBPA 0.657 Quantitative Significant
c-jun 1.060 1.040 1.001 1.003 c-jun 1.002 Quantitative Unchanged
Ferritin 0.531 0.750 0.748 0.822 Ferritin 0.53 Quantitative Significant
JNK3 0.606 1.020 0.954 0.915 JNK3 0.606 Quantitative Significant
Appendix III 
ii 
   365 
 
 
TableAIII-V1(b) 
Data representing overall ratios based on the separate ratios from the first
Tunicamycins Low Dose array (1.1) vs. each of the three Low Dose
Corynetoxins triplicates (2.1, 2.2, 2.3)  
Gene RATIO 1 RATIO 2 RATIO 3 Overall Ratio Category
CEBPA 0.644 0.891 0.657 0.650 Quant. Significant
c-jun 0.641 0.940 1.002 0.641 Quant. Significant
ferritin 0.643 0.902 0.530 0.586 Quant. Significant
JNK3 0.606 0.946 0.606 0.606 Quant. Significant
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 Table A III-VII (a) (i): 
Represents ratio values based on separate gains measured for array 1.2
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 Ratio 1
ACO 1.51 1.43 1.48 1.51 1.51
Ahr 1.54 1.44 1.45 1.48 1.46
APOE 1.63 1.59 1.47 1.34 1.61
APOJ 1.56 1.52 1.54 1.57 1.55
Bclx 1.98 1.94 1.95 2.03 1.99
CASP3 2.21 2.57 2.24 2.29 2.27
CEBPA 1.81 1.50 1.44 1.87 1.84
c-jun 1.84 1.74 1.74 1.81 1.77
cnb1 1.02 1.02 1.02 1.40 1.21
ferritin 0.11 0.10 0.09 0.16 0.16
FN 0.06 0.05 0.03 0.04 0.04
GSTP 0.44 0.36 0.47 0.47 0.47
Hdac 0.86 0.92 0.30 0.33 0.33
HOX2 4.09 4.12 4.41 4.53 4.47
HSP27 0.92 0.92 0.92 0.63 0.63
mt_Co1 1.12 0.30 0.21 0.21 0.24
NaOx 0.56 0.53 0.25 0.26 0.25
Osteon 0.49 0.45 0.45 0.27 0.46
PCNA 0.61 0.29 0.26 0.27 0.27
p38 2.24 1.95 2.48 2.52 2.50
p53 0.71 0.71 0.28 0.29 0.29
TGFB 1.39 1.38 1.40 1.44 1.42
TNFR 1.42 1.39 1.39 1.44 1.41
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Table A III-VII (a) (i): 
Represents ratio values based on separate gains measured for array 1.2
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 Ratio 1
ACO 1.51 1.43 1.48 1.51 1.51
Ahr 1.54 1.44 1.45 1.48 1.46
APOE 1.63 1.59 1.47 1.34 1.61
APOJ 1.56 1.52 1.54 1.57 1.55
Bclx 1.98 1.94 1.95 2.03 1.99
CASP3 2.21 2.57 2.24 2.29 2.27
CEBPA 1.81 1.50 1.44 1.87 1.84
c-jun 1.84 1.74 1.74 1.81 1.77
cnb1 1.02 1.02 1.02 1.40 1.21
ferritin 0.11 0.10 0.09 0.16 0.16
FN 0.06 0.05 0.03 0.04 0.04
GSTP 0.44 0.36 0.47 0.47 0.47
Hdac 0.86 0.92 0.30 0.33 0.33
HOX2 4.09 4.12 4.41 4.53 4.47
HSP27 0.92 0.92 0.92 0.63 0.63
mt_Co1 1.12 0.30 0.21 0.21 0.24
NaOx 0.56 0.53 0.25 0.26 0.25
Osteon 0.49 0.45 0.45 0.27 0.46
PCNA 0.61 0.29 0.26 0.27 0.27
p38 2.24 1.95 2.48 2.52 2.50
p53 0.71 0.71 0.28 0.29 0.29
TGFB 1.39 1.38 1.40 1.44 1.42
TNFR 1.42 1.39 1.39 1.44 1.41
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Appendix III 
TableAIII-VII(a)(ii):  
Represents overall data ratio values based on separate gains measured
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 Ratio 2
ACO 1.70 1.73 1.73 1.75 1.74
Ahr 1.64 1.73 1.76 1.78 1.77
APOE 1.43 1.86 1.72 1.56 1.79
APOJ 1.67 1.75 1.75 1.76 1.76
Bclx 1.78 1.81 1.76 1.81 1.78
CASP3 2.30 2.36 2.40 2.48 2.44
CEBPA 1.09 1.40 1.30 1.67 1.67
c-jun 2.19 2.15 2.11 2.16 2.15
cnb1 1.41 1.33 1.31 1.81 1.81
ferritin 0.21 0.21 0.19 0.38 0.38
FN 0.04 0.05 0.04 0.04 0.04
GSTP 0.94 0.86 1.10 1.10 1.04
Hdac 0.63 1.58 0.53 0.57 0.57
HOX2 10.96 10.00 10.47 10.55 10.55
HSP27 1.90 1.86 1.90 1.29 1.90
mt_Co1 0.16 0.22 0.15 0.16 0.17
NaOx 0.38 0.79 0.35 0.36 0.35
Osteon 0.70 0.68 0.68 0.69 0.69
PCNA 0.44 0.49 0.45 0.46 0.46
p38 1.54 3.15 3.87 3.95 3.91
p53 0.48 1.14 0.44 0.45 0.46
TGFB 1.58 1.48 1.48 1.53 1.53
TNFR 1.61 1.73 1.71 1.74 1.74
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 Table A III-VII (a)  (iii) 
Represents overall data ratio values based on separate gains
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 Ratio 3
ACO 1.68 1.67 1.67 1.69 1.68
Ahr 1.73 1.72 1.72 1.74 1.73
APOE 1.58 1.69 1.59 1.47 1.62
APOJ 1.33 1.39 1.40 1.43 1.42
Bclx 1.67 1.61 1.61 1.63 1.62
CASP3 2.40 2.16 2.14 2.15 2.15
CEBPA 1.59 1.46 1.43 1.87 1.87
c-jun 1.65 1.49 1.46 1.47 1.47
cnb1 1.02 1.22 1.23 1.71 1.71
ferritin 0.09 0.09 0.08 0.15 1.02
FN 0.06 0.05 0.04 0.04 0.05
GSTP 0.38 0.41 0.53 0.54 0.54
Hdac 1.12 1.05 0.35 0.38 0.38
HOX2 4.65 4.34 4.71 4.77 4.74
HSP27 1.25 1.23 1.24 0.86 1.05
mt_Co1 0.92 0.27 0.19 0.19 0.22
NaOx 0.82 0.74 0.33 0.34 0.34
Osteon 0.57 0.54 0.54 0.55 0.55
PCNA 0.77 0.38 0.36 0.37 0.37
p38 2.82 2.59 3.23 3.31 3.27
p53 0.74 0.75 0.29 0.31 0.30
TGFB 1.89 1.82 1.92 1.97 1.94
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Table A I II-VIII  Data representing overall ratios based on the separate
overall ratios from the second Tunicamycins Low Dose array (1.2) vs. each
of the three Low Dose Corynetoxins triplicates (2.1, 2.2, 2.3) 
 
Gene RATIO 4 RATIO 5 RATIO 6 Overall 
ratio
Category
ACO 1.68 1.51 1.74 1.64 Quant. Significant
Ahr 1.73 1.46 1.77 1.75 Quant. Significant
APOE 1.62 1.61 1.79 1.67 Quant. Significant
APOJ 1.42 1.55 1.76 1.65 Quant. Significant
Bclx 1.62 1.99 1.78 1.70 Quant. Significant
CASP3 2.15 2.27 2.44 2.30 Quant. Significant
CEBPA 1.87 1.84 1.67 1.79 Quant. Significant
c-jun 1.47 1.77 2.15 1.77 Quant. Significant
cnb1 1.71 1.21 1.81 1.76 Quant. Significant
ferritin 0.10 0.16 0.38 0.27 Quant. Significant
FN 0.05 0.04 0.04 0.04 Quant. Significant
GSTP 0.54 0.47 1.04 0.50 Quant. Significant
Hdac 0.38 0.33 0.57 0.42 Quant. Significant
HOX2 4.74 4.47 10.55 6.59 Quant. Significant
HSP27 1.05 0.63 1.90 1.27 Quant. Significant
mt_Co1 0.22 0.24 0.17 0.21 Quant. Significant
NaOx 0.34 0.25 0.35 0.31 Quant. Significant
Osteon 0.55 0.46 0.69 0.51 Quant. Significant
PCNA 0.37 0.27 0.46 0.37 Quant. Significant
p38 3.27 2.50 3.91 3.23 Quant. Significant
p53 0.30 0.29 0.46 0.35 Quant. Significant
TGFB 1.94 1.42 1.53 1.74 Quant. Significant
TNFR 1.55 1.41 1.74 1.65 Quant. Significant
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TableAIII-IX 
Ultimate combined quantitatively significant values based on overall ratios (1
to 6) Tables 4-5 b and 4-6 b for Tunicamycins Low Dose 24 hours (Array 1.1,
1.2) vs. Corynetoxins (Arrays 2.1, 2.2, 2.3) 
Gene R1 R2 R3 R4 R5 R6 Ratio Significance
FN 0.906 0.995 0.852 0.047 0.042 0.044 0.045 Quant. Significant
NaOx 0.992 0.977 0.980 0.337 0.251 0.353 0.313 Quant. Significant
mt_Co1 0.810 1.120 0.647 0.216 0.241 0.173 0.319 Quant. Significant
p53 0.710 0.925 1.037 0.300 0.285 0.456 0.347 Quant. Significant
PCNA 0.943 0.968 1.136 0.370 0.273 0.461 0.368 Quant. Significant
ferritin 0.666 0.902 0.531 0.102 0.163 0.383 0.436 Quant. Significant
Hdac 0.664 0.760 0.782 0.377 0.330 0.565 0.484 Quant. Significant
CEBPA 0.644 0.891 0.657 1.870 1.839 1.674 1.337 Quant. Significant
ACO 0.915 0.986 1.021 1.675 1.506 1.736 1.639 Quant. Significant
APOE 0.901 1.036 1.023 1.622 1.609 1.791 1.674 Quant. Significant
Bclx 0.649 0.974 0.768 1.616 1.991 1.782 1.699 Quant. Significant
p38 0.992 1.035 1.150 3.271 2.500 3.910 3.227 Quant. Significant
HOX2 1.023 1.138 1.033 4.738 4.470 10.553 6.587 Quant. Significant
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TableAIII-X(a)(i)to(iii) 
Represents ratio values based on the separate gains measured for each of the
replicate array combinations: i) Array 4.1 (Tunicamycins High Dose 24 hours) vs.
Array 4.2 (Corynetoxins High Dose 24 hours); ii) Array 4.1 (Tunicamycins High
i 
i
ii
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 GAIN 5 Ratio 1
APOE 1.790 1.670 1.822 1.090 1.305 APOE 1.81
GSTM 1.335 1.316 1.480 0.857 1.295 GSTM 1.26
GSTM5 1.595 1.533 1.864 1.200 1.468 GSTM5 1.86
GSTA 2.050 1.989 2.510 1.646 1.880 GSTA 2.11
MDH1 1.705 1.656 1.528 1.000 1.635 MDH1 1.63
HSP40 1.488 1.529 1.511 0.979 1.550 HSP40 1.53
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 Ratio 3
APOE 1.253 0.938 0.881 1.371 APOE 1.11
GSTM 1.900 1.450 1.209 1.820 GSTM 1.82
GSTM5 2.000 1.680 1.660 2.040 GSTM5 2.04
GSTA 2.330 2.040 1.770 2.050 GSTA 2.05
MDH1 2.017 1.056 1.098 1.781 MDH1 1.90
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 GAIN 5 Ratio 2
APOE      1.530     1.411     1.583     1.091     1.652 APOE 1.56
GSTM 1.85      1.710      1.780      1.140      1.700 GSTM 1.82
GSTM5      1.810     1.760     1.790     1.350     1.646 GSTM5 1.79
GSTA      1.876      1.845      2.106      1.490      1.740 GSTA 1.94
MDH1      1.906     1.883     1.687     1.152     1.866 MDH1 1.89
HSP40      2.581      2.574      2.368      1.749      2.693 HSP40 2.69
Appendix III 
   373 
  
 
 
TableAIII-X(b)  
Overall ratio values based on separate gains measured for Array 4.1
(Tunicamycins High Dose 24 hours) v array 4.2, 5.2, 6.2 (Corynetoxins
High Dose 24 hours). 
Gene Ratio 1 Ratio 2 Ratio 3 Overall ratio Significance
APOE 1.81 1.56 1.11 0.94 Quant. Significant
GSTM 1.26 1.82 1.83 1.82 Quant. Significant
GSTM5 1.86 1.79 2.05 1.90 Quant. Significant
GSTA 2.11 1.94 2.05 2.04 Quant. Significant
MDH1 1.63 1.89 1.90 1.81 Quant. Significant
HSP40 1.53 2.69 1.27 2.69 Quant. Significant
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i 
ii 
iii 
TablesAIII-XI(a)(i,ii,iii) 
Represents overall data ratio values based on the separate gains measured for
each replicate array combination: i) Array 5.1 (Tunicamycins High Dose 24
hours) vs. Array 4.2 (Corynetoxins High Dose 24 hours); ii) Array 5.1
Gene Gain 1 Gain 2 Gain 3 Gain 4 Ratio 4
FN 0.484 0.435 0.559 0.272 FN 0.397
G153 0.515 0.555 0.819 0.454 G153 0.492
APOE 0.754 0.750 1.163 0.647 APOE 0.518
GSTP 0.666 0.634 0.885 0.522 GSTP 0.515
ferritin 0.691 0.689 1.345 0.511 ferritin 0.511
HSP40 0.705 0.745 1.030 0.655 HSP40 0.653
GA45 0.671 0.718 1.050 0.715 GA45 0.624
mt_Co1 1.070 0.958 1.154 0.679 mt_Co1 0.617
Gene Gain 1 Gain 2 Gain 3 Gain 4 Ratio 5
FN 0.453 0.646 0.932 13.967 FN 0.453
G153 1.000 0.863 1.273 0.726 G153 0.683
APOE 0.791 0.778 1.239 0.794 APOE 0.945
GSTP 1.000 0.990 1.504 0.853 GSTP 1.030
ferritin 0.810 0.830 1.230 0.627 ferritin 0.627
HSP40 1.479 1.536 1.954 1.400 HSP40 1.390
GA45 1.025 1.110 1.571 0.978 GA45 1.130
mt_Co1 1.230 1.117 1.510 0.796 mt_Co1 3.243
Gene Gain 1 Gain 2 Gain 3 Gain 4 Ratio 6
FN 0.655 0.560 0.325 0.318 FN 0.443
G153 0.661 0.648 0.522 0.469 G153 0.496
APOE 0.478 0.542 0.473 0.492 APOE 0.502
GSTP 0.641 0.630 0.539 0.522 GSTP 0.531
ferritin 0.759 0.752 0.530 0.348 ferritin 0.530
HSP40 0.659 0.667 0.564 0.559 HSP40 0.561
GA45 0.780 0.785 0.674 0.669 GA45 0.669
mt_Co1 0.859 0.910 0.730 0.723 mt_Co1 0.814
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Table A III-XI (b) 
Table representing overall data ratio values based on separate gains
measured for Array 5.1 (Tunicamycins High Dose 24 hours) vs. Arrays
4.2, 5.2, 6.2 (Corynetoxins High Dose 24 hours). 
Gene Ratio 4 Ratio 5 Ratio 6 Overall Significance
FN 0.397 0.453 0.443 0.431 Quant. Significant
G153 0.492 0.864 0.496 0.494 Quant. Significant
APOE 0.518 0.946 0.502 0.510 Quant. Significant
GSTP 0.515 1.035 0.531 0.523 Quant. Significant
ferritin 0.511 0.627 0.530 0.556 Quant. Significant
HSP40 0.654 1.394 0.561 0.561 Quant. Significant
GA45 0.624 1.132 0.669 0.647 Quant. Significant
mt_Co1 0.617 3.243 0.814 1.930 Quant. Significant
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Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 GAIN 5 Ratio 7
cyp1b1 0.591 0.637 0.830 0.605 0.573 cyp1b1 0.573
GSTP 0.689 0.557 0.672 0.509 0.504 GSTP 0.531
GA45 0.574 0.596 0.812 0.579 0.556 GA45 0.565
APOE 1.179 0.987 1.078 0.829 0.651 APOE 0.651
FN 1.091 0.913 0.742 0.672 0.770 FN 0.855
ecoa 1.576 1.320 1.663 1.120 1.070 ecoa 1.577
mt_Co1 1.200 1.030 1.160 0.713 0.593 mt_Co1 0.593
IGF1R 1.318 1.560 3.049 1.046 1.400 IGF1R 1.404
HSP40 1.447 1.668 2.050 2.250 2.240 HSP40 2.250
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 GAIN 5 Ratio 8
cyp1b1 0.491 0.516 0.648 0.509 0.487 cyp1b1 0.498
GSTP 1.091 0.914 1.200 0.875 0.862 GSTP 0.989
GA45 0.922 0.969 1.277 0.833 0.912 GA45 0.983
APOE 1.324 1.095 1.230 1.091 1.080 APOE 1.164
FN 1.406 1.869 1.706 47.480 54.560 FN 1.869
ecoa 1.260 1.069 1.130 0.893 0.810 ecoa 1.034
mt_Co1 1.489 1.354 1.349 0.896 3.339 mt_Co1 3.339
IGF1R 1.474 1.623 2.380 1.600 2.193 IGF1R 2.193
HSP40 3.257 3.645 4.178 5.226 5.074 HSP40 5.150
TablesAIII-XI(i,ii,iii)  
Overall data ratio values based on the separate gains measured for each of the replicate
array combinations: i) Array 6.1 (Tunicamycins High Dose 24 hours) vs. Array 4.2
(Corynetoxins High Dose 24 hours); ii) Array 6.1 (Tunicamycins High Dose 24 hours) vs.
i 
i
ii
Appendix III 
Gene GAIN 1 GAIN 2 GAIN 3 GAIN 4 Ratio 9
cyp1b1 0.860 0.828 0.790 0.860 cyp1b1 0.816
GSTP 0.811 0.585 0.634 0.811 GSTP 0.621
GA45 0.186 0.743 0.730 0.816 GA45 0.668
APOE 0.897 0.603 0.743 0.897 APOE 0.603
FN 1.543 0.777 0.933 1.543 FN 1.543
ecoa 1.980 1.210 1.110 1.543 ecoa 1.983
mt_Co1 1.200 0.900 0.835 1.206 mt_Co1 0.967
IGF1R 1.255 1.279 1.838 1.255 IGF1R 1.838
HSP40 1.640 1.610 2.335 1.640 HSP40 2.344
   377 
  
 
Table A III-XII (b) 
Table representing overall ratio values based on separate ratios measured
for Array 6.1 (Tunicamycins High Dose 24 hours) vs. Arrays 4.2, 5.2, 6.2
(Corynetoxins High Dose 24 hours). 
Gene RATIO 7 RATIO 8 RATIO 9 Overall ratio Significance
cyp1b1 0.573 0.498 0.816 0.536 Quant. Significant
GSTP 0.531 0.989 0.621 0.576 Quant. Significant
GA45 0.565 0.983 0.668 0.616 Quant. Significant
APOE 0.651 1.164 0.603 0.627 Quant. Significant
FN 0.855 1.869 1.543 1.706 Quant. Significant
ecoa 1.577 1.034 1.983 1.780 Quant. Significant
mt_Co1 0.593 3.339 0.967 1.966 Quant. Significant
IGF1R 1.404 2.193 1.838 2.016 Quant. Significant
HSP40 2.250 5.150 2.344 3.747 Quant. Significant
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Table A III-XIII  
Table representing ultimate data ratio values based on separate gains measured for Array 5.1
(Tunicamycins High Dose 24 hours) vs. Arrays 4.2, 5.2, 6.2 (Corynetoxins High Dose 24
hours). 
Gene R1 R2 R3 R4 R5 R6 R7 R8 R9 Ultimate ratio Significance
APOE 1.806 1.557 1.11 0.518 0.946 0.502 0.651 1.164 0.603 0.939 Quant significant
FN 0.976 2.116 1.02 0.397 0.453 0.433 0.855 1.899 1.543 1.137 Quant significant
MDHI 1.631 1.895 1.899 0.923 1.258 0.824 1.074 1.697 1.152 1.808 Quant significant
mt_Co1 0.915 4.202 0.91 0.617 3.423 0.814 0.593 3.339 0.967 2.399 Quant significant
HSP40 1.529 2.693 1.266 0.654 1.394 0.561 2.25 5.15 2.344 2.687 Quant significant
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Overall combined ratio values for Tunicamycins Low dose 48 hours 
(Array 7.1) vs. Corynetoxins (Arrays 7.2, 8.2, 9.2) 
Gene Ratio 1 Ratio 2 Ratio 3 Overall Significance
cnd1 1.445 2.059 0.098 0.098 Quant. Significant
CND3 1.518 1.268 0.115 0.115 Quant. Significant
ecoa 0.973 0.326 0.087 0.207 Quant. Significant
HSP70 2.143 1.456 0.559 0.559 Quant. Significant
Hdac 1.136 8.184 0.625 0.625 Quant. Significant
MDH1 1.228 2.163 0.644 0.644 Quant. Significant
FN 1.495 8.462 0.073 0.784 Quant. Significant
cdk4 1.634 0.829 0.084 0.859 Quant. Significant
mt_Co1 0.117 2.262 0.424 0.934 Quant. Significant
MAO-A 1.589 6.043 0.664 1.127 Quant. Significant
p53 0.819 4.247 1.684 1.684 Quant. Significant
GSTP 1.977 1.506 1.077 1.741 Quant. Significant
PCNA 1.811 7.240 1.225 1.811 Quant. Significant
HMG 1.844 2.805 0.940 1.844 Quant. Significant
GA45 2.163 275.391 1.543 1.853 Quant. Significant
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TableAIII-XV  
Overall combined ratio values for Tunicamycins Low dose 48 hours
(Array 8.1) vs. Corynetoxins (Arrays 7.2, 8.2, 9.2) 
Gene Ratio 4 Ratio 5 Ratio 6 Overall Significance
ecoa 0.498 0.269 0.739 0.384 Quant. Significant
PEPT1 0.525 0.280 1.066 0.403 Quant. Significant
p53 0.603 4.447 1.343 0.603 Quant. Significant
GSS 1.106 1.382 1.505 1.505 Quant. Significant
MAO-A 1.571 6.281 0.954 1.571 Quant. Significant
ferritin 0.534 3.448 1.015 1.991 Quant. Significant
mt_Co1 0.216 3.991 0.900 2.103 Quant. Significant
HMG 2.216 3.437 1.311 2.216 Quant. Significant
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TableAIII-XVI 
Overall combined ratio values for Tunicamycins Low dose 48 hours
(Array 9.1) vs. Corynetoxins (Arrays 7.2, 8.2, 9.2) 
Appendix III 
Gene Ratio 7 Ratio 8 Ratio 9 Overall 
PEPT1 0.432 0.214 1.031 0.323
FN 1.402 15.957 0.396 0.396
ecoa 0.839 0.441 0.410 0.426
cnd1 1.360 3.800 0.474 0.474
erk1 1.357 1.818 0.483 0.483
cyp1b1 1.780 8.965 0.508 0.508
CND3 1.342 2.272 0.529 0.529
p53 0.622 3.887 1.535 1.079
APOE 0.551 1.415 1.619 1.085
MDH1 1.566 1.936 1.031 1.566
HSP40 1.563 102.817 1.574 1.574
IGF2 1.675 4.804 1.497 1.586
ACO 2.008 1.498 1.606 1.606
GPX1 1.905 4.364 1.772 1.838
MAO-A 1.869 5.448 1.067 1.869
GSTP 2.333 1.296 1.572 1.952
GSTM5 2.384 4.769 1.868 2.126
Hdac 2.17819 16.3466 1.30594 2.17819
GA45 2.531 257.281 1.957 2.244
GSS 1.988 1.820 2.565 2.276
mt_Co1 0.346 5.153 1.520 2.340
GSTM5 2.554 NaN 2.190 2.372
HMG 2.928 4.059 2.415 2.671
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TableAIII-XVII:  
Ultimate combined ratio values for Tunicamycins Low dose 48 hours (Array 7.1, 8.1, 9.1)
vs. Corynetoxins (Arrays 7.2, 8.2, 9.2) 
Gene R1 R2 R3 R4 R5 R6 R7 R8 R9 Overall Si gnificance
ecoa 0.930 3.260 0.087 0.498 0.269 0.739 0.839 0.441 0.410 0.339 Quant. Significant
PEPT1 0.719 0.282 1.174 0.525 0.280 1.066 0.432 0.214 1.031 0.347 Quant. Significant
FN 1.495 8.462 0.073 0.969 9.522 0.846 1.402 15.957 0.396 0.654 Quant. Significant
p53 0.819 4.247 1.684 0.603 4.447 1.343 0.622 3.887 1.535 1.111 Quant. Significant
MAO-A 1.589 6.043 0.664 1.571 6.281 0.954 1.869 5.448 1.067 1.424 Quant. Significant
mt_Co1 0.117 2.262 0.424 0.216 3.991 0.900 0.346 5.153 1.520 1.754 Quant. Significant
GSTP 1.977 1.510 1.080 1.600 1.180 1.000 2.333 1.296 1.572 1.798 Quant. Significant
GSS 0.999 1.810 1.060 1.110 1.380 1.505 1.989 1.820 2.656 2.019 Quant. Significant
GA45 2.163 275.390 1.540 1.750 232.170 1.271 2.531 257.281 1.957 2.049 Quant. Significant
HMG 1.844 2.805 0.940 2.216 3.473 1.311 2.928 4.059 2.415 2.351 Quant. Significant
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